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Abstract 
 
 
Aims Thiazolidinediones have been advocated as second or third line insulin-
sensitizing agents in the management of type 2 diabetes (T2DM). Their widespread 
use has been hampered by concerns about their cardiovascular safety, including fluid 
retention. Metformin is established as first-line glucose-lowering pharmacotherapy 
in T2DM.  It has also been suggested that it may have benefits in alleviating insulin 
resistance in type 1 diabetes (T1DM). This thesis examined: (i) cardiovascular, renal 
and metabolic differences between individuals with T2DM ‘tolerant’ or ‘intolerant’ 
of TZDs; (ii) risk factors for TZD-associated oedema in T2DM; and (iii) the 
potential for metformin as adjunct therapy in T1DM. 
 
Methods  (i) A small clinical study characterising TZD tolerant and intolerant 
individuals with T2DM; (ii) A population-based epidemiological study of TZD-
induced oedema in individuals with T2DM in Tayside, Scotland (using incident loop 
diuretic prescription as a surrogate); (iii) A systematic review and meta-analysis of 
published studies of adjunct metformin in T1DM. 
 
Results  (i) During a five-day high sodium diet, two known TZD-intolerant 
individuals with T2DM had reductions in haematocrit, aldosterone, and diastolic BP 
and increases in ANP and central and peripheral augmentation indices which were 
outwith reference ranges derived from nine TZD-tolerant individuals; (ii) Predictors 
of time to loop diuretic prescription included age, body mass index, systolic BP, 
haematocrit, ALT and macrovascular disease but rates of this outcome did not differ 
by therapy: 4.3% (TZDs) vs 4.7% (other agents ) [unadjusted OR 0.909 (95% CI 
xxv 
 
   
0.690, 1.196); p = 0.493]; (iii) In meta-analysis of nine small studies in T1DM 
(192.8 patient-years of follow-up), metformin was associated with a reduction in 
total daily insulin dose (6.6 units/day; p < 0.001) but no studies examined 
cardiovascular surrogates or outcomes. 
 
Conclusions   Hypotheses were generated for several potential biomarkers predictive 
of TZD-induced oedema but the clinical importance of TZDs as a risk factor for 
oedema in individuals with T2DM was questioned. As there is some evidence for the 
safety of metformin as an adjunct therapy in T1DM but little evidence of efficacy, 
larger studies are warranted. 
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Chapter 1 - Introduction and literature review 
 
Section I - Physiological mechanisms underpinning insulin action in 
relation to metformin and thiazolidinedione therapy 
 
The incidence and prevalence of diabetes is rising worldwide in epidemic 
proportions [1, 2]. Its associated morbidity and mortality are imposing a major 
burden on health care systems [1, 3, 4]. Type 2 diabetes (T2DM), accounting for 
over 90% of diabetes cases worldwide [5], is characterised by two major 
pathophysiological processes: insulin resistance (impaired responsiveness to insulin) 
and beta-cell failure. The hyperbolic relationship between insulin sensitivity and 
insulin secretion is well established; insulin secretion increases in response to a 
reduction in insulin sensitivity only up to the point at which the beta-cell cannot cope 
with the added demands such that any further increase in insulin resistance will 
cause a fall in insulin secretion [6, 7]. Data extrapolated from the United Kingdom 
Prospective Diabetes Study (UKPDS) suggest that loss of beta-cell function 
commences some 10-12 years before T2DM is diagnosed [8].  
 
Insulin sensitivity varies between different ethnic groups [9] and populations, up to 
seven fold at any given age [10]. It is influenced by genetic susceptibilities [11], 
constitutional factors (such as obesity [12] and physical inactivity [13]) or both. The 
principal sites for insulin resistance are the skeletal muscle and the liver; adipose 
tissue and peripheral tissues are also implicated [14-16]. Skeletal muscle glucose 
transport alone accounts for 75% of the insulin-mediated glucose uptake in healthy 
individuals [17]. Insulin resistance has been associated with reduced expression of 
3 
 
   
insulin receptors at the surface of insulin-responsive cells [17], alterations in signal 
transduction pathways that are activated following insulin binding to the receptor 
[18], and abnormalities in glucose transport and glycogen synthesis [19, 20]. The 
role of leptin, adiponectin, and adipocytokines in adipose tissue inflammation, and 
their contribution to insulin resistance is also generating considerable interest [21].  
 
Although type 1 diabetes (T1DM) is characterised by autoimmune beta-cell failure, 
insulin resistance is being increasingly recognized as an important 
pathophysiological feature, resulting in an association of this disease with the 
components of the metabolic syndrome [22-24]. The relevance of this association is 
further enhanced by the observation that insulin resistance is an independent risk 
factor for vascular complications, both in type 1  [24-32] and in type 2 diabetes [33-
35]. Randomized controlled trials in T2DM have shown that a pharmacologically-
mediated reduction in insulin resistance decreases the incidence of diabetes and the 
risk of macrovascular complications keep [36-39]. Tight glycaemic control has been 
shown in the Diabetes Control and Complications Trial (DCCT) to reduce rates of 
microvascular complications in T1DM [40]. 
 
Targeting insulin resistance and hyperglycaemia through different and 
complementary mechanisms, metformin and thiazolidinediones are widely used, 
alone or in combination, in the management of T2DM. However, the benefits of 
thiazolidinediones have been hampered by their association with fluid retention, 
bone fractures [41], and a possible association with myocardial infarction 
(rosiglitazone) and bladder cancer (pioglitazone) [42]. While metformin’s use in 
T2DM is firmly established, there is currently considerable interest in its potential in 
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T1DM. This review will address the issues surrounding thiazolidinedione-associated 
fluid retention in T2DM patients. Moreover, it will examine the evidence supporting 
insulin resistance in type 1 and type 2 diabetes and benefits associated with the use 
of metformin in T2DM. 
 
1.1 The insulin signalling pathway 
 
The pleiotropic effects of insulin are mediated through its interaction with a 
signalling network of molecules that are set in motion following the hormone’s 
binding to its receptor (figure 1.1). The insulin receptor is an integral membrane 
glycoprotein existing as a dimer. Each monomer contains an α- and a β chain. The α-
subunits link to each other and to the β-subunits by disulfide bonds, and are located 
on the extracellular side of the plasma membrane [43, 44]. The β-subunits traverse 
the membrane, and are characterised by a tyrosine kinase (TK) enzyme domain on 
the cytoplasmic side [44-46]. Insulin binding to an α-subunit activates the TK 
domain on the β-chain, leading to autophosphorylation of the TK domains in each β-
subunit. Insulin receptor substrate proteins (IRS) are then recruited to the plasma 
membrane through an interaction with the phosphorylated insulin receptor, resulting 
in phosphorylation of IRS tyrosine residues [47, 48]. Phosphorylated IRS in turn 
recruit additional signalling proteins. 
 
The lipid kinase phosphatidylinositol (PI) 3-kinase binds to IRS proteins and 
converts phosphoinositol 4,5 biphosphate (PIP2) to phosphoinositol 3,4,5 
triphosphate (PIP3) [49]. This in turn recruits peckstrin homology domain containing 
proteins to the membrane, altering their conformation and activating protein kinase 
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cascades. The best characterised of these is the phosphoinositide dependent protein 
kinase (PDK1) pathway. PDK is a master regulator of a number of protein kinases, 
including protein kinase B (PKB, also known as Akt), PKC, p90, RSK, p70, S6K 
and SGK [50], which in turn phosphorylate and regulate a wide variety of proteins 
involved in growth and metabolism. Of relevance to glucose homeostasis, PKB 
phosphorylates and inactivates glycogen synthase kinase-3 (GSK3) [51, 52] and 
forkhead box-containing protein O (FOXO) [53, 54] transcription factors. By 
regulating the transcription of PEPCK and glucose-6-phosphatase genes, these two 
transcription factors modify two important rate controlling steps in gluconeogenesis. 
Hepatic expression of both PEPCK and glucose-6-phosphatase is high in animal 
models of diabetes, and overexpression of PEPCK is sufficient to induce diabetes in 
animals [55].  
 
How does insulin regulate the expression of PEPCK and glucose 6-phosphatase? 
During starvation, glucagon promotes the assembly of a nuclear transcription 
complex comprising CREB (c-AMP response element binding protein), CBP (CREB 
binding protein) and CRTC2 (CREB-regulated transcription co-activator 2, also 
known as TORC2). This complex increases the expression of PPAR-γ co-activator 1 
(Ppargc1), PEPCK, glucose-6-phosphatase, and other key gluconeogenic enzymes. 
Postprandial activation of the PI3-PKB pathway stimulates salt-inducible kinase 2 
(SIK2), which inactivates the CREB-CBP-CRTC2 complex by phosphorylating 
CRTC2 at Ser171 and targeting it for degradation in the cytosol [56] (figure 1.1). 
 
Although the IRS/PI 3-kinase/PDK1/PKB pathway is considered a major pathway of 
insulin action, it is not the only pathway downstream of IRS. The Ras-ERK pathway 
6 
 
   
has also been elucidated. In summary, the protein complex Grb2/mSOS interacts 
with phospho-IRS (tyrosine residues being phosphorylated at sites distinct to those 
that recruit PI 3-kinase). Bound mSOS exchanges GDP for GTP on the small G-
protein Ras, activating Ras [57]. This in turn activates the oncogene c-Raf, which 
additionally has protein kinase activity. c-Raf phosphorylates and activates 
MAP/ERK kinase (MEK) [58], which in turn phosphorylates and activates ERK1/2 
[59]. The latter acts on multiple substrates, most of which are related to cell growth. 
 
Insulin has also been reported to regulate several other proteins relevant to glucose 
homeostasis, such as Rab, atypical PKC (PKCζ,), CAP and GLUT4 (all involved in 
glucose transport) and PDE3, hormone sensitive lipase and ATP citrate lyase 
(involved in fat metabolism) [60]. In particular, the translocation of the glucose 
transporter GLUT-4 from the intracellular pool to the plasma membrane plays a 
crucial role in insulin-mediated glucose entry into skeletal muscle [61], and is 
thought to be mediated by PI3-kinase and its downsteam phosphorylation of PKB 
[62] or atypical PKC [63, 64]. In summary, insulin signalling is a complex, as yet 
incompletely unravelled pathway potentially prone to dysregulation or mutation at 
several molecular points, resulting in insulin resistance.  
 
1.2 Diabetes is associated with defective insulin signalling 
 
The molecular pathology of insulin resistance is not yet established. It is likely to 
result from a post-receptor defect, reducing the ability of insulin to mediate its 
pleiotropic actions at hepatic, skeletal muscle and adipose tissue level. Although it is 
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assumed that obesity predates and promotes the molecular defects, this has not been 
formally proven in man [60].  
 
Insulin resistance can be generated in mice by deleting key insulin signalling 
molecules. Thus, a partial loss of the insulin receptor (IR +/-), combined with a 
partial loss of IRS1 (+/-), results in severe insulin resistance, and a greatly increased 
prevalence of diabetes [65]. Reduced IRS expression has been reported in 
association with obesity and T2DM [66]. Reduced IRS1 signalling has also been 
reported in human T2DM [67-69]. Phosphorylation of IRS on serine and threonine 
residues, as opposed to tyrosine residues (as discussed previously), reduces the 
interaction of IRS with the insulin receptor and downstream signalling components 
[70, 71]  and increases the rate of IRS degradation. Serine phosphorylation has been 
ascribed to feedback from downstream components (eg p70S6K) and protein kinases 
induced by obesity, such as PKC or JNK [72-76], providing a link between obesity 
and insulin resistance. Several isoforms of PKC, IKK, Mtor/p70S6K and GSK-3, 
implicated in serine/threonine phosphorylation, are activated by  free fatty acids, 
ceramide, TNF-α and chronic hyperinsulinaemia [71, 77, 78]. 
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Figure 1.1 - Schematic diagram illustrating the main insulin signalling pathways regulating glycaemic control and metformin’s 
pharmacological effects 
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There is evidence suggesting that the Ras-ERK pathway may be defective in at least 
one insulin resistant state, called polycystic ovary syndrome [79, 80], and in many 
young males with a BMI exceeding 29kg/m2 [60]. Similarly, in a study of 22 
normoglycaemic young men with a body mass index (BMI) ranging from 20 to 37 
kg/m2, Ruiz-Alcaraz et al. concluded that the MAP-ERK pathway (amongst other 
insulin signalling pathways) is defective in obese insulin resistant individuals [81], 
implicating that such defects predate a clinical presentation with overt diabetes. 
 
The analysis of the intracellular insulin signalling process in man is technically 
problematic. Individually, insulin signalling mutations have little effect owing to 
considerable apparent redundancy of pathways. In summary, in humans, insulin 
resistance is thought to arise from the synergistic effect of multiple minor molecular 
signalling defects [60].  
 
1.3 Metformin – a multifaceted therapeutic approach to insulin resistance 
 
Metformin is most widely prescribed oral anithyperglycaemic agent worldwide, and 
is recommended as a first line agent in the treatment of T2DM by several national 
and international diabetes guidelines, such as those issued by the National Institute 
for Health and Clinical Excellence (NICE) [82], the Scottish Intercollegiate 
Guideline Network (SIGN) [83], the European Association for the Study of Diabetes 
and the American Diabetes Association (EASD/ADA) [84], and the International 
Diabetes Federation (IDF) [85]. Used for approximately 55 years in the UK 
(although for only 18 years in the US), metformin decreases intestinal glucose 
absorption, reduces hepatic glucose production by over 30% [86] and increases 
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peripheral glucose disposal through complex insulin-sensitizing and insulin-
independent mechanisms [87]. 
 
1.3.1 Metformin and AMPK 
 
The highly conserved energy sensor adenosine monophosphate (AMP)-activated 
protein kinase (AMPK) has been identified as a key modulator of the 
pharmacological effects of metformin [88] and thiazolidinediones [89]. AMPK is 
activated by a range of physiological and pathological stresses that increase the 
intracellular AMP: adenosine triphosphate (ATP) ratio, either by decreasing ATP 
generation (eg ischaemia or hypoxia) or increasing ATP consumption (eg muscle 
contraction). This kinase acts to restore cellular energy balance by favouring ATP 
generating pathways (eg fatty acid oxidation) while inhibiting ATP utilizing 
pathways (eg fatty acid synthesis and gluconeogenesis). This is achieved initially by 
direct phosphorylation of key metabolic enzymes, and in the long term by effects on 
gene transcription [90-92]. Additionally, AMPK is also involved in the central 
regulation of food intake and energy expenditure in response to hormones such as 
leptin, ghrelin and adiponectin [93]. 
 
AMPK exists as a heterotrimeric complex containing a catalytic subunit (α), and two 
regulatory subunits (β and γ) [94]. The α-subunit contains the catalytic domain, 
including the all important Thr172 subunit, which is phosphorylated by upstream 
kinases. The major upstream kinase in mammalian cells is a complex of the protein 
kinase LKB1 and two accessory subunits STRAD (Ste20-related adaptor) and MO25 
(mouse protein 25) [95-97]. LKB1 is dependent on the STRAD subunit in order to 
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phosphorylate the Thr172 subunit [96]. Besides LKB1, STRAD and MO25, AMPK 
can also be activated by an LKB1-independent mechanism involving 
calcium/calmodulin-dependent protein kinase kinase (CaMKK) [98-100]. The β 
subunit has a glycogen binding C-terminal domain; high glycogen content exerts an 
inhibitory effect on AMPK through an interaction with the β-subunit in skeletal 
muscle, although the exact mechanism is unknown [101]. The γ subunit contains 
four repeats forming two tandem domains, each of which bind one molecule of ATP 
or AMP in a mutually exclusive manner [102]. The tandem domains bind AMP with 
a high degree of cooperativity [102], suggesting that the second site is inaccessible to 
AMP until the latter has bound to the first tandem domain. Interestingly, insulin and 
AMPK signalling pathways work in the same direction at the level of skeletal 
muscle, liver and adipose tissue, particularly for processes that regulate glucose 
homeostasis [103]. As with insulin, AMPK-mediated skeletal muscle glucose 
disposal is achieved through an increased translocation of the glucose transporter 
GLUT4 to the plasma membrane, although the fate of the glucose is different: 
glycogen synthesis in the case of insulin and glycolysis/oxidation in the case of 
AMPK [104, 105]. Both insulin and AMPK inhibit hepatic gluconeogenesis by 
repressing the expression of gluconeogenic enzymes, such as phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6 phosphatase (G6p) [106]. Both insulin and 
AMPK inhibit hormone-sensitive lipase, and hence lipolysis [107-109], albeit 
through different mechanisms. Thus, AMPK phosphorylates hormone sensitive 
lipase at Ser565, an effect that antagonises activation by cAMP-dependent protein 
kinase [110], whereas insulin causes phosphorylation and activation of 
phosphodiesterase 3B by PKB, thus lowering cAMP [111].  
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Metformin is thought to activate AMPK indirectly through an inhibition of complex 
1 of the respiratory chain [112], causing an increase in the AMP/ATP ratio. 
Inhibition of the respiratory chain in the intestinal mucosa may account for the 
gastrointestinal adverse effects of this drug [113]. The same mechanism may also 
underlie the propensity of its biguanide predecessor phenformin (now withdrawn) to 
precipate lactic acidosis [113]. It is pertinent to point out, however, that metformin 
pharmacotherapy has not been associated with a significantly increased risk of lactic 
acidosis in a recent Cochrane review [114].  
 
Metformin has been reported to activate AMPK in cardiac myocytes [115-117], 
hepatocytes [88] and skeletal muscle cells [88]. LKB1 plays a crucial role in 
metformin’s interaction with AMPK, such that liver specific knock-out of LKB1 
ablates metformin’s ability to lower blood glucose in obese rodents [118].  Like 
insulin, metformin also stimulates the phosphorylation of  CREB-regulated 
transcriptional coactivator 2 (CRCT2) at Ser171. This sequesters CRCT2 into the 
cytosol, and away from the nucleus, barring any effects on gluconeogenic gene 
transcription. In obese and insulin resistant individuals, CRCT2 is O-glycosylated at 
Ser171, blocking any benefical phosphorylation by metformin at this site [119]. Both 
insulin and metformin circumvent this block by activating atypical Protein Kinase C, 
which phosphorylates CBP at Ser436, initiating the dissociation of the CBP:CRTC2 
from CREB, and targeting CREB for dissociation in the cytosol [120].  Despite these 
findings, the relevance of a metformin-AMPK interaction has recently been 
questioned, following observations that metfomin-treated mice lacking AMPK in the 
liver achieved comparable glycaemic control as wild-type mice [121]. Moreover,  
Forretz et al. observed that metformin-induced inhibition of glucose production was 
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higher in AMPK- and LKB1-deficient hepatocytes compared with wild-type 
hepatocytes, and that this inhibition correlated in a dose-dependent manner with a 
reduction in intracellular ATP content. This led the authors to suggest that metformin 
reduces hepatic gluconeogenesis through a reduction in hepatic energy state 
(possibly through an interaction with complex 1 of the respiratory chain), 
independently of any AMPK- or LKB1- related repression of gluconeogenic genes 
[121].   
 
In contrast, metformin is reported to inhibit AMPK in the hypothalamus, by 
inhibiting low glucose-induced AMPK phosphorylation and neuropeptide-Y mRNA 
expression [122]. This mechanism is thought to underlie metformin’s anorectic 
effects. Indeed, a recent study carried out on a new delayed-release formulation of 
metformin (newmet) concluded that higher plasma concentrations of metformin do 
not confer increased therapeutic efficacy. Bypassing the upper gastrointestinal tract, 
lowering systemic exposure and improving tolerability through its special pH-
sensitive coating, newmet is reportedly able to maintain its glucose-lowering effect 
through an activation of nutrient receptors located on enteroendocrine cells. The 
latter produce key glucose-regulating hormones such as peptide YY (which signals 
satiety to the brain) and glucagon-like peptide-1 (GLP-1) [123]. Other studies 
suggest that metformin may have a deletirious effect on pancreatic beta-cell function 
by reducing mitochondrial ATP synthesis, a scenario that impairs responsiveness, 
inhibits insulin release, and possibly induces beta-cell apoptosis [124] [125].     
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1.3.2 The insulin-independent effects of metformin: effects on glucose 
absorption 
 
The contribution of the intestine in metformin’s antihyperglycaemic effects is often 
overlooked because of paucity of clinical data. In a study on normal 18 hour fasted 
mice, Wilcock and Bailey reported that metformin (administered as an intragastric 
bolus) decreased intestinal glucose absorption in a dose dependent manner through 
effects on mucosal and serosal glucose transfer, mostly in the middle portion of the 
small intestine [126]. Animal studies suggest that metformin delays glucose 
absorption, such that this occurs more distally in the gastrointestinal tract [126, 127]. 
Metformin administration results in the accumulation of very high drug 
concentrations in the intestinal wall [128]. This is accompanied by an increased 
utilization of glucose by the intestine, particularly through anaerobic metabolism 
[129-131], explaining, at least in part, the apparent shortfall in the passage of glucose 
from the luminal to the serosal surface of the intestine. To this effect, Bailey et al. 
reported that incubation of human jejunal biopsy tissue with metformin significantly 
increased lactate production within the tissue sample by 35%. Additionally, in a 
study on eight recently-diagnosed, obese, drug naïve T2DM patients,  the authors 
showed that incident metformin administration is associated with metformin jejunal 
concentrations ranging from 30 to 300 times higher than plasma metformin 
concentrations [132].  
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1.3.3 Metformin and the organic cation transporter  
 
Primarily excreted unchanged in the urine, metformin is a substrate of a number of 
organic cation transporters; those identified so far are organic cation transporters 1 
and 2 (OCT1 and OCT2) and plasma membrane monoamine transporter (PMAT). 
Organic cation transporters are polyspecific transporters most commonly expressed 
in the liver and the kidney, where they play a role in the elimination of organic 
cations from the systemic circulation.[133-135].  In particular, OCT1 is thought to be 
a major determinant of metformin’s pharmacological effects in the liver [136, 137]; 
passive diffusion and other transporters may account for a small portion [137]. In a 
transgenic mouse model, knockout of liver OCT1 virtually abolished biguanide-
induced hepatic lactate production [136]. Deletion of the OCT1 gene in mouse liver 
reduces metformin’s effects on gluconeogenesis and the drug’s interaction with 
AMPK [137]. OCT1 polymorphisms have been reported to reduce metformin effects 
on the response to oral glucose, and affect serum metformin concentrations [137, 
138], and may, at least partly, explain why about 40% of metformin-treated T2DM 
patients fail to achieve target fasting plasma glucose levels [139, 140]. Expressed in 
the basolateral membrane of renal tubular cells, OCT2 is implicated in the renal 
excretion of the drug [141, 142]. While both OCT1 and OCT2 are expressed at low 
levels in the basolateral membranes of entrocytes [133, 135, 143], PMAT has 
recently been identified as a more important metformin transporter in the small 
intestine, and is expressed at higher levels in the apical membrane of these cells 
[143-145] 
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1.4 Thiazolidinediones – a ‘novel’ class of insulin sensitizers 
 
The thiazolidinediones (TZDs) rosiglitazone and pioglitazone were approved by the 
US Food and Drugs Administration (FDA) as pharmacological agents in the 
management of individuals with T2DM in 1999. Thiazolidinediones are currently 
recommended as second or third line T2DM pharmacotherapy by NICE and SIGN  
[82, 83]. The 2009 consensus statement of the EASD and the ADA did not 
recommend the use of rosiglitazone in view of concerns about its cardiovascular 
safety profile, while suggesting that pioglitazone may be used as a second line agent 
in specific clinical circumstances, such as ‘when hypoglycaemia is particularly 
undesirable’ [84]. The updated 2012 EASD/ADA recommendations, guided by the 
principle of 'primum non nocere' ('first do no harm')  retain a potential role for 
pioglitazone as a second-line add-on agent. However the authors seemingly prefer to 
focus on its safety and adverse effect profile [146]. Concerns about the 
cardiovascular safety profile of rosiglitazone, initially raised by (the much disputed) 
Nissen and Wolski’s meta-analysis [147], and confirmed by some [148-150], but not 
other [151-154] studies and meta-analyses led the US Food and Drug Administration 
(FDA) to issue guidance detailing the approach for acquiring, analysing and 
reporting the necessary safety information from all Phase II and III trials  [155]. 
Acting upon updated meta-analyses data [156, 157], FDA restricted rosiglitazone’s 
use in the management of T2DM [158]. The European Medicines Agency (EMA) 
went further, withdrawing its marketing authorization with immediate effect in 
September 2010 [159]. A recent editorial has questioned the wisdom of curtailing 
rosiglitazone's marketing authorization, given the limitations imposed by the 
available medical evidence [160]. 
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Thiazolidinediones lower fasting and postprandial blood glucose levels by increasing 
insulin sensitivity in muscle, fat and liver cells. This is achieved through modulation 
of peroxisome-proliferator-activated receptor-γ (PPARγ) activity. Troglitazone, the 
first widely used thiazolidinedione introduced in 1997, was withdrawn from clinical 
practice on account of liver toxicity [161]. The association between 
thiazolidinedione therapy and heart failure (HF) was reported in the same year, when 
Hirsch et al. described two cases of pulmonary oedema complicating the use of 
troglitazone in two diabetes patients with preserved left ventricular function. This 
clinical condition improved after the drug was discontinued [162]. Fluid retention 
and weight gain have since been confirmed as the principal adverse effects of 
rosiglitazone and pioglitazone, such that drug manufacturers do not recommend their 
use in patients with New York Heart Association (NYHA) functional class III or IV 
HF [163, 164]. Both NICE and SIGN guidelines have adopted a more stringent 
approach, such that they do not recommend the use of these drugs in any patient with 
HF [82, 83]. This chapter aims to review the current understanding of the 
pathophysiology of PPAR-γ agonists. Additionally, it shall discuss the clinical 
evidence and mechanisms underlying thiazolidinedione-induced oedema. 
 
1.4.1 Peroxisome Proliferator Activated Receptors - a heterogenous family of 
nuclear receptors 
 
The identification of the insulin-sensitizing properties of thiazolidinediones in 
animals and humans has generated significant interest into the mechanism of action 
of these drugs. Thiazolidinediones act as peroxisome proliferator-activated receptor 
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(PPAR)-γ agonists. Together with PPAR-α and PPAR-δ, PPAR-γ belongs to a 
nuclear receptor superfamily of transcription factors [165] which are activated by 
polyunsaturated fatty acids, prostanoids and oxidised fatty-acids found in low 
density lipoproteins (LDLs) [166-168]. PPAR-α, -δ and –γ are encoded on three 
different genes (PPARA, PPARD, and PPARG) located at chromosomes 22, 6, and 
3, respectively [165]. While PPAR-δ is ubiquitously expressed [169], PPAR-α 
distribution is largely restricted to tissues where active fatty acid catabolism occurs. 
Thus, although predominantly expressed in the liver, it has additionally also been 
identified at moderate levels in the kidney and brown adipose tissue, and at relatively 
lower levels in heart and intestine [170]. It has also been localised in skeletal muscle 
[171]. PPAR-γ is mostly, though not exclusively, expressed in white and brown 
adipose tissue; additionally, it has been localised in the intestine, vascular 
endothelium, macrophages, pancreatic beta cells [172, 173] and skeletal muscle 
[174]. It is characterised by several splice variants, named PPAR-γ1 to PPAR-γ7 
[175-177] , the relative distribution of which is further outlined in table 1.1. 
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Table 1.1 - Peroxisome proliferator-activated receptor-γ (PPAR-γ) receptor isotype 
distribution (adapted from [175-177]) 
 
PPAR-γ receptor isotype 
 
 
Physiological distribution 
 
PPAR-γ1 
 
 
 
 
 
PPAR-γ2 
 
 
PPAR-γ3 
PPAR-γ4 
PPAR-γ5 
PPAR-γ6 
PPAR-γ7 
 
Mostly expressed in adipose tissue and 
large   intestine 
Intermediate expression in liver, kidney 
and small intestine 
Very limited expression in muscle 
 
Same distribution as for PPAR- γ1, but 
much less abundantly expressed 
 
Adipose tissue and large intestine 
Macrophages  
Macrophages  
Adipose tissue 
Adipose tissue 
 
PPARs and other class II nuclear receptors are composed of six structural regions (A 
to F) in four functional domains  [178] (figure 1.2). The A/B region is a variable 
region located in the NH2 end of the receptor. It encompasses a ligand-independent 
transactivation domain (activation-function 1) (AF-1) that is transcriptionally active 
in the absence of ligands. The ligand-binding activity of the receptor can be modified 
positively (in the case of PPAR-α) [179] or negatively (in the case of PPAR-γ) [180, 
181] by phosphorylation [182] or sumoylation [183]. The C-region holds the DNA-
binding domain (DBD), which is the most conserved domain in all nuclear receptors. 
It targets the PPAR to a sequence of nucleotides within the regulatory regions of 
responsive genes. This sequence is called the PPAR response element (PPRE) [184]. 
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The E/F region contains the ligand binding domain and a co-activator/co-repressor 
binding surface [185]. X-ray crystallography has revealed that this ligand-binding 
domain is characterised by a large binding pocket that allows the transcription 
receptor to bind to a wide variety of structurally unrelated ligands [186]. The 
activation-function 2 domain (A-F2), located close to the C-terminal region of the 
receptor, is an integral component of the ligand binding domain. The binding of 
antagonists to AF-2 stabilises the PPAR into an unliganded state [187]. Conversely, 
agonists alter the structural conformation of AF-2 on binding to this domain, locking 
the receptor into an active conformation, which results in an increased activity of the 
receptor [186]. The mutable linker region D permits the rotation of DBD, connecting 
it the E/F region [178, 185]. 
 
Like other class II nuclear receptors, PPAR-γ are thought to exist as heterodimers 
with retinoid-X-receptors (RXRs) and, as discussed, bind to PPRE within the 
promoter domains of target genes via the DBD [178]. The unliganded PPAR-γ•RXR 
heterodimer is associated with a multiprotein corepressor complex that contains 
histone deacetylase activity. The latter inhibits nucleosome transcriptional activity. 
PPAR-γ receptor ligand binding results in dissociation of the corepressor complex 
and the recruitment of a coactivator complex containing histone acetylase activity. 
This in turn favours chromatin remodelling and active gene transcription [188]. 
PPAR-γ activation favours the differentiation of adipocytes and other cell types and 
the induction of lipogenic enzymes and glucoregulatory proteins. The existence of 
multiple PPAR-γ isoforms and their wide range of distribution may increase the 
diversity of ligands and their tissue-specific transcriptional responses [185]. 
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Figure 1.2 - Structure of the peroxisome proliferator-activated receptor-γ (PPAR-γ) 
(adapted from [189]) 
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                  Figure 1.3 - Schematic diagram of the mechanism of PPAR-γ action (adapted from [190]) 
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1
 Denotes the situation arising in the presence of an unliganded PPAR-γ receptor;  2 Denotes the sequence of events set forth 
following PPAR-γ receptor ligand binding.  
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1.4.2 Physiological consequences of PPAR-γ activation  
 
PPAR-γ activation, as evidenced by PPAR-γ mRNA expression, has been shown to 
play a critical role in adipogenesis and adipocyte differentiation [191, 192]. PPARγ 
interacts with CCAAT/enhancer-binding protein (-alpha, -beta, -delta), setting a 
transcriptional network that plays a central role in adipogenesis [191]. This is 
achieved in a series of steps. Adipogenic hormones, such as insulin and 
dexamethasone, relay signals to CCAAT/enhancer binding protein-beta and -delta. 
In turn, CCAAT/enhancer binding protein-beta and -delta synergistically induce the 
expression of both CCAAT/enhancer binding protein-alpha and PPAR-γ by 
heterodimerizing with each other [193-196]. CCAAT/enhancer binding protein-alpha 
and PPAR-γ subsequently enhance each other [197, 198], turning on a battery of 
genes which are required for the synthesis, uptake and storage of fatty acids and 
increasing the number of adipocytes [199-201]. 
 
Transcription factor PPAR-γ increases insulin sensitivity through a number of 
mechanisms acting in tandem. PPAR-γ favours the selective expression of genes 
encoding for proteins involved in fatty acid uptake in adipose tissue, namely 
adipocyte fatty acid binding protein, acyl-Co A synthase and lipoprotein lipase, 
without affecting their expression in muscle tissue. This adipocyte  free fatty acid 
‘steal phonomenon’ causes a relative depletion of fatty acids in muscle [202, 203]. 
Moreover, PPAR-γ activation favours the retention of fatty acids in tissues through 
activation of fatty acid transporters [fatty acid transporter 1 (FATP1) and CD36], 
phosphoenylpyruvate carboxykinase (PEPCK) and glycerol kinase. PPAR-γ also 
regulates adipocyte hormone gene expression, enhancing the expression of genes 
24 
 
 
encoding for insulin sensitizing adipocytokines such as adiponectin, while repressing 
the expression of genes encoding for adipocytokines implicated in insulin resistance, 
such as leptin, resistin, tumour necrosis factor-α, 11-β hydroxysteroid dehydrogenase 
type-1, interleukin-6 and plasminogen activator inhibitor-1. Additionally, PPAR-γ 
directly enhances adipocyte glucose disposal by inducing glucose transporter-4 
(GLUT-4) and c-Cbl associating protein (CAP), the latter being crucial for GLUT4 
translocation to the cell surface [204]. 
 
1.4.3 Thiazolidinediones and AMPK activation 
 
AMP-activated protein kinase (AMPK), a highly conserved major regulator of 
cellular and whole-body energy homeostasis, is also a target of thiazolidinedione 
action [89]. Thiazolidinediones are reported to activate AMPK via two independent 
mechanisms. Like the biguanides, thiazolidinediones appear to exert their acute 
effects on AMPK by inhibiting complex 1 of the respiratory chain [205], therebye 
explaining the associated drug-induced increase in the cellular AMP:ATP ratio [206, 
207]. Morerover, as outlined above, thiazolidinedione-induced PPAR-γ activation 
induces the expression and release of adiponectin from human and rodent adipocytes 
[208]. Adiponectin in turn activates AMPK in the liver and skeletal muscle, reducing 
hepatic gluconeogenesis, and favouring glucose uptake and fatty acid oxidation 
[209]. Mice lacking adiponectin fail to exhibit thiazolidinedone-induced AMPK 
activation and improvements in glucose tolerance [210].  
 
In conclusion, metformin and thiazolidinediones improve insulin sensitivity through 
multifaceted but complementary approaches: both act as AMPK activators, but 
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metformin predominantly targets hepatic glucose output while thiazolidinediones 
regulate peripheral glucose and fatty acid uptake predominantly in adipose tissue via 
PPAR-γ receptor modulation. In both cases, glucose control is improved with a 
minimal risk of hypoglycaemia. 
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Section II - Heart failure in diabetes, with particular reference to 
thiazolidinedione therapy 
 
1.5 Concurrence of diabetes and heart failure 
 
In recent years, the relationship between HF and diabetes has been increasingly 
recognised and investigated. The American Heart Association classifies diabetes as a 
high risk factor for the development of HF [211]. There is evidence for diabetes 
related effects on HF prevalence, incidence and mortality. It is to be noted that large 
diabetes trials either excluded patients with HF [e.g. UKPDS [212], Non-Insulin 
Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular 
Events, and Ramipril (DIABHYCAR) [213], DCCT [214]] or did not report HF as a 
co-morbidity [e.g. Collaborative Atorvastatin Diabetes Study (CARDS) [215], 
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) [216], 
PROspective pioglitAzone Clinical Trial in macroVascular Events (PROactive) 
[217]]. As for the occurrence of diabetes in HF, figures need to be interpreted with 
caution, given that the strict recruitment criteria for the individual trials exclude 
individuals at higher risk of diabetes (such as older age groups, and renal 
dysfunction). Similarly, it is difficult to extract population-based estimates of the 
incidence of HF in diabetes from large trials such as the UKPDS, which solely 
recruited patients with newly diagnosed diabetes (mean age = 53 years). Given these 
constraints, prevalence and incidence data have been retrieved largely from 
population based studies.  
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1.5.1 Prevalence 
 
Prevalence of heart failure in diabetes: The prevalence of HF in diabetes stands at 
12% [218], increasing to 22% among individuals aged above 64 years [219], 
compared to 1-4% in the general population [218].  
 
Prevalence of diabetes in heart failure: Diabetes was reported as being four times 
more prevalent among patients with newly diagnosed HF [220]. Diabetes occurs in 
12-30% of individuals with symptomatic HF [218, 220-222], and in 33-40% of 
hospital admissions resulting from HF [223-225]. A retrospective analysis of around 
45,000 patients with idiopathic cardiomyopathy confimed similar results, namely 
significantly higher prevalence rates among the diabetic sub-population [26.6% vs 
17.2%, corresponding to a relative odds of 1.58 (95% CI 1.55, 1.62) after adjusting 
for age, sex, hypertension and median income [226]]. Data from other smaller 
epidemiological studies of patients with left ventricular systolic dysfunction (ranging 
from 188 to 3960 patients) reported diabetes prevalence rates of 6-25.5%, although 
there were considerable differences in patient age and in the definition of left 
ventricular systolic dysfunction between studies [227-233]. It is as yet unclear 
whether the prevalence of diabetes in HF varies according to ethnic group [224, 
225]. 
 
1.5.2 Incidence  
 
Incidence of heart failure in diabetes: Diabetes has also been identified as a major 
contributor to the incidence of this cardiac condition. A diagnosis of HF was 2.4 
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times as likely among diabetic men and 5.1 times as likely among diabetic women 
who participated in the Framingham Heart Study (age range 45-74 years). This 
association was independent of age, obesity, hypertension, dyslipidaemia and 
coronary artery disease. The effect was even more pronounced in individuals 
younger than 65 years, where the risk of developing HF was estimated at 4 fold and 
8 fold higher for diabetic men and women respectively [234]. The National Health 
and Nutrition Examination Survey (NHANES) [235] and Cardiovascular Health 
Study [236] reported hazard ratios of 1.85 (95% CI 1.51, 2.28) and 1.74 (95% CI 
1.38, 2.19) respectively for HF development in diabetic patients. In Iceland, the age-
adjusted odds ratio for the development of HF was 2.8 (95% CI 2.2, 3.6) in diabetic 
patients, compared to their non-diabetic counterparts [218]. 
 
A cross-sectional study comparing the incidence of HF between diabetic and non-
diabetic subgroups of 2737 American elderly patients (mean age 81 ± 9 years) 
revealed that HF developed in 39% of diabetic patients compared with 23% of non-
diabetic individuals (p < 0.0001). Relative risk was estimated at 1.3 for the diabetic 
population [237]. A large US cohort study of 115,803 diabetes patients over 64 years 
of age reported 126 cases of incident HF per 1000 patient years [219]. 
 
The United Kingdom Diabetes Prospective Diabetes Study (UKPDS) reported that 
the risk of HF increased with worsening glycaemic control in T2DM patients, such 
that there was a 16% reduction in the risk of HF for every 1% reduction in 
glycosylated haemoglobin (HbA1c) [212]. Conversely, each 1% increase in HbA1c 
was linked to an 8% increase in HF risk (95% CI 5, 12%) in a US study [238]. A 2.5 
unit increase in BMI has been associated with a 12% increase in the risk of HF in 
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diabetic patients [239]. A similar relationship was reported in another study [240]. 
Increasing age [213, 219, 239], use of insulin [239], and duration of diabetes [239] 
have also been identified as risk factors. 
 
Coronary heart disease is a risk factor for HF in diabetes [219, 239, 240]. Morerover, 
diabetic patients are more likely to develop HF following a myocardial infarction 
despite comparable infarct sizes [241]. Diabetic patients with retinopathy have also 
been recognised as being at an increased risk of HF [242]. Subgroup analysis of the 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort showed broadly similar 
findings, namely an association between retinal arteriolar narrowing and left 
ventricular remodelling [243]. Other studies reported proteinuria and albuminuria 
[213, 240, 244], nephropathy [219] and end-stage renal disease [219, 239] as 
additional risk factors for HF in diabetes. Overall, these results support the concept 
of microvascular aetiology for HF in diabetes, or an interaction between large and 
small vessel disease. 
 
Incidence of diabetes in heart failure: Only one non-clinical trial population study 
investigated the development of diabetes among patients diagnosed with HF. The 3 
year incidence of diabetes was 28.8% in elderly Italian patients with HF compared 
with 18.3% in individuals without HF [220].  
 
1.6 Mortality risks associated with heart failure 
 
Diabetes and mortality in patients with heart failure: Diabetes is a recognised 
independent risk factor of death among patients with established HF. This is borne 
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out of the results of a number of studies. However, it is unclear whether this risk 
holds only for individuals in whom HF is caused by a specific aetiology. Analysis of 
clinical trial population data from the Studies of Left Ventricular Dysfunction 
(SOLVD) [245, 246], Beta-blocker Evaluation in Survival Trial (BEST) [247] and 
Digitalis Investigation Group (DIG) [248] studies suggested that mortality risk was 
confined to individuals with HF of ischaemic aetiology, in contrast to a US 
community cohort based study, which reported an association with non-ischaemic 
HF [222]. In contrast, diabetes posed a mortality risk to HF patients of either 
category in the Danish Investigations of Arrhythmia and Mortality ON Dofetilide 
Heart Failure (DIAMOND-HF) [249] and Candesartan in Heart failure Assessment 
of Reduction in Mortality and morbidity (CHARM) [250] clinical trials. Differences 
in study outcomes may be borne out of underdiagnosis of coronary artery disease in 
diabetes and differences in study population characteristics and study design. The 
hazard ratios for death from pump failure in diabetic individuals were reported as 
1.44 (95% CI 1.18, 1.76) and 1.50 (95% CI 1.15, 1.74) in the SOLVD [245, 246] and 
BEST [247] trials respectively. Subgroup analysis of data from the Framingham 
study suggested that the risk of diabetes related mortality was confined to female HF 
patients [251]. The results may have been influenced by the small sample size, and 
may explain why such gender differences were not confirmed in other studies.  
 
Interestingly, a low HbA1c has been identified as a mortality risk factor for HF in 
diabetic patients in one observational study [252]. Analysing for 123 individuals 
with advanced HF, 2 year all-cause mortality rates were significantly higher for 
patients with an HbA1c of 7 or less compared to those with higher values (35% vs 
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20%). These figures need to be interpreted with caution, and probably reflect the 
effects of cachexia, which is inherent to individuals with advanced HF. 
 
Heart failure and mortality in patients with diabetes: Current evidence suggests 
that diabetes patients who develop HF are at an increased risk of mortality.  The 
DIABHYCAR study showed that T2DM  patients who develop HF had a twelve-fold 
higher annual mortality rate compared to diabetic individuals who were not 
diagnosed with HF (36.4% vs 3.2%). This study was carried out in individuals above 
50 years of age and urinary albumin concentrations equalling or exceeding 20mg/L 
[213]. A large US population study recruiting data from diabetic patients aged 65 
years or older reported a five year survival of 12.5% for individuals who developed 
HF, as compared to 80% for those who did not develop this cardiovascular condition 
[219]. 
 
1.7 Thiazolidinediones and oedema          
 
A meta-analysis of 26 prospective, randomised, placebo-controlled or comparative 
studies investigating the incidence of oedema in thiazolidinedione-treated patients 
concluded that the latter are associated with a doubling of risk [pooled OR 2.26 
(95% CI 2.02, 2.53); p < 0.00001]. Oedema rates were approximately three fold 
higher for rosiglitazone-treated patients [pooled OR 2.74 (95% CI 2.33, 3.14)]. Open 
labelled studies reported a higher thiazolidinedione-associated risk [pooled OR 6.74 
(95% CI 3.32, 13.71); p < 0.00001] [253]. However, recruited studies adopted 
different definitions of oedema. Moreover, only two studies used objective methods 
to evaluate this adverse effect, while severity was only reported in three studies. 
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Available data did not permit investigating whether concomitant drugs mitigate or 
exacerbate the risk of fluid overload [253]. 
 
1.8 Thiazolidinediones and heart failure 
 
The clinical benefits and widespread use of thiazolidinediones have been hampered 
by concerns on their cardiovascular safety profile, namely ischaemic heart disease 
(rosiglitazone) and an association with fluid retention/HF. Early clinical 
efficacy/safety (phase II) trials had failed to clearly demonstrate any relationship 
between pioglotazone or rosiglitazone monotherapy and the development of HF, 
although the risk may be increased when the drug is used in combination with 
insulin. On the other hand, four major prospective randomized trials and recent meta-
analyses of data from these and other studies have attested this relationship. 
 
1.8.1 Clinical efficacy/safety trials 
 
The package inserts for rosiglitazone maleate (Avandia®) [254]  and pioglotazone 
hydrochloride (Actos®) [255]  yield useful prescribing advice in this regard. Both 
drugs are deemed contraindicated in individuals with New York Heart Association 
(NYHA) HF classes III and IV. Additionally, the manufacturers do not recommend 
their use in individuals with symptomatic HF. Individuals with NYHA HF classes I 
and II are deemed as being at an increased risk of ‘other cardiovascular effects’ when 
treated with Avandia®. The manufacturers of Actos® recommend that this drug 
should be commenced at the lowest approved dose if contemplated for use in T2DM 
patients with NYHA HF class II. Any further dose escalation, if necessary, should be 
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carried out after ‘several months of treatment’ and ‘careful monitoring for weight 
gain, oedema, or signs and symptoms of CHF exacerbation’. When evaluating 
available data, one must keep in mind that individuals with NYHA HF class III and 
IV were not included in the pre-approval clinical trials. 
 
(i) Unpublished clinical safety trials for pioglitazone hydrochloride (Actos®) 
 
In their package insert [255], the manufacturers of pioglitazone hydrochloride refer 
to a double-blind placebo controlled pre-approval clinical trial involving 566 insulin-
treated T2DM patients followed up for 16 weeks. Participants were randomised to 
pioglitazone at 15mg or 30 mg daily, or placebo, and included individuals with 
arterial hypertension (57.2%), coronary heart disease (19.6%), history of MI (8.8%), 
history of angina pectoris (4.4%), congestive heart failure (2.3%) and stroke and/or 
transient ischemic attack (4.1%). 2 patients on pioglitazone 15mg and 2 of those on 
pioglitazone 30mg developed CHF. Although this adverse event was not reported in 
placebo-treated individuals, it was restricted to individuals with a past history of 
cardiovascular disease.  
 
A 24 week post-marketing study compared the safety profile of pioglitazone (n = 
262) and glyburide (n = 256) in uncontrolled T2DM patients (mean baseline HbA1c 
8.8%) characterised by NYHA class III and IV HF and a baseline ejection fraction 
less than 40% (mean 30%). Overnight hospitalization for HF was increased, reported 
in 9.9% of pioglitazone-treated patients compared to 4.7% of those managed with 
glyburide. Treatment differences were first noted after 6 weeks of therapy. 
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Pioglitazone-associated hospitalization for HF was more common in individuals 
aged over 64 years and those treated with insulin at baseline. 
 
Statistical analyses of the differences between treatment groups are not reported for 
either of the two studies, which are not referenced in the package insert. 
 
(ii) Unpublished clinical safety trials for rosiglitazone maleate (Avandia®) 
 
The package insert for rosiglitazone maleate [254] refers to a 52 week double-blind 
placebo-controlled study carried out in 224 T2DM patients with NYHA class I or II 
HF and a baseline ejection fraction equalling or less than 45%, treated with 
background antidiabetic and CHF therapy. While the investigators reported no 
differences in change in ejection fraction between treatment groups, rosiglitazone-
treated patients were more prone to adverse cardiovascular events (new or worsening 
oedema, new or worsening dyspnoea, increases in CHF medication, cardiovascular 
hospitalization, cardiovascular deaths) compared to their placebo-treated 
counterparts. It is not clear whether this study was carried out in the pre-approval 
phase, and statistical analysis of the differences between treatment groups is not 
reported. This study is not referenced in the package insert.  
 
1.8.2 Prospective randomized trials  
 
Four large-scale randomized prospective trials (tables 1.2 and 1.3) cumulatively 
recruiting over nineteen thousand patients have yielded valuable information on the 
safety profile of thiazolidinediones. They recruited individuals from four very 
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different populations: patients with pre-diabetes (impaired glucose tolerance or 
impaired fasting glucose) and no evidence of cardiovascular disease [Diabetes 
REduction Assessment with ramipril and rosiglitazone Medication (DREAM)] 
[152], pharmacologically naïve T2DM patients [A Diabetes Outcome Progression 
Trial (ADOPT)] [154], T2DM patients (some with previous cardiovascular disease) 
inadequately controlled on a sulphonylurea or metformin [Rosiglitazone Evaluate for 
Cardiovascular outcomes in ORal agent combination therapy for type 2 Diabetes 
(RECORD)] [153], and high risk T2DM patients with established cardiovascular 
disease [PROspective pioglitAzone Clinical Trial in macroVascular Events 
(PROactive)] [256]. Two of these trials compared thiazolidinedione treatment with 
placebo therapy (DREAM, PROactive) [152, 256], while the other two trials 
(ADOPT, RECORD) [153, 154] compared thiazolidinedione therapy with metformin 
and sulphonylureas. Three studies (DREAM, ADOPT, RECORD) randomised 
patients to thiazolidinedone treatment with rosiglitazone [152-154], while the 
PROactive study randomised individuals to pioglitazone [256]. The mean age of the 
patients at recruitment ranged from 54.7 to 61.8 years. Baseline HbA1c was sub-
optimal, ranging from 7.4-7.9 in three [153, 154, 256] out of four [152-154, 256] 
trials (it was not reported in the DREAM trial which recruited patients with pre-
diabetes [152]). The PROactive trial excluded patients with NYHA HF class II or 
above [256]. The DREAM [152], ADOPT [154] and RECORD [153] studies 
excluded any individual with HF at recruitment. 
 
All four trials reported a significant excess of thiazolidinedione-treated patients with 
HF. The DREAM trial [152] defined HF as acute treatment with at least two of the 
following criteria: typical signs and symptoms, typical radiological evidence and the 
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use of diuretics, vasodilators or inotropes. 14 rosiglitazone-treated patients and 2 
placebo-treated patients developed HF during the study [HR 7.03 (95% CI 1.60, 
30.9); p = 0.01). There were no reports of deaths from HF during the study, although 
the investigators reported a death from myocardial infarction in one rosiglitazone-
treated patient who had developed HF. Additionally, 174 (6.8%) of the 2547 
rosiglitazone-treated patients had developed peripheral oedema by the final visit, 
compared to 124 (4.9%) of the 2554 patients randomised to a placebo (p = 0.003). 
The authors also reported a significant mean body weight increase of 2.2 kg in the 
rosiglitazone-treated group compared to placebo (p < 0.0001). While rosiglitazone 
therapy significantly reduced the composite endpoint of incident diabetes or death (p 
< 0.0001), there were no significant differences between treatment groups in 
composite cardiovascular endpoints (comprising myocardial infarction, stroke, 
cardiovascular death, revascularization procedure, HF, new angina with objective 
evidence of ischaemia, ventricular arrhythmias requiring resuscitation), overall 
mortality, myocardial infarction, new angina or stroke between the treatment groups. 
The study did not report information on differences in changes in lipid profile 
between rosiglitazone and placebo-treated groups.  
 
The ADOPT trial [154] sought to investigate differences in outcomes between 
T2DM patients randomised to monotherapy with rosiglitazone (n = 1456), 
metformin (n = 1454) or glyburide (n = 1441). Although the study protocol excluded 
patients with known CHF, retrospective analysis of source data identified this 
diagnosis in 17 study patients at recruitment (5 in the rosiglitazone group, 6 in the 
metformin group and 6 in the glyburide group). Only 1 of these patients, randomised 
to metformin, subsequently developed a HF event during the study. There were no 
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significant differences in the number of patients with HF between the rosiglitazone 
and metformin-treated groups at the end of the study [22 vs 19; HR 1.22 (95% CI 
0.66, 2.26); p = 0.52). Although a greater number of rosiglitazone-treated patients 
developed HF compared to those randomised to glyburide (22 vs 9), the difference 
achieved only borderline statistical significance [HR 2.20 (95% CI 1.01, 4.79); p = 
0.05]. Serious HF events (defined as life threatening, fatal, disabling, requiring 
hospitalization or prolongation of hospital stay, associated with a congenital 
anomaly, cancer or a drug overdose, regarded as such by the investigator or 
suggesting substantial hazard, contraindication, side-effect or precaution) affected 12 
patients in the rosiglitazone-treated group, 12 patients in the metformin-treated group 
and 3 glyburide-treated individuals (p < 0.05 for the comparison between 
rosiglitazone and glyburide-treated patients). A significantly greater number of 
rosiglitazone-treated patients developed peripheral oedema compared to those on 
metformin (205 vs 104; p < 0.001) or glyburide (205 vs 123, p < 0.001). 
Rosiglitazone-treated patients gained 4.8kg (95% CI 4.3, 5.3) in weight compared to 
a reduction of 2.9 kg (95% CI -3.4, -2.3) for metformin-treated patients and an 
increase of 1.6kg (95% CI 1.0, 2.2) for glyburide-treated individuals. At the end of 
the study, rosiglitazone-treated patients were 6.9 kg heavier (95% CI 6.3, 7.4) than 
their metformin-treated counterparts (p < 0.001) and 2.5 kg (95% CI 2.0, 3.1) 
heavier than patients randomised to glyburide (p < 0.001). The study confirmed that 
thiazolidinedione treatment is associated with a lower rate of monotherapy failure at 
5 years (defined as fasting plasma glucose exceeding 10 mmol/L) compared to 
metformin or glyburide (p < 0.001 for both comparisons). Rosiglitazone-treated 
patients achieved significantly greater reductions in their glycated haemoglobin level 
compared to those randomized to metformin [reduction difference of 0.13% (95% CI   
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-0.22, -0.05); p = 0.002] or glyburide [reduction difference of 0.42% (95% CI -0.50, 
-0.33); p < 0.001]. Despite rosiglitazone being associated with higher LDL 
cholesterol levels at the end of the study, compared to metformin [2.69 (95% CI 
2.63, 2.75) vs 2.50 (95% CI 2.44, 2.55) mmol/L; p < 0.001] and glyburide [2.69 
(95% CI 2.63, 2.75) vs 2.57 (95% CI 2.51, 2.64); p = 0.008], this did not translate 
into any significant differences in the number of patients with fatal or nonfatal MI, 
stroke or overall mortality between the treatment groups.  
 
The conclusions borne out of the ADOPT study have been the subject of 
considerable debate. Although the study yielded useful data concerning drug 
associated changes in body weight, oedema and HF, it was primarily designed to 
compare durability of glycaemic control between three treatment groups. Given that 
the investigators only reported outcomes at the end of the study period (48 months 
for metformin and rosiglitazone-treated patients, 39.6 months for glyburide-treated 
patients), it is not possible to compare outcomes after 1, 2 or 3 years. Morerover, 
high dropout rates were reported for the three treatment groups (63% for 
rosiglitazone, 62.1% for metformin, 56% for glyburide), potentially introducing 
hidden biases in reported adverse event rates [257]. Complications such as weight 
gain would be expected to adversely affect drug compliance.  
 
The RECORD trial [153] comprised an unblinded prospective study recruiting 
T2DM patients inadequately controlled on metformin or sulphonylurea 
monotherapy. The investigators compared primary and secondary cardiovascular 
prevention between patients randomised to treatment with rosiglitazone or 
metformin-sulphonylurea combination. By the end of the trial, a significantly greater 
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number of rosiglitazone-treated patients had developed new-onset HF leading to 
hospitalization (undefined in the study) or death compared to their comparator-
treated counterparts [61 vs 29; HR 2.1 (95% CI 1.35, 3.27); p < 0.001]. There were 
10 deaths attributed to HF in the rosiglitazone-treated group and 2 in the 
sulphonylurea/metformin group; these figures were not compared statistically. 
However there was no significant difference in all cause mortality between the 
treatment groups [136 (rosiglitazone) vs 157 (comparator)], as the higher mortality 
from HF was offset by a lower occurrence of death from stroke [0 (rosiglitazone) vs 
5 (comparator)], myocardial infarction [7 (rosiglitazone) vs 10 (comparator)] and 
other cardiovascular causes [43 (rosiglitazone) vs 54 (comparator)]. The authors did 
not report any significant differences in the occurrence of myocardial infarction [64 
(rosiglitazone) vs 56 (comparator)] and stroke [46 (rosiglitazone) vs 63 
(comparator)] between the treatment groups. The authors maintained that the 
excessive mortality from HF for rosiglitazone-treated patients was compatible with 
the increased occurrence of HF seen in this treatment group, and that the excess 
relative risk of HF for these patients was similar for individuals with and without 
ischaemic heart disease. Metformin-treated patients randomised to additional 
treatment with rosiglitazone gained more weight compared those treated with adjunct 
sulphonylurea (+3.8 vs 0.0 kg; p < 0.0001). Sulphonylurea-treated patients 
randomized to adjunct rosiglitazone gained more weight than those randomised to 
additional treatment with metformin (+4.1 vs -1.5 kg; p < 0.0001). 
 
A follow-up paper focussing on occurrence of HF events in RECORD [258] reported 
that the mean duration (± SD) of admission for HF in the rosiglitazone group [69 
events, 10.5 (± 6.6) days] was similar to that for the active control group [36 events, 
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9.6 (± 5.3) days]. Despite more incident HF events in the rosiglitazone group than in 
the active control group [61 (rosiglitazone) vs 29 (active control); HR 2.10 (95% CI 
1.35, 3.27); p < 0.001], recurrent HF events were similar in both treatment groups 
[12 (rosiglitazone) vs 6 (active control)]. The estimated excess event rate for HF was 
2.6 (95% CI 1.1, 4.1) per 1000 person-years. Of the ten deaths complicating HF in 
the rosiglitazone group, four were incident HF events while six deaths occurred 
following a recurrent HF episode. There were no fatal incident HF events in the 
control group, while two deaths complicated a recurrent HF episode. 17 (30%) of the 
57 rosiglitazone-treated patients who survived a first HF event subsequently died, 
compared with 8 (28%) of patients in the active control group. Thiazolidinedone 
treatment was associated with a similar relative risk increase but a doubled absolute 
risk for HF events in patients with a history of ischaemic heart disease (IHD) 
compared with their IHD  free counterparts [4.4% of rosiglitazone-treated patients 
with prior IHD vs 2.4% of rosiglitazone-treated patients without prior IHD; RR 2.16 
(95% CI 0.94, 4.94) for patients with prior IHD vs RR 2.10 (95% CI 1.25, 3.51) for 
patients without prior IHD]. Rosiglitazone assignment [HR 2.34 (95% CI 1.47,  
3.72) vs control], age [1.10 (95% CI 1.07, 1.13) per one-year increase], BMI [HR 
1.11 (95% CI 1.06, 1.15) per 1kg/m2 increase], systolic blood pressure at baseline 
[HR 2.74 (95% CI 1.40, 5.36) for baseline antihypertensive therapy vs no therapy; 
HR 1.66 (95% CI 1.06, 2.62) for uncontrolled hypertension vs no uncontrolled 
hypertension] and urinary albumin:creatinine ratio [HR 2.95 (95% CI 1.90, 2.47) for 
microalbuminuria/proteinuria vs normoalbuminuria] were independent predictors of 
HF events. A history of previous cardiovascular disease, gender and duration of 
diabetes were not predictive of HF in this cohort [258].   
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Although RECORD remains the only large, randomised, long-term trial assessing the 
cardiovascular safety of rosiglitazone compared to other glucose lowering agents in 
T2DM, its results have been questioned on account of certain built-in limitations, 
namely its open-labelled design, its relatively small size (for a cardiovascular trial) 
and the choice of primary endpoint. Importantly, the provision for investigator 
option in referring potential events for adjudication and the publication of an 
unplanned interim analysis of its results [259] triggered by the publication of meta-
analyses questioning the cardiovascular safety of thiazolidinediones may have 
inherently biased the cardiovascular outcome results of RECORD. These 
observations led the FDA to request a re-analysis of RECORD data in a bid to clarify 
these conflicting conclusions [158]. Including an additional 328 patient-years of 
follow-up, RECORD investigators confirmed initial findings [revised HR for 
rosiglitazone vs metformin/sulphonylurea for the composite endpoint of death 
(cardiovascular/unknown cause), myocardial infarction or stroke being 0.95 (95% CI 
0.78, 1.17) vs 0.93 (95% CI 0.74, 1.15) in the original analysis; revised HR for 
myocardial infarction 1.13 (95% CI 0.80, 1.59) vs 1.14 (0.80, 1.63); revised HR for 
stroke 0.79 (95% CI 0.54, 1.14) vs 0.72 (95% CI 0.49, 1.06); unchanged for all-cause 
death]. This re-analysis made no reference to HF events or oedema [260].  
 
The PROactive study [256] randomized high risk T2DM patients with a background 
of macrovascular disease to additional treatment with pioglitazone or placebo for a 
mean duration of 34.5 months. Despite an unfavourable effect on LDL cholesterol 
[+7.2% over baseline (pioglitazone) vs +4.9% over baseline (placebo); p = 0.003], 
pioglitazone was shown to reduce the composite endpoint of all-cause mortality, 
non-fatal myocardial infarction and stroke in high risk T2DM patients [301 
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(pioglitazone) vs 358 (placebo) HR 0.84 (95% CI 0.72, 0.98); p = 0.02] [256]. The 
investigators reported that a HF event (defined as evidence of ventricular 
dysfunction e.g. electrocardiogram (ECG), echocardiogram or auscultation, 
accompanied by signs or symptoms of HF) occurred in 10.8% of pioglitazone-treated 
patients compared with 7.5% of those randomized to a placebo (p<0.0001). 
Although pioglitazone therapy was associated with a significantly increased risk of a 
serious HF event, (defined as HF leading to or prolonging a hospitalisation stay) 
[149 (5.7%) (pioglitazone) vs 108 (4.1%) (placebo); HR 1.41 (95% CI 1.10, 1.80); p 
= 0.007], mortality rates from HF were comparable to placebo-treated patients [25 
(0.96%) (pioglitazone) vs 22 (0.84%) (placebo); HR 1.15 (95% CI 0.65, 2.03); p = 
0.639] [256]. Further analyzing data from patients with a serious HF event, a follow-
up paper reported that subsequent all-cause mortality was proportionately lower with 
pioglitazone, although the difference did not reach statistical significance [40 
(26.8%) (pioglitazone) vs 37 (34.3%) (placebo); HR 0.71 (95% CI 0.454, 1.111); p = 
0.1338] [261]. Significantly fewer such patients subsequently developed an event in 
the secondary endpoint, comprising a composite of all-cause mortality, non-fatal 
myocardial infarction and stroke [52 of 149 (34.9%) (pioglitazone) vs 51 of 108 
(47.2%) (placebo); HR 0.64 (95% CI 0.436, 0.946); p = 0.025] [261]. Although 
fewer pioglitazone-treated patients who had developed a serious HF event went on to 
develop an event in the primary endpoint (composite of all-cause mortality, non-fatal 
myocardial infarction [including silent myocardial infarction], stroke, acute coronary 
syndrome, endovascular or surgical intervention in the coronary or leg arteries, and 
amputation above the ankle), the difference did not reach statistical significance [71 
of 149 (47.7%) (pioglitazone) vs 62 of 108 (57.4%) (placebo); HR 0.72 (95% CI 
0.512, 1.013); p = 0.0593] [261]. Analyzing data from individuals who developed 
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serious HF, there were no significant differences between the treatment groups in the 
median number of days spent in hospital (11 days in each treatment group) and in the 
median number of days spent in intensive care/high dependency unit [4 days 
(pioglitazone) vs 3 (placebo); p = 0.584] [261]. Most serious HF events resolved in 
either group [77.9% (pioglitazone) vs 74.1% (placebo); p = 0.4822]. 22.8% of 
pioglitazone-treated patients and 15.7% of placebo-treated patients had a serious HF 
event that resulted in discontinuation from the study; this difference did not reach 
statistical significance (p = 0.1602) [261]. Significant predictors of a serious HF 
event on multivariate analysis were randomisation to pioglitazone [HR 1.53 (95% CI 
1.183, 1.979)], age in years [HR 1.07 (95% CI 1.044, 1.087)], BMI [HR 1.03 (95% 
CI 1.007, 1.061)], HbA1c of/exceeding 7.5% [HR 1.43 (95% CI 1.078, 1.895)], 
diabetes duration of/exceeding 10 years vs less than 5 years [HR 1.53 (95% CI 
1.107, 2.115)], creatinine > 130 μmol/L [HR 2.7 (95% CI 1.796, 4.061)], diuretic use 
[HR 2.10 (95% CI 1.62, 2.732)], LDL cholesterol > 4 mmol/L vs < 3mmol/L [HR 
1.74 (95% CI 1.245, 2.442)], and previous myocardial infarction [HR 1.70 (95% CI 
1.317, 2.205)] [261]. Despite its usefulness, HF data from the PROactive trial need 
to be interpreted with caution given the occurrence of potentially confounding 
baseline differences between pioglitazone and placebo patients who developed 
serious HF, namely higher baseline prevalence rates for percutaneous coronary 
intervention/coronary artery bypass graft and transient ischaemic attacks. Such 
patients were also characterized by a higher baseline systolic blood pressure (data 
not shown) [261] – the latter having been reported as a predictor of HF events 
complicating rosiglitazone therapy in the RECORD trial [262] Moreover, a higher 
proportion of pioglitazone-treated patients who went on to develop serious HF had 
been receiving nonsteroidal anti-inflammatory drugs [12% (pioglitazone) vs 1% 
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(placebo)] and loop diuretics [40% (pioglitazone) vs 30% (placebo)] at baseline, 
albeit the reverse was true for baseline insulin therapy [36% (pioglitazone) vs 44% 
(placebo)] [261].  Pioglitazone therapy was associated with significantly higher risk 
for a non-serious HF event [6.4% (pioglitazone) vs 4.3% (placebo); p = 0.0007], 
although a similar proportion of such patients progressed to a serious HF event [21 
(pioglitazone) vs 20 (placebo)]. In keeping with the results of other studies, Erdmann 
et al. reported significant differences in change in weight between the treatment 
groups at the end of the study [+3.6 kg (pioglitazone) vs -0.4 kg (placebo); 
p<0.0001]. Peripheral oedema occurring in the absence of HF occurred more 
commonly in pioglitazone-treated patients [563 (21.6%) (pioglitazone) vs 341 
(13.0%) (placebo); p < 0.0001] [261]. Oedema was more likely to precede a serious 
HF event in pioglitazone-treated patients [51 out of 149 (34.2%) (pioglitazone) vs 26 
out of 108 (24.1%) (placebo)]; this difference was not statistically compared between 
allocation groups [261].  
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Table 1.2 - The four major prospective thiazolidinedione trials: study design and baseline characteristics of participants 
 
Study  
 
Year 
 
Design 
 
Blinding of  
investigator 
(patients) 
 
Diabetes 
status and 
treatment 
 
Baseline 
macrovascul
ar disease 
(%) 
 
 
Number of 
patients 
randomised 
(completed) 
 
 
TZD (daily 
dose in mg) 
 
Comparator 
(daily dose 
in mg) 
 
Duration in 
months (or 
as stated) 
 
Mean age at 
recruitment  
(years) 
 
 
Baseline 
anthropomet
ry 
 
Baseline 
HbA1c (%) 
 
DREAM 
 
 
 
 
 
ADOPT 
 
 
 
 
 
RECORD 
 
 
 
 
 
 
PROactive 
 
2006 
 
 
 
 
 
2006 
 
 
 
 
 
2009 
 
 
 
 
 
 
2005 
 
Prospective 
randomized 
 
Intention to 
treat analysis 
 
Prospective 
randomized  
 
Intention to 
treat analyses 
 
Prospective 
randomized  
 
Intention to 
treat analysis 
 
 
Prospective  
Randomized 
 
Intention to 
treat analysis 
 
Yes  
(Yes)  
 
 
 
 
Yes 
(Yes) 
 
 
 
 
No 
(No) 
 
 
 
 
 
Yes 
(Yes) 
 
Pre-diabetes 
(IFG or IGT) 
 
 
 
 
Pharmacolog
ically naive 
T2DM 
 
 
 
T2DM 
inadequately 
controlled 
with SU or 
MF 
monotherapy 
 
T2DM 
treated with 
diet or OHAs 
or insulin 
 
No evidence 
 
 
 
 
 
b ¶ 
 
 
 
 
 
IHD: 17.4 
Stroke: 2.4 
TIA: 2.2 
PAD: 4.9 
 
 
 
All patients 
 
 
 
 
 
 
Rosi: 2635 
(1863) 
PL: 2634 
(1976) 
 
 
Rosi 1456 (917) 
MTF 1454 (903) 
Glyb 1441 (807) 
 
 
 
Rosi: 2220 
(1835) 
Comp: 2227 
(1798) 
 
 
 
Pio: 2605 (2427) 
PL: 2633 
(2446) 
 
 
Rosi (8) 
forced 
titration 
 
 
 
Rosi (4-8) 
 
 
 
 
 
Rosi (4-8) 
 
 
 
 
 
 
Pio (15-45) 
 
PL 
 
 
 
 
 
MTF (500-
2000) or 
glyb (2.5-
7.5) 
 
 
MTF (2550) 
or Glib (15) 
/glic(240)/gli
m (4) 
 
 
 
PL  
 
36 
 
 
 
 
 
Rosi:48 
MTF:48 
Glyb: 39.6 
 
 
 
66 
 
 
 
 
 
 
34.5 
 
54.7 
 
 
 
 
 
56.9 
 
 
 
 
 
58.4 
 
 
 
 
 
 
61.8  
 
Wt  
84.9 kg 
 
BMI 
30.9 kg/m2 
 
Wt 
91.7kg 
 
BMI 
32.2kg/m2 
 
Wt 
89.0 kg 
 
 
 
 
 
BMI 
30.9 kg/m2 
 
a 
 
 
 
 
 
7.4 
 
 
 
 
 
7.9 
 
 
 
 
 
 
7.9 
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Table 1.3 - The four major prospective thiazolidinedione trials: study outcomes 
 
Study  
 
Year 
 
Primary endpoint 
 
Effect on primary 
endpoint 
 
Vascular secondary endpoint(s) 
 
Effect on 
secondary 
endpoint 
 
 
Effect on HF 
 
 
Effect on HF 
mortality 
 
Peripheral 
oedema  
 
Effect on 
weight (kg) 
 
DREAM 
 
 
 
 
 
ADOPT 
 
 
 
 
 
 
 
 
 
RECORD 
 
 
 
 
 
 
 
 
 
 
PROactive 
 
 
 
2006 
 
 
 
 
 
2006 
 
 
 
 
 
 
 
 
 
2009 
 
 
 
 
 
 
 
 
 
 
2005 
 
Composite of incident 
diabetes or death 
 
 
 
 
Monotherapy failure at 5 
years (FPG>10 mmol/L) 
 
 
 
 
 
 
 
 
Cardiovascular 
hospitalisation or 
cardiovascular death 
 
 
 
 
 
 
 
 
Composite of all-cause 
mortality, non-fatal MI, 
ACS, stroke, 
leg/coronary 
endovascular/surgical 
intervention, 
above ankle amputation 
 
 
306 (Rosi) vs 686 
(PL) § 
HR 0.40 
(0.35-0.46) 
(p<0.0001) 
 
15% (Rosi) vs 
21% (MTF) § 
(p<0.001); 
15% (Rosi) vs 
63% (Glyb) § 
(p<0.001) 
 
 
 
 
321 (Rosi) vs 323 
(Comp) § 
HR 0.99 (0.85-
1.16) 
(p = 0.93) 
 
 
 
 
 
 
514 (Pio) vs 572 
(PL) § 
HR 0.90 (0.8-1.02) 
(p  = 0.095) 
 
 
Composite CVS events (MI, 
stroke, CVS death, revasc proc, 
HF, new angina with objective 
ischaemia evidence, vent 
arrhythmia requiring resusc 
 
c 
 
 
 
 
 
 
 
 
 
Composite of cardiovascular 
death, MI and stroke 
 
 
 
 
 
 
 
 
 
Composite of all-cause mortality, 
non-fatal MI (excluding silent 
MI) or stroke 
 
75 (Rosi) vs 55 
(PL) § 
 HR 1.37 (0.97-
1.94) 
(p= 0.08) 
 
c 
 
 
 
 
 
 
 
 
 
154 (Rosi) vs 
165 (Comp) § 
HR 0.93 
(0.74-1.15) 
(p = 0.50) 
 
 
 
 
 
 
301 (Pio) vs 358 
(PL) §  
HR 0.84 (0.72-
0.98) 
(p = 0.027) 
 
 
14 (Rosi) vs  
2 (PL)  
HR 7.03 
(1.60-30.9) 
(p=0.01) 
 
22 (Rosi) vs 19 
(MTF) §  
HR 1.22 (0.66-
1.26) 
(p = 0.52) ; 
22 (Rosi) vs 9 
(Glyb) § HR 2.20 
(1.01-4.79) 
(p=0.05) 
 
61 (Rosi) vs 29 
(Comp) § 
HR 2.1 (1.35-3.27) 
(p= 0.001) 
 
 
 
 
 
 
 
281 (Pio) vs 198 
(PL) § (p<0.0001) 
Admissions 
149 (Pio) vs 108 
(PL) § (p = 0.007) 
 
None reported 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All cause 
136 (Rosi) vs 
157 (Comp) § 
(p = 0.19) 
 
Fatal HF 
10 (Rosi) vs 2 
(Comp) b 
 
 
 
Fatal HF 
25 (Pio) vs 22 
(PL) § 
(p=0.634) 
 
174 (Rosi) vs 
124 (PL) §  
(p = 0.003) 
 
 
 
205 (Rosi) vs 
104 (MTF) §  
(p < 0.001); 
205 (Rosi) vs 
123 (Glyb)§ 
(p<0.001) 
 
 
 
 
a 
 
 
 
 
 
 
 
 
 
 
In the absence 
of HF 
562 (Pio) vs 341 
(PL) § b 
 
Rosi increased 
wt by 2.2kg 
compared to PL 
(p<0.0001) 
 
 
Rosi vs MTF 
6.9 (6.3-7.4) 
(p<0.001) 
 
Rosi vs Glyb 
2.5 (2.0-3.1) 
(p<0.001) 
 
 
 
Background 
MTF +3.8 
(Rosi) vs 0.0 
(SU) 
(p<0.0001) 
 
Background SU 
+4.1 (Rosi) vs -
1.5 (MTF) 
(p<0.0001) 
 
+3.6 (Pio) vs  
-0.4 (PL) 
(p<0.0001) 
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Table 1.3 continued  - The four major prospective thiazolidinedione trials - study outcomes. 
 
Author 
 
Year 
 
Effect on IHD 
 
Effect on IHD 
mortality 
 
 
Effect on stroke 
 
Effect on stroke 
mortality 
 
Overall effect on 
mortality 
 
Effect on HbA1c 
 
Effect on LDL 
(mmol/L) 
 
DREAM 
 
 
 
 
 
 
 
ADOPT 
 
 
 
 
 
 
 
 
RECORD 
 
 
 
 
 
 
 
 
 
 
 
PROactive 
 
 
 
2006 
 
 
 
 
 
 
 
2006 
 
 
 
 
 
 
 
 
2009 
 
 
 
 
 
 
 
 
 
 
 
2005 
 
MI 15 (Rosi) vs 9 (PL) § 
HR 1.66 (0.73-3.80) (p-
0.2) 
 
New angina 24(Rosi) vs 
20 (PL) § HR 1.20 (0.66-
2.17)(p=0.5) 
 
Nonfatal MI  
25 (Rosi) vs 21(MTF) § 
(p = NS) 
25(Rosi) vs 15 (Glyb) § 
(p = NS) 
 
 
 
 
MI 
64 (Rosi) vs 56 (Comp) § 
HR 1.14 (0.80-1.63) 
(p= 0.47) 
 
 
 
 
 
 
 
Non-fatal MI (excluding 
silent MI) 119 (Pio) vs 
144 (PL) § HR 0.83 
(0.65-1.06) b 
 
 
a 
 
 
 
 
 
 
 
Fatal MI 
2 (Rosi) vs 2 (MTF) § 
(p = NS) 
2 (Rosi) vs 3 (Glyb) § 
(p = NS) 
 
 
 
 
7 (Rosi) vs 10 (Comp) 
§ b 
 
 
 
 
 
 
 
 
 
 
a 
 
7 (Rosi) vs 5 (PL) § 
HR 1.39 (0.44-4.40) 
(p=0.6) 
 
 
 
 
 
16 (Rosi) vs 19 (MTF) 
§ (p= NS) 
16 (Rosi) vs 17 (Glyb) 
§ (p= NS) 
 
 
 
 
 
46 (Rosi) vs 63 
(Comp) § 
HR 0.72 (0.49-1.06) 
(p=0.10) 
 
 
 
 
 
 
 
 
86 (Pio) vs 107 (PL) § 
HR 0.81 (0.61-1.07) b 
 
a 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
 
0 (Rosi) vs 5 (Comp) 
§ b 
 
 
 
 
 
 
 
 
 
 
a 
 
30 (Rosi) vs 33 (PL) § 
HR 0.91 (0.55-1.49) (p 
= 0.7) 
 
 
 
 
 
34 (Rosi) vs 31 (MTF) 
§ (p = NS) 
34 (Rosi) vs 31 (Glyb) 
§ (p = NS) 
 
 
 
 
 
Overall death 
136 (Rosi) vs 157 
(Comp) § 
HR 0.86 (0.68-1.08) 
(p= 0.19) 
 
Cardiovascular death 
60 (Rosi) vs 71 
(Comp) § 
HR 0.84 (0.59-1.18) 
(p = 0.32) 
 
177 (Pio) vs 186 (PL)  
HR 0.96  
(0.78-1.18) b 
 
a 
 
 
 
 
 
 
 
Rosi vs MTF -0.13 (-
0.22 to -0.05) ( p = 
0.002);  
Rosi vs Glyb -0.42 (-
0.50 to -0.33) 
(p<0.001) 
 
 
 
Background MTF  
-0.28 (Rosi) vs +0.01 
(SU) (p<0.0001) 
 
Background SU  
-0.44 (Rosi) vs 
-0.18 (MTF) 
(p<0.0001) 
 
 
 
 
- 0.8 (Pio) vs  
- 0.3 (PL) 
(p<0.0001) 
 
a 
 
 
 
 
 
 
 
2.69 (2.63 to 2.75) 
(Rosi) vs 2.50 (2.44 to 
2.55)(MTF) (p <0.001) 
2.69 (2.63 to 
2.75)(Rosi) vs 2.57 
(2.51 to 2.64)(MTF) 
(p=0.008) 
 
 
Background MTF  
-0.33 (Rosi) vs -0.5 
(SU) (p=0.0001) 
 
Background SU 
 -0.22 (Rosi) vs 
-0.53 (MTF) 
(p<0.0001) 
 
 
 
 
+7.2% over baseline 
(Pio) vs +4.9% over 
baseline (PL) 
(p=0.003) 
 
 
Comp, comparator; Glib, glibenclamide; glic, gliclazide; glim, glimepiride; glyb, glyburide;  MTF, metformin; Pio, piogliotazone; PL, placebo; a, data unavailable; b, not compared statistically; c , not applicable;  
§figures expressed in terms of number of affected patients; ¶Patients with unstable/ severe angina, HF, uncontrolled HT were excluded from this study. 
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1.8.3 Meta-analyses and retrospective case control studies 
 
A number of meta-analyses and retrospective studies have sought to explore the 
relationship between thiazolidinediones and cardiovascular disease (table 1.4). 
Generally speaking, these studies have confirmed the association of 
thiazolidinediones with HF.  
 
A meta-analysis of data from 20191 patients recruited into 19 randomised controlled 
double blind studies analyzed congestive heart failure and cardiovascular mortality 
outcomes for rosiglitazone-treated (5 trials) and pioglitazone-treated (2 trials) 
patients [263].  Comparing with controls, thiazolidinedione-treated patients were at 
an increased risk of HF [2.3% vs 1.4%; RR 1.72 (95% CI 1.21, 2.42); p < 0.002]. 
There were no significant differences in cardiovascular mortality between treatment 
groups. Lago et al. did not report data for oedema and weight [263]. 
 
In a meta-analysis of 19 studies involving 16390 patients randomised to treatment 
with pioglitazone or placebo/active comparator, Lincoff et al. reported significantly 
higher rates of serious HF for pioglitazone-treated patients [2.34% vs 1.77%; HR 
1.41 (95% CI 1.14, 1.76); p = 0.002] [264]. However, pioglitazone therapy conferred 
a significant reduction in the composite endpoint of death, myocardial infarction and 
stroke compared to a placebo/active comparator [4.4 % (pioglitazone) vs 5.7% 
(placebo/active comparator); HR 0.82 (95% CI 0.72, 0.94); p = 0.005], despite the 
absence of a similar relationship for each individual outcome [264]. An earlier 
Cochrane review of the safety profile of pioglitazone did not yield any meta-analysis 
of HF related data [265]. Analyzing randomized controlled trials lasting at least 24 
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weeks, the authors could only retrieve suitable data from the PROactive study, the 
results of which have been discussed earlier. However, the authors pointed out that 
data from the recruited studies showed that pioglitazone therapy was associated with 
a weight increase of up to 3.9 kg and a BMI rise of up to 1.5 kg/m2. Moreover, 
pioglitazone was reported to increase the risk of significant oedema almost threefold 
[RR 2.86 (95% CI 2.14, 3.18); p < 0.00001] [265].  
 
A meta-analysis by Clar et al. compared glycaemic control, hypoglycaemia, weight 
change, lipids and adverse events for studies recruiting patients randomized to 
treatment with insulin with/out adjunct pioglitazone [266]. Although adjunct 
pioglitazone therapy was again associated with a greater increase in body weight (1.4 
to 4.4 kg for adjunct pioglitazone vs -0.04 to +4.9 kg for insulin-only groups), there 
was insufficient data for a formal meta-analysis of this relationship. Similarly, the 
investigators reported that mild to moderate oedema seemed to be more commonly 
reported for pioglitazone-treated patients, although p values were rarely reported 
[266]. Formal reports of HF were sparse, largely reflecting the fact that most studies 
were not sufficiently powered to investigate cardiovascular adverse outcomes. The 
authors were however able to conclude that adjunct pioglitazone therapy afforded 
beneficial effects on glycaemic control [a mean HbA1c reduction of 0.58% (95% CI 
-0.70, -0.46); p < 0.001] albeit at the expense of a greater risk of hypoglycaemia [RR 
1.40 (95% CI 1.14, 1.73); p < 0.002] [266].  
 
Both Singh et al. [149] and Richter et al. [267] analyzed data for rosiglitazone-
treated patients. Focussing on randomized controlled studies of at least 24 weeks 
duration, the latter reported a rosiglitazone-associated increased risk of oedema [OR 
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2.27 (95% CI 1.83, 2.81); p < 0.001] [267]. Given that this meta-analysis showed 
moderate heterogeneity, the authors carried out a sensitivity analysis excluding the 
largest study at the time (ADOPT [154]); this reported that rosiglitazone therapy is 
associated with an OR for oedema of 6.04 (95% CI 3.31, 11.2) (p < 0.00001) [267]. 
Richter et al. also reported that rosiglitazone therapy was associated with a body 
weight increase of up to 5 kg in 11 studies and a BMI increase of up to 1.5 kg/m2 in 
four studies [267]. The authors concluded that only the ADOPT study [154] yielded 
sufficient data for HF, diabetes-related outcomes, and overall mortality [267]. This 
contrasts with the approach taken by Singh et al. [149]. Analyzing data from 
randomized controlled studies which included at least 12 months of rosiglitazone 
therapy follow-up, the authors concluded that rosiglitazone therapy is associated 
with an increased risk of HF [1.59% of rosiglitazone-treated patients vs 0.79% of 
control-treated patients; RR 2.09 (95% CI 1.52, 2.88); p < 0.001] and myocardial 
infarction [1.46% of rosiglitazone-treated patients vs 1.05% of control-treated 
patients; RR 1.42 (95% CI 1.06, 1.91); p = 0.02]. The meta-analysis additionally 
reported no difference in cardiovascular mortality between rosiglitazone and control-
treated patients [149]; the latter result generally agrees with that reported by the two 
largest prospective rosiglitazone studies to date (ADOPT [154] and RECORD[153]). 
 
Despite their undisputed relevance in secondary medical research, meta-analyses 
need to be interpreted with caution, particularly as the resulting data are bound to 
guide patient management. An interesting study by Friedrich et al. showed that 
different methodological approaches to the rosiglitazone cardiovascular safety 
related meta-analyses can yield increased or decreased risks that are statistically 
significant or not significant at the p = 0.05 level [268]. An editorial by Farkouh and 
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Fouster maintained that p values hovering around 0.05 should be regarded with 
extreme caution. Indeed, some experts believe that values of 0.01 or lower should be 
adopted [269]. It is widely accepted that the reliability of a meta-analysis is linked to 
the overall number of events accrued. This is particularly of relevance when the 
meta-analysis includes data from predominantly small studies, as is the case with a 
considerable number of thiazolidinedione-related studies. In conclusion, while meta-
analysis generates valuable information related to the direction of treatment effects, 
the mainstay of evidence based medicine relies on the outcomes of large, sufficiently 
powered, well-designed, randomized controlled studies [269]. 
 
In a retrospective nested case control analysis of patients on a health care database in 
Ontario (Canada), Lipscombe et al. studied the association between 
thiazolidinedione therapy and congestive HF, myocardial infarction and mortality 
among T2DM patients aged 66 years or older, by comparing outcomes with similarly 
aged individuals on other oral hypoglycaemic agents [270]. Analyzing emergency 
department visit and hospital admission data, the authors concluded that treatment 
with thiazolidinediones was associated with increased risk of HF, and that the risk 
was higher for those on monotherapy [adjusted RR 1.60 (95% CI 1.21, 2.10); p < 
0.001] than those on combination therapy (ie thiazolodinediones combined with 
other oral hypoglycaemic agents) [adjusted RR 1.31 (95% CI 1.17, 1.47);  p < 
0.001]. Although the authors suggested that the increased risk was limited to patients 
treated with rosiglitazone, both as monotherapy [adjusted RR 1.98  (95% CI 1.44, 
2.72); p < 0.001] or as part of combination therapy [adjusted RR 1.43 (95% CI 1.25, 
1.63);  p < 0.001],  they indicated that their study may have been not sufficiently 
powered to identify a similar association for pioglitazone-treated individuals. Past 
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thiazolidinedione use was also associated with an increased risk of HF [adjusted RR 
for rosiglitazone 1.87 (95% CI 1.53, 2.28); p < 0.001]; the authors ascribed this to 
residual effects of the drug or to discontinuation in individuals with a past history of 
HF. While thiazolidinedione monotherapy was also associated with an increased risk 
of acute myocardial infarction [adjusted RR 1.40 (95% CI 1.05, 1.86), p = 0.02] and 
death [adjusted RR 1.29 (95% CI 1.02, 1.62); p = 0.03], combination therapy was 
only associated with an increased risk of the latter [adjusted RR 1.24 (95% CI 1.11, 
1.39);  p < 0.001]. As for the risk of HF, these associations were restricted to 
rosiglitazone-treated individuals.  
 
In a retrospective cohort study of 91251 diabetes patients, Tzoulaki et al. analyzed 
the association of oral anthyperglycaemic pharmacotherapy with incident myocardial 
infarction (n = 3588), incident congestive HF (n = 6900) and death (n = 18548) 
[271]. Individually, rosiglitazone monotherapy, rosiglitazone combination therapy 
and pioglitazone therapy (monotherapy + combination therapy) did not show any 
significant association with incident myocardial infarction when compared with 
metformin.monotherapy, irrespective of the Cox regression model used. Neither 
thiazolidinedione was associated with a significantly increased risk of incident HF in 
the fully adjusted model, irrespective of its use as monotherapy or combination 
therapy. Pioglitazone therapy (alone + combined) was associated with a reduced risk 
of all cause mortality compared with metformin [HR 0.69 (95% CI 0.49, 0.98); p = 
0.024] in the fully adjusted model. The authors compared the cardiovascular risks of 
the two thiazolidinedione drugs, reporting no significant risk differences for 
myocardial infarction (albeit a trend towards a higher risk with rosiglitazone). 
Although Tzoulaki et al. suggest that rosiglitazone is associated with a higher risk of 
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all-cause mortality, the reported 95% confidence intervals (CI) span unity in the fully 
adjusted model [HR 1.34 (95% CI 0.90, 1.97)] [271], rendering the conclusion 
dubious. While the overall results are reassuring, the thiazolidinedione-related data 
borne out of this retrospective study must be interpreted with caution – indeed the 
authors acknowledge the possibility of false negative results owing to a marked 
reduction in sample size in the fully adjusted model, such that each 
thiazolidinedione-associated statistical outcome was based on the analysis of less 
than 90 incident cases. 
 
A retrospective analysis of electronic health data from a cohort of 20450 T2DM 
patients reported no differences in risk of CHF (defined via ICD-9 code and/or a 
post-baseline left ventricular ejection fraction <40%) between initial rosiglitazone 
monotherapy and initial metformin monotherapy, while suggesting an increased risk 
with initial pioglitazone monotherapy [HR 1.38 (95% CI 1.0, 1.90); p = 0.05] [272]. 
The former finding is consistent with the results of ADOPT [154]. There was no 
difference in CHF risk between initial rosiglitazone therapy and initial sulphonylurea 
therapy. Similarly, Pantalone et al. did not report differences between initial 
pioglitazone monotherapy and initial sulphonylurea therapy [272]. The equivalence 
of CHF risk for initial rosiglitazone and sulphonylurea monotherapy contrast with 
those reported in ADOPT [154]. Moreover, Pantalone et al. reported that initial 
metformin monotherapy was associated with a 24% reduction in the risk of CHF 
compared with initial sulphonylurea monotherapy [HR 0.76 (95% CI 0.64, 0.91); p = 
0.003] [272]. 
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Another retrospective cohort study sought to investigate the incidence of CHF 
among male T2DM patients seen in the South Central U.S. Veterans Administration 
health care network between 1st October 1996 and 31st December 2004 (n = 3956) 
[273]. Bivariate analysis showed that the risk of CHF was increased by a history of 
peripheral vascular disease (p < 0.0001) and higher levels of BMI (p < 0.0001), 
HbA1c (p < 0.0001), low-density lipoprotein (p = 0.0002), triglycerides (p < 0.0001) 
and systolic blood pressure (p < 0.0001). Prescription of a higher total number of 
glucose lowering agents (p < 0.0001), prescription of metformin (p<0.0001), 
exposure to HMG-CoA reductase inhibitors (p < 0.0001) and (surprisingly) 
treatment with thiazolidinediones (p < 0.0001) was associated with a lower risk of 
incident CHF. After adjustment for multiple cardiac risk factors, prescription of 
thiazolidinediones remained a lower risk factor for incident CHF [HR 0.69 (95% CI 
0.60, 0.79)] [273]. In addition to the limitations imposed by a retrospective design in 
which treatment assignment was neither random nor blinded, the investigators 
acknowledged that the results of this study may have been influenced by prescribing 
practice, such that thiazolidinedione exposure was limited among patients perceived 
to be at an increased risk of HF. Additionally, Toprani et al. had no access to data 
showing duration of diabetes, length of treatment with thiazolidinediones and the 
reason for drug withdrawal. The latter may have biased study outcomes if patients 
developing signs of early fluid retention were withdrawn from thiazolidinedione 
therapy before they developed CHF as defined in the study. Moreover, a diagnosis of 
HF based on ICD-9 criteria may have been based on the presence of oedema or 
dyspnoea rather than a formal assessment of cardiac function. Finally, the study was 
carried out in male veterans (mean age 61.5 years), limiting extrapolation of results 
to female patients, and individuals in other age groups.  
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Habib et al. published a large retrospective cohort study of 39736 T2DM patients 
aged 66 years or older who were prescribed thiazolidinedione therapy between 1st 
April 2002 and 31st March 2008 yielded comparative data on incident HF among 
rosiglitazone and pioglitazone-treated patients [274]. Adjusting for demographic and 
clinical factors and drug doses, pioglitazone-treated patients were reported to be at a 
lower risk of developing the composite outcome of death or hospital admission for 
either acute myocardial infarction or HF than their rosiglitazone-treated counterparts 
[adjusted HR 0.83 (95% CI 0.76, 0.90)]. Pioglitazone therapy was also associated 
with lower rates of incident congestive HF and all-cause death [adjusted HR 0.77 
(95% CI 0.69, 0.87) for HF; adjusted HR 0.86 (95% CI 0.75, 0.98) for mortality], 
despite no significant differences in the risk for myocardial infarction [adjusted HR 
0.95 (95% CI 0.81, 1.11)]. Compared with high dose rosiglitazone, low dose 
rosiglitazone was not associated with a significant lower risk of the composite 
outcome [adjusted HR 0.94 (95% CI 0.83, 1.07)], whereas both low dose [adjusted 
HR 0.83 (95% CI 0.70, 0.97)] and high dose pioglitazone [adjusted HR 0.76 (95% 
CI 0.66, 0.88)] were [274].  
 
Using time-updated propensity score adjusted analysis (modelling the probability of 
being treated with a thiazolidinedione), Habib et al. examined data from 19171 
T2DM patients treated with oral glucose lowering agents and followed longitudinally 
within a US health system between 1st January 2000 and 1st December 2006 [275]. 
The authors compared rates of hospitalization for congestive HF between 
thiazolidinedione-treated patients and those not exposed to these drugs, concluding 
that the former were at a greater risk of CHF hospitalization [adjusted HR with 
56 
 
 
propensity adjustment (PA) 1.24 (95% CI 1.07, 1.44)] but a significantly lower risk 
of all-cause mortality [adjusted HR with PA 0.69 (95% CI 0.52, 0.90)]. 
Thiazolidinedione use was not associated with an increased risk of the composite 
endpoint of fatal and nonfatal acute myocardial infarction [adjusted HR with PA 
0.92 (95% CI 0.73, 1.17)]. Similarly, thiazolidinedione exposure did not increase the 
risk of any of the other secondary outcomes, namely cerebrovascular accidents 
/transient ischaemic attacks [adjusted HR with PA 0.97 (95% CI 0.79, 1.20)] or 
combined coronary heart disease events [adjusted HR with PA 0.92 (95% CI 0.77, 
1.10)]. Rosiglitazone exposure was associated with an increased risk of CHF 
hospitalization [adjusted HR with PA 1.65 (95% CI 1.25, 2.19)] but no significant 
effects on acute myocardial infarction [adjusted HR with PA 1.06 (95% CI 0.66, 
1.70)], cerebrovascular events/transient ischaemic attacks [adjusted HR with PA 1.20 
(95% CI 0.79, 1.82)], combined coronary heart disease events [(adjusted HR with 
PA 1.22 (95% CI 0.91, 1.63)] or all-cause mortality [adjusted HR with PA 0.91 
(95% CI 0.57, 1.48)]. Pioglitazone treatment carried an increased risk of CHF 
hospitalization when analysed without propensity adjustment [adjusted HR 1.25 
(95% CI 1.05, 1.50)]; this risk disappeared once the probability of being treated with 
pioglitazone was factored into the model [adjusted HR with PA 1.14 (95% CI 0.96, 
1.37]. Pioglitazone was associated with a reduction in all-cause mortality [adjusted 
HR with PA 0.60 (95% CI 0.42, 0.96)], but no significant effects on acute 
myocardial infarction [adjusted HR with PA 0.91 (95% CI 0.69, 1.21)], 
cerebrovascular events/transient ischaemic attacks [adjusted HR with PA 0.93 (95% 
CI 0.72, 1.20)] or combined coronary heart disease events [adjusted HR with PA 
0.86 (95% CI 0.69, 1.06)].  Comparing outcomes between pioglitazone- and 
rosiglitazone-treated patients, Habib et al. concluded that exposure to pioglitazone is 
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generally associated with a lower risk than rosiglitazone for all the above outcomes, 
although the difference only reached statistical significance for CHF hospitalizations 
(p = 0.013) and combined coronary heart disease events (p = 0.048) [275]. 
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  Table 1.4 - Meta-analyses and major retrospective analyses of thiazolidinedione related outcomes and side-effect profile. 
 
 
Author  
 
 
Year 
 
Design 
 
Study 
inclusion 
criteria 
 
Number 
of 
patients 
(trials) 
 
 
TZD 
 
Evidence of 
heterogeneity 
 
Primary 
endpoint 
 
Effect on 
primary 
endpoint 
 
Effect on 
heart failure 
 
 
Oedema  
 
Effect 
on 
weight  
 
Effect on  
IHD 
 
Effect on 
stroke 
 
Effetc on 
mortality 
 
Lincoff 
et al. 
 
 
 
 
 
 
 
 
Singh et 
al. 
 
 
 
 
 
 
 
Lago et 
al. 
 
 
 
2007 
 
 
 
 
 
 
 
 
 
2007 
 
 
 
 
 
 
 
 
2007 
 
 
 
 
 
 
 
 
 
 
 
 
meta-
analysis  
 
 
 
 
 
 
 
 
meta-
analysis 
 
 
 
 
 
 
 
meta-
analysis 
 
 
 
double-
blind, 
randomized, 
controlled 
with 
PL/aComp 
 
 
 
 
randomized 
controlled, 
at least 12 
months of 
follow-up  
 
 
 
 
randomized,  
controlled, 
double-
blind 
 
 
 
 
 
 
 
 
 
16390 
(19) 
 
 
 
 
 
 
 
 
14291 
(4) 
 
 
 
 
 
 
 
20191 
(7) 
 
 
 
 
 
 
 
 
 
 
 
Pioglitazone 
 
 
 
 
 
 
 
 
 
Rosiglitazone 
 
 
 
 
 
 
 
 
Rosiglitazone 
(5 trials)  
and 
Pioglitazone  
(2 trials) 
 
 
 
 
no evidence  
 
 
 
 
 
 
 
 
 
no evidence  
 
 
 
 
 
 
 
 
no evidence 
 
 
 
 
 
 
 
 
 
 
 
 
 
composite of 
death, MI or 
stroke 
 
 
 
 
 
 
 
MI, HF and 
cardiovascular 
mortality 
 
 
 
 
 
 
development 
of congestive 
HF and risk of 
cardiovascular 
death 
 
 
 
 
 
 
 
decrease 
4.4% (Pio) 
vs 5.7% 
(PL/aComp)a 
HR 0.82 
(0.72, 0.94)b 
p=0.005 
 
 
 
d 
 
 
 
 
 
 
 
 
d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serious HF 
increase 
2.34% (Pio) 
vs  
1.77% 
(PL/aComp)a 
HR 1.41 
(1.14., 1.76) 
b  p=0.002 
 
increase 
1.59% 
(Rosi) vs 
0.79 % (CL) 
e
 RR 2.09 
(1.52, 2.88) a 
p<0.001 
 
 
2.3% (TZD) 
vs 1.4% 
(comp)e 
RR 1.72 
(1.21, 2.42) b  
p = 0.002 
 
 
 
c 
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
 
 
 
 
 
MI 
none 
1.53% (Pio)  
vs 2.03% 
(PL/aComp)a 
HR 0.81 
(0.64, 1.02)b 
p=0.08 
 
 
MI 
increase 
1.46% (Rosi) 
vs 1.05%  
(CL)e  
RR 1.42 (1.06, 
1.91)b p=0.02 
 
 
c 
 
 
 
 
 
 
 
 
 
 
 
 
none  
1.22 % (Pio) 
vs 1.67 % 
(PL/aComp)a 
HR 0.80 
(0.62, 1.04)b 
p=0.09 
 
 
 
c 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
 
 
none 
2.44% (Pio) vs  
2.86% 
(PL/aComp) 
HR 0.92 (0.76, 
1.11)b  
p= 0.38   
 
 
 
cardiovascular 
mortality  
none 
0.92% (Rosi) 
vs 0.91% (CL) 
RR 0.90 (0.63, 
1.26)b 
p = 0.53 
 
cardiovascular 
mortality 
none  
0.7% (Rosi) vs 
0.7% (Comp)e 
RR 0.93 (0.67, 
1.29)b 
p = 0.68 
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 Table  1.4 continued - Meta-analyses and major retrospective analyses of thiazolidinedione related outcomes and side-effect profile 
 
Author  
 
 
Year 
 
Design 
 
Study 
inclusion 
criteria 
 
Number  
of 
patients 
(trials) 
 
TZD 
 
Evidence of 
heterogeneity 
 
Primary 
endpoint 
 
Effect 
on 
primary 
endpoint 
 
Effect on 
heart failure 
 
 
Oedema  
 
Effect 
on 
weight  
 
Effect on IHD 
 
Effect 
on 
stroke 
 
Effect on 
mortality 
 
Lipscombe 
et al. 
 
 
2007 
 
retrospective 
case control  
 
 
diabetes 
patients 66 
years or 
older, 
1/more 
OHA, 
2002-2005 
and 
followed 
up until 
31/03/2006 
 
 
159026 
(f) 
 
 
 
Rosiglitazone   
and 
pioglitazone 
 
 
f 
 
 
emergency 
department 
visit or 
hospitalization 
for congestive 
HF 
 
 
 
d 
 
 
hospitalization 
/ED visit 
increased risk 
with TZDh 
 
TZD 
monotherapy  
aRaR 1.60 
(1.21, 2.10)b 
p<0.001e g  h 
 
TZD 
combination 
therapy  
aRaR 1.31 
(1.17, 1.47)  
p <0.001 e g  h 
 
 
c 
 
 
c 
 
 
 
Hospitalization 
/EDvisit 
increased risk 
with TZD 
monotherapyh 
aRaR 1.40 
(1.05, 1.86)b  
p = 0.02eg 
 
 
c 
 
 
increased risk 
with TZDh   
 
monotherapy 
aRaR 1.29 
(1.02, 1.62) 
p=0.03eg 
 
combination 
therapy 
aRAR 1.24 
(1.11-1.39) p< 
0.001 
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              Table 1.4 continued - Meta-aanlysis and major retrospective analyses of thiazolidinedione related outcomes and side-effect profile 
 
Author  
 
 
Year 
 
Design 
 
Study 
inclusion 
criteria 
 
Number  
of 
patients 
(trials) 
 
 
TZD 
 
Evidence of 
heterogeneity 
 
Primary 
endpoint 
 
Effect on 
primary 
endpoint 
 
Effect on 
heart failure 
 
 
Oedema  
 
Effect 
on 
weight  
 
Effect on 
IHD 
 
Effect 
on 
stroke 
 
Effect on 
mortality 
 
Clar et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2009 
 
 
meta-
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
trials 
comparing 
pioglitazone  
+ insulin 
with same 
insulin 
regimen  
alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3092 (8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pioglitazone 
 
 
 
 
 
 
 
 
 
 
 
 
no evidence 
(unless 
indicated) 
 
 
 
glycaemic 
control, 
hypoglycaemia, 
wt change, 
lipids, adverse 
events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
glycaemic 
control 
lower HbA1c 
for Pio + 
insulin  
-0.58% 
(-0.70, -0.46)b 
p<0.0001a 
 
hypoglycaemiaj 
increased for 
Pio + Insulin 
RR 1.40 (1.14, 
1.73)b p= 
0.002a j 
 
wt change c 
TC, LDL 
No difference 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
commoner 
for Pio + 
insulini 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
average 
weight 
gain of 
3kg in 
with 
Pioi 
 
 
 
 
 
 
 
 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c 
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           Table 1.4 continued  - Meta-analyses and major retrospective analyses of thiazolidinedione related outcomes and side-effect profile 
 
 
Author  
 
 
Year 
 
Design 
 
Study 
inclusion 
criteria 
 
Number of 
patients 
(trials) 
 
TZD 
 
Evidence of 
heterogeneity 
 
Primary 
endpoint 
 
Effect on 
primary 
endpoint 
 
 
Effect on 
heart 
failure 
 
 
Oedema  
 
Effect 
on 
weight  
 
Effect on IHD 
 
Effect on 
stroke 
 
Effect on 
mortality 
 
Richter et 
al. 
 
 
 
 
 
 
 
 
 
Richter et 
al. 
 
 
2006 
 
 
 
 
 
 
 
 
 
 
2009 
 
 
 
meta-
analysis 
 
 
 
 
 
 
 
 
 
meta-
analysis 
 
 
 
randomized 
controlled, 
lasting at 
least 24 
weeks  
 
 
 
 
 
 
randomized 
controlled, 
lasting at 
least 24 
weeks  
 
 
6200 (22) 
 
 
 
 
 
 
 
 
 
 
3888 (18) 
 
 
 
 
pioglitazone 
 
 
 
 
 
 
 
 
 
 
rosiglitazone 
 
no evidence 
unless 
indicated 
 
 
 
 
 
 
 
 
no evidence 
unless 
otherwise 
indicated 
 
 
 
 
 
 
 
 
all-cause and 
diabetes-
related 
morbidity and 
mortality, 
adverse events 
 
 
 
 
 
all-cause and 
diabetes-
related 
morbidity and 
mortality, 
adverse events 
 
‘somewhat 
lower rates 
of 
hypoglyca
emia’; 
hypoglyca
emia 
commoner 
with Pio + 
insulini 
 
‘somewhat 
lower rates 
of 
hypoglyca
emia’ with 
Rosi, 
‘especially 
when 
compared 
to SU’; 
‘severe 
hypo were 
rarely 
reported’i 
 
 
HF 
requiring 
hospital 
admission 
data only 
for 
PROactive 
(Dormand
y et al.)i 
 
 
data only 
for  
ADOPT 
(Kahn et 
al.)i  
 
 
RR 2.86 
(2.14, 
3.18) 
p<0.0000
1 
 
 
 
 
 
 
increased 
risk with 
Rosi 
OR 2.27 
(1.83, 
2.81) 
p<0.0000
1k 
 
excluding 
Kahn et 
al.: 
OR 6.04 
(3.31, 
11.2) 
p<0.0000
1l 
 
Pio 
increas
es wt 
by up 
to 3.9 
kg and 
BMI up 
to 
1.5kg/
m2 
 
Rosi 
increas
ed  
weight 
by up 
to 5kg 
in 11 
studies 
and 
BMI by 
up to 
1.5kg/
m2 in 4 
studies 
 
 
data only for 
PROactive 
(Dormandy et 
al.)i 
 
 
 
 
 
 
 
data only for 
ADOPT (Kahn 
et al.)i 
 
data only 
for 
PROactive 
(Dormandy 
et al.)i 
 
 
 
 
 
 
data only 
for 
ADOPT 
(Kahn et 
al.)i 
 
 
 
data only 
for 
PROactiv
e 
(Dormand
y et al.)i 
 
 
 
 
 
data only 
for 
ADOPT 
(Kahn  et 
al.)i 
 
 
 
          aComp, active comparator; aRaR, adjusted rate ratio; Comp, comparator; CL, control; ED, emergency department; HR, hazard ratio; pio, pioglitazone; PL, placebo; rosi, rosiglitazone; RR, relative  
          risk; TC, total cholesterol;/ LDL, low-density lipoprotein cholesterol; OR, odds ratio; a number of affected patients; b 95% confidence intervals; cdata unavailable;  d data included in adjacent  
          columns; e event rate; f not applicable; g comparing TZD therapy with other oral hypoglycaemic agent combination therapies; h risk appeared limited to rosiglitazone use; i meta-analysis not possible;  
               j sensitivity analysis showing moderate heterogeneity; k sensitivity analysis showing heterogeneity (I2 = 53.4%); l sensitivity analysis showing no significant heterogeneity.   
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1.9 Association of comparator 'first and second line' oral glucose lowering 
agents (metformin, sulphonylureas) with incident heart failure 
 
Evidence supporting or refuting a possible association between other glucose 
lowering agents and incident HF is surpisingly sparse. Although the US Food and 
Drug Administration relatively recently removed its contraindication to prescribing 
metformin in patients with HF, it strongly cautions its use in this setting. This 
clinical concern is likely to account for an absence of randomised control trials 
exploring outcomes in metformin-treated T2DM individuals with, or prone to HF. 
The only prospective data exploring incident HF events in metformin-treated patients 
were provided by the RECORD study [153]. Three retrospective studies recruiting 
patients from a US register of T2DM patients shed valuable information in this 
regard.  Nichols et al. reported that incident congestive HF rates were lowest in 
regimens that included metformin and highest in those that included insulin. 
Compared with patients on metformin monotherapy (typical ‘early stage’ diabetes), 
adjusted incident congestive HF rates (per 1000 patient years) were 32% higher 
among patients treated with sulphonylurea monotherapy, 28% higher among patients 
on metformin-sulphonylurea combination therapy, and 2.6 times higher in patients 
on insulin monotherapy [276]. These findings are consistent with those from an 
earlier retrospective study [277]. In contrast, use of metformin or sulphonylureas did 
not influence incident congestive HF rates over a follow-up period of 72 months, 
unlike insulin [HR 1.25 (95% CI 1.06, 1.48); p < 0.001] [239]. Analyzing data from 
6900 incident cases of congestive HF occurring in 91521 patients with T2DM who 
were followed up for a mean period of 7.1 years, Tzoulaki et al. reported that, 
compared with metformin monotherapy, second generaton sulphonylurea 
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monotherapy was associated with an 18% to 30% excess risk of new onset 
congestive HF in adjusted Cox regression models. Rosiglitazone combination 
therapy (with meformin and/or sulphonylurea) was associated with an increased risk 
of incident HF compared with individuals prescribed metformin monotherapy in two 
Cox regression models. Neither sulphonylureas (first or second generation) nor 
thiazolidinediones rosiglitazone or pioglitazone) emerged as significant risk factors 
for new onset congestive HF in a fully adjusted model [271]. 
 
The effect of duration of therapy on incident HF rates was investigated by Maru and 
colleagues. Analyzing data from 25, 690 newly diagnosed T2DM patients registered 
in the UK General Practice Research Database, glucose lowering agent use 
(metformin or sulphonylurea or insulin) within the first year of diagnosis carried a 
4.75 fold (hazard ratio) increased risk of incident HF compared with their drug free 
counterparts. This risk did not persist beyond the first year (mean follow-up 2.5 
years) and seemed unrelated to type-specific drug exposures [278].  
 
A retrospective study recruiting 5631 T2DM patients newly treated with a single oral 
glucose lowering agent and followed up for almost five years further supported 
evidence for an association between high sulphonylureas and incident HF [adjusted 
HR 1.24 (95% CI 1.01, 1.54)]. Additionally, McAlister and colleagues reported that 
high dose sulphonylurea therapy was more likely to result in incident HF [HR 1.38 
(95% CI 1.20, 1.60)] than low dose sulphonylureas. No such association existed for 
metformin users [279].  
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1.10 Use of comparator 'first and second' line oral glucose lowering agents 
(metformin, sulphonylureas) in patients with established heart failure 
 
Compared with data for incident HF, a larger number of studies (mostly 
observational) looked at additional HF events and outcomes in patients with T2DM 
and established HF. Using propensity score matched samples, Aguilar et al. reported 
that metformin therapy was associated with lower mortality rates [HR 0.76 (95% CI 
0.63, 0.92)], albeit no effect on hospitalization rates [280]. A retrospective analysis 
of data from 12 272 HF patients who were newly prescribed with oral glucose 
lowering agents for T2DM reported that both metforin monotherapy and metformin-
sulphonylurea combination therapy were associated with fewer deaths than 
sulphonylurea monotherapy [adjusted HR 0.70 (95% CI 0.54, 0.91) and 0.61 (95% 
CI 0.52, 0.72) respectively] [281]. A reduction in the composite of all-cause deaths 
or all-cause hospitalizations was also observed [HR 0.83 (95% CI 0.70, 0.99) for 
metformin monotherapy vs sulphonylurea monotherapy; HR 0.86 (95% CI 0.77, 
0.96) for metformin monotherapy vs metformin-sulphonylurea combination 
therapy]. Risks of all-cause death, all-cause hospitalization and the composite (all-
cause hospitalization or  all-cause death) seemingly increased at study end (mean ± 
SD duration of follow-up 2.5 ± 2 years) compared with results at one year [281]. 
These results generally agree with those reported by Andersson et al. in a cohort of 
Danish patients treated with metformin, sulphonylureas or insulin in the setting of 
established HF. Using sulphonylurea monotherapy as a reference, these authors 
reported that metformin monotherapy carries the lowest mortality risk in this setting 
[adjusted HR 0.85 (95% CI 0.75, 0.98)] followed by metformin-sulphonylurea 
combination therapy [adjusted HR 0.89 (95% CI 0.82, 0.96)] and insulin [adjusted 
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HR 1.14 (95% CI 1.06, 1.20)] [282]. A retrospective review of 16 417 T2DM with 
established HF showed that treatment with both metformin [adjusted HR 0.86 (95% 
CI 0.78, 0.97)] and thiazolidinediones [adjusted HR 0.87 (95% CI 0.80, 0.94)] was 
associated with a lower risk of death compared with patients not treated with an 
insulin sensitizer (sulphonylurea or insulin). Readmission with HF was more likely 
in patients treated with a thiazolidinedione [adjusted HR 1.06 (95% CI 1.00, 1.09)] 
and less likely in patients on metformin [adjusted HR 0.92 (95% CI 0.86, 0.99)] 
[283]. 
 
A systematic review and meta-analyses of randomised studies or controlled trials 
revealed that metformin significantly reduced all cause mortality in two studies [HR 
0.86 (95% CI 0.78, 0.97)] compared with other anitdiabetic drugs and insulin; a 
similar trend was seen in a third study. Metformin was also associated with reduced 
all cause hospital admissions at one year compared to other treatments [pooled OR 
0.85 (95% CI 0.76, 0.95); p = 0.004] [284]. In 1633 patients newly diagnosed with 
T2DM and HF, both metformin monotherapy [adjusted OR 0.65 (95% CI 0.48, 
0.87)] and metformin combined with/out other agents [adjusted OR 0.72 (95% CI 
0.59, 0.90)] were associated with reduced mortality rates compared with antidiabetic 
treatment naïve patients [285].  
 
In conclusion, both prospective and retrospective studies support an association 
between thiazolidinediones and oedema/heart failure. Absolute rates may be higher 
in the setting of cardiovsacular disease, and are possibly influenced by the 
concurrent use of other glucose lowering pharmacotherapies. 
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Section III - Mechanisms underpinning fluid retention following 
thiazolidinedione therapy 
 
While the association between thiazolidinedione therapy, cardiac failure and fluid 
retention has been demonstrated by several prospective and retrospective 
studies/meta-analyses, the pathophysiological mechanisms underlying these 
complications remain unclear. It is clear that the current paucity of research data in 
this field impairs the identification of any predisposing factors of thiazolidinedione 
induced fluid overload, an issue which hampers the development of clearer clinical 
guidelines governing their use. Moreover, concerns regarding the cardiovascular 
safety profile of rosiglitazone, initially reported in Nissen and Wolski’s meta-
analysis [147] and culminating in an FDA’s ruling (since revised) that this drug 
increases cardiovascular events [150, 160], influenced prescribing practices 
worldwide. Indeed, this has been outlined in a recent study of prescribing data in 
Tayside, Scotland for the period October 2006-March 2008, which confirmed a 34% 
decrease in the number of prescriptions for rosiglitazone (alone or as combination 
therapy with metformin), and an accompanying increase in those for pioglitazone 
(alone or as combination with metformin) [286]. These developments, call for a 
concerted effort in this regard towards a better understanding of the relevant 
mechanisms.  
 
1.11 Renal haemodynamics 
 
As outlined earlier, the PPAR-γ1 receptor isotype has been shown to be moderately 
expressed in the kidneys. Guan et al. examined the distribution of the different PPAR 
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receptors within the human kidney and urinary tract using in situ hybridization 
techniques, concluding that renal PPAR-γ receptors are exclusively expressed in the 
medullary collecting duct, ureter and bladder [287]. PPAR-γ is also expressed to a 
lesser extent in the glomeruli and renal microvasculature [288]. Low but significant 
expression has been reported in the proximal tubules and in many other nephron 
segments [289]. Other studies have reported constitutive expression of PPAR-γ 
receptors in cultured glomerular mesangial cells, podocytes, proximal epithelial cells 
and epithelial cells of collecting ducts [290]. This distribution suggests diverse roles 
for PPAR-γ in the kidney, both therapeutically and in its modulation of 
thiazolidinedione-induced fluid overload.  
 
1.11.1 The collecting duct and distal tubule  
 
The localisation of PPAR-γ receptors in the medullary collecting duct lead to the 
hypothesis that PPAR-γ activation increases sodium retention through its action at 
this critical site in fluid metabolism that responds to the integrated effects of multiple 
hormones such as aldosterone, arginine vasopressin (AVP), insulin and atrial 
natriuretic peptide (ANP) [291]. Acting via the mineralocorticoid receptor, 
aldosterone enhances the absorption of sodium by the principal cells of the collecting 
duct. This is achieved by inducing the expression of key genes that encode for key 
regulators of sodium transport, namely the epithelial sodium channel-α (ENaCα,), 
serum and glucocorticoid regulated kinase-1 (Sgk) and the sodium-potassium-
ATPase-α (Na-K-ATPase-α) [292, 293] (table 1.5). Reabsorption of sodium in the 
distal nephron is a two-step process. Sodium first enters renal cells from the luminal 
compartment via the rate-limiting apical ENaC, and is then actively transported out 
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of the cell by the basolateral Na-K-ATPase [294]. ENaC consists of three subunits 
designated ENaC- α, -β and -γ [295]. Expression of the ENaCγ subunit (encoded by 
the Scnn1g gene) plays a crucial role in the trafficking of the ENaCα, and ENaCβ to 
the cell membrane [296]. Sgk is a novel member of the serine/threonine kinase gene 
family, comprising three highly organ-specific isoforms (Sgk-1, -2, -3) sharing 80% 
amino acid identity [297, 298]. Skg-1 is thought to be a key mediator of aldosterone-
induced sodium reabsorption through the ENaC at the collecting duct [299], and has 
been reported as a target gene of PPAR-γ in a murine study [291]. Similarly, Hong et 
al. have shown that PPAR-γ can bind to specific elements in the Sgk-1 promoter  in 
human collecting duct cells [300].  Hypotonic conditions increase Sgk-1 expression 
and sodium transport in A6 cells, a cultured cell line derived from the Xenopus 
laevis distal nephron [301]. This contrasted with findings by Guan et al., who did not 
find any evidence for increased expression of Sgk-1 in cultured mouse inner 
medullary collecting duct cells. [302] 
 
Two elegant murine studies sought to investigate the hypothesis that 
thiazolidinediones induce fluid retention through PPAR-γ mediated activity at the 
collecting duct. Deletion of PPARg (which encodes for PPAR-γ) in the murine 
collecting duct prevented thiazolidinedione-induced weight gain, decreased renal 
sodium retention and increased plasma aldosterone (a reliable index of plasma 
volume) in a study by Guan et al. [302]. Mice pre-treated with amiloride (an 
aldosterone antagonist) at a dose of 2mg/kg/day were also immune to the weight 
increasing effect of pioglitazone. Additionally, the authors reported that the 
treatment of cultured collecting ducts with thiazolidinediones increased amiloride-
sensitive sodium absorption through the epithelial sodium channel (ENaC); this 
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effect was abolished in PPAR-γ deficient collecting duct cells. Guan et al. [302] 
demonstrated that Scnn1g expression is increased by thiazolidinedione therapy, 
identifying Scnn1g as a direct and specific target gene of PPAR-γ in the medullary 
collecting duct. A contemporary study by Zhang et al. comparing outcomes in 
PPAR-γ collecting duct knock-out and control mice reported similar 
thiazolidinedione-induced PPAR-γ mediated differences in body weight, sodium 
balance,  ENaC sodium transport and plasma aldosterone levels [303].  
 
The data from the above two studies somewhat contrast with those from another 
study investigating the renal effects of the highly potent and selective PPAR-γ 
agonist farglitazar [291]. Murine administration of this pharmacological agent led to 
plasma volume expansion, a small but significant decrease in plasma potassium, 
lower aldosterone concentrations and a small but significant increase in plasma 
sodium and chloride concentrations. These changes are consistent with aldosterone’s 
role at the level of the medullary collecting duct, favouring sodium reabsorption and 
potassium excretion. Paradoxically however, low dose amiloride (1mg/kg/day) 
exacerbated farglitazar-induced plasma volume expansion and significantly 
increased the renal expression of ENaCα. One notes however that the investigators 
used a lower dose of amiloride in this study (1mg/kg/day) compared with Guan et al. 
[302], which may, at least in part, explain the difference in treatment outcomes.  
 
Artunc et al. compared body weight, haematocrit, plasma aldosterone, leptin, blood 
pressure and renal Sgk-1 expression in Sgk knockout mice and their wild type 
littermates treated with pioglitazone [304]. Pioglitazone treatment significantly 
increased Sgk-1 mRNA and protein expression and plasma volume only in wild type 
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mice. The latter group also exhibited a significantly greater increase in in body 
weight and a significantly more pronounced reduction in haematocrit in response to 
treatment. Pioglitazone therapy decreased plasma aldosterone and blood pressure, 
and increased leptin levels in both litter genetic subtypes. The authors concluded that 
Sgk-1 contributes, but does not fully explain thiazolidinecdione-induced fluid 
retention. 
 
Nofziger et al. reported no change in Sgk-1 transcript or protein expression after 
incubating mouse principal kidney cortical collecting duct cells with the PPAR-γ 
agonists GW7845 (a potent non-thiazolidinedione) and pioglitazone [305]. Although 
the authors were able to identify PPAR-γ in 3 different in vitro models of renal 
principal cells, the same agents did not increase basal or insulin-stimulated sodium 
flux via the ENaC, supporting the possibility that these agonists may be favouring 
water and sodium retention at a more proximal site within the nephron. Consistent 
with these observations, Vallon et al. reported that mice selectively lacking the 
ENaC α subunit in the collecting duct were still prone to thiazolidinedione-induced 
water retention, and that thiazolidinediones increased the activity of an unspecified 
nonselective cation channel [306]. Indeed, in a recent publication, the latter research 
group found that thiazolidinediones may actually repress the ENaC γ subunit 
transcription by suppressing histone H4K5 acetylation in murine M1 collecting duct 
cells [307]. 
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1.11.2 The proximal tubule 
 
As discussed earlier, PPAR-γ is also reportedly expressed in human proximal tubular 
cells. Moreover, this expression is up-regulated in the presence of high glucose and 
PPAR-γ agonists [308]. The proximal tubule constitutes more than 90% of renal 
tissue, and together with the descending limbs of Henle’s loop, account for the 
reabsorption of approximately 80% of the water and solutes, and 60% of the sodium 
filtered at glomerular level. This is mediated through the activity of membrane-
inserted water channel proteins called aquaporins (AQPs). AQP1 and AQP7 are the 
principal isoforms expressed in the proximal tubule [309, 310].  
 
Strongly expressed in the apical and basolateral plasma membranes of proximal 
tubular cells, AQP1 plays a major role in proximal tubular transcellular transport 
[310-312]. Experiments on AQP1 knockout mice reduced proximal tubular transport 
by 90%, suggesting that 90% of water transport at the proximal convoluted tubule is 
transcellular and 10% is paracellular  [313, 314]. Schnermann et al. concluded that 
other AQPs and non-AQP transporters play little, if any role in determining proximal 
tubule water reabsorption [314]. AQP7 is an aquaglyceroporin, which allows the 
rapid transport of glycerol and water; it is expressed on the apical membrane of the 
proximal straight tubules [315]. Murine experiments using AQP7 knockout and 
AQP1/AQP7 knockout mice concluded that the estimated relative contribution of 
AQP7 to water permeability on the proximal straight tubules was one-eight that of 
AQP1 [316].  
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Although rosiglitazone has been reported to induce AQP2 and AQP3 in whole 
kidney homogenates in rats and AQP1, AQP2 and AQP3 in the inner medulla [310], 
the effect of PPAR-γ on AQP expression in the proximal tubule is largely unknown. 
AQP7 has been identified as a PPAR-γ target gene [317]. Saad et al. reported that 
PPAR-γ agonists enhance the expression of AQP1 and AQP7 in humans through an 
Sgk-1 mediated pathway [318]. The clinical relevance of these findings remains 
unclear. 
 
The type 3 sodium hydrogen exchanger (NHE3) is another key modulator of sodium 
reabsorption at the proximal tubule. Rosiglitazone was reported to increase NHE3 
(and the α1 subunit of the sodium-potassium-ATPase, the bumetanide sensitive 
sodium-potassium-2 chloride cotransporter, aquaporins 2 and 3, and endothelial 
nitric oxide synthase) expression in a murine model [319]. The  effect of 
thiazolidinediones on NHE3 expression was later confirmed in human proximal 
tubular cells, occurring through an Sgk-1 dependent pathway [318].  The basolateral 
type 1 sodium-bicarbonate cotansporter has also been implicated in 
thiazolidinedione-induced fluid retention, as evidenced by data from a study by Muto 
et al. [320]. Using in vitro electrophysiological studies on rabbit proximal straight 
tubule cells, the authors established that troglitazone stimulated this cotransporter in 
a dose dependent fashion. Endo et al. described similar findings in rat, rabbit, human 
but not in mouse proximal tubular cells. Additionally, these authors reported that 
stimulation of the sodium-bicarbonate cotransporter is mediated in a non-genomic 
fashion through PPAR-γ induced stimulation of the Src-EGFR-ERK signalling 
pathway [321].     
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Zanchi et al. investigated the effects of pioglitazone on renal salt water handling in 
response to a low salt (20 mmol/day) and a high salt (>200 mmol/day) diet [322]. 
This double-blind, randomized, placebo controlled, cross-over study recruiting 10 
healthy normotensive male subjects demonstrated that a 6 week course of 
pioglitazone therapy (45 mg daily) significantly lowered urinary sodium excretion 
and reduces lithium clearance when patients were subjected to a low salt diet, 
suggesting that the drug increases proximal tubular sodium reabsorption. A high salt 
diet produced similar trends (albeit not statistically significant); the authors ascribed 
this to individual variability.  
 
In summary, the physiological mechanisms underlying thiazolidinedione- induced 
salt and water retention in the kidney remain largely unravelled and the subject of 
considerable debate, despite their clear clinical importance.  
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Table 1.5 - Distribution of sodium transporters and sodium channel proteins in the 
nephron. Transporters marked with an asterisk (*) have been implicated to play a 
role in PPARγ mediated salt retention. 
 
 
Nephron location 
 
Transporter/channel protein 
 
 
Cellular location 
 
All locations 
 
Proximal tubule 
Proximal tubule 
Proximal tubule 
 
Descending limb of Henle’s loop 
 
Thick ascending limb of Henle’s loop 
 Thick ascending limb of Henle’s loop 
 
Distal convoluted tubule  
 
Connecting tubule 
 
Collecting duct 
 
 
Na-K-ATPase*  
 
Type 3 Na-H exchanger* 
Type 2 Na-phosphate cotransporter* 
Type 1 Na-bicarbonate cotransporter* 
 
Type 3 Na-H exchanger* 
 
Type 3 Na-H exchanger* 
Type 2 Na-K-2Cl transportera* 
 
Na-Cl cotransporterb 
 
Epithelial Na channelc* 
 
Epithelial Na channel α subunitc* 
 
Basolateral 
 
Apical  
Apical 
Basolateral  
 
Apical  
 
Apical  
Apical  
 
Apical  
 
Apical 
 
Apical 
 
a bumetanide sensitive;  b thiazide sensitive; camiloride sensitive 
 
 
1.11.3 Evidence for an ‘escape mechanism’ and the ‘salt handling paradox’ 
 
The observation that PPAR-γ agonist treatment is associated with a lowering of 
blood pressure suggests the existence of an interaction with the cardiovascular 
system. This is further supported by the observation that patients with a dominant 
negative mutation in PPAR-γ exhibit early onset hypertension [323]. One of the 
major regulators of systemic blood pressure is the renin-angiotensin-aldosterone 
system. Thiazolidinedione treatment was reported to prevent an increase in blood 
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pressure caused by the infusion of angiotensin II in rats [324]. Additionally, it 
decreases blood pressure and improves endothelial function in a mouse model of 
lifelong hypertension caused by the overexpression of both human renin and human 
angiotensinogen transgenes [325]. Morerover, thiazolidinedione therapy was also 
reported to downregulate angiotensin II type I receptor gene expression via a PPAR-
γ dependent mechanism in vascular smooth muscle cells [326].  
 
Renin is the rate limiting step in angiotensin II synthesis. In their study on healthy 
normotensive male volunteers subjected to a low and high salt diet, Zanchi et al. 
[322] reported that pioglitazone therapy increased plasma renin activity in both salt-
loading states, despite recording no significant blood pressure changes in response to 
thiazolidinedione treatment or alteration in dietary sodium load. However, the 
authors did note that piogliazone therapy was associated with a significant increase 
in daytime heart rate, which reached statistical significance only on a low salt diet. In 
the absence of any effect on supine (nocturnal) blood pressure, the authors postulated 
that the raised renin is a physiological response to thiazolidinedione induced 
peripheral vasodilatation. This hypothesis was consistent with earlier reports that 
thiazolidinediones exert several vasodilatory effects on the vascular system, namely 
reducing endothelin-1 secretion by endothelial cells [327], modulating its 
endogenous production in endothelin-dependent hypertension [328] and inhibiting 
vascular smooth muscle calcium currents [329, 330]. In a later study on human renin 
secreting Calu-6 cells (derived from a pulmonary carcinoma), Todorov et al. 
reported that rosiglitazone increases renin gene expression via a PPAR-γ dependent 
mechanism. This association is however disputed, since other studies have reported 
that PPAR-γ has no influence on renin mRNA levels [331, 332]. Despite the lack of 
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consistent data, a delicate balance may exist between the effects of 
thiazolidinediones on the renin-angiotensin-aldosterone system and other mediators 
of vascular tone. Further studies are warranted to clarify this relationship. 
 
Nonetheless, these observations cannot adequately explain the dietary sodium related 
differences in renal salt handling during thiazolidinedione therapy [322]. Animal 
studies suggest that sodium reabsorption from the collecting duct during 
rosiglitazone treatment reaches a peak at day 6, and that balance returns to normal by 
day 9 [303]. This led to the hypothesis that an ‘escape mechanism’ plays a role in 
thiazolidinedione-associated sodium handling under salt-loading conditions, similar 
to that seen with mineralocorticoid excess [333, 334]. ANP is thought to play a 
critical role in this mechanism [333, 334], particularly in low renin states. To this 
effect, Goenka et al. [335] investigated the effects of water immersion to the level of 
the neck (which causes a 16% increase in plasma volume and a redistribution of 700 
mls of blood centrally to the thoracic cavity) on renal and hormonal dynamics in 
normal and T2DM individuals. The investigators confirmed earlier reports that 
T2DM patients are characterized by an impaired natriuretic response, diminished 
ANP and a blunted cGMP response to volume expansion [335]. Rosiglitazone 
treatment for 7 days restored these responses in T2DM individuals, and significantly 
increased the ANP response in control individuals [335]. These findings may, at least 
in part, explain the salt handling differences reported by Zanchi et al. [322], such that 
individuals on a chronic high salt diet would have already suppressed the renin-
angiotensin-aldosterone system and increased their ANP secretion, limiting further 
physiological responses to thiazolidinedione therapy [335].  
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Available data suggest that thiazolidinedione therapy paradoxically increases, rather 
than decreases natriuresis in response to volume expansion. Rosiglitazone treated 
Zucker rats (an animal model of T2DM) exposed to an acute sodium load (a volume 
expansion stimulus) showed a more rapid natriuresis compared to control animals 
[336]. Goenka et al. reported similar results in humans, suggesting that in 
thiazolidinedione treated individuals, the initial increased sodium retention leads to 
increased ANP levels or sensitivity, which in turn contributes to an enhanced 
natriuretic response to an acute sodium load. This may prove to be a protective 
mechanism against fluid retention [335].  
 
Given that the common praline-to-alanine substitution at codon 12 (Pro12Ala) of 
exon B in the PPAR-γ gene may be a pharmacogenetic risk factor for 
thiazolidinedione-induced oedema [337], and that ACE inhibitors may be less 
effective in individuals with this polymorphism [338], studies are warranted to 
investigate whether the propensity for thiazolidinedione-induced fluid retention 
arises as a result of a lower state of activation of the renin-angiotensin-aldosterone 
system. Moreover, although Black and Asian ethnic group individuals with low renin 
volume mechanisms have been shown to have higher proximal tubular sodium 
reabsorption [339], it is unclear whether such individuals are more prone to 
thiazolidinedione-induced oedema. 
 
1.11.4 Endothelial dysfunction and peripheral vascular resistance 
 
Increased arterial stiffness and endothelial dysfunction associated with diabetes and 
the metabolic syndrome may in part explain the increased cardiovascular risk 
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associated with these conditions [340]. Biopsy specimens from subcutaneous fat 
have demonstrated that endothelial dysfunction [341] and structural alteration [342] 
of small resistance arteries contribute to peripheral vascular resistance in diabetic 
patients. In healthy individuals, vascular endothelial secretion of nitric oxide 
(vasodilator) and endothelin (vasoconstrictor) is kept in balance by circulating 
insulin levels [343, 344]. Hyperinsulinaemia disrupts this fine balance, favouring an 
enhancement of endothelin secretion and a reduction in nitric oxide secretion [344]. 
In turn, this increases vascular tone, arterial stiffness and peripheral vascular 
resistance. Not surprisingly, arterial stiffness has been identified as a risk factor for 
HF [345]. Moreover, arterial stiffness has recently been associated with early and 
asymptomatic impairment of systolic and diastolic myocardial function [346]. 
 
The mechanism by which thiazolidinediones reduce peripheral vascular resistance is 
likely to be multifactorial. PPAR-γ is expressed in various components of the 
vascular system, including endothelial cells, the vascular smooth muscle cells of the 
intimal and medial layers, and monocytes/macrophages [347]. As discussed earlier, 
thiazolidinediones downregulate endothelin-1 secretion, inhibit vascular smooth 
muscle currents, and are likely to restore the fine balance between circulating levels 
of endothelin and NO, by virtue of their insulin sensitizing effects.  These drugs have 
also been shown to have a favourable on low grade inflammation, as evidenced, for 
example, by a reduction in circulating levels of plasminogen activator inhibitor-1, 
interleukin-6, tumour necrosis factor-α (TNF-α) and non-esterified fatty acids, all of 
which have been associated with insulin resistance[348], and its associated vascular 
endothelial dysfunction [349]. 
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These effects cumulatively translate into a thiazolidinedione-associated improvement 
in arterial stiffness, as shown in clinical trials [350, 351]. This beneficial effect 
should theoretically reduce (rather than increase) the risk of development of HF and 
its associated fluid retention. Nonetheless, there are no studies evaluating whether 
T2DM individuals with a history of thiazolidinedione-induced HF are characterised 
by a greater degree of arterial stiffness compared to their ‘thiazolidinedione tolerant’ 
counterparts. Such a ‘susceptiblity factor’, if existent, could in turn be influenced by 
sodium balance, and possibly by relative thiazolidinedione-induced improvements in 
insulin sensitivity. The oedematogenic properties of insulin are well documented 
[352]. Indeed, insulin has been shown to favour sodium reabsorption along various 
nephron segments [353]. Blazer-Yost et al. described insulin-induced, PI3K-
mediated, activation of the ENaC at the distal convoluted tubule/medullary 
collecting duct [354]. The PI3K pathway has also been shown to mediate insulin-
induced sodium reabsorption at the proximal convoluted tubule [355, 356]. It has 
long been been suggested that the association of thiazolidinediones with oedema 
may occur on account of its favourable effects on insulin sensitivity, and may well 
explain why the prevalence of oedema is higher in patients treated with a 
combination of insulin and thiazolidinediones [357]. Other authors have ascribed this 
phenomenon to a synergistic effect of thiazolidinediones and insulin on renal sodium 
handling [358], particularly given the observation that the oedematogenic effects of 
insulin require IRS2 rather than IRS1 [356]. Insulin resistance is often associated 
with defects in the IRS1-dependent signalling, while IRS2-dependent signalling 
seems to be sometimes preserved in adipocytes and skeletal muscle [66, 359-361]. 
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1.11.5 Effects on vascular permeability 
 
Increased capillary permeability has also been postulated to contribute to 
thiazolidinedione-induced oedema. This hypothesis was first investigated by Idris et 
al. [362], who examined the effects of rosiglitazone on endothelial barrier function 
using an in vitro system of pulmonary artery endothelial cell monolayers, and Evans 
blue-labelled albumin to measure transendothelial albumin flux. Exposure of the 
cells to high concentrations of rosiglitazone (10 μM to 100 μM) for 4 hours resulted 
in a dose-dependent increase in transendothelial albumin flux. This effect was fully 
reversible on washing rosiglitazone off the monolayer, and subsided if exposure was 
prolonged to 24-48 hours.  
 
The mechanism(s) underlying thiazolidinedione-induced capillary permeability 
remain obscure. Several factors, notably vascular endothelial growth factor (VEGF), 
nitric oxide and protein kinase C have been implicated.  
 
(i) Vascular Endothelial Growth Factor (VEGF) 
 
VEGF is estimated to be 50 times more potent than histamine in enhancing vascular 
permeability [363]. Lower extremity oedema was induced following gene transfer of 
naked plasmid DNA encoding the 165 amino-acid isoform of VEGF in patients with 
peripheral artery disease [364]. Emoto et al. reported that plasma levels of VEGF 
were significantly higher in troglitazone treated T2DM patients compared to those 
treated with dietary measures alone, sulphonylurea or insulin [365]. Additionally, a 
longitudinal study of 5 glibenclamide treated T2DM patients showed that adjunct 
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troglitazone therapy was associated with a reversible increase in plasma VEGF 
levels [365]. The same investigators reported that therapeutic concentrations of 
troglitazone and rosiglitazone are associated with an increase in VEGF mRNA 
expression in 3T3-L1 adipocytes. In a study on Zucker rats, Sotirpoulos et al. 
established that rosiglitazone treatment increased VEGF mRNA expression in 
epididymal fat, and that this correlated with increased vascular permeability [366]. 
Similar findings were reported in retinal tissue, although the increase in VEGF 
mRNA did not reach statistical significance [366]. Troglitazone, pioglitazone and 
two other experimental PPAR-γ agonists (LY171883 and 15d-PGI2) increased 
VEGF secretion from cultured human umbilical artery vascular smooth muscle cells 
[367]. While these studies support a role for VEGF in thiazolidinedione-induced 
oedema, they are not consistent with the results of other investigations, which 
suggest that PPAR-γ negatively regulates VEGF signalling.  
 
Both rosiglitazone and 15-deoxy-delta 12, 14-prostaglandin decreased VEGF protein 
expression in transformed and primary endometrial cells in a study by Peeters et al. 
[368]. Using PPRE3 luciferase reporter transfected Ishikawa adenocarcinoma cells, 
rosiglitazone was shown to repress VEGF promoter activity in a dose-dependent 
fashion (IC50  around 50 nM). Cotransfecting full-length and truncated VEGF 
promoter-luciferase constructs and PPAR-γ expression vectors into Ishikawa cells, 
Peeters et al. also revealed that the PPAR-γ regulated domain is a direct repeat-1 
motif - 443 bp upstream of the transcriptional start site [368]. Sander et al. [369] 
reported that rosiglitazone inhibits VEGF-induced proliferation and migration of 
human pulmonary valve endothelial cells, by antagonizing VEGF-mediated nuclear 
factor of activated T cells, Cytoplasmic 1 (NFATc1) (essential for heart valve 
82 
 
 
formation). This inhibitory mechanism was confirmed in a parallel study on human 
umbilical vein endothelial cells [369]. In another study on identical cells, 
rosiglitazone was reported to markedly reduce VEGF-induced tube formation and 
endothelial cell migration, which are critical steps in angiogenesis [370]. Tooke et al. 
reported no significant difference in change in VEGF levels among insulin treated 
T2DM patients who were randomized to treatment with pioglitazone (n = 14) or 
placebo (n = 15) [371]. 
 
The conflicting data summarized above might result from a PPAR-γ induced, 
possibly cell specific, dual effect on VEGF signalling. The relative contribution of 
these factors, if any, in thiazolidinedione-induced oedema remains obscure. 
 
(ii) Nitric oxide (NO) 
 
Synthesised by endothelial cells from the amino acid L-arginine through the activity 
of endothelial nitric oxide synthase (eNOS), the ubiquitous naturally occurring 
molecule nitric oxide (NO) is an important regulator of vascular function, including 
vascular permeabilty. eNOS is regulated at the level of expression [372-374], post-
translationally through its interaction with multiple proteins [375-378], and by eNOS 
phosphorylation [379-382]. A possible relationship between thiazolidinediones and 
NO was first reported by Vinik et al.. In a 16 week, randomized, double-blind, 
placebo-controlled, crossover to open-label single blind trial, NO production was 
significantly increased in rosiglitazone treated T2DM patients [383]. Treating human 
umbilical vein endothelial cells with the PPAR-γ ligands 15d-PGI2, ciglitazone and 
rosiglitazone increased nitric oxide synthase (NOS) activity and NO release through 
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a PPAR-γ dependent mechanism in a study by Polikandriotis et al. [384]. 
Furthermore, the investigators reported that rosiglitazone and 15d-PGI2 treatment 
lead to eNOS ser1177 phosphorylation, an effect that is attenuated by the PPAR-γ 
antagonist GW9962 [384]. In an in vivo study on the fructose-fed rat model, St-
Pierre et al. investigated vascular permeability by assessing the extravasation of 
Evans blue dye in distinct muscle groups [385]. Rosiglitazone increased 
extravasation by 30-50% in the rectus femoris, soleus, gastrocnemius lateralis, vastus 
lateralis and tibialis cranialis skeletal muscles. In homogenates of skeletal muscles 
(vastus lateralis) from fructose-fed rats, rosiglitazone treatment resulted in a 
significant increase in NOS activity and eNOS immunoreactive mass, compared to 
control animals. Interestingly, the authors reported no significant change in the level 
of neuronal NOS (the most common muscle NOS isoform) [385].      
 
(iii) Protein kinase C (PKC) 
 
Protein kinase C (PKC) constitutes an important determinant of vascular 
permeability through its phosphorylation of cytoskeletal proteins that make up the 
tight intercellular junction [386-389]. In a study on Zucker rats, Sotiropoulos et al. 
reported that the rosiglitazone-associated increases in vascular permeability and 
weight were associated with selective activation of PKC and its potent activator 
diacylglycerol (DAG) in fat and retinal tissues [366]. The same investigators 
established that these rosiglitazone-induced effects in adipose tissue were abolished 
by the specific PKCβ inhibitor ruboxistaurin and in PKCβ knockout mice [366].  
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(iv) Other potential permeability factors 
 
Analyzing 384 single nucleotide polymorphisms (SNPs) from 222 cardiovascular 
and metabolic genes in 87 thiazolidinedione treated T2DM patients, Ruano et al. 
sought to discover associations between thiazolidinedione therapy and oedema [390]. 
The investigators reported significant associations with the genes for neuropeptide 
Y, glycogen synthase-1 muscle (Gsk-1 muscle), chemokine C-C motif  ligand 2, 
oxidized LDL receptor 1 and Growth Hormone Releasing Hormone [390]. Despite 
being a long-lasting vasoconstrictor, neuropeptide Y increases endothelial 
permeability [391], and has been implicated in neurogenic pulmonary oedema [392], 
laryngeal oedema [393] and inflammatory paw oedema in rats [394]. Chemokine C-
C motif ligand 2 increases the permeability of the blood-brain barrier, and 
contributes to vasogenic brain oedema [395]. Encoded by the ORL1 gene, the 
oxidized LDL receptor 1 is expressed on vascular endothelial cells [396] and is 
involved in capillary formation [397]. In summary, Ruano et al. conclude that the 
physiogenomic associations suggest a link between vascular permeability and 
thiazolidinedione-induced oedema [390]. 
 
1.12 Thiazolidinediones and cardiac pump function 
 
Partients with diabetes have a high prevalence of subclinical systolic and diastolic 
cardiac dysfunction and impaired cardiac reserve, likely due to a number of 
abnormalites such as impaired coronary flow reserve, even in the absence of 
obstructive epicardial disease [398, 399], autonomic dysfunction [400-402], 
myocardial fibrosis [403]  and maladaptive myocardial energy metabolism [404]. 
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Although cardiac expression of PPAR-γ is relatively lower than PPAR-α, the former 
is thought to be an important modulator of cardiac structure and function, 
particularly in the left ventricle. In a murine study by Duan et al., cardiac-specific 
deletion of the PPAR-γ receptor resulted in mild cardiac hypertrophy [405]. These 
findings were consistent with earlier reports that the pressure-overload induced 
increases in heart weight-to-body weight ratio and wall thickness were more 
prominent in heterozygous PPAR-γ deficient mice compared to their wild type 
counterparts [406].  
 
The effects of exogenous PPAR-γ treatment on cardiac function is controversial. 
Studies have shown that PPAR-γ agonist therapy inhibits mechanical strain- [407], 
angiotensin-II- [406, 407] and phenylephrine-induced [407] cardiac hypertrophy of 
neonatal cardiac rat myocytes in vitro. Asakawa et al. reported similar results in vivo, 
showing that pioglitazone inhibits pressure overload-induced cardiac hypertrophy 
strongly in wild type mice, and moderately so in heterozygous PPAR-γ deficient 
mice [406]. These pioglitazone-related effects on pressure-overload induced cardiac 
hypertrophy were associated with a significant reduction in the expression of 
endothelin-1 mRNA [408]. Endothelin-1 has positive inotropic and chronotropic 
actions, and induces cardiac hypertrophy [409]. In a murine study investigating 
effects at a pathophysiological level, Tsuji et al. showed that a pioglitazone induced 
reduction in left ventricular weight to body weight ratio was accompanied by a 
reduction in left ventricular collagen content, left ventricular diastolic dysfunction 
and plasma malondialdehyde-thiobarbituric acid (a marker of oxidative stress) [410]. 
Studies on intact animal models showed that PPAR-γ agonists improve cardiac 
contractility, systolic performance [411-414] and diastolic performance [412-415]. 
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Myocardial intracellular calcium concentrations increase in response to myocyte 
stretch, in a bid to  enhance cardiac output. The calcium, calmodulin-dependent 
phosphatase calcineurin plays a critical role in this process, through 
dephosphorylation of a family of transcription factors known as nuclear factors of 
activated T cells (NFATs) [416]. Four calcineurin sensitive NFAT isoforms have 
been identified (NFATc1, NFATc2, NFATc3, NFATc4) [417, 418]. 
Dephosphorylated by calcineurin, NFAT transcription factors translocate to the 
nucleus and regulate the expression of target myocardial genes [416, 419]. 
Activation of calcineurin or NFATc4 was shown to induce cardiac hypertrophy and 
HF in murine models [416]. Treatment of cardiomyocytes with rosiglitazone 
inhibited endothelin-1 induced calcineurin activity, enhanced the association of 
PPAR-γ with calcineurin/NFATc4 and suppressed the nuclear translocation of 
NFATc4 [420]. This observation is consistent with genotypic observations from the 
DREAM study, in which one single nucleotide polymorphism (SNP) in NFATC2 
(rs6123045) was significantly associated with oedema [OR 1.89 (95% CI 1.47, 2.42) 
[421]. The effect is seemingly additive, with oedema rates being highest among 
patients homozygous for the risk allele, intermediate in heterozygous individuals, 
and lowest among subjects homozygous for the protective allele [421]. 
 
Multiple human studies have demonstrated no untoward effects on various 
parameters of cardiac performance and some trends toward improved systolic 
function associated with longer-term thiazolidinedione therapy. Ghazzi et al. 
compared echocardiographic data before and 48 weeks after randomizing 154 T2DM 
patients to treatment with troglitazone or glyburide, showing that thiazolidinedione 
therapy was associated with significant improvements from baseline in stroke 
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volume index and cardiac index, with no change in left ventricular mass index. There 
were no significant changes in any echocardiographic parameter in the glyburide-
treated group [411]. A similar randomized, blinded clinical trial that included 203 
patients did not report any significant differences in left ventricular mass index, 
ejection fraction or left ventricular end-diastolic volume between patients 
randomized to rosiglitazone versus glyburide [422]. A smaller study by Hirayama 
and co-workers investigated echocardiographic parameters in 10 male hypertensive 
T2DM men and 12 normotensive T2DM men treated with pioglitazone for 6 months. 
There was no change in fractional shortening (a simple way of measuring ejection 
fraction) in either group. Pioglitazone was however associated with a significant 
reduction in left ventricular mass in the normotensive group [423]. In a 52 week 
placebo controlled study of 224 T2DM patients with NYHA class I/II HF, 
rosiglitazone was not associated with any changes in left ventricular volumes, left 
ventricular ejection fraction or cardiac index [424]. Similarly, albeit a different study 
population, Horio et al. did not report changes in the absolute values of left atrial or 
left ventricular end-diastolic diameter in 30 non-diabetic patients with essential 
hypertension treated with pioglitazone for 6 months [425].  
 
The cardiac antihypertrophic properties of exogenous PPAR-γ agonist therapy 
discussed above contrast with the results of other studies. Duan et al. reported that 
rosiglitazone treatment caused cardiac hypertrophy in wild type and cardiac-specific 
PPAR-γ knockout mice, suggesting that although PPAR-γ is essential for normal 
cardiac development, treatment with exogenous PPAR-γ agonists might be 
detrimental [405]. This raised the hypothesis that exogenous PPAR-γ-associated 
cardiac hypertrophy could reflect the anabolic consequences of improved insulin 
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sensitivity. However, comparing outcomes in wild type mice and mice with 
cardiomyocyte restricted knockout of insulin receptors, the non-thiazolidinedione 
PPAR-γ agonist 2-(2-(4-phenoxy-2-propylphenoxy) ethyl) indole-5-acetic acid 
increased heart weights by 16% in the former group and 22% in the latter, and 
induced similar fold increases in the expression of hypertrophic markers such as α-
skeletal actin, brain natriuretic peptide, and ANP in both type of mice [426]. These 
outcomes suggested that thiazolidinedione-induced myocardial hypertrophy occurs 
independently of insulin signalling [426]. Indeed, it is plausible to hypothesize that 
cardiac hypertrophy is a consequence of thiazolidinedione-induced water retention 
[427], in keeping with the observation that 2-(2-(4-phenoxy-2-propylphenoxy) ethyl) 
indole-5-acetic acid-treated mice had typical echocardiographic features of volume 
overload (increased left ventricular diastolic diameters and increased cardiac output) 
[426]. In a pilot study randomizing 30 T2DM patients inadequately controlled in 
metformin and sulphonylurea to treatment with pioglitazone or insulin glargine for 
26 weeks, Dorkhan et al. reported that left ventricular end-diastolic volume increased 
by 11% and left atrial systolic volume increased by 17% in the pioglitazone group (p 
< 0.05 for the difference between pioglitazone- and insulin-treated groups). There 
were no differences in the change of ejection fraction or left ventricular mass 
between the randomization arms [428]. The reported increases in left atrial volume 
may be of particular clinical significance in thiazolidinedione-treated T2DM 
patients, given the observation that this echocardiographic parameter carries 
prognostic significance in a variety of cardiac disorders and in the general population 
[429]. Moreover, one case series suggested that T2DM patients with diastolic 
dysfunction are more prone to developing thiazolidinedione-induced HF [430]. 
Although most patients can tolerate a 6-8% plasma volume expansion occurring 
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subacutely after initiation of thiazolidinedione therapy [163, 164, 431], diabetic 
patients with impaired cardiac reserve may manifest signs and symptoms of CHF in 
this setting.  
 
There is currently considerable interest in the concept of ‘cardiac lipotoxicity’, 
wherein triglycerides are deposited in cardiac myocytes [432, 433], particularly in 
the setting of obesity or absolute or relative leptin deficiency/resistance (a phenotype 
associated with T2DM). Intracardiac triglyceride content was reported to be higher 
in obese human subjects, and was associated with increased left ventricular mass and 
decreased septal wall thickening [434]. Intramyocardial accumulation of ectopic 
fatty acid results in cellular dysfunction and non-oxidative fatty acid metabolism, 
which increases traffic through the ceramide pathway [432], resulting in 
lipoapoptosis, impairing cardiac compliance and contractility [435]. Troglitazone 
was shown to reduce intra-cardiomyocyte lipid concentrations and prevent loss of 
myocardial contractile function in a Zucker rat model [433]. 
 
In summary, the effects of PPAR-γ agonists on cardiac performance remain unclear, 
particularly given the conflicting results from animal studies. Human studies have 
been reassuring in this regard, albeit limited by the number of recruited patients and 
duration of follow-up. Further mechanistic research based on careful phenotyping is 
clearly warranted to clarify these issues further, particularly given the ongoing lack 
of large scale, prospective trials. 
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1.13 Other suggested ‘fluid-retaining’ mechanisms 
 
Thiazolidinedione-induced oedema has also been ascribed to altered water-ion 
transport in the gastrointestinal tract. The latter hypothesis is borne out of the results 
of a study investigating the effects of troglitazone on rat and human duodenal 
mucosa cells. In this study, Hosokawa et al. demonstrated inhibition of electrogenic 
bicarbonate secretion by these cells, possibly interfering with passive sodium and 
water movement into the gastrointestinal tract lumen via a paracellular pathway 
[436].  
 
1.14 Thiazolidinediones and heart failure: unanswered questions 
 
Guided by the data summrised above, the manufacturers of rosiglitazone and 
pioglitazone excluded diabetic patients with New York Heart Association (NYHA) 
functional class III or IV HF from their applications for marketing licenses [163, 
164]. The NICE guidelines have adopted a more stringent approach, and do not 
recommend the use of these drugs in any patient with HF, irrespective of severity 
[82]. While this approach is likely to minimize the risk of fluid retention, it does not 
eliminate it completely. Although thiazolidinedione-associated oedema is a clinically 
important adverse effect, absolute rates are low and the time course is uncertain. 
Traditional observational study designs have encountered difficulties in finding 
informative cases. Given the hypothesis that some individuals are more sensitive to 
the phenotype than others, it seems appropriate (and cost-effective) to study 
previously-intolerant individuals in some depth. The most appropriate comparator 
group is patients who are tolerant of thiazolidinediones.  
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Based on a case-control design, one of the aims of this thesis was therefore to 
identify and compare the baseline characteristics of matched cohorts of patients 
tolerant and previously intolerant of thiazolidinediones with the aim of assessing 
whether patients known to be intolerant to thiazolidinediones are characterised 
during acute or chronic ‘high salt’ loading by differences in their metabolic, 
cardiovascular and renal responses. 
 
Given the anticipated difficulties in identifying thiazolidinedione intolerant patients, 
a parallel project was conceived in collaboration with the Health Informatics Centre 
(HIC) at the University of Dundee to identify and characterize NHS patients exposed 
to thiazolidinediones in routine clinical care. Prescription and hospital admission 
data were used to identify thiazolidinedione-treated patients whose treatment was 
apparently complicated by HF. Moreover, the Diabetes Audit and Research in 
Tayside Scotland (GoDARTS) cohort [437], a well-validated electronic data linkage 
– based register of diabetes patients in Tayside, Scotland enabled genetic 
characterization of the phenotypic characteristics identified at population level. At 
the time these studies were conceived, it was intended that they would provide 
sufficient background data to embark on a large prospective trial validating the 
usefulness of one or more biomarkers in the prediction of thiazolidinedione-
associated fluid retention. Better characterization of thiazolidinedione intolerant 
patients, together with an adequate understanding of the mechanisms underlying 
thiazolidinedione-associated fluid retention was intended to guide the development 
and future assessment of PPAR-γ receptor modulators (and related agents such as 
dual PPARγ/δ agonists) with apparently more favourable adverse event profiles. 
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.Section IV -  Insulin resistance in type 1 diabetes - is there a role for 
metformin? 
 
1.15 Insulin resistance – a common co-morbidity in type 1 diabetes   
 
While insulin resistance is undoubtedly a central pathognomonic feature of T2DM, 
its association with T1DM is also increasingly recognized. Insulin resistant patients 
with T1DM have been shown to express lower tissue levels of the insulin receptor 
[438]. Moreover, the expression of the GLUT-4 transporter in skeletal muscle is 
lower in obese patients with T1DM [439]. Insulin-insensitive patients with T1DM 
and T2DM have been reported to have raised intramyocellular lipid [440], which as 
discussed, interferes with insulin signalling. Comparing adipocytokine levels in 91 
T1DM and 91 healthy children, Celi et al. reported that circulating adiponectin levels 
were higher in prepubertal diabetic children and positively correlated with HbA1c, 
while BMI-adjusted leptin concentrations were higher in pubertal diabetic children 
and positively correlated with daily insulin dose. There were no differences in TNF-
α concentrations between the two groups [441]. Luna et al. similarly reported that 
children with T1DM were characterized by higher leptin concentrations compared 
with their healthy counterparts, but did not associate this finding with HbA1c, daily 
insulin dose or duration of the disease [442]. Two small studies investigating the 
kinetic mechanisms of insulin resistance in T1DM reported that impaired insulin-
stimulated vasodilation impairs glucose delivery, and hence extraction at the level of 
skeletal muscle [443, 444].  
 
93 
 
 
Additional factors are thought to contribute to insulin resistance in pubertal T1DM 
patients. Insulin resistance increases in puberty, and reaches a peak at Tanner stage 3 
[445]. The situation is further compounded by the fact that obesity is a growing 
problem in young patients with T1DM. Indeed, Libman et al. [446] showed that 50% 
of young Americans with T1DM were overweight or obese. Produced in the liver, 
insulin growth factor (IGF-1) plays a insulin-like role in glucose homeostasis, 
influencing hepatic glucose output and peripheral glucose uptake.  Circulating IGF-1 
levels are reduced in T1DM [447], possibly secondary to portal hypoinsulinaemia 
[448]. This results in a compensatory increase in Growth Hormone (GH) secretion 
(which antagonizes the effects of insulin) and IGF-1 binding protein synthesis [448, 
449], diminishing free (and hence biologically active) IGF-1 levels further. 
 
1.15.1 The 'accelerator' hypothesis 
 
Although the functional effects of these multi-level differences are yet to be clearly 
elucidated, they have the potential to contribute to the mechanism of insulin 
resistance in T1DM individuals. It has been noted that T1DM is increasing in 
incidence and generally presenting at a younger age. Moreover, a smaller proportion 
of newly diagnosed patients are characterised by high risk and protective HLA 
haplotypes [450, 451], while a larger number have intermediate genetic susceptibility 
[452]. This suggests an increasing role of the environment in the aetiology of T1DM. 
Some [446, 453, 454], though not all studies [455, 456], have reported that obese 
patients with T1DM present at a younger age, possibly reflecting genetic and ethnic 
differences between study populations [457]. Additionally, BMI may have been too 
crude a measure of insulin resistance in pubertal patients [445]. Four studies carried 
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out in different continents analyzed data from prospective follow-up studies of 
autoantibody positive first degree relatives of patients with T1DM. Using the 
homeostasis model of insulin resistance (HOMA-IR) to first phase insulin response 
(FPIR) as an index that standardizes insulin resistance to residual β-cell function and 
corrects for falling FPIR as the T1DM process progresses, all four studies reported 
that insulin resistance is an independent risk factor for the development of T1DM 
[458-461]. Insulin resistance in pre-T1DM may not genetically determined, as 
suggested in a twin study by Hawa et al., in which patients developing T1DM had 
higher fasting insulin levels compared to their monozygotic twin counterpart who 
did not progress to the disease after 18 months of follow-up [462]. The hyperbolic 
insulin secretory response of the β-cells is dependent on normal insulin sensitivity 
[7]. Given that several studies have reported that islet-cell antibody individuals who 
progress to T1DM have greater insulin resistance for their level of insulin secretion 
[458-461], the insulin resistant state may unmask β-cell deficiency at an earlier stage 
[456, 463]. Adipocytokine receptors are expressed on the surface of immune cells 
[464], an observation that is likely to be relevant in the aetiopathogenesis of T1DM 
given that the intraperitoneal injection of leptin accelerated the autoimmune 
destruction of insulin-producing β cells and significantly increased interferon-γ 
production in peripheral T-cells in the non-obese diabetic mouse (a model of T1DM) 
[465]. Reports that insulin resistance is associated with a lower frequency of entering 
the ‘honeymoon phase’ in T1DM [466, 467] follow the same line of thought, 
potentially further justifying pharmacological attempts at reducing insulin resistance 
in T1DM. Thus, in summary, the accelerator hypothesis suggests that, while T1DM 
is essentially triggered by an immune mediated process, its progression is expedited 
by potentially modifiable factors such as insulin resistance and BMI [468]. This 
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essentially implies that, in the absence of a triggering immunological event, such 
patients would have developed T2DM at some point in their lives. 
 
1.15.2 The concept of 'double diabetes' 
 
The term 'double diabetes' was coined from the observation that patients with T1DM 
and a family history of T2DM were more likely to be overweight,  required higher 
insulin doses and yet were less likely to achieve adequate glycaemic control [469]. 
This hypothesis considers T1DM and insulin resistance/obesity as independent 
processes. A study of 427 patients with T1DM reported that 15% fulfilled the WHO 
criteria for the metabolic syndrome, and of these 26.9% were insulin resistant, 
compared with 3.4% of those without metabolic syndrome (OR 8.9; p = 0.001). 
Those with the metabolic syndrome required higher median insulin dosage [0.9 
(interquartile range = 0.7, 1.2) vs 0.6 (interquartile range = 0.5, 0.9) U/kg; p = 0.03], 
were older [median 35.0 (interquatile range = 26.2, 47.3) vs. 29.7 (interquartile range 
= 23.4, 36.4) years, p = 0.002], and had longer duration of diabetes [median 19.7 
(interquartile range = 10.7, 25.6) vs. 12.1 (interquartile range = 6.3, 17.9) years, p = 
0.0001] [23]. 21% and 44% of patients with T1DM met WHO diagnostic criteria of 
the metabolic syndrome in the Pittsburgh EDC [470] and FiannDiane [471]  cohorts 
respectively. A parental history of hypertension has been associated with 
albuminuria in both men and women with T1DM. Additionally, albuminuria in 
women with T1DM was associated with parental diabetes in a cross-sectional study 
of 3250 patients recruited into the EURODIAB study [472]. Analyzing data from the 
Pittsburgh Epidemiology of Diabetes Complications Study, Erbey et al. concluded 
that T1DM patients with a first degree family member with T2DM were at higher 
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risk of coronary artery disease [OR 1.89 (95% CI 1.27, 2.84)]. However, this effect 
did not remain significant after adjusting for T1DM duration, triglycerides, 
hypertension, Beck depression and nephropathy status [OR 1.45 (95% CI 0.87, 
2.28)] [473]. Nonetheless, a T1DM patient's risk of developing coronary artery 
disease increased with an increasing number of first degree family members 
suffering from T2DM (p = 0.001 for trend), such that the presence of two, rather 
than one family member virtually increased a T1DM individual's OR from 1.62 to 
5.13 [473]. 
 
1.16 Consequences of insulin resistance in type 1 diabetes 
 
McGill et al. reported that patients with T1DM and features of the metabolic 
syndrome were characterised by a higher macrovascular composite endpoint (OR = 
3.3, p = 0.02), and a higher combined macrovascular and microvascular endpoint 
(OR = 3.1, p = 0.0001). Subdividing individuals with T1DM into duration of 
diabetes quartiles, the same investigators additionally reported that individuals 
diagnosed 20 or more years earlier and fulfilling the criteria for the metabolic 
syndrome were at a higher risk of stroke (OR = 22.8, p = 0.008) and severe 
retinopathy (OR = 3.7, p = 0.01); the risk of peripheral vascular disease was 
borderline (OR = 7.3, p = 0.05) [23]. Investigating 1337 Caucasian patients with 
T1DM fulfilling IDF diagnostic criteria for the metabolic syndrome and participating 
in the DCCT trial, Kilpatrick et al. [24] reported that insulin sensitivity (measured as 
estimated glucose disposal rate [eGDR] in mg/kg/min) strongly protected against the 
development of retinopathy (HR 0.75 per mg/kg/min; p < 0.001), nephropathy (HR 
0.88 per mg/kg/min; p = 0.005) and cardiovascular disease (HR 0.70 per mg/kg/min; 
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p = 0.002). The authors also reported that the prevalence of the metabolic syndrome 
in these patients increased from 15.5% at baseline to 27.2% at year nine in 
conventionally-treated patients. The corresponding rise was higher in intensively-
treated individuals (13.7% to 45.4%). These changes were attributed to weight gain 
[24]. 
 
Similar associations between markers of the metabolic syndrome, insulin resistance 
and individual macro-/micro-vascular complications in T1DM were reported in other 
studies [25-32]. A historical prospective cohort study of 603 patients with T1DM  
recruited from the Pittsburgh epidemiology of diabetes complications study and 
followed up for 10 years (excluding individuals with prevalent coronary artery 
disease) showed that insulin resistance, (measured using eGDR, and comparing 
lowest quintile versus the rest), predicted hard coronary artery disease endpoints 
(myocardial infarction, coronary artery disease death or angiographically proven 
stenosis) [HR 2.7 (95% CI 1.3, 5.6); p = 0.007 (from Cox proportional hazards 
model)] [27]. In general, this result is in agreement with that published by 
Soedamah-Muthu et al., who reported a relationship between waist-hip ratio (a 
surrogate measure of insulin resistance) and coronary heart disease in men 
participating in the EURODIAB Prospective Complications Study (n = 2329 
patients) [HR 1.32 (95% CI 1.08, 1.62); p < 0.01 (from Cox proportional hazards 
model)] [28].  
 
Olson et al. investigated the relationship between insulin resistance and peripheral 
artery disease in a cohort of patients from the Pittsburugh epidemiology of diabetes 
complications study (n = 586 patients), concluding that eGDR predicts the 
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development of lower extremity arterial disease (defined as claudication, foot 
ulceration or lower extremity claudication) in women [HR 0.45 (95% CI 0.32, 0.64); 
p < 0.001 (from Cox proportional hazards model)] [32].  
 
A review of the relationship between insulin resistance and microvascular 
complications also yields significant data. In a separate publication based on follow-
up data of patients from the Pittsburgh epidemiology of diabetes complications study 
(n = 485 patients), insulin resistance was reported to be a predictive factor for overt 
nephropathy in T1DM, both in the short term (1-5 years of follow-up) and in the 
long term (6-10 years of follow-up) [p < 0.001 for both associations (from Cox 
proportional hazards model)] [31].  Giorgino et al. analyzed data from 352 
microalbuminuric patients with T1DM from 31 European centres recruited in the 
EURODIAB Prospective Diabetes Study. The investigators compared risk factors at 
baseline between patients who remained microalbuminuric, progressed to 
macroalbuminuria or reverted to normoalbuminuria. Baseline body weight was 
associated with progression to macroalbuminuria [Standardised estimate of relative 
risk (SERR) 1.5 (95% CI 1.1, 2.3); p = 0.03], together with HbA1c [SERR 2.1 (95% 
CI 1.4, 3.0); p = 0.0003] and albumin excretion rate [SERR 1.9 (95% CI 1.3, 2.8); p 
= 0.0006]. [30]. de Boer et al. investigated whether waist circumference is associated 
with incident microalbuminuria and a change in creatinine clearance among 1279 
patients with T1DM who were enrolled in the Diabetes Control and Complications 
Trial (DCCT). Each 10 cm increase in waist circumference was associated with a 
significantly increased risk of incident microalbuminuria [HR 1.34 (95% CI 1.07, 
1.58)], after adjusting for age, gender, race, duration of diabetes, treatment group, 
99 
 
 
smoking status, waist circumference, HbA1c and albumin excretion rate (each of 
which were measured at DCCT close-out) [25].  
 
Analyzing data from 764 patients with T1DM recruited into the EURODIAB study 
and followed up for 7.3 years, Chaturvedi et al. reported that waist-hip ratio is a risk 
factor for developing retinopathy [standardized regression estimate (SRE) 1.32 (95% 
CI 1.07, 1.63); p = 0.01], together with duration of diabetes [SRE 1.32 (95% CI 1.07, 
1.61); p = 0.008], HbA1c [SRE 1.93 (95% CI 1.52, 2.44); p = 0.0001] and fasting 
triglyceride levels [SRE 1.24 (95% CI 1.01, 1.54); p = 0.04] [26]. 
 
Data from the EURODIAB study was also used to investigate the association 
between insulin resistance, its surrogate measures and incident distal symmetric 
neuropathy in 1172 patients with T1DM. Adjusting for HbA1c values and duration 
of diabetes, weight [OR 1.34 (95% CI 1.17, 1.54); p < 0.001], BMI [OR 1.40 (95% 
CI 1.22, 1.61); p <  0.001] and a lower eGDR [OR 1.37 (95% CI 1.08, 1.73); p = 
0.01] were associated with an increased risk of incident neuropathy [29].     
 
1.17 Is there a conceptual role for metformin in type 1 diabetes? 
 
Intensive glycaemic control in patients with T1DM was reported to decrease the long 
term risk of cardiovascular disease by 42% and the risk of nonfatal myocardial 
infarction, stroke or cardiovascular death by 57% [474], with changes in HbA1c 
(rather than changes in cardiovascular risk factors) seemingly accounting for most of 
the benefit. However, the DCCT showed that intensive insulin therapy is hampered 
by excessive weight gain, resulting in visceral adiposity [475], and deletirious effects 
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on lipids, blood pressure [476] and inflammatory markers [477]. Similar findings 
were reported in the EURODIAB study, with T1DM patients gaining more than 5 kg 
over a mean observation period of 7.3 years being characterised by better glycaemic 
control at the expense of higher blood pressure, LDL-cholesterol and triacylglycerol, 
and lower HDL-cholesterol [478]. Subcutaneous insulin administration is associated 
with relative peripheral hyperinsulinaemia and relative hepatic hypoinsulinaemia 
[479]. Surprisingly, although portal administration of insulin increased IGF-1 and 
reduced prevalent GH levels, this occurred at the expense of a more atherogenic lipid 
profile (reduced HDL-cholesterol, increased LDL-cholesterol:HDL-cholesterol ratio) 
[480-484].  Whether this effect translates into a adverse cardiovascular outcomes 
remains to be determined. Despite relative hepatic hypoinsulinaemia, glucagon 
secretion is preserved in T1DM, favouring lipid oxidation. Exogeneous 
subcutaneous insulin administration further enhances this process, increasing 
circulating levels of non-esterified fatty acids and fuelling lipid accumulation in 
skeletal muscle [440, 479, 485, 486].   
 
These findings may justify the addition of the weight neutral insulin-sensitizing drug 
metformin, the use of which (in T2DM) has been associated with modest reductions 
in serum triacylglycerol, VLDL and LDL levels, decreased C reactive protein, 
decreased platelet activation and a reduction in procoagulant factors (such as factor 
VII and fibrinogen) [487]. 
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1.18 Metformin in type 2 diabetes - benefits beyond glycaemic control 
 
The United Kingdom Prospective Diabetes Study (UKPDS) was the first major study 
underpinning the cardiovascular benefits of metformin in T2DM. The study 
randomized 1704 overweight patients with T2DM to initial treatment with 
metformin (342 patients), sulphonylurea/insulin (951 patients) or dietary measures 
alone (411 patients). Compared with dietary measures, metformin (but not 
sulphonylurea/insulin therapy) was associated with a 32% lower incidence of any 
diabetes-related endpoint (micro and macrovascular) (95% CI 13, 47; p = 0.002), 
42% fewer diabetes related deaths (95% CI 9, 63; p = 0.017), 36% lower all-cause 
mortality (95% CI 9, 55; p = 0.011), and 39% fewer myocardial infarctions (MIs) (p 
= 0.010) [488]. These effects persisted after 10 years of follow-up [risk reductions of 
21% for any diabetes related end-point (p = 0.01), 33% for myocardial infarction (p 
= 0.005), and 27% for death from any cause (p = 0.002)], despite the fact that 
differences in glycaemic control (as assessed by HbA1c levels) were lost after one 
year of follow-up [489]. 
 
The cardiovascular benefits of metformin in high risk patients with T2DM was 
elucidated by the the Prevention of Restenosis with Tranilast and its Outcomes 
(PRESTO) trial. This double-blind randomised controlled trial compared 
cardiovascular outcomes in patients treated with tranilast following a percutanouse 
coronary intervention. After 9 months of follow-up, patients treated with metformin 
(with or without additional therapy, n = 887) were at a significantly lower risk of 
death [OR 0.39 (95% CI 0.19, 0.77); p = 0.007) and myocardial infarction [OR 0.31 
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(95% CI 0.15, 0.66); p = 0.002] compared to those treated with insulin and/or 
sulphonylurea (n = 1110) [490]. 
 
Similar beneficial outcomes were noted following retrospective analysis of data from 
several large databases of patients with T2DM. The Diabetes and Audit in Research 
Tayside Scotland (DARTS) study (n = 5730 patients) reported that mortality was 
significantly lower after 5 years among drug-naïve T2DM patients initially treated 
with metformin compared to a sulphonylurea [491]. McAfee et al. compared 
cardiovascular outcomes in T2DM patients commenced on metformin, a 
sulphonylurea or rosiglitazone over a period of 4.5 years and whose data were 
extracted from a large US insurance database (n = 33363). Metformin monotherapy 
was associated with a lower risk of  the composite endpoint of myocardial infarction 
and coronary revascularization after 5 years of follow-up compared to sulphonylurea 
monotherapy [HR 0.77 (95% CI 0.62, 0.96)] [492]. These findings are consistent 
with the results of other studies. Eurich et al. analyzed data of 12,272 new users of 
oral hypoglycaemic agents suffering from T2DM and HF, recruited from the 
Saskatchewan Health Database (n = 1833, average age 72 years) and followed up for 
a mean of 2.5 years. Metformin monotherapy was associated with a lower risk of 
mortality [HR 0.70 (95% CI 0.54, 0.91)] and a lower risk of the composite outcome 
of deaths or hospitalizations [HR 0.83 (95% CI 0.70, 0.99)] compared to 
sulphonylurea monotherapy [281]. A retrospective study of 16417 Medicare 
beneficiaries with HF discharged after hospitalization with a principal diagnosis of 
HF showed that metformin pharmacotherapy was associated with a reduction in 
crude 1-year mortality rates (24.7% vs 36.0% of patients not treated with an insulin 
sensitizing drug; p < 0.0001), a result confirmed in multivariate analysis [HR 0.87 
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(95% CI 0.78, 0.97)] [283]. Metformin was also associated with a modestly reduced 
risk of readmission with HF [HR 0.92 (95% CI 0.86, 0.99)] but no effect on all-cause 
readmissions [283]. A systematic review and meta-analysis of eight controlled 
studies compared outcomes between different antihyperglycaemic agents in T2DM 
patients with HF [284]. Metformin was associated with significantly reduced all 
cause mortality in two studies [HR 0.86 (95% CI 0.78, 0.97)] (n = 1861 patients), 
and with similar trends in a third study, compared with non-sensitisers 
(sulphonylureas, non-sulphonylurea insulin secretagogues, alpha glucosidase 
inhibitors or insulin) (n = 12069 patients). Formal meta-analysis showed that 
metformin was not associated with any significant effects on all-cause 
hospitalization, albeit a lower risk for heart-failure related readmissions [HR 0.92 
(95% CI 0.86, 0.99)] [284], in keeping with the findings of Masoudi et al. [283].  
 
Of potential direct relevance to T1DM, Kooy et al. compared outcomes in 390 
insulin-treated patients with T2DM randomized to treatment with metformin or 
placebo therapy and followed up for 4.3 years [493]. Adjunct metformin 
pharmacotherapy was associated with a reductions in body weight [-3.07 kg (range -
3.85 to -2.28); p < 0.001], HbA1c level [mean -0.4% (95% CI -0.25, -0.55); p < 
0.001] and insulin requirements [mean -19.63 IU/day (95% CI -14.36, -24.91); p < 
0.001]. Additionally, metformin was reported to decrease macrovascular morbidity 
and mortality (HR 0.61 [95% CI 0.40, 0.94]; p = 0.02), an effect that was partly 
explained by the difference in weight [493].  
 
In a retrospective study on 8063 patients with no prior history of congestive HF, 
Nichols et al. compared the incidence of HF between individuals who were 
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commenced on additional treatment for T2DM over a period of 4 years [494]. The 
prescription of metformin to insulin-treated patients with T2DM reduced the 
congestive HF rate ratio to 0.63 (95% CI 0.3, 1.07), a development which is 
particularly desirable given that initial insulin therapy was associated with a higher 
incidence of congestive HF [44.5/1000 patients/year (95% CI 37.9, 52.3)] than 
metformin [15.3/1000 patients/year (95% CI 8.9, 26.3)] or sulphonylureas 
[19.9/1000 patients/year  (95% CI 17.2, 23.1)] [494]. In a similar vein, the 
systematic review by Eurich et al. had also reported that insulin treatment was 
associated with increased cardiovascular morbidity (hospital admission for HF, 
prescription for open label angiotensin converting enzyme inhibitor, or myocardial 
infarction) and mortality [HR 1.38 (95% CI 1.06, 1.80)] [284].  
 
1.19 Use of adjunct metformin in type 1 diabetes: what is the evidence? 
 
As suggested above, the available data underpinning the use of metformin in T2DM 
justify examining the safety and efficacy of this drug in T1DM. Its low cost, proven 
safety profile and promising short and long-term macro- and microvascular benefits 
in T2DM justify studies to define its use in a disease increasingly associated with 
insulin resistance and other components of the metabolic syndrome. This thesis will 
therefore examine the available evidence supporting the use of this drug in T1DM, 
and investigate the hypothesis that adjunct metformin is associated with (i) a 
decrease in insulin dose and weight, and (ii) an improvement in glycaemic control 
and lipid profile. 
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Chapter 2 - Clinical study  
Characterising thiazolidinedione 'tolerant' and 'intolerant' patients 
A physiological approach 
 
Section I - Methods 
 
2.1 Study design  
   
This clinical study was a case-control biomarker study in T2DM patients aged 40 to 
70 years. It compared physiological parameters between thiazolidinedione 'tolerant' 
and 'intolerant' patients in response to a low, acute high and chronic high salt diet. 
This was achieved during three study visits.  
 
2.2 Good clinical practice 
 
The study was conducted in accordance with the protocol, protocol amendments, 
Good Clinical Practice (GCP) as described in the International Conference on 
Harmonization (ICH) tripartite harmonized guidelines of technical requirements for 
registration of pharmaceuticals for human use [495], the Declaration of Helsinki 
(2000 Edinburgh) [496],  the ‘Research Governance Framework for Health and 
Community Care’, second edition, 2006 [497], and applicable legal and regulatory 
requirements 
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2.3 Ethics 
 
In accordance with the above guidelines governing medical research, the study 
protocol and its subsequent amendments were subjected to ethical approval by the 
Tayside Research Ethics committee. The protocol for this study was approved in 
February 2008. A number of amendments pertaining to study documentation were 
subsequently submitted for ethical approval in view of difficulties with patient 
recruitment, funding withdrawal by Wyeth Pharmaceuticals, and a re-location of the 
principal investigator. Patient recruitment and study procedures were allowed to 
commence and/or proceed only when the ethics committee approval letter had been 
received by the Principal Investigator at each stage. Protocol amendments were 
prepared by the undersigned, working as a Clinical Research Fellow in this project, 
and approved by the Principal Investigator. Administrative amendments that did not 
affect the conduct of the study or patient safety, and did not significantly reduce the 
scientific value of the protocol did not require a formal review and approval from the 
Ethics Committee. A copy of all correspondence between the investigator and the 
Ethics Committee was kept in the appropriate section of the study file. The Clinical 
Research Fellow or Principal Investigator was bound to follow local institutional 
guidelines on reporting serious adverse events.   
 
2.4 Caldicott-Guardian approval 
 
ICH GCP section 2.13 states that ‘systems with procedures that assure the quality of 
every aspect of the trial should be implemented’ [495]. The identification of 
potentially suitable patients was aided by access to SCI-DC datasets. With this in 
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mind, the data collection process was subjected to Caldicott-Guardian approval in 
accordance with established protocols [498], and only commenced once the 
necessary approval letter was received by the Principal Investigator. A copy of all 
study-related correspondence pertaining to Caldicott-Guardian approval was kept at 
the appropriate section of the study file. 
 
2.5 Study objectives 
 
2.5.1 Objective 1 – to compare the baseline characteristics of two cohorts of 
patients with type 2 diabetes who are either sensitive or insensitive to 
thiazolidinedione-associated fluid retention 
 
Although thiazolidinedione-induced oedema is a clinically important adverse effect, 
absolute rates are low and the time course is uncertain. Traditional observational 
studies have encountered difficulties in finding informative cases. Given the 
hypothesis that some individuals may be more prone to thiazolidinedione-associated 
oedema than others, it seemed appropriate and cost-effective to study these 
'intolerant' individuals in some depth. The most appropriate comparator group was a 
cohort of thiazolidinedione 'tolerant' patients. The potentially confounding effect of 
thiazolidinedione therapy was avoided by substituting these antihyperglycaemic 
agents with sulphonylurea therapy for 4 weeks prior to the study interventions, while 
maintaining stable glycaemic control. 
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2.5.2 Objective 2 – to compare the characteristics of the above two cohorts 
during an acute and chronic ‘high normal’ sodium loading in order to detect 
differences in metabolic, cardiovascular and renal characteristics. 
 
This case-control study, comparing cohorts of matched thiazolidinedione 'tolerant' 
and previously 'intolerant' patients, was designed to address the following 
hypotheses: 
 
Primary hypotheses: 
 
Are patients known previously to have been intolerant of thiazolidinediones 
characterised during either acute or chronic “high normal” sodium loading by: 
1) Increased ankle-foot volume (AFV) (a measure of oedema)  
2) Impaired left ventricular diastolic function (including tissue Doppler) 
3) High pulse wave velocity 
4) Salt sensitivity of blood pressure 
5) High plasma VEGF levels 
 
Secondary hypotheses: 
 
Do renin-angiotensin system activation, fractional sodium excretion, free water 
handling and/or total body water (deuterium dilution) differ between cohorts 1 and 2 
during acute or chronic sodium loading? 
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2.6 Study population  
 
The study recruited male and female T2DM patients aged between 40 and 70 years 
of age with a history of thiazolidinedione exposure. These patients were subdivided 
into two cohorts: 
 
• A thiazolidinedione 'tolerant' cohort (cohort 1) defined by T2DM individuals 
previously initiated on thiazolidinediones (usually, but not exclusively in 
combination with metformin), with HbA1c ≤9.0% and without diuretic 
therapy, whose current thiazolidinedione therapy was not complicated by 
fluid retention and/or HF. 
 
• A thiazolidinedione 'intolerant' cohort (cohort 2) defined by T2DM patients 
whose thiazolidinedione therapy was withdrawn within three months of onset 
of thiazolidinedione exposure as a consequence of drug-associated fluid 
retention and/or HF, and now with an HbA1c of ≤9.0% on one or two non-
thiazolidinedione agents (sulphonylreas/metformin) and without diuretic 
therapy. 
 
The cohorts were matched as far as possible for age and gender. Only patients who 
met all inclusion criteria and no exclusion criteria were considered for participation 
in this study. 
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2.7 Inclusion criteria 
 
All patients recruited into the study were required to fulfil all of the following 
criteria:  
• Adult patients tolerant (cohort 1) or previously-intolerant (cohort 2) of 
thiazolidinediones 
• T2DM 
• Aged ≥40 years and ≤70 years 
• Recorded HbA1c ≤9.0% within last six weeks  
• Non-microalbuminuric (either negative single morning sample or tested at 
screening)  
• Recorded blood pressure ≤145/85 mmHg on no therapy, monotherapy or dual 
therapy  
• Ability to understand and willingness to sign the informed consent form 
 
Patients in Cohort 1 (tolerant of thiazolidinediones) were additionally required to 
fulfil all of the following criteria:  
• Previously initiated and currently continuing on thiazolidinedione therapy 
without diuretic therapy 
• Prepared to discontinue thiazolidinedione therapy with informed consent 
• Prepared to take an alternative treatment instead of thiazolidinedione therapy 
 
Patients in cohort 2 (previously intolerant of thiazolidinediones) were likewise 
additionally required to fulfil all of the following inclusion criteria: 
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• Previously withdrawn from thiazolidinedione therapy at any stage because of 
reported fluid retention (including oedema and/or HF)  
• Currently being treated with one or two non-thiazolidinedione oral anti-
hyperglycaemic agents  
• No current diuretic therapy 
 
2.8 Exclusion criteria 
 
Patients were excluded from the study if they met any of the following criteria: 
• BMI > 40 kg/m2  
• HbA1c > 9.0% 
• Patients (Cohort 2) withdrawn from thiazolidinedione therapy for reasons 
other than oedema (e.g. weight gain without oedema, liver dysfunction, lack 
of efficacy, other adverse events).   
• Hypertension requiring treatment with three or more anti-hypertensive agents 
• HF (NYHA Classes II, III, IV or left ventricular systolic ejection fraction < 
40%) 
• Significant renal or hepatic dysfunction (defined as a serum creatinine level 
exceeding 130 µmol/L or a > 2.5 fold increase in prevalent alanine 
aminotransferase (ALT) levels respectively) 
• Known to be HIV-positive 
• Known active hepatitis B and/or hepatitis C infection 
• Pregnant or lactating women 
• Known drug/alcohol abuse 
• Known psychiatric condition 
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Both men and women and members of all ethnic groups were eligible for this study. 
Pregnant women were excluded for safety reasons. Children were not eligible – the 
study population encompassed individuals aged 18 – 70 years.  
 
2.9 Withdrawal from the study 
 
Patients had the right to withdraw from the study at any stage, for any or no specific 
reason, without affecting any of their statutory rights as patients or continuing care. 
The investigator had the right to withdraw patients in accordance with the following 
guidelines: 
  
• At his discretion, if it was perceived to be in the best interests of the patient 
to withdraw 
• Intercurrent illness: a condition, injury or disease unrelated to diabetes, that 
rendered continuing the study unsafe or regular follow-up impossible 
• General or specific changes in the patient's condition that rendered the patient 
ineligible  
• Noncompliance with study procedures or protocol-required evaluations 
• Termination of the clinical study by the sponsor or funding body  
 
The reasons for any withdrawal(s) were clearly explained in the case report form 
(CRF).  
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2.10 Recruitment process 
 
The study recruited T2DM patients whose routine management is monitored within 
the Scottish Care Information – Diabetes Collaborative (SCI-DC) clinical 
information system in Tayside, Scotland. This confidential password-protected 
national computerised clinical system provides up-to-date single patient records, 
yielding a Scottish-wide register of all patients with diabetes based on a unique nine-
digit patient identifying number [Community Health Identifying (CHI) number]. 
Primarily designed to deliver integrated diabetes care to all members of the diabetes 
care team, it is also an invaluable research tool for recruitment purposes [437]. The 
original Diabetes Audit and Research Tayside (DARTS) database for Tayside has a 
sensitivity of 96% and a positive predictive value of 95% for ascertainment of 
known diabetes [437]. At the time of the study, SCI-DC consisted of two separate 
elements, called SCI-DC clinical and SCI-DC network. The former was a secondary 
care clinical management system whilst the latter was a web-based clinical system 
containing data from primary and secondary care (both were superceded in 2012 by 
a single web-based system, SCI-Diabetes). SCI-DC data is linked to the Medicines 
Monitoring Unit (MEMO) database. The latter was developed for 
pharmacoepidemiological research in the population of Tayside, and contains 
detailed records of all prescription items dispensed to patients at community 
pharmacies [499]. Thus, at the time of the study, detailed records of all prescriptions 
dispensed for thiazolidinediones, insulin, diuretics, and all other drugs referred to 
hereafter were available for all Tayside patients (now across Scotland). This highly 
integrated clinical information system proved indispensable in identifying the two 
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groups of thiazolidinedione-treated patients fitting the very specific inclusion criteria 
for this study. 
  
The method of approaching T2DM patients followed the Standard Operating 
Procedures developed by the Scottish School of Primary Care, formerly Scottish 
Practices and Professionals Involved in Research (SPPIRe) [500].  Thus, the 
University of Dundee Health Informatics Centre produced a computer diskette 
permitting the interrogation of the computer systems of participating practices by 
study research nurses. An algorithm was used to identify patients on 
thiazolidinedione therapy (cohort 1) or in receipt of up to three (but not more) 
previous prescriptions for rosiglitazone or pioglitazone in the last two years (cohort 
2). Individual general practitioners were contacted regarding patients who were 
likely to fit the inclusion criteria. General practitioners who agreed were invited to 
forward a signed letter to the patient inviting them to participate in the study. This 
approach ensured that only patients who were likely to fit the inclusion criteria were 
actually contacted, minimizing patient inconvenience. 
 
Additionally, the University of Dundee Health Informatics Centre identified 
potential patients who had been recruited into the Wellcome Trust Case Control 
Genetics study (LREC ref 053/04). These patients had consented to be re-contacted 
regarding participation in future research. Patients fulfilling the preliminary 
recruitment criteria (as assessed on the SCI-DC clinical information system) were 
written to using a standard letter specific to the cohort, accompanied by an 
information sheet outlining the nature of the study. Where telephone contact details 
were available in this Wellcome Trust dataset, this correspondence was followed up 
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by means of a phone call made by the author, a clinical research fellow in this study. 
An alternative recruitment approach was used in those instances where the patient’s 
telephone number was not available from the study database. A letter of invitation 
was sent to these patients. This included a tear- off slip allowing invited patients to 
indicate whether they were interested in participation and to provide current contact 
details in the prepaid envelope provided. For patients who are willing to participate, 
screening of suitable patients was aided by clinical data available on the SCI-DC 
clinical information system. This recruitment approach commenced after obtaining 
Caldicott-Guardian approval.  
 
The author personally invited participation by T2DM patients who were likely to 
fulfil the study inclusion criteria (as suggested by available SCI-DC records) when 
they attended the Diabetes Clinic at Ninewells Hospital between December 2008 and 
April 2010. This process commenced after obtaining the necessary Caldicott-
Guardian approvals. 
 
2.11 Study procedure - visit 1 
 
Patients identified as potentially suitable either for inclusion into cohort 1 
(thiazolidinedione tolerant) or cohort 2 (thiazolidinedione intolerant) were provided 
with one of two specific patient information sheet, outlining the aims and method of 
this study. They were also informed about the potential benefits and adverse effects 
associated with participation. The information sheet explained that participation, 
while greatly appreciated, was entirely voluntary. Patients were free to decline the 
invitation, or withdraw from participating at any stage. They were not obliged to 
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explain their reasons for doing so; additionally, it was clarified that such a decision 
did not adversely affect their statutory rights as patients. Subjects were offered the 
opportunity to clarify any concerns with the study research nurses, myself, the 
principal investigator or an external advisor (Professor Ewan Pearson). All patients 
considered for participation were recorded on a screening log that was maintained at 
the study site.  
 
Patients expressing an interest were thus scheduled for a first study visit, which also 
encompassed a screening procedure. Transport was provided for all study and 
monitoring visits. In accordance with procedures approved by ethics committee, 
patients were compensated for time and inconvenience incurred as a result of 
participation in this study (£50 for each study visit), and for any travelling costs 
incurred if they opted to travel to the study site, as per ethical approval. 
 
Patient participants were once again familiarised with the study schedule and given 
the opportunity to ask questions. I was delegated with responsibility for obtaining 
informed consenting using the approved form. The consent encompassed the 
extraction of routine clinical data from the SCI-DC system.  
 
The following data were subsequently collected: 
• Date of birth and age 
• Gender  
• A brief structured questionnaire detailing patient’s experience of 
thiazolidinedione therapy, with particular emphasis of duration of 
thiazolidinedione therapy, ankle swelling, fluid retention, symptoms or signs 
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of HF, other adverse effects while on thiazolidinedione therapy (including 
hypoglycaemia)  
• Diabetes related history with collection of data on diagnosis, macrovascular 
and microvascular complications. Status was assessed through available SCI-
DC records. Retinal screening was repeated if not assessed within the last 12 
months 
• Past medical history 
• Concomitant medications 
• Weight was measured to the nearest 0.1 kilogram (kg) using an electronic, 
recently calibrated weighing scale. Patients were asked to stand unattended 
and barefoot on both feet at the centre of the weighing platform scale.  
• Standing height was measured to the nearest 0.5 centimetre (cm) using a 
Leicester height measure. The subject was asked to remove any head dress or 
head ornaments and to stand barefoot with his/her back against the height 
rule, such that the back of the head, back, buttocks, calves and heels were 
touching the vertical scale, feet together. The attending clinical research 
fellow ensured that the patient was looking straight ahead, with the top of the 
external auditory meatus level with the inferior margin of the bony orbit. The 
apparatus’ horizontal measure was lowered to touch the top of the head once 
the latter was correctly positioned.  
• Waist circumference was measured using a flexible but non-stretchable 
measuring tape to the nearest 0.1 cm midway between the lower rib margin 
and the iliac crest at the mid-axillary line. The measuring points on each side 
were determined by marking these bony margins using a water-soluble 
marker pen, and determining and marking the midway point for each side. 
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Patients were asked to remove clothing from around the waist and hips. 
Measurement was taken with the subjects standing on both feet, with their 
feet pointing forwards and approximately 25-30 cm apart. They were asked 
to breathe normally. The reading of the measurement was taken at the end of 
a gentle exhalation. BMI was calculated by dividing each subject’s weight in 
kilograms by the square of the height in metres 
• Pregnancy test (if applicable) – patients with a positive pregnancy test were 
excluded 
• Pulse and blood pressure were recorded in triplicate after 5 minutes of rest, in 
the non-dominant arm and sitting posture, using an automated 
sphygmomanometer placed at the level of the patient’s heart and approved by 
the British Hypertension Society. Patients were asked not to cross their legs 
while sitting. They were also advised to refrain from smoking, drinking tea, 
coffee or cola, and participating in any arduous activity for one hour prior to 
blood pressure measurement. Adherence to these recommendations was 
verified at the study visit. Measurements were taken using an appropriately 
sized cuff that covered 80% of the circumference of the midpoint of the 
upper arm, after removing or loosing any clothing covering this site. Care 
was taken to ensure that the cuff was rotated such that the indicated mark on 
the cuff was placed over the brachial artery. The arm was rested on a pillow 
or bed while the measurement was being taken. Patients were asked to refrain 
from moving and speaking for a minute while the blood pressure was being 
recorded. Subjects were rested for five minutes before repeating the readings. 
All three pulse and blood pressure readings were recoded on the CRF, 
enabling the calculation of a mean reading for each clinical parameter. 
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Patients were excluded from participation if their mean blood pressure (on 
current antihypertensive therapy if applicable) exceeded 145/85mmHg.  
• Physical examination of the cardiovascular, respiratory, abdominal, 
neurological, locomotor and endocrine systems was carried out. 
• Venous blood samples were taken for estimation of full blood count, HbA1c, 
sodium, urea, creatinine, glucose, liver function tests and lipid profile.  
• Dipstick urinalysis and urine for microalbuminuria – A second morning mid-
stream urine sample was collected in a sterile universal container for this 
purpose. Patients were appropriately counselled by the research nurse or 
clinical research fellow prior to this procedure   
• ECG 
 
Cohort 1 patients were asked to replace their current thiazolidinedione therapy with 
gliclazide therapy at the same visit. They were provided with a glucose meter, and 
advised to check and record their blood glucose readings on the diary provided. The 
clinical research fellow maintained telephone contact with these patients, titrating 
sulphonylurea dose if necessary to maintain prevailing HbA1c at <9%. Cohort 2 
(thiazolidinedione 'intolerant' patients were advised to continue therapy with their 
current antihyerglycaemic agents. 
 
Individuals treated with (one or two) antihypertensive agents were advised to 
discontinue these agents, one at a time, with careful follow-up of blood pressure 
readings at each stage. Patients were withdrawn from the study if their blood 
pressure exceeded 160/110 mmHg following the withdrawal of one or both 
antihypertensive agents. Aspirin-treated individuals were advised to discontinue this 
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agent 10 days prior to visit 2. Patients were advised to recommence treatment with 
aspirin and antihypertensives once visit 3 was completed.  
 
Participating individuals were asked to follow a moderate low (100 mmol/day) 
sodium diet for five days prior to visit 2; written information was provided in this 
regard. They were additionally supplied with self-weighing scales and urine 
specimen collecting containers enabling self-weighing and the collection of early 
spot urine samples for urinary sodium and urinary creatinine estimation for 5 
consecutive days prior to the next visit.  
 
2.12 - Study procedure - visit 2  
 
Visit 2 was scheduled 4-7 weeks after visit 1, allowing adequate ‘wash-out’ of 
thiazolidinedione effects in thiazolidinedione 'tolerant' individuals (cohort 1). 
Patients were instructed to follow a moderately low (100 mmol/day) salt diet for five 
consecutive days prior to the study visit. On these days, participating subjects were 
asked to collect an early morning urine sample for urinary sodium and creatinine 
estimation, and to weigh themselves on awakening, dressed in their underwear, using 
the electronic self-weighing scale provided, recording the measurements on a diary. 
Patients arrived at the vascular research laboratory at around 08.30 hours. They were 
instructed to consume 300 mg lithium carbonate at 22.00 hrs the previous night and 
subsequently remain starved. Patients were asked to refrain from smoking and 
consuming alcohol and caffeine-containing beverages for the duration of the fast; 
compliance to this advice was verbally ascertained at the start of the study visit. On 
arrival, patients were made comfortable on a bed, and remained supine, except for 
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voiding and ankle-fluid measurements. Patients remained fasted until the end of the 
study visit, which lasted till about 16.00 hours. Patients were permitted to drink a 
volume of water equivalent to urinary losses throughout this visit.  They were 
additionally provided with a sandwich meal before leaving the unit 
 
2.12.1 Baseline measurements  
 
During this study visit, the following baseline assessments and measurements were 
made: 
• Echocardiography including tissue Doppler  
• Concomitant therapy 
• Compliance with diet 
• Compliance with medication  
• Assessment of occurrences of hypoglycaemia 
• Dipstick urinalysis and urine for microalbuminuria 
• Weight and waist measurement 
• Blood pressure (in triplicate) 
• AFV by water displacement  
• Pulse wave analysis and velocity.   
• HbA1c  
• Plasma for biochemistry (urea and electrolytes, liver function tests) 
• ANP  
• Aldosterone  
• Renin  
• BNP and NT-proBNP  
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• VEGF  
• AVP  
 
2.12.2 Biochemistry  
 
Blood samples for HbA1c estimation were collected in a vacuum collection tube 
containing EDTA. while plasma glucose samples were collected in a vacuum 
collection tube containing FX sodium fluoride/potassium oxalate. Sera for renal, 
liver and lipid profiles, serum albumin and lithium measurement were collected in a 
Z serum clot activator vacuum collection tube with gel separator. Details pertaining 
to assay methodology are outlined in table 2.1 below. Urinary lithium levels were 
measured by Mr Neil R Johnston in Professor David Webb’s laboratory at the 
Clinical Pharmacology Unit, Queens' Medical Research Institute, University of 
Edinburgh, Edinburgh, using the flame photometry technique. The latter is 
characterized by an intra-assay CV of 1.54% and an inter-assay CV of 2.98%, based 
on repeated analysis of the control sample. The measuring instrument, a BWB-1 
Flame Photometer (BWB Technologies) has a working range of between 1 and 100 
ppm lithium. All other analyses were carried out at NHS Tayside laboratories, 
Ninewells Hospital and Medical School, Dundee.   
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Table 2.1 - Biochemistry assay methodology 
 
Assay 
 
System 
 
 
Method principle 
 
  
Serum sodium Roche SWA Indirect measuring ion-selective electrode 
Serum potassium Roche SWA Iindirect measuring ion-selective electrode 
Serum urea Roche SWAa Kinetic urease 
Serum creatinine Roche SWAa Compensated kinetic Jaffe 
Plasma glucose Roche SWAa Hexokinase 
Bilirubin Roche SWAa Diazo 
Serum alkaline phosphatase Roche SWAa IFCC 
Serum alanine 
aminotransferase 
Roche SWAa IFCC without pyridoxal phosphate 
activation 
Serum GGT Roche SWAa IFCC 
Serum AST Roche SWAa IFCC without pyridoxal phosphate 
activation 
Serum albumin Roche SWAa Bromocresol green 
Serum total cholesterol Roche SWAa Cholesterol oxidase/peroxidase 
Serum HDL-cholesterol Roche SWAa PEG-modified cholesterol esterase/PEG-
modified cholesterol oxidase/peroxidase 
Serum triglycerides Roche SWAa lipoprotein lipase/glycerokinase/glycerol 
phosphate oxidase/peroxidase 
Glycosylated haemoglobin 
(HbA1c) 
Menarini HA 
8160 
 
Serum lithium Roche AVL 
9181 
Direct measuring ion-selective electrode 
 
  
Urine  sodium Roche SWA Indirect measuring ion-selective electrode 
Urine creatinine Roche SWAa Compensated kinetic Jaffe 
Urine microalbumin Roche Integra 
800 
Immunoturbidimetry 
Urine  lithium BWB 
Technologies 
Flame Photometer 
 
  
a
 P800 module  
           
Estimated glomerular filtration rate (eGFR) was derived using the abbreviated 
MDRD equation (GFR [mL/min/1.73m2] = 175*serum creatinine in mg/dL-1.154*age 
in years-0.203*0.742 if female*1.212 if African American) [501]. Low density 
lipoprotein cholesterol (LDL-C) was indirectly derived from serum total cholesterol, 
high density lipoprotein cholesterol (HDL-C) and triglyceride values using the 
Friedewald formula [LDL-C = total cholesterol – HDL-C  – (triglycerides/2.22)], all 
values being in mmol/L [502].  
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2.12.3 Biomarkers  
 
Plasma samples for measurement of Vascular Endothelial Growth Factor (VEGF) 
and high sensitivity copeptin were assayed by Dr. Paul Welsh in the laboratory of 
Professor Naveed Sattar at the Institute of Cardiovascular and Medical Sciences, 
University of Glasgow. The high sensitivity copeptin assay used is characterised by a 
functional assay sensitivity of less than 2 pmol/L, an intra-assay CV of < 3% (for hs 
copeptin concentrations exceeding 50 pmol/L) to < 15 % (for hs copeptin 
concentrations of 3-4 pmol/L) and an inter-assay CV of < 5% (for hs copeptin 
concentrations exceeding 50 pmol/L) to < 17% (for hs copeptin levels of 3 to 4 
pmol/L). The VEGF assay used gives a functional assay sensitivity of < 5 pg/mL, an 
intra-assay CV of 4.5% to 6.7% and an inter-assay CV of 6.2% to 8.8%. Blood 
samples for estimation of hs copeptin and VEGF concentrations were both collected 
in vacuum collection tubes containing EDTA, stored at -80 ºC until assay, thawed 
overnight in a refrigerator at 4 ºC, and mixed by inversion prior to assay. The rest of 
the biomarkers [ANP, B-type natriuretic peptide (BNP), N-terminal prohormone of 
brain natriuretic peptide (NT-pro-BNP), aldosterone and renin] were analysed by 
Ms. Leslie McFarlane at the laboratories of the Division of Cardiovascular and 
Research Medicine, Medical Research Institute, University of Dundee. Blood 
samples for ANP, BNP, and renin were collected in vacuum collection tubes 
containing EDTA, and immediately spun (3000 rpm) for 10 minutes at 4ºC. Two 2 
mL plasma aliquots were collected in 5mL plastic tubes and frozen at  - 70ºC until 
formal analysis of ANP and BNP levels. Two 1mL plasma aliquots were likewise 
collected in 1.5mL plastic tubes and frozen at -20ºC pending formal renin level 
estimation.  Both ANP (reference range: 8.6 ± 0.8 pg/mL) and BNP (reference range: 
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3.9 ± 0.3 pg/mL) assays were characterised by intra- and inter-assay CVs of 12.5 and 
20% respectively. The renin assay kit (reference range: 0.2-2.8 ng/mL/hr supine; 1.5-
5.7 ng/mL/hr upright) was characterised by an intra-assay CV of 4% and an inter-
assay CV of 7.3%. Sensitivity was deemed at <20 pg/mL (95% confidence limit). 
Blood samples for NT-pro-BNP and aldosterone were collected in vacuum collection 
tubes containing lithium-heparin. They were immediately kept on ice and spun for 
10 minutes at 3000 rpm at 4ºC.  Two 1mL plasma aliquots (one for each of NT-pro-
BNP and aldosterone) were then collected in a 1.5 mL plastic tubes, and frozen at -
70ºC, pending formal analysis. The aldosterone assay kit (reference range: 75-150 
pg/mL supine; 35-300 pg/mL upright) gives an intra-assay coefficient of variation 
(CV) of 5.5% and an inter-assay CV of 5.2%. Sensitivity is deemed at <20 pg/mL 
(95% confidence limit). The assay for NT-pro-BNP is characterised by an intra-assay 
CV of 10%.  All blood samples for biomarkers were measured in the supine position 
following an hour's rest. Individual biomarker assay methodology is outlined in table 
2.2.  
 
 
Table 2.2  - Biomarker assay methodology 
 
Assay 
 
System 
 
 
Method principle 
 
  
VEGF R and D systems ELISA 
ANP Bachem Radioimmunoassay 
BNP Bachem Radioimmunoassay 
NT-pro-BNP Oxford Biosystems ELISA 
Aldosterone Diasorin Radioimmunoassay 
Renin Diasorin Radioimmunoassay 
High sensitivity copeptin B.R.A.H.M.S. Kryptor Time-Resolved Amplified 
Cryptate Emission 
(TRACE)  
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2.12.4 Echocardiography (including tissue doppler) 
 
At the start of this study visit, the patient underwent echocardiography enabling a 
baseline assessment of left ventricular function in moderate low sodium states. This 
procedure was repeated after infusion of one litre of 0.9% saline for each 
participating subject, allowing additional assessment of cardiac function in response 
to acute salt loading. All echocardiographic measurements were carried out by Dr. 
Adnan Nadir (Clinical Research Fellow, Division of Cardiovascular and Diabetes 
Medicine, Ninewells Medical School). 
 
The Philips iE33 echocardiography system enables semi-automated analysis of true 
left ventricular volumes, using all the voxels to generate a full three dimensional 
endocardial border. This approach is characterised by higher accuracy and less 
dependency on left ventricular shape assumptions than conventional methods. Its 
three dimensional quantification advanced (3D QA) waveform display provides 
accurate data for the assessment of global function based on left ventricular volume, 
ejection fraction and stroke volume, while allowing simultaneous display of 17 
regional waveforms, enabling temporal comparisons between the segments. Any 
patients found to have previously-undetected baseline left ventricular systolic 
ejection fraction below 40% were excluded by protocol at this stage of this study. 
The E-wave/A-wave (E/A) ratio was used to assess left ventricular systolic and 
diastolic function. E prime (E’) was measured at the level of the mitral valve annulus 
as a sensitive index of longitudinal axis left ventricular relaxation [503]. The latter 
method is well established in the University of Dundee Division of Medicine and 
Therapeutics. Three dimensional echocardiography also allowed accurate, 
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assumption free and reproducible quantification of left ventricular mass. The 3D QA 
waveform display was thus poised to characterise the baseline 
echocardiocardiographic features of thiazolidinedione 'tolerant’ and 'intolerant’ 
patients, and to investigate the effects of dietary and therapeutic interventions on 
cardiac function among patients in either cohort.  
 
2.12.5 Ankle-foot volume measurements  
 
AFV was measured close to the start of visit 2, and repeated after infusion of one 
litre of 0.9% saline, allowing analysis of data in both low and acute high sodium 
states. Measurements were made using a plastic water bath (measuring 390 mm long 
by 330 mm wide by 280 mm high) with an outlet tap for water overflow at the top of 
the bath, located 200 mm from the bottom of the water bath (figure 2.1). This tap had 
a tube attached, from which the overflow water was collected into a plastic 
container. Patients were verbally familiarised with the procedure prior to 
commencing the measurements. The water bath (including all its grooves) was filled 
with water at 26-27 °C, and water was allowed to flow out through the overflow tap 
into the plastic collecting container until the water within the water bath levelled 
with the overflow tap. The latter was fully closed at this point. Water temperature 
was assessed using an electronic thermometer. The plastic collecting container was 
then emptied and weighed on an electronic scale, ensuring it was placed at the centre 
of the weighing scale platform, without touching the bath or its attached water tap. 
The subject was then asked to dip their bare feet slowly into the bath of water until 
their feet were flat at the bottom of the bath, as they sat at the edge of a bed with 
their knees flexed at right angles. His/her feet were positioned into a reproducible 
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position, facing forwards, in the water bath. The subject was then asked to sit still, 
while being kept comfortable to rest their arms on a pillow placed over their knees. 
Once the water level within the bath had settled, the water tap was turned open and 
left in this position for five minutes (timed using an electronic stopwatch). The 
volume/weight of the water displaced was weighed at the end of this time-interval. 
The procedure was repeated thrice, enabling the calculation of mean values for the 
ankle fluid volume at each stage of the study. Displaced water was replaced within 
the water bath at each repeat ankle fluid volume measurement procedure.  
 
Figure 2.1 – Schematic diagram of a water bath used to measure ankle-foot 
volume by water displacement 
 
390 mm
280 mm
200 mm
330 mm
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2.12.6 Pulse wave velocity and analysis  
 
Arterial stiffness was measured in this study using applanation tonometry 
(SphygmoCor). The latter is a computerised diagnostic tool permitting accurate 
description of pulse wave characteristics and pulse wave velocity, and the 
extrapolation of findings to central cardiac and aortic physiological events. 
SphygmoCor derives central aortic pressure waveform non-invasively from the 
pressure pulse recorded at a peripheral site by applanation tonometry. The apparatus 
reconstructs the aortic waveform from the non-invasively derived radial waveform 
by a validated mathematical model termed transfer function [504]. While the 
characteristics of transfer function are determined by the physical properties of the 
arterial system (namely arterial diameter, wall elasticity, wall thickness, amount of 
branching and the condition of the peripheral arterial beds), its main components do 
not change markedly between normal individuals with age. This is consistent with 
the observation that most of the ageing changes occur in the aortic trunk rather than 
in the arteries of the arm [505].  
 
Although arterial stiffness is a major risk factor for cardiovascular disease, and 
predicts the development of left ventricular failure [506-508], traditional methods 
detecting left ventricular failure do not provide information on the arterial dynamics 
that determine left ventricular hypertrophy. To this effect, this study utilized the 
technique of applanation tonometery to investigate the hypothesis that individuals 
prone to develop HF after incident thiazolidinedione prescription are characterised 
by greater arterial stiffness compared with their ‘thiazolidinedione tolerant’ 
counterparts. 
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The patient was advised to lie supine, calm and relaxed on a bed, with their head 
supported on a pillow and their arms relaxed by their sides, in a temperature 
controlled room. The patient’s right wrist was supported, such that the palm faced 
upwards. I ascertained that the radial pulse was identical in both arms and that the 
arterial pressure by cuff sphygmomanometry was within 10mmHg systolic. A 
baseline ECG ruled out significant arrhythmias while baseline echocardiography 
carried out immediately prior to this procedure rule out significant aortic stenosis 
(gradient > 60 mmHg). Both aortic stenosis and cardiac arrhythmias adversely affect 
the reproducibility of pulse wave analysis and velocity measurements [509, 510]. For 
pulse wave analysis, the SphygmoCor tonometer was placed on the patient’s radial 
artery by the clinical research fellow. The patient was advised to dorsiflex the wrist 
while supporting it on a small cushion, so as to push the artery towards the surface, 
easing access. The tonometer was pressed gently and steadily on the patient’s radial 
artery, adjusting the tonometer slightly backwards and forwards until a consistent 
large arterial waveform was displaced completely within the laptop computer 
monitor screen. The pulse wave signal was captured only after ascertaining that the 
pulse waveform was characterised by a steady vertical waveform position, constant 
pulse height and consistent waveform profiles for two complete screens (at least 10 
seconds). The study report was generated by the computer software. Data were 
recorded on the CRF. 
 
For pulse wave velocity measurement, which was carried out immediately following 
pulse wave analysis, the patient was positioned as previously. Three ECG electrodes 
were attached to the patient’s skin. Skin was prepared beforehand, by shaving excess 
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hair over the electrode site (if indicated) and briskly rubbing the site with a cotton 
pad soaked in isopropyl alcohol, to ensure a stable, artefact free ECG trace. The 
SphygmoCor system uses a LEAD II ECG lead configuration system. Leads were 
placed on the chest wall to increase QRS height. The pulse wave velocity was 
calculated using a three-stage process. The distance from the suprasternal notch to 
the arterial pulse site was measured and recorded in millimetres in the 
SphygomoCor computer software. The distance between the suprasternal notch and 
the carotid pulse was likewise measured and recorded. The subtraction of these two 
measurements was automatically performed by the software once the proximal and 
distal values were entered. The tonometer was used to capture steady pulse 
waveforms, intially on the distal (radial artery) site, and subsequently on the 
proximal (carotid artery) site, once good quality waveforms were ascertained for 
each site. The study report was then generated by the computer software. Data were 
recorded on the CRF.  
 
2.12.7 Assessment of glomerular filtration rate (inulin clearance method) 
 
Glomerular filtration rate (GFR) cannot be measured directly in humans, and is 
determined by measuring the clearance of an ideal filtration marker. Inulin, an 
uncharged polymer of fructose derived from plant tubers, fulfils this requirement on 
account of  the following characteristics, which render it the gold standard method in 
this field [511, 512]: 
(i) its low molecular weight 
(ii) physiologically inert 
(iii) being unbound to plasma proteins  
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(iv) ability to reach a stable plasma concentration 
(v)  free filtration at the glomerulus 
(vi) not reabsorbed, secreted or metabolised in the kidney 
(vii) does not alter renal function 
The CV in serum and urine inulin levels ranging from 100 to 250 mg/L is less than 
5%. The intra-test CV in inulin clearance is around 10%  [512].  
 
As outlined earlier, following informed consent, patient participants were requested 
to fast from 22.00 hours prior to visit 2, refraining from smoking and consuming 
alcohol and caffeine containing beverages for the duration of the fast (free fluids 
permitted). On arrival for visit 2, two intravenous cannulae were inserted into the 
antecubital veins, one for infusion of inulin, and the second one into the contralateral 
vein for drawing blood. The patient was made comfortable on a bed, and was 
advised to remain supine throughout the test procedure, except for voiding. Baseline 
levels of inulin were measured at t = -130 minutes. Blood samples were collected in 
a Z serum clot activator vacuum collection tube with gel separator and allowed to 
settle at room temperature for about ten minutes. They were then spun for ten 
minutes at 3000 rpm and stored at -20ºC,  prior to transfer on dry ice for analysis by 
Mr Neil R Johnston in Professor David Webb's laboratory at the Clinical 
Pharmacology Unit, Queens' Medical Research Institute, University of Edinburgh, 
Edinburgh. Plasma inulin was measured using an in-house colorimetric microplate 
assay based upon the chemical reaction between fructose and resocinol, following an 
initial acid hydrolysis of inulin to its fructose subunits [513]. This method gives 
sensitivity of 50 ug/mL, an intra-assay CV of 3.7% and an inter-assay CV of 5.35%. 
A priming dose of inulin (Inutest® 25%) was commenced at t = -120 minutes, 
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administered as an intravenous bolus of 50 mg/kg inulin, followed by a continuous 
intravenous infusion at a rate of 25mg/min, infused in 0.9% saline until t = 130 
minutes (ie over 250 minutes) [514]. Venous blood samples for plasma inulin were 
again measured at t = - 10 minutes and t = - 5 minutes. Plasma levels of inulin reach 
a steady state after approximately 60 to 90 minutes of administration [512, 514]. One 
litre of 0.9% saline was then infused over two hours (as per salt loading protocol, 
section 2.12.11), commencing at t = 0 minutes, with measurements of plasma inulin 
levels at t = 120 minutes and t = 130 minutes. The patient’s glomerular filration rate 
was estimated from the steady state infusion of inulin according to the calculation 
method described by Schnurr et al. [515].  
 
Normally, clearance (C) is calculated from serum and urine samples using the 
formula:  
                            
U*V/ S ml/min 
 
where U = urine concentration, V = urine volume and S = serum concentration 
 
In the method outlined here, clearance is calculated by replacing U*V by the 
infusion rate IC*IV  
 
where IC = concentration of the test substance in the infusion fluid and IV = rate of 
the infusion. 
 
i.e. C = IC*IV/ S ml/min 
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The result was corrected for body surface area using the standard nomogram. 
 
Inulin is not considered a hazardous compound according to EU Directive 
67/548/EC. Therefore, any risks associated with inulin infusion were related only to 
the procedures of intravenous cannulation and infusion. Inulin had been infused in 
the same vascular research laboratory on several occasions, without adverse effects 
[516]. 
 
2.12.8 Fractional excretion of sodium 
 
Fractional excretion of sodium (FENa) was calculated from spot measurements of 
urine sodium, serum sodium, urine creatinine and plasma creatinine, using the 
formula: 
 
FENa = (UNa*Pcr/PNa*Ucr)*100  
 
where UNa = urine sodium, Pcr = serum creatinine, PNa = serum creatinine and Ucr = 
urine creatinine [517].  
 
All four measurements were made at t = -120 minutes and t = 0 minutes (before 
infusion of 0.9% saline), enabling a calculation of mean FENa at low sodium states). 
Similar measurements were made at t = 120 minutes and t = 240 minutes (after 0.9% 
saline infusion, enabling a calculation of mean FENa following acute high salt 
loading. 
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2.12.9 Fractional excretion of lithium 
 
Renal reabsorption of lithium is virtually confined to the proximal tubules, and 
occurs in the same proportion as that of sodium and water. Post-proximal tubule 
reabsorption of lithium has been deemed limited [518, 519]), and probably 
unimportant in humans [520].  This method has been deemed the best available 
estimate of proximal tubule function [521]. Hence calculation of fractional excretion 
of lithium (FELi) gives an accurate and non-invasive assessment of sodium and 
water delivery to the distal tubules.  
 
FELi was likewise calculated from spot measurements of urine lithium, serum 
lithium, urine creatinine and plasma creatinine , using the formula 
 
FELi = (ULi*Pcr/PLi*Ucr)*100  
 
where ULi = urine lithium, Pcr = serum creatinine, PLi = serum lithium and Ucr = urine 
creatinine 
 
Once again, all four measurements were made at t = -120 minutes, t = 0 minutes, t = 
120 minutes and t = 240 minutes, enabling calculation of FELi at low sodium and 
acute high sodium states.  
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2.12.10 Fractional reabsorption of distally delivered sodium 
 
Fractional reabsorption of distally delivered sodium (FRDDNa) was calculated at t = 
-120 minutes, t = 0 minutes, t = 120 minutes and t = 240 minutes, using the formula: 
 
(FELi - FENa/FELi)*100  
 
Each result was expressed as a percentage [522, 523]. 
 
2.12.11 Salt sensitivity of blood pressure 
 
Pulse, blood pressure and respiratory rate readings were taken at ten minute intervals 
from the non-dominant arm using an automated sphygmomanometer while a litre of 
0.9% saline was infused over two hours in the recombinant position, as discussed 
earlier. The attending clinical research fellow also assessed the patient for signs of 
fluid overload at each time-point. Participants complaining of dyspnoea or whose 
respiratory rate exceeded 20 breaths per minute at rest (or increased by more than 
five breaths per minute from baseline) were assessed earlier. Patients with a priori 
HF were excluded from the study. Moreover, baseline echocardiography performed 
at the start of visit 2 excluded patients whose left ventricular ejection fraction was 
estimated at less than 40%. The saline infusion was discontinued immediately if 
patients were deemed to be developing signs of fluid overload, showing other signs 
of decompensation, or developing a blood pressure rise exceeding 170/95 mmHg at 
rest (mean of two duplicates). 
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2.13  Study procedure - visit 3 
 
Visit 3 was scheduled one to two weeks after visit 2, following five days on a ‘high 
normal’ 200 mmol/day sodium diet, essentially comprising the previous ‘low salt’ 
diet supplemented by ten slow sodium tablets (HK Pharma, each 10 mmol/sodium) 
daily. On these five preceding days, participating subjects were asked to collect an 
early morning urine sample for urinary sodium and creatinine estimation. They were 
also instructed to weigh themselves on awakening, dressed in their underwear, using 
the electronic self-weighing scale provided, recording the measurements on a diary. 
Patients arrived at the vascular research laboratory at around 08.30 hours, having 
consumed 300 mg lithium carbonate at 22.00 hrs and subsequently fasted the 
previous night. Patients were asked to refrain from smoking and consuming alcohol 
and caffeine-containing beverages for the duration of the fast; compliance to this 
advice was verbally ascertained at the start of the study visit. On arrival, patients 
were made comfortable on a bed, and remained supine, except for voiding and ankle-
fluid measurements. Patients remained fasted until the end of the study visit, which 
lasted until about 13.30 hours. They were provided with a sandwich meal before 
leaving the research unit. 
 
During this study visit, the following baseline assessments and measurements were 
repeated: 
• Echocardiography including tissue Doppler  
• Concomitant pharmacological therapy 
• Compliance with a ‘high normal’ 200 mmol/day sodium diet 
• Compliance with medication  
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• Assessment of occurrences of hypoglycaemia 
• Dipstick urinalysis and urine for microalbuminuria 
• Weight/waist measurement 
• Blood pressure (in triplicate) 
• AFV by water displacement 
• Pulse wave analysis and velocity.   
• HbA1c  
• Plasma for biochemistry (urea and electrolytes, liver function tests) 
• ANP  
• Aldosterone  
• Renin  
• BNP and NT-proBNP  
• VEGF  
• AVP  
 
2.13.1 Total body water estimation 
 
Total body water (TBW), comprising both intracellular and extracellular fluid, was 
measured in this study visit using deuterium, a natural stable isotope of hydrogen. 
The isotope dilution technique has been dubbed as the most robust method of TBW 
estimation [524-526], with a reproducibility of  approximately 0.5% [525]. A basal 
spot urine sample was collected at the onset of  study visit 3. A 25 ml aliquot of this 
sample was stored in a labelled universal bottle in a  freezer for eventual analysis by 
Ms. Alexandra Small in Professor Tom Preston’s Stable Isotope Biochemistry 
Laboratory, Scottish Universities Environmental Research Centre (SUERC), 
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Glasgow. 4g deuterium oxide were administered as an oral stable isotope dilution at t 
= -120 minutes, ie 2 hours prior to the administration of the inulin infusion. 
Deuterium oxide had been previously produced gravimetrically at SUERC, diluted 
with around 50 ml tap water and stored in a leak proof container in a specific  freezer 
until thawed for use. The dose bottle was rinsed with tap water, and the latter was 
also drunk by the patient, ensuring complete ingestion of the deuterium oxide dose.  
The participating patient was asked to provide three post dose urine samples at 
approximately two hourly intervals (approximately t = 0 minutes, t = 120 minutes  
and t =  240 mins). from the start of the inulin infusion.  Patients were encouraged to 
void at an earlier stage or at additional time points if they so required. The time and 
volume of each sample was accurately recorded and a ~25mL aliquot stored in a 
labelled universal bottle in a  freezer for IRMS analysis at SUERC.  The residue of 
each sample was discarded.  Patients were permitted to drink a volume of water 
equivalent to urinary losses throughout this visit.  
 
Fat-free mass (FFM, also known as lean body mass) was derived from TBW by 
dividing the latter by the water content of fat free tissue (73.2%) [524]. Fat mass 
(FM) was derived by subtracting FFM from each individual patient's total body 
mass. Percentage FM and percentage FFM were calculated relative to total body 
weight [527]. Derived FFM values were validated against non-linear regression 
models published by Wang et al. (FFM = 10.8*height (m) 2.95 for males and 
10.1*height (m) 2.90 for females) [528]. 
 
Use of deuterium for TBW measurement has been deemed  free from the hazards 
associated with radioisotopes. An adult male of 80kg may have a TBW of 40 kg or 
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greater. This will naturally contain 155 ppm deuterium or 6.2g deuterium oxide in 40 
kg water [527]. Isotope ratio mass spectrometry employed for TBW estimation 
allowed minimalization of deuterium dosage, such that all doses used were less than 
that naturally present in the human body. This approach, coupled with the sourcing 
of deuterium oxide of guaranteed purity and the use of a non-invasive protocol 
combining oral doses of heavy water and urine sampling, ensured that the TBW 
protocol was completely risk  free. 
 
2.13.2 Glomerular filtration rate  
 
Glomerular filtration rate was once again assessed in visit 3 using the inulin 
clearance method outlined earlier. Following a bolus dose (50 mg/kg), inulin was 
administered at a rate of 25 mg/min over 130 minutes (starting at t = 0 minutes). 
Venous plasma samples were withdrawn pre-infusion (t = -10 minutes), t = 120 
minutes and t = 130 minutes, and sent for measurement of inulin levels.  
 
2.13.3 Salt and water handling techniques 
 
FENa, FELi and FRDDNa were calculated on a chronic moderately high sodium diet 
using the formulas discussed earlier. The relevant urine and serum samples were 
collected at t = -120 minutes, t = 0 minutes, t = 120 minutes and t = 130 minutes. 
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2.14 Biostatistical considerations 
 
2.14.1 Sample size 
 
About five months into recruitment for this study, Wyeth Pharmaceuticals, who had 
provided funding via the Scottish Translational Medicines Research Collaboration 
(TMRC) underwent a merger with Pfizer. An initial threat that funding would be 
completely withdrawn was successfully challenged on ethical grounds (given that 
patients had already been enrolled and undergone invasive procedures). However, 
the project had to be scaled down to a to a maximum of 30-40 patients, enabling a 
comparison between 10 thiazolidinedione intolerant patients and 20 
thiazolidinedione tolerant completed patients, which was a significant reduction from 
the original recruitment plan for this study (40-60 patients comprising at least 20 
thiazolidinedione tolerant and 20 thiazolidinedione intolerant patients). It should also 
be acknowledged that recruitment had proved more difficult than anticipated, 
especially for thiazolidinedione intolerant patients (as confirmed section II), despite 
adopting an integrated and multifaceted approach.  
 
This was an exploratory study aimed at assessing the potential of ankle−foot volume 
(and/or other specified measurements) under acute and/or chronic sodium challenge 
as biomarkers of TZD intolerance.  This was of interest to Wyeth Pharmaceuticals, 
who provided funding via the TMRC.  We did not find data in the literature to 
permit  a formal power calculation for ankle-foot volume measurements.  The 
background literature from which the sample size was derived was a study in which 
AFV had a between-day intra-subject coefficient of variation of 1.76% [529]; 
143 
 
 
amlodipine therapy increased this parameter by 23% in 80 unselected hypertensive 
patients in a study by Fogari et al [530]. I found no previous data measuring AFV on 
high salt diets either in TZD-tolerant or intolerant patients with or without diabetes.  
Other endpoints were purely exploratory.  It was pre-specified that there would be no 
adjustment for multiple comparisons.   
 
Once the study had been initiated, as already mentioned (page 142), following the 
merger of Wyeth and Pfizer, subsequent limitations on funding imposed by the 
TMRC dictated a reduced sample size from that originally intended. Thus, a revised 
submission was made to the TMRC adopting a more constrained exploratory 
analysis defining a reference range (with 95% CIs) from thiazolidinedione tolerant 
patients, and plotting individual data from the thiazolidinedione intolerant patients 
individually against these reference ranges to examine and explore the data formally 
for trends [531]. The ultimate power of these analyses was lower than originally 
intended and can be visualised for those results that were positive from the graphs 
showing 95% CIs for the reference range in the TZD-tolerant patients. 
 
 2.14.2 Statistical analyses 
 
Objective 1: All patients who completed visit 1 were considered in the analysis of 
baseline characteristics.  Any patient(s) withdrawing consent after visit 1 had their 
data included in the analysis.  
 
Objective 2: All patients who completed all the study visits, or had completed visits 
1 and 2 (including patients who have withdrawn due to hypertension) were 
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considered in the analysis.  If the patient withdrew consent after visit 2, their data 
were included in the analysis.  Patients who withdrew prior to visit 2 were not 
considered in the analysis. 
 
Patients judged not to have complied with diet on the basis of urinary sodium 
excretion were excluded from the analysis. Given the limited sample size, only 
descriptive statistics were used. 
 
2.15 Follow-up of these patients  
 
All cohort 1 patients were offered the option of switching back from gliclazide to 
their usual thiazolidinedione at completion of visit 3. They were also advised to 
recommence their usual antihypertensive therapy, and switch back to their ‘usual’ 
sodium diet. All patients were offered a follow-up visit within a few days of 
completing visit 3, so as to address issues pertaining to drug therapy modification, 
glucose monitoring or any other potential queries arising out of their participation in 
this study. General practitioners were advised regarding any long-term therapeutic 
modifications once patients completed their participation in this study. 
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2.16  Validation of ankle-foot volume measurement by the water displacement 
technique 
 
2.16.1 Aim 
 
The water displacement technique is establishing itself as a useful volumetric 
method for monitoring peripheral oedema. However, it is also considered to be time 
consuming and difficult to perform [532, 533]. Its day-to-day reproducibility has 
only been validated over a mean duration of 4.8 days [529], which limits its use to 
monitor longer-term volumetric changes. This is particularly relevant in research 
practice, where rigorous objective assessment is crucial. This study aimed to 
investigate intra-subject variability of the water displacement technique over a longer 
period of 2 weeks. 
 
2.16.2 Methods 
 
Ten healthy individuals without signs of peripheral oedema were recruited for this 
single centre prospective cohort study carried out at the Vascular Research 
Laboratory of the Department of Clinical Pharmacology and Therapeutics, Division 
of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of 
Dundee. Recruitment was carried out by emailing potentially interested participants 
working at Ninewells Medical School. No particular instructions on physical 
activity, working hours or break time was given to participants. Subjects were 
excluded if any of the following criteria were met: current hospitalization, known 
history of selected medical conditions (hypertension, cardiac failure, renal 
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impairment/failure, liver disease, lymphoedema, chronic venous insufficiency, deep 
vein thrombosis), treatment with diuretics, calcium channel antagonists, statins, 
insulin or thiazolidinediones, known pregnancy, presence of superficial skin ulcers, 
open sores, wounds, or other skin conditions on the lower extremity, history of an 
ankle injury or lower extremity surgery within the past 30 days.  
 
I carried out a simplified clinical examination of the lower limbs, essentially 
comprising an assessment for signs of chronic venous insufficiency, ulcers, ankle/leg 
injuries or skin conditions that precluded subjects from participation.  
 
Subjects fitting inclusion criteria had their cumulative (bilateral) ankle volume 
measured in triplicate at weekly intervals for three successive weeks. Measurements 
were taken at approximately the same time each week (± 1 hour), minimising diurnal 
variation. An outline of the method used has been described elsewhere. All 
measurements were carried out by myself. Shoes and socks were removed before 
each examination. Height, weight and blood pressure were measured for each 
participant. Standing height was measured using a stadiometer and standing weight 
using the same validated electronic scale, as outlined earlier. Blood pressure was 
measured using a British Hypertensive Society validated automated 
sphygmomanometer with the patient sitting comfortably at rest for five minutes. 
Waist circumference was measured using a non-elastic measuring tape in accordance 
with Scottish Diabetes Research Network (SDRN) standard operation procedures. 
 
Distribution of baseline demographic data and clinical characteristics were presented 
as mean (± SD) or as percentages. An estimate of the analytical variance (also 
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known as measurement error), defined as the average variance of repeated 
measurements at the same time point, was defined for the cohort of participating 
subjects at each study visit using one way ANOVA (subject as term). Within-
individual variance, the average variance of repeated measurement in the same 
subject at different time points was likewise calculated for each individual using 
two-way ANOVA (subject and day as terms). Residuals were deemed to be normally 
distributed using the Kolmogorov-Smirnov test and by constructing Q-Q plots. The 
CV in each case was calculated by dividing the square root of the total error term of 
the adjusted mean squares from ANOVA by the mean of the observations and 
expressed as a percentage. Intra-class correlation coefficient (ICC) (with 
corresponding 95% CI value) was calculated as an overall estimation of the 
reproducibility of leg volume measurements. All statistical analyses were performed 
using SPSS® version 21.0. 
 
2.16.3 Results 
 
Descriptive statistics for the ten participating subjects (five males, five females) are 
summarised in table 2.3. Although mean (SD) BMI was in overweight range, mean 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) readings were in 
the normotensive range.  
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Table 2.3 – Demographic and clinical characteristics of the ankle-foot volume 
validation study participants (n = 10) 
 
Subject characteristica 
 
 
Mean (SD)b or absolute valuec 
  
Age (years) 41.80 (9.3)b 
Females  5 (50%)c 
Weight (kg) 77.4 (13.2)b 
Body mass index (kg/m2) 26.5 (3.9)b 
Waist circumference (cm) 76.2 (21.6)b 
Resting heart rate (min-1) 68.5 (10.2)b 
Resting systolic blood pressure (mmHg) 123.2 (11.9)b 
Resting diastolic blood pressure (mmHg) 75.6 (6.8)b 
  
aData accrued from all participants in each of the three study visits. 
 
Tables 2.4, 2.5 and 2.6 summarise individual and mean (± SD) AFV measurements 
for each of the ten participating subjects at each of the three study visits. CV for 
individual subjects ranged from 0.62% to 3.73% in visit 1, 0.70% to 2.72% in visit 2 
and 0.66% to 2.59% in visit 3. Cumulative CV for all participating subjects was 
1.96% , 1.66% and 1.57% for visits 1, 2 and 3 respectively. The corresponding ICC 
values were 0.995 (95% CI 0.986, 0.999), 0.997 (95% CI 0.992, 0.999) and 0.997 
(95% CI 0.992, 0.999). Mean (± SD) AFV measurements for individual patients over 
the cumulative observation period of two weeks are plotted on figure 2.2. Plots of the 
difference in AFV measurements between two individual study visits against the 
mean AFV for these study visits are given in figures 2.3 to 2.5, as a visual 
appreciation of the amounts of variability which can be expected using this 
technique. 
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Table 2.4 - Leg volume measurements and derived coefficient of variation for each 
subject at visit 1 
 
Subject number 
 
AFV1a AFV1b AFV1c AFVmean 1 CV1 
      
1 2761 2904 2911 2858.7 (84.7) 2.96 
2 2990 2998 2944 2977.3 (29.1) 0.98 
3 3617 3755 3702 3691.3 (69.6) 1.89 
4 3524 3557 3566 3549.0 (22.1) 0.62 
5 3275 3252 3211 3246.0 (32.4) 1.00 
6 2396 2412 2281 2363.0 (71.5) 3.02 
7 2921 2735 2746 2800.7 (104.4) 3.73 
8 2514 2410 2473 2465.7 (52.4) 2.12 
9 3648 3673 3609 3643.3 (32.3) 0.89 
10 3353 3386 3367 3368.7 (16.6) 0.49 
      
AFV, ankle-foot volume (mls); AFV1a, first ankle-foot volume reading for visit 1; AFV1b, second ankle-
foot volume reading for visit 1; AFV1c, third ankle-foot volume reading for visit 1; AFV mean 1, mean 
(SD)  ankle-foot volume for visit 1; CV1, coefficient of variability for visit 1(%) 
 
Table 2.5 - Leg volume measurements and derived coefficient of variation for each 
subject at visit 2 
 
Subject number 
 
AFV2a AFV2b AFV2c AFVmean 2 CV2 
      
1 2777 2742 2774 2764.33 (19.40) 0.70 
2 2783 2924 2912 2873.00 (78.17) 2.72 
3 3767 3617 3613 3665.67 (87.78) 2.39 
4 3615 3664 3675 3651.33 (31.94) 0.87 
5 3342 3433 3335 3370.00 (54.67) 1.62 
6 2306 2347 2376 2343.00 (35.17) 1.50 
7 2753 2768 2786 2769.00 (16.52) 0.60 
8 2367 2411 2372 2383.33 (24.09) 1.01 
9 3774 3711 3729 3738.00 (32.45) 0.87 
10 3357 3474 3435 3422.00 (59.57) 1.74 
      
AFV, ankle-foot volume (mls); AFV2a, first ankle-foot volume reading for visit 2;  AFV2b, second 
ankle-foot volume reading for visit 2; AFV2c, third ankle-foot volume reading for visit 2; AFV mean 2, 
mean (SD) ankle-foot volume for visit 2; CV2, coefficient of variability for visit 2(%) 
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Table 2.6 - Leg volume measurements and derived coefficient of variation for each 
subject at visit 3 
 
Subject number 
 
AFV3a AFV3b AFV3c AFVmean 3 CV3 
      
1 2734 2743 2797 2758.00 (34.07) 1.24 
2 3074 2988 3040 3034.00 (43.31) 1.43 
3 3520 3534 3489 3514.33 (23.03) 0.66 
4 3738 3654 3733 3708.33 (47.12) 1.27 
5 3355 3267 3321 3314.33 (44.38) 1.34 
6 2312 2234 2301 2282.33 (42.22) 1.85 
7 2710 2803 2852 2788.33 (72.13) 2.59 
8 2315 2359 2311 2328.33 (26.63) 1.14 
9 3658 3716 3644 3672.67 (38.18) 1.04 
10 3521 3394 3395 3436.67 (73.04) 2.13 
      
AFV, ankle-foot volume (mls); AFV3a,  first ankle-foot volume reading for visit 3; AFV3b, second 
ankle-foot volume reading for visit 3; AFV3c, third ankle-foot volume reading for visit 3; AFV mean 3, 
mean (SD) ankle-foot volume for visit 3; CV3, coefficient of variability for visit 3(%) 
 
The overall CV of the AFV measurement technique observed over a period of 2 
weeks (spanning from visit 1 to visit 3) stood at 1.74%. The corresponding ICC 
value was 0.995 (95%  CI = 0.985, 0.999). 
Figure 2.2 – Mean (SD) ankle-foot volume values in ten healthy subjects 
measured at each of three successive visits (1-3) one week apart 
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-foot volume measurements between visits 1 and 2 
a; ICC = 0.993 (95% CI 0.974, 0.998
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2.16.4 Discussion 
 
This study demonstrated that the water displacement technique is a relatively easy, 
yet reproducible  method of measuring ankle
Cumulative CV for all participating subjects ranged from 1.96% in visit 1 to 1.57% 
in visit 3, which compares well with those reported in the literature. In a study on 
patients with lymphoedema, Auvert and Vayssairat reported a reproducibility of 
1.3% for the water displacement technique 
report use of a water displacement device with a lower CV value of 0.30% 
This study reports ICC values of 0.995 (95% CI 0.986, 0.999), 0.997 (95% CI 0.992, 
0.999) and 0.997 (95% CI 0.992, 0.999) for visits 1, 2 and 3 respectively. These 
values compare excellently with those reported by Brodovicz
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-foot volume measurements between visits 1 and 3 
a; ICC = 0.989 (95% CI 0.958, 0.997
 
-fluid volumes in human subjects. 
[534]. Van Hamersvelt and colleagues 
 et al. (0.93
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Average ankle fluid volume (mls) for visits 1 and 3
)] 
 
[535]. 
-0.96) in a 
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study which evaluated foot and ankle volumes in each leg separately [536].  
Additionally, this study's CV and ICC values confirm that measurements are highly 
reproducible over a period of two weeks in the absence of any significant 
intervention. This renders interpretation of temporal effects on AFV using this 
measurement technique highly plausible in an experimental setting. To this effect, 
Brijker et al. reported a CV of 1.76% over a mean observation period of 4.8 days 
[529], which is considerably shorter than this study's observation period of two 
weeks. Diurnal variation in leg volume, and hence fluid displacement have been 
reported in several studies [529, 537, 538]. This possibility was minimised by 
ensuring that participating subjects had their fluid volumes measured at 
approximately identical times each week [539]. None of the subjects reported 
significant alteration in their daily lifestyle over the intervening observation period. 
 
2.16.5 Conclusion 
 
Measuring leg volume by water displacement is relatively easy, cheap, and highly 
reproducible. It can be used to monitor temporal changes in peripheral oedema over 
an extended period of time.  
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Section II - Results 
 
2.17 Phenotype  
 
2.17.1 Baseline demographic characteristics 
 
Thirteen Caucasian patients attended and completed the initial screening visit for this 
study (visit 1). Of these, 11 (subjects 1 to 9, subject A and subject B, comprising 
seven males and four females) reported themselves to be tolerant of 
thiazolidinediones, and two (subjects 11 and 12, both females) had been withdraawn 
from TZDs on account of fluid retention. In one of the latter cases, thiazolidinedione 
had been withdrawn less than three months after index thiazolidinedione prescription 
on account of 'severe bilateral hand oedema'. The second had discontinued her 
thiazolidinedione within one to two weeks after developing 'weight gain and severe 
abdominal, bilateral upper limb and ankle swelling'. Adverse effects resolved 
spontaneously on drug withdrawal in both instances. Thiazolidinedione tolerant 
subject A had to be withdrawn soon after recruitment into this study on account of 
development of proteinuria soon after withdrawal of his losartan therapy (as per 
study Protocol). Subject B was likewise withdrawn after developing an excessively 
high blood pressure ( > 160/110 mmHg) on withdrawal of his antihypertensive 
(atenolol 50 mg). Thiazolidinedione tolerant subjects were on average older [mean 
(95% CI) age = 61.6 (58.9, 64.2) years] than their  thiazolidinedione intolerant 
counterparts (both aged 55) at recruitment into the study (table 2.7). 
Thiazolidinedione 'intolerant' subject 10 had been diagnosed slightly earlier (166 
months) than her 'tolerant' counterparts [114.2 (95% CI 76.8, 151.5) months]. The 
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corresponding value for 'intolerant' subject 11 (82 months) was well within the 95% 
CI range for 'tolerant' subjects. Analyzing for patients who progressed to visits 2 and 
3, the difference in diabetes duration between subject 10 and the lower 95% CI range 
for thiazolidinedione 'tolerant' subjects decreased to approximately 10 months [166 
(subject 10) vs 112.9 (95% CI 69.0, 156.8) (TZD tolerant) months]. 
 
Table  2.7 - Demographic characteristics of thiazolidinedione - 'tolerant' and 
'intolerant' patients  
 
 
Subject number/letter 
by category 
 
Age  
(years) 
 
Gender  
 
Duration of diabetes 
(months) 
 
                
TZD tolerant a, b    
1 57 male 24 
2 66 female 266 
3 62 male 105 
4 54 male 65 
5 66 female 123 
6 65 male 95 
7 59 male 113 
8 65 male 144 
9 59 female 81 
A 57 male 77 
B 67 female 164 
Mean 
(95% CI) c 
61.6 
(58.9, 64.2)  
114.2 
(76.8, 151.5) 
 
   
TZD intolerant    
10 55 female 166 
11 55 female 82 
    
a
 Subjects 1 to 9 progressed to visit 2; b subjects A and B were withdrawn after visit 1; c mean (95% 
CI) values refer to all participating thiazolidinedione 'tolerant' subjects, irrespective of their 
progression or otherwise to visit 2. 
 
 
2.17.2 Past medical history  
 
Thiazolidinedione tolerant patient number 2 had retinopathy diagnosed 37 months 
prior to recruitment into the study. Tolerant patients 1 and 8 gave a past history of 
coronary artery disease. TZD tolerant patient 1 also suffered from peripheral 
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vascular disease; however none of the patients had undergone any peripheral 
vascularization procedure or amputation. Tolerant patient A had sustained a 
cerebrovascular accident in the past. TZD tolerant patient 1 had been diagnosed with 
C5/C6 radiculopathy. None of the patients gave a history of peripheral neuropathy, 
autonomic neuropathy or erectile dysfunction. As expected, more than 50% of 
thiazolidiedione tolerant patients suffered from hypertension (patients 1, 2, 6, 8, A 
and B), whereas an even higher proportion suffered from dyslipidaemia (patients 1, 
2, 3, 5, 7,  8,  9, A, B, and thiazolidinedione intolerant patient number 14). None of 
the participants were known to suffer from HF at recruitment. 
 
2.17.3 Drug history 
 
Eight out of 11 thiazolidinedione tolerant patients (61.5%) were being treated with 
pioglitazone at visit 1, with dose ranging from 15 to 45 mg. Daily rosiglitazone dose 
ranged from 4 to 8 mg. Both intolerant patients were being treated with the lowest 
possible dose on withdrawal of the offending thiazolidinedione. Duration of 
thiazolidinedone therapy for 'tolerant' subjects ranged from 7 to 51 months. All 
participating patients, except one, were being treated with a statin (table 2.8). 
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Table 2.8 - Oral glucose lowering agent and statin therapy of thiazolidinedione 
'tolerant' and 'intolerant' patients.  
 
Subject 
number/letter 
by category 
 
TZD 
 
TZD - daily 
dose 
prescribed 
(mg) c,d 
 
 
Duration of 
TZD therapy 
at visit 1 
(months) 
 
Metformin 
daily dose 
(mg) 
at visit 1 
 
 
Statin 
 
      
TZD tolerant 
a, b
 
 
 
 
  
1 rosiglitazone 4 c 11 1500 atorvastatin 
2 pioglitazone 30 c 51 2500 simvastatin 
3 pioglitazone 15 c 14 2000 simvastatin 
4 pioglitazone 15 c 7 2000 atorvastatin 
5 rosiglitazone 8 c 33 1500 simvastatin 
6 pioglitazone 30 c 28 1000  
7 pioglitazone 45 c 49 2550 simvastatin 
8 pioglitazone 30 c 33 2700 simvastatin 
9 rosiglitazone 8 c 42 2000 atorvastatin 
A pioglitazone 30 c 30 2000 rosuvastatin 
B pioglitazone 30 c 30 1700 atorvastatin 
 
     
TZD 
intolerant   
 
  
10 rosiglitazone 4 d e 2500 simvastatin 
11 pioglitazone 15 d e 1000 atorvastatin 
      
TZD, thiazolidinedione;  a subjects 1 to 9 progressed to visit 2; b subjects A and B were withdrawn 
after visit 1; c thiazolidinedione dose at visit 1; d thiazolidinedione dose at withdrawal; e not 
applicable 
 
 
2.17.4  Clinical measurements  
 
Table 2.9 summarises the clinical parameters (including anthropometric 
measurements) of thiazolidinedione 'tolerant' and 'intolerant' patients. All recorded 
baseline blood pressure readings were generally within the desired range at visit 1 
[mean (95% CI) SBP (thiazolidinedione tolerants) = 136.2 (132.2, 140.2) mmHg; 
mean (95% CI) DBP (thiazolidinedione tolerants) = 75.0 (71.2, 78.8) mmHg]. 
Patients who did not report symptoms of fluid overload following thiazolidinedione 
exposure tended to be overweight or obese [mean (95% CI) BMI = 32.54 (30.23, 
34.85) kg/m2]. They were also characterised by an excessive waist circumference 
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[mean (95% CI) = 113.9 (107.5, 120.3) cm], as outlined in table 2.9. Baseline 
exploratory data therefore suggested no major differences in baseline body weight, 
BMI and waist circumference between the tolerant and intolerant groups. 
 
2.17.5 Biochemistry 
 
Patient' glycaemic control was within the range specified by the Protocol (i.e. HbA1c 
< 9%) at recruitment. Baseline biochemical parameters, namely haematorit, sodium, 
serum creatinine (and eGFR) and lipid profile (total cholesterol, HDL-cholesterol, 
LDL-cholesterol and triglycerides) were also within the Protocol range for most 
patients, as attested by mean (95% CI) values for thiazolidinedione 'tolerant' 
subjects. Thiazolidinedione 'intolerant' subject 11 had severe dyslipidaemia. Her 
LDL-cholesterol concentration could not be determined using the Friedewald 
equation on account of her triglyceridemia (4.46 mmol/L) (table 2.10). 
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Table 2.9 - Clinical measurements of thiazolidinedione 'tolerant' and 'intolerant' patients. 
 
 
Subject number 
/letter by category 
 
 
Mean pulse 
(beats min-1) 
 
Mean SBP  
(mmHg) 
 
Mean DBP 
(mmHg) 
 
Height 
(m) 
 
Weight 
(kg) 
 
BMI  
(kg/m2) 
 
 
WC 
 (cm) 
 
        
TZD tolerant a, b        
1 71 124 81 1.68 76.4 27.07 98.0 
2 53 139 61 1.60 64.9 25.35 d 
3 82 127 75 1.80 93.7 28.90 103.0 
4 70 143 72 1.65 89.3 32.80 109.5 
5 92 130 79 1.60 90.2 35.23 129.5 
6 73 145 79 1.72 101.9 34.44 114.5 
7 70 137 78 1.74 94.7 31.28 109.0 
8 72 136 79 1.80 121.4 37.46 127.5 
9 81 135 81 1.60 87.7 34.26 108.0 
A 84 140 73 1.73 105.9 35.38 121.0 
B 71 141 67 1.57 88.1 35.74 119.0 
Mean 
(95% CI) c 
74.5 
(68.5, 80.4) 
136.2 
(132.2, 140.2) 
75.0 
(71.2, 78.8) 
1.68 
(1.63, 1.73) 
92.2 
(83.5, 100.9) 
32.54 
(30.23, 34.85) 
113.9 
(107.5, 120.3) 
 
       
TZD intolerant        
10 83 141 85 1.57 88.2 35.78 123.0 
11 81 127 75 1.60 85.6 33.65 103.5 
        
TZD, thiazolidinedione; WC, waist circumference (cm);  a subjects 1 to 9 progressed to visit 2; b subjects A and B were withdrawn after visit 1 
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Table 2.10 - Baseline biochemistry results of thiazolidinedione 'tolerant' and 'intolerant' patients.  
 
 
Subject 
number/letter 
by category 
Haematocrit 
(%) 
HbA1c  
(%) 
Sodium 
(mmol/L) 
 
Serum 
creatinine 
(µmol/L) 
 
 
Total 
cholesterol 
(mmol/L) 
 
HDL-C 
(mmol/L) 
 
LDL-C 
(mmol/L) 
 
 
Triglycerides 
(mmol/L) 
 
         
TZD tolerant a, b         
1 42.8 7.0 140 69 3.57 0.80 c c 
2 39.9 6.5 146 64 3.30 1.45 1.45 0.88 
3 42.7 8.0 138 66 3.37 1.11 1.27 2.21 
4 41.5 8.5 139 86 4.10 1.13 1.90 2.38 
5 43.0 8.8 141 51 4.14 0.66 d 4.97 
6 43.7 6.3 142 76 3.70 0.91 1.94 1.88 
7 44.0 7.4 142 76 3.82 1.49 1.81 1.16 
8 41.2 8.7 144 94 3.69 1.92 1.45 0.71 
9 42.4 7.0 144 61 4.68 1.44 2.33 2.03 
A 41.5 7.2 140 55 4.34 1.05 4.30 2.46 
B 36.7 6.8 142 63 4.35 1.57 2.32 1.02 
Mean 
(95% CI) c 
41.8 
(40.6, 43.0) 
7.5 
(6.9, 8.0) 
141.6 
(140.2, 143.1) 
69.2 
(61.6, 76.8) 
3.91 
(3.65, 4.17) 
1.23 
(1.01, 1.45) 
2.09 
(1.50, 2.68) 
1.97 
(1.20, 2.74) 
 
      
 
 
TZD intolerant         
10 37.4 7.5 143 70 4.76 1.65 2.24 1.94 
11 c 7.3 139 47 8.28 1.47 c 4.46 
         
a
 subjects 1 to 9 progressed to visit 2; b subjects A and B were withdrawn after visit 1; c data unavailable; d LDL-C level could not be derived from the Friedewald equation 
on account of an excessively high serum triglyceride concentration  
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2.17.6 Sodium exposure - low and high salt diets 
 
Daily morning spot urinary sodium concentrations pertaining to thiazolidinedione 
'tolerant' subjects 1 to 9, and 'intolerant' subjects 10 and 11, were measured for five 
days prior to visit 2 (during which patients followed a moderately low salt diet), and 
for an additional five days prior to visit 3 (high salt diet). Despite daily variations in 
urinary sodium excretion, patients were generally compliant to dietary instructions 
given. Calculation of the area under the curve for thiazolidinedione 'tolerant' and 
'intolerant' subjects between days -5 (five days before visit) to 0 (day of visit) (as a 
surrogate of total dietary sodium exposure) showed that the former increased their 
urinary sodium excretion by 49 (95% CI 43.5, 59.7)% (vs 20.6% and 125.9% for 
subjects 10 and 11 respectively) (data not shown). 
  
2.18 Arterial stiffness 
 
Data were accrued from all eleven participating patients [nine thiazolidinedione 
'tolerant' (subjects 1 to 9) and two thiazolidinedione 'intolerant' (subjects 10 and 11)] 
who proceeded to visits two and three. Pulse wave analysis and velocity estimations 
were carried out once in visit two in patients exposed to a moderately low sodium 
diet (and before being treated with an intravenous 0.9% saline infusion), and once in 
visit three following exposure to a high sodium diet. Percentage shift in central 
augmentation index (cAI), peripheral augmentation index (pAI) and pulse wave 
velocity (PWV) readings across sodium load categories (chronic high sodium - low 
sodium) was derived for all participating subjects. 
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2.18.1 Pulse wave analysis 
 
(i) Central augmentation index 
 
cAI was derived from the ratio of augmentation pressure to pulse pressure. Data are 
summarised in table 2.11 below. Mean cAI readings for thiazolidinedione 'tolerant' 
patients exposed to a moderately low sodium diet and a chronic high sodium load 
were 30.9 (95% CI 25.2, 36.7)% and 30.2 (95% CI 24.0, 36.4)% respectively  (table 
2.11, figure 2.6). Available data suggest that thiazolidinedione intolerant patients 
increase their cAI values when exposed to a chronic high sodium load (37.0%, 
88.2%), unlike their thiazolidinedione tolerant counterparts [mean (95% CI) = -1.59 
(-10.76, 7.58)%], as outlined in table 2.11 and figure 2.7. 
 
Table 2.11 - Central augmentation index (cAI) measurements (%) and derived % 
differences between sodium load exposures.  
 
 
Subject 
number by 
category 
 
cAI 
(low sodium) 
 
(%) 
 
cAI 
(chronic high sodium) 
 
(%) 
 
 
% difference cAI 
(chronic high sodium - 
low sodium) 
    
TZD tolerant    
1 30 30 0 
2 46 49 6.5 
3 16 20 25.0 
4 21 18 -14.3 
5 38 36 -5.3 
6 31 33 6.5 
7 29 22 -24.1 
8 32 32 0 
9 35 32 -8.6 
Mean  30.9 30.2 -1.59 
(95% CI) (25.2, 36.70) (24.0, 36.4) (-10.76, 7.58) 
    
TZD 
intolerant 
 
  
10 27 37 37.0 
11 17 32 88.2 
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Figure 2.6 – Mean (95% CI) central augmentation index (cAI) values (%) for  
thiazolidinedione (TZD) tolerant (n = 9, plotted in blue) and individual cAI 
readings for thiazolidinedione intolerant (n = 2, plotted in red) subjects exposed to 
a low sodium diet and a chronic high sodium load. 
 
 
 
Figure 2.7  – Percentage difference in central augmentation index (cAI) readings 
(%) between exposure to a moderately low sodium diet and a chronic high sodium 
load for thiazolidinedione (TZD) tolerant (n = 9, plotted in blue) and TZD 
intolerant (n = 2, plotted in red) subjects. Mean and 95% confidence intervals were 
derived for TZD tolerant subjects. 
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(ii) Peripheral augmentation index 
 
Peripheral augmentation index (pAI) was likewise derived using applanation 
tonometry from the ratio of late systolic pressure (P2) to early systolic pressure (P1). 
Percentage shifts in pAI readings were also estimated for visits 2 and 3, as outlined 
in table 2.12. 
 
Table 2.12 - Peripheral augmentation index (pAI) measurements (%) and derived 
% differences between sodium load exposures.  
 
 
Subject number 
by category 
 
pAI 
(low sodium) 
 
(%) 
 
pAI 
(chronic high sodium) 
 
(%) 
 
 
% difference pAI 
(chronic high sodium - 
low sodium) 
    
TZD tolerant    
1 143 142 -0.7 
2 185 196 5.9 
3 119 126 5.0 
4 127 122 -3.9 
5 162 156 -3.7 
6 145 150 3.4 
7 141 129 -8.5 
8 146 148 0.7 
9 153 148 -3.9 
Mean 147.1 146.3 -0.6 
(95% CI) (134.7, 159.5) (131.9, 160.7) (-3.74, 2.54) 
    
TZD intolerant    
10 136 159 16.9 
11 120 147 22.5 
    
Mean pAI readings for thiazolidinedione tolerant patients were 147.1 (95% CI 134.7, 
159.5) % and 146.3 (95% CI 131.9, 160.7)% under moderately low and high sodium 
dietary conditions respectively (table 2.12, figure 2.8). Oedema prone TZD patients 
seemingly increase their pAI when subjected to a chronic sodium load, unlike their 
thiazolidinedione tolerant counterparts [-0.6 (95% CI -3.74, 2.54)% (TZD tolerant) 
vs 16.9%, 22.5% (TZD intolerant)] (table 2.12, figure 2.9). 
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Figure 2.8 – Mean (95% CI) peripheral augmentation index (pAI) values (%) for  
thiazolidinedione (TZD) tolerant (n = 9, plotted in blue) and individual pAI 
readings for thiazolidinedione intolerant (n = 2, plotted in red) subjects exposed to 
a low sodium diet and a chronic high sodium load. 
 
 
Figure 2.9 – Percentage difference in peripheral augmentation index (pAI) 
readings (%) between exposure to a moderately low sodium diet and a chronic high 
sodium load for thiazolidinedione (TZD) tolerant (n = 9, plotted in blue) and TZD 
intolerant (n = 2, plotted in red) subjects. Mean and 95% confidence intervals were 
derived for TZD tolerant subjects. 
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2.18.2 Pulse wave velocity 
 
Pulse wave velocity data pertaining to the participating subjects are summarised in 
table 2.13 below. Mean (95% CI) PWV readings for thiazolidinedione 'tolerant' 
patients exposed to a moderately low sodium diet and a chronic high sodium load 
were 8.57 (7.84, 9.30) m/s and 8.32 (7.61, 9.03) m/s respectively. Available data do 
not suggest any differences in baseline PWV between oedema prone and 
thiazolidinedione tolerant patients, irrespective of sodium exposure. Likewise, there 
seems to be no appreciable difference in % PWV shift across sodium load exposures 
between the two groups [-2.82 (95% CI -5.34, -0.30)% (TZD tolerant) vs -9.4%, 
11.4% (TZD intolerant)], as outlined in table 2.13. 
 
Table 2.13 - Pulse wave velocity (PWV) measurements (m/s) and derived % 
differences between sodium load exposures.  
 
 
Subject 
number by 
category 
 
PWV 
(low sodium) 
 
(m/s) 
 
PWV 
(chronic high sodium) 
 
(m/s) 
 
 
% difference PWV 
(chronic high sodium - 
low sodium) 
    
TZD tolerant    
1 10.6 9.9 -6.6 
2 8.0 7.6 -5.0 
3 9.7 9.2 -5.2 
4 8.7 9.2 5.7 
5 7.0 6.6 -5.7 
6 7.7 7.6 -1.3 
7 8.2 8.1 -1.2 
8 9.3 9.2 -1.1 
9 7.9 7.5 -5.1 
Mean 8.57 8.32 -2.82 
(95% CI) (7.84, 9.30) (7.61, 9.03) (-5.34, -0.30) 
    
TZD 
intolerant 
   
10 8.5 7.7 -9.4 
11 7.9 8.8 11.4 
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2.19 Echocardiography 
 
Echocardiographic parameters (left ventricular ejection fraction, E/A ratio, E prime, 
E/e prime ratio, left ventricular mass) were captured for participating subjects in 
visits two and three. Data were collected for nine, eight and nine thiazolidinedione 
tolerant subjects following exposure to a moderately low, acute high and chronic 
high sodium loads respectively (one patient declined an echo following intravenous 
saline administration). Data were captured from both TZD 'intolerant' patients in all 
three instances. Preliminary exploratory data suggests no differences in any of the 
measured echocardiographic parameters between thiazolidinedione patient 
categories. Plotting percentage change in any of these measurements across sodium 
load categories for both TZD tolerant and intolerant patients did not yield any 
consistent trends (appendix tables II.1 to II.5). 
 
 
2.20 Biomarkers 
 
In a bid to identify predisposing factors for thiazolidinedinoe-associated fluid 
retention, this study measured a number of biomarkers of interest, as outlined in 
section I. Plasma samples were collected to measure vascular endothelial growth 
factor (VEGF), ANP, BNP, N-terminal prohormone of B-type natriuretic peptide 
(NT-pro-BNP), aldosterone, renin and copeptin for each patient at visit 2 (moderately 
low sodium diet, before infusion of intravenous saline) and visit 3 (chronic sodium 
load). This enabled a relative comparison between thiazolidinedione 'tolerant' and 
'intolerant' subjects. 
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2.20.1 Vascular endothelial growth factor 
 
Plasma was sampled for VEGF level estimation from eight and nine 
thiazolidinedione tolerant patients at visits 2 and 3 respectively, and from both 
thiazolidinedione intolerant patients at either visit. Mean (95% CI) VEGF readings 
for 'tolerant' subjects were 57.3 (12.0, 102.6)  pg/mL and 38.6 (24.1, 53.1) pg/mL 
after exposure to a moderately low and a chronic high sodium load respectively 
(appendix table II.6). Generally decreasing for 'tolerant' patients on sodium loading, 
available data suggest no significant difference in VEGF levels between 
thiazolidinedione categories on exposure to a low sodium diet. However, exposure to 
a moderately high sodium diet for five days resulted in seemingly lower VEGF levels 
for thiazolidinedione intolerant subjects compared to their intolerant counterparts 
(appendix table II.6). Plotting percentage change in VEGF readings between 
exposure to a moderately low sodium diet and a chronic high sodium load showed a 
mean (95% CI) VEGF reduction of 11.6 (-32.5, 9.3)% for thiazolidinedione tolerant 
individuals. The two intolerant subjects exhibited  VEGF changes on either side of 
the 95% CI range for their tolerant counterparts (appendix table II.6).  
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2.20.2 Atrial natriuretic peptide 
 
ANP data were available from eight and seven thiazolidinedione tolerant patients, 
and from both intolerant subjects after exposure to a moderately low and a chronic 
high sodium load respectively. Mean (95% CI) ANP readings for TZD tolerant 
patients were 40.33 (7.37, 73.29) fmol/mL and 21.3 (9.45, 33.15) fmol/mL  
respectively. No significant difference in ANP levels between either 
thiazolidinedione category, irrespective of sodium exposure (table 2.14, figure 2.10) 
was detected.  However, plots of percentage change in ANP between the period of 
low and high sodium diets suggests an 80-129% increase for TZD intolerant patients 
compared with a mean (95% CI)  5.2% increase (-53.4, 63.8) for thiazolidinedione 
tolerant patients (table 2.14, figure 2.11). 
 
Table 2.14 - Atrial natriuretic peptide (ANP) measurements (fmol/mL) and derived 
% differences between sodium load exposures for visits 2 and 3 
 
 
Subject number by 
category 
 
ANP (fmol/mL) 
(low  sodium) 
 
ANP (fmol/mL)  
(chronic high sodium) 
 
% difference ANP 
(chronic high sodium 
- low sodium) 
 
    
TZD tolerant    
1 21.162 16.506 -22.0 
2 26.289 43.736 66.4 
3 65.473 8.938 -86.3 
4 5.4796 12.298 124.4 
5 1.999 0.134 -93.3 
6 26.022 30.531 17.3 
7 28.152 36.659 30.2 
8 148.033 a c 
9  b  b c 
Mean  
(95% CI) 
40.330 
(7.370, 73.290) 
21.300 
(9.450, 33.150) 
5.2 
(-53.4, 63.8) 
 
   
TZD intolerant    
10 25.726 46.297 80.0 
11 10.815 24.802 129.3 
 
   
a
 haemolyzed sample, rendering result dubious;  b patient's ANP data are unavailable; c derivation of 
% difference not possible due to missing data 
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Figure 2.10 – Mean (95% CI) atrial natriuretic peptide (ANP) values (fmol/mL) 
for thiazolidinedione (TZD) tolerant [n = 8 (low sodium diet), n = 7 (chronic high 
sodium load) plotted in blue] and individual ANP readings for thiazolidinedione 
intolerant (n = 2, plotted in red) subjects exposed to a low sodium diet and a 
chronic high sodium load. 
 
 
 
 
Figure 2.11 – Percentage difference in atrial natriuretic peptide (ANP) readings 
(fmol/mL) between exposure to a moderately low sodium diet and a chronic high 
sodium load for thiazolidinedione (TZD) tolerant [n = 7 (low sodium diet), n = 8 
(chronic high sodium load) plotted in blue] and intolerant (n = 2, plotted in red) 
subjects. Mean and 95% confidence intervals were derived for thiazolidinedione 
tolerant subjects. 
 
0
20
40
60
80
100
120
140
160
ANP
(fmol/mL)
-150
-100
-50
0
50
100
150
0 20 40 60 80 100 120 140 160
% ANP difference
(chronic high 
sodium - low 
sodium)
Baseline ANP (fmol/mL) on a moderately low sodium diet
                   Low sodium diet                                Chronic high sodium load 
171 
 
 
2.20.3 B-type natriuretic peptide 
 
BNP concentrations were measured in eight thiazolidinedione tolerant and both TZD 
intolerant patients in each of visits two and three. Mean (95% CI) BNP levels 
decreased for the oedema free subjects on sodium exposure [16.87 (1.08, 32.66) 
pg/mL (low sodium) vs 8.50 (5.53, 11.47) pg/mL (high sodium)] (table 2.15, figure 
2.12). Exploratory data suggest no significant difference in BNP levels between 
thiazolidinedione categories after exposure to a low sodium diet. Individually plotted 
data for oedema prone subjects lie beyond, albeit on either side, of the mean (95% 
CI) reference range for thiazolidinedione 'tolerant' subjects on exposure to a chronic 
moderately high sodium load (figure 2.12). The latter subgroup were characterised 
by a mean (95% CI) 27.5% increase (-37.22, 92.22) in prevailing BNP 
concentrations on progressing from a moderately low to a moderately high sodium 
diet. TZD intolerant subjects tended to exhibit a greater increase (90.1% and 249.7% 
respectively). However, any conclusions are rendered dubious by the observation 
that the 90.1% increase reported for one of the oedema prone patients marginally 
overlaps with the upper limit of the 95% CI reference range for tolerant subjects 
(table 2.15, figure 2.13). 
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Table 2.15 - B-type natriuretic peptide (BNP) measurements (pg/mL) and derived 
% differences between sodium load exposures for visits 2 and 3 
 
 
Subject number by 
category 
 
BNP (pg/mL) 
(low  sodium) 
 
BNP (pg/mL)  
(chronic high sodium) 
 
% difference BNP 
(chronic high sodium - 
low sodium) 
 
    
TZD tolerant    
1 5.284 9.399 77.9 
2 4.645 11.082 138.6 
3 3.511 4.610 31.3 
4 29.089 4.687 -83.9 
5 68.905 12.482 -81.9 
6 1.975 5.138 160.2 
7 7.656 4.917 -35.8 
8 13.868 15.697 13.2 
9 a a b 
Mean  
(95% CI) 
16.870 
(1.080, 32.660) 
8.500 
(5.530, 11.470) 
27.5 
(-37.22, 92.22) 
 
   
TZD intolerant    
10 2.303 4.379 90.1 
11 6.440 22.523 249.7 
    
 
a patient's BNP data were unavailable; b calculation not possible due to missing data 
 
 
Figure 2.12 – Mean (95% CI) B-type natriuretic peptide (BNP) values (pg/mL) for  
thiazolidinedione (TZD) tolerant (n = 8, plotted in blue) and individual BNP 
readings for thiazolidinedione intolerant (n = 2, plotted in red) subjects exposed to 
a low sodium diet and a chronic high sodium load. 
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Figure 2.13  – Percentage difference in B-type natriuretic peptide (BNP) readings 
(pg/mL) between exposure to a moderately low sodium diet and a chronic high 
sodium load for thiazolidinedione (TZD) tolerant (n = 8, plotted in blue) and 
intolerant (n = 2, plotted in red) subjects. Mean and 95% confidence intervals were 
derived for thiazolidinedione tolerant subjects 
 
 
 
 
 
2.20.4 N-terminal prohormone of B-type natriuretic peptide 
 
N-terminal prohormone of B-type natriuretic peptide (NT-pro-BNP) was measured in 
eight thiazolidinedione 'tolerant' subjects [mean (95% CI) 440.29 (347.05, 533.53) 
fmol/mL (low sodium); 501.1 (355.08, 647.12) fmol/mL (high sodium)]. Plotting 
individual data points for TZD intolerant patients suggest no significant difference 
between either thiazolidinedione category at either visit (table 2.16). In a similar 
vein, thiazolidinedione tolerant patients were characterised by a mean (95% CI) 14.8 
% increase (-21.86, 51.46) in prevailing NT-pro-BNP (vs 4.4% and 31.8% increase 
for TZD intolerant ones) (table 2.16). 
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Table 2.16 - N-terminal prohormone of B-type natriuretic peptide (NT-pro-BNP) 
measurements (fmol/mL) and derived % differences between sodium load 
exposures for visits 2 and 3. 
 
 
Subject number by 
category 
 
NT-pro-BNP 
(fmol/mL) 
(low  sodium) 
 
NT-pro-BNP 
(fmol/mL)  
(chronic high sodium) 
 
% difference  
NT-pro-BNP 
(chronic high sodium 
- low sodium) 
 
    
TZD tolerant    
1 377.184 300.216 -20.4 
2 379.128 453.702 19.7 
3 471.018 981.57 108.4 
4 759.132 293.82 -61.3 
5 359.022 586.938 63.5 
6 411.786 359.736 -12.6 
7 348.504 446.826 28.2 
8 416.568 386.472 -7.2 
9 a 700.788 b 
Mean  
(95% CI) 
440.29 
(347.05, 533.53) 
501.1 
(355.08, 647.12) 
14.8 
(-21.86, 51.46) 
 
   
TZD intolerant    
10 535.656 559.014 4.4 
11 344.214 453.666 31.8 
    
 
a
 patient's NT-pro-BNP data were unavailable; b estimation of % difference not possible due to 
missing data 
 
 
2.20.5 Aldosterone 
 
As expected, plasma aldosterone concentrations decreased in response to chronic salt 
loading for either thiazolidinedione category. Mean (95% CI) values for 
thiazolidinedione tolerant subjects were 292.59 (155.87, 429.31) pg/mL and 99.4 
(22.77, 176.03) pg/mL after exposure to a moderately low and a chronic high sodium 
load respectively (table 2.17, figure 2.14). Exploratory data suggest no significant 
difference in plasma aldosterone readings between the two thiazolidinedione 
categories (figure 2.14). While thiazolidinedione intolerant subjects generally 
exhibited a greater reduction in prevailing plasma aldosterone concentrations on salt 
loading (-69.7% and -86.2% respectively), these values overlap with the lower end-
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point of the 95% CI for tolerant subjects [mean (95% CI) = -50.9 (-87.07, -14.73)%] 
(table 2.17, figure 2.15). 
 
Table 2.17 - Plasma aldosterone measurements (pg/mL) and derived % differences 
between sodium load exposures for visits 2 and 3 
 
 
Subject number by 
category 
 
Aldosterone (pg/mL) 
(low  sodium) 
 
Aldosterone (pg/mL)  
(chronic high sodium) 
 
% difference 
aldosterone 
(chronic high sodium - 
low sodium) 
 
    
TZD tolerant    
1 421.018 32.506 -92.3 
2 199.085 110.64 -44.4 
3 194.593 20.289 -89.6 
4 93.108 154.133 65.5 
5 699.726 386.860 -44.7 
6 127.101 81.291 -36.0 
7 255.647 50.408 -80.3 
8 350.456 52.320 -85.1 
9 a 6.447 b 
Mean  
(95% CI) 
292.590 
(155.870, 429.310) 
99.400 
(22.770, 176.030) 
-50.9 
(-87.07, -14.73) 
 
   
TZD intolerant    
10 108.970 32.967 -69.7 
11 358.130 49.375 -86.2 
    
a Patient's plasma aldosterone data unavailable; bderivation of % difference not possible due to 
missing data 
 
Figure 2.14 – Mean (95% CI) plasma aldosterone values (pg/mL) for  
thiazolidinedione (TZD) tolerant [n = 8 (low sodium diet), n = 9 (chronic high 
sodium load) plotted in blue] and individual aldosterone readings for 
thiazolidinedione intolerant (n = 2, plotted in red) subjects exposed to a low sodium 
diet and a chronic high sodium load. 
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Figure 2.15 – Percentage difference in plasma aldosterone readings (pg/mL) 
between exposure to a moderately low sodium diet and a chronic high sodium load 
for thiazolidinedione (TZD) tolerant [n = 8 (low sodium diet), n = 9 (chronic high 
sodium load) plotted in blue] and intolerant (n = 2, plotted in red) subjects. Mean 
and 95% confidence intervals were derived for thiazolidinedione tolerant subjects 
 
 
 
 
2.20.6 Renin 
 
Plasma renin levels were measured in eight and nine thiazolidinedione tolerant 
patients, and in both TZD intolerant subjects at visits 2 and 3 respectively. In 
concordance with earlier reported aldosterone results, exposure to a chronic sodium 
load was associated with a reduction in prevailing renin concentrations in either 
thiazolidinedione category [mean (95% CI) = -71.2 (-82.5, -59.9) % for 
thiazolidinedione tolerant subjects vs -86.2% and -99.9% (thiazolidinedione 
intolerant)] (table 2.18, figure 2.17). Thus, this preliminary data suggest that patients 
prone to thiazolidinedione-induced oedema decrease their prevalent plasma renin by 
a greater margin than their tolerant counterparts. Plots of individual plasma renin 
readings for intolerant subjects at either visit and comparing these to the mean (95% 
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CI) values for their TZD tolerant counterparts suggests no significant differences 
between either patient category (table 2.18, figure 2.16).  
 
Table 2.18 - Plasma renin measurements (ng/mL/hour) and derived % differences 
between sodium load exposures for visits 2 and 3 
 
 
Subject number by 
category 
 
Renin (ng/mL/hour) 
(low  sodium) 
 
Renin (ng/mL/hour)  
(chronic high sodium) 
 
% difference  
renin 
(chronic high sodium 
- low sodium) 
 
    
TZD tolerant    
1 3.234 0.269 -91.7 
2 0.314 0.134 -57.3 
3 1.798 0.262 -85.4 
4 0.468 0.191 -59.2 
5 3.644 1.946 -46.6 
6 0.281 0.053 -81.1 
7 1.644 0.263 -84.0 
8 1.860 0.659 -64.6 
9 a 0.062 b 
Mean  
(95% CI) 
1.655 
(0.76, 2.55) 
0.427 
(0.04, 0.82) 
-71.2 
(-82.5, -59.9) 
 
   
TZD intolerant    
10 1.649 0.227 -86.2 
11 1.767 0.001 -99.9 
    
a
 patient's plasma renin data were unavailable;   b estimation of % difference not possible due to 
missing data 
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Figure 2.16 – Mean (95% CI) plasma renin values (ng/mL/hour) for 
thiazolidinedione (TZD) tolerant [n = 8 (low sodium diet), n = 9 (chronic high 
sodium load) plotted in blue] and individual renin readings for thiazolidinedione 
intolerant (n = 2, plotted in red) subjects exposed to a low sodium diet and a 
chronic high sodium load. 
 
 
 
 
 
Figure 2.17 – Percentage difference in plasma renin readings (ng/mL/hour) 
between exposure to a moderately low sodium diet and a chronic high sodium load 
for thiazolidinedione (TZD) tolerant [n = 8 (low sodium diet), n = 9 (chronic high 
sodium load) plotted in blue] and intolerant (n = 2, plotted in red) subjects. Mean 
and 95% confidence intervals were derived for thiazolidinedione tolerant subjects 
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2.20.7 Copeptin  
 
Copeptin was measured using a highly sensitive assay from eight and nine 
thiazolidinedione 'tolerant' patients at visits 2 and 3 respectively, and from both 
thiazolidinedione 'intolerant' subjects at either visit. Mean (95% CI) copeptin 
readings decreased for such patients when progressing from a moderately low 
sodium to a chronic high sodium load [5.83 (3.73, 7.93) (low sodium) vs 4.1 (3.19, 
5.01) (high sodium)] (appendix table II.7). Individual readings for thiazolidinedione 
'intolerant' subjects stood beyond, albeit on either side, of the 95% CI range for their 
'oedema  free' counterparts (appendix table II.7). Thiazolidinedione 'tolerant' subjects 
experienced a mean (95% CI) copeptin reduction of 17.2% (-40.87, 5.67) on chronic 
salt loading. Plots did not suggest that differences from TZD intolerant counterparts 
(-30.4% and 7.5% respectively) (appendix table II.7). 
 
 
2.21 Haematocrit shifts in response to salt loading  
 
Consistent with the observations on urinary sodium excretion, both thiazolidinedione 
tolerant and intolerant patients exhibited a decrease in their haematocrit (i.e. 
haemodiluted) in response to salt loading, whether acute or chronic (table 2.19, 
figure 2.18). Thiazolidinedione intolerant subjects 10 and 11 were characterised by 
lower haematocrit values at all three salt loading states (table 2.19, figure 2.18). The 
degree of reduction (expressed as a percentage) for thiazolidinedione tolerant 
subjects tended to be greater following acute compared with chronic salt loading 
(table 2.19, figures 2.19 and 2.20). Comparing % change in haematocrit across 
thiazolidinedione categories, both intolerant subjects had a larger decrease in 
180 
 
 
haematocrit following exposure to a five day high sodium diet  [-6.99%, -7.54% 
respectively vs mean (95% CI) values of -3.69 (-5.89, -1.49) % for 'tolerant' patients] 
(table 2.19, figure 2.20). Analyzing for the percentage difference across low and 
acute high salt loading, TZD intolerant patient 10 had a numerically larger decrease 
in haematocrit (-5.52%) compared with her thiazolidinedione tolerant counterparts 
[mean (95% CI) =  -4.13 (-5.29, -2.97) %], but this was not the case for subject 11 
(table 2.19, figure 2.19).  
 
 
Table 2.19 - Haematocrit measurements (%) and derived % differences between 
sodium load exposures for visits 2 and 3 
 
 
Subject 
number by 
category 
 
Haematocrit 
(low Na) 
(%) 
 
Haematocrit  
(acute high Na) 
(%) 
 
Haematocrit  
(chronic high 
Na) 
(%) 
 
% difference 
haematocrit  
(acute high 
Na - low 
sodium) 
 
% difference 
haematocrit 
(chronic 
high Na - 
low sodium) 
 
      
TZD tolerant      
1 44.40 a 42.45 b  -4.39 
2 38.88 36.35 36.68 -6.50 -5.66 
3 42.05 40.45 41.13 -3.80 -2.20 
4 39.15 37.45 39.58 -4.34 1.09 
5 43.00 40.45 41.43 -5.93 -3.66 
6 45.18 44.00 40.78 -2.60 -9.74 
7 44.45 43.15 43.75 -2.92 -1.57 
8 41.00 39.85 39.60 -2.80 -3.41 
9 a a 38.95  b b  
Mean 42.26 40.24 40.48 -4.13 -3.69  
(95% CI) (40.58, 43.94) (38.20, 42.28) (39.13, 41.83) (-5.29, -2.97) (-5.89, -1.49) 
      
TZD 
intolerant    
  
10 37.58 35.50 34.95 -5.52 -6.99 
11 39.48 37.70 36.50 -4.50 -7.54 
      
a
 data unavailable; b calculation not possible due to missing data 
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Figure 2.18 – Mean (95% CI) haematocrit readings (%) for thiazolidinedione 
(TZD) tolerant [n = 8 (low sodium diet); n = 7 (acute high sodium load); n = 9 
(chronic high sodium diet), plotted in blue] and individual haematocrit readings 
for thiazolidinedione intolerant (n = 2, plotted in red) subjects exposed to a low 
sodium diet, an acute high sodium load and a chronic high sodium load. 
 
 
Figure 2.19 – Percentage difference in haematocrit between exposure to a 
moderately low sodium diet and an acute high sodium load for thiazolidinedione 
(TZD) tolerant [n =  8 (low sodium), n = 7 (acute high sodium), plotted in blue] 
and intolerant (n = 2, plotted in red) subjects. Mean and 95% confidence intervals 
were derived for TZD tolerant subjects. 
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Figure 2.20 – Percentage difference in haematocrit between exposure to a 
moderately low sodium diet and a chronic high sodium load for thiazolidinedione 
(TZD) tolerant [n =  8 (low sodium), n = 9 (chronic high sodium), plotted in blue] 
and intolerant (n = 2, plotted in red) subjects. Mean and 95% confidence intervals 
were derived for TZD tolerant subjects. 
 
 
 
2.22 Weight change in response to salt loading 
 
All participating patients tended to gain weight on progressing from a low to a high 
salt diet. Exploratory data suggest no significant differences between 
thiazolidinedione categories (table 2.20). Plotting % change in weight secondary to 
dietary adjustments yielded a mean (95% CI) increase of 0.67 (0.20, 1.14)% for 
thiazolidinedione tolerant patients. TZD intolerant patient 11 exhibited a 
substantially greater increase in body weight on chronic sodium exposure (2.14%); 
however, this result was not replicated in intolerant subject 10 (table 2.20).   
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Table 2.20 - Body weight (kg) and derived % differences between sodium load 
exposures for visits 2 and 3. 
 
 
Subject number 
by category 
 
Body weight 
(low sodium) 
 
(kg) 
 
Body weight 
(chronic high sodium) 
 
(kg) 
 
 
% difference body weight 
(acute high sodium - low 
sodium) 
    
TZD tolerant    
1 74.8 76.4 2.14 
2 62.8 63.3 0.80 
3 92.1 92.6 0.54 
4 89.2 89.0 -0.22 
5 88.4 89.4 1.13 
6 98 98.6 0.61 
7 93.6 93.4 -0.21 
8 118.6 119.0 0.34 
9 86.0 86.8 0.93 
Mean 89.3 89.8 0.67 
(95% CI) (79.25, 99.31) (79.91, 99.75) (0.20, 1.14) 
    
TZD intolerant    
10 88.6 88.8 0.23 
11 84.0 85.8 2.14 
    
 
2.23 Ankle-foot volume changes in response to dietary sodium exposure 
 
Data from participating thiazolidinedione tolerant and intolerant subjects are 
summarised in table 2.21, figures 2.21 to  2.23 below. One thiazolidinedione tolerant 
subject declined to pursue with AFV measurements after exposure to intravenous 
0.9% saline infusion (acute sodium load); hence AFV data for acute sodium load 
exposure are limited to eight subjects. Mean (95% CI) for the %AFV difference 
between acute high sodium load exposure and low dietary sodium exposure for 
thiazolidinedione tolerant subjects amounted to 2.5 (-2.2, 7.2)%. The corresponding 
values for the difference between chronic high and low dietary sodium exposure was 
2.2 (0.3, 4.1)%. Available data suggest that exposure to a acute high sodium load 
may result in a reduction in AFV in thiazolidinedione intolerant subjects, but not in 
TZD tolerant patients (table 2.21, figure 2.22). However, data must be interpreted 
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with caution, given (i) the small number of participating subjects in each 
thiazolidinedione category, and (ii) wide 95% CIs for AFV change in 
thiazolidinedione 'tolerant' subjects. TZD intolerant subject 11 reduced her AFV by a 
greater extent than her 'tolerant counterparts  in response to acute salt loading [-2.4% 
vs mean (95% CI) 2.5 (-2.2, 7.2)% for 'tolerant subjects]. A similar, thought 
seemingly insignificant change, was reported for intolerant subject 10 (table 2.21, 
figure 2.22). Analyzing percentage change in AFV following five days of high 
sodium intake, TZD intolerant subject 11 was characterised by a greater increase 
[5.5% vs mean (95% CI) 2.2 (0.3, 4.1)%  for thiazolidinedione tolerant subjects]. 
TZD intolerant subject 10's % AFV increase was similar to that of TZD tolerant 
patients subjected to chronic sodium loading (table 2.21, figure 2.23). 
 
Table 2.21 - Ankle-foot volume (AFV) measurements and derived % differences 
between sodium load exposures for visits 2 and 3 
 
 
Subject number 
by category 
 
AFV 
(low Na) 
 
AFV  
(acute high 
Na) 
 
AFV  
(chronic high 
Na) 
 
% 
difference 
AFV  
(acute high 
Na - low 
sodium) 
 
% 
difference 
AFV 
(chronic 
high Na - 
low sodium) 
 
      
TZD tolerant      
1 2779 a 3013 b 8.4 
2 2394 2868 2497 19.8 4.3 
3 3101 3085 3100 -0.5 0.0 
4 3167 3254 3194 2.7 0.9 
5 2875 2872 2858 -0.1 -0.6 
6 3617 3654 3630 1.0 0.4 
7 3055 3013 3106 -1.4 1.7 
8 3559 3613 3706 1.5 4.1 
9 3548 3441 3569 -3.0 0.6 
Mean  3122  3225  3186  2.5  2.2  
(95% CI) (2855, 3389) (3006, 3444) (2929, 3443) (-2.2, 7.2) (0.3, 4.1) 
      
TZD intolerant      
10 3572 3503 3627 -1.9 1.5 
11 2743 2677 2894 -2.4 5.5 
      
a Patient declined to measure ankle-foot volume by ankle displacement on this occasion; b 
calculation not possible due to missing data. 
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Figure 2.21 – Mean (95% CI) ankle-foot volume (AFV) readings (mLs) for  
thiazolidinedione (TZD) tolerant [n = 9 (low sodium diet); n = 8 (acute high 
sodium load), plotted in blue) and individual AFV readings for thiazolidinedione 
intolerant (n = 2, plotted in red) subjects exposed to a low sodium diet, an acute 
high sodium load and a chronic high sodium load. 
 
 
Figure 2.22 – Percentage difference in ankle-foot volume (AFV) between exposure 
to a moderately low sodium diet and an acute high sodium load for 
thiazolidinedione (TZD) tolerant [n = 9 (low sodium diet); n = 8 (acute high 
sodium load) plotted in blue) and intolerant (n = 2, plotted in red) subjects. Mean 
and 95% confidence intervals were derived for TZD tolerant subjects. 
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Figure 2.23 – Percentage difference in ankle-foot volume (AFV) between exposure 
to a moderately low sodium diet and a chronic high sodium load for 
thiazolidinedione (TZD) tolerant (n = 9, plotted in blue) and intolerant (n = 2, 
plotted in red) subjects. Mean and 95% confidence intervals were derived for TZD 
tolerant subjects. 
 
 
2.24 Salt sensitivity of blood pressure  
 
SBP and DBP values were compared at the beginning of visits 2 and 3, enabling an 
assessment of salt sensitivity in response to a chronic salt loading. Mean arterial 
pressure  (MAP) values were derived for each patient at each time-point using the 
formula [(2*DBP) + SBP]/3.  
 
2.24.1 Systolic blood pressure 
 
Thiazolidinedione tolerant patients exhibited no significant shift in their baseline 
SBP readings when progressing from a moderately low sodium diet to a chronic high 
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shifted their SBP readings in either direction, as outlined in appendix table x.x 
Derived percentage SBP shifts across sodium load categories were more marked for 
either thiazolidinedione intolerant subject, albeit in opposite directions, as outlined in 
appendix table II.8. 
 
2.24.2 Diastolic blood pressure 
 
Thiazolidinedione tolerant patients’ DBP readings showed only marginal change on 
progressing from a moderately low sodium diet [mean (95% CI) DBP = 83.4 (79.0, 
87.8) mmHg) to a chronic high sodium diet [mean (95% CI) DBP = 83.1 (78.3, 87.9) 
mmHg], as outlined in table 2.22 and figure 2.24. Exploratory data suggest that mean 
(95% CI) percentage DBP change for thiazolidinedione tolerant subjects [-0.2 (-4.1, 
3.7)] is lower than the individual % DBP reduction values for intolerant patients (-
7.5%, -4.6% respectively) (table 2.22, figure 2.25). 
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Table 2.22 - Diastolic blood pressure (DBP) readings (mmHg) and derived % 
differences between sodium load exposures for visits 2 and 3.  
 
 
Subject number by 
category 
 
DBP (mmHg) 
(low  sodium) 
 
DBP (mmHg)  
(chronic high sodium) 
 
% difference DBP 
(chronic high sodium - 
low sodium) 
 
    
TZD tolerant    
1 84.3 89.7 6.3 
2 74.0 73.0 -1.4 
3 76.7 84.0 9.6 
4 91.0 92.0 1.1 
5 75.7 70.7 -6.6 
6 88.0 87.0 -1.1 
7 87.3 80.0 -8.4 
8 92.0 88.0 -4.3 
9 81.7 84.0 2.9 
Mean 
(95% CI) 
83.4 
(79.0, 87.8) 
83.1 
(78.3, 87.9) 
-0.2 
(-4.1, 3.7) 
 
   
TZD intolerant    
10 93.3 86.3 -7.5 
11 93.7 89.3 -4.6 
    
 
 
Figure 2.24 – Mean (95% CI) diastolic blood pressure (DBP) values (mmHg) for 
thiazolidinedione (TZD) tolerant (n = 9, plotted in blue) and individual systolic 
blood pressure readings for thiazolidinedione intolerant (n = 2, plotted in red) 
subjects exposed to a low sodium diet and a chronic high sodium load. 
 
 
 
70
75
80
85
90
95
100
DBP
(mmHg)
                      Low sodium diet                                           Chronic high sodium load 
189 
 
 
Figure 2.25 – Percentage difference in diastolic blood pressure (DBP) readings 
(mmHg) between exposure to a moderately low sodium diet and exposure to a 
chronic high sodium load for thiazolidinedione (TZD) tolerant (n = 9, plotted in 
blue) and intolerant (n = 2, plotted in red) subjects. Mean and 95% confidence 
intervals were derived for thiazolidinedione tolerant subjects. 
 
 
 
2.24.3 Mean arterial pressure 
 
Comparing MAP values following exposure to five days of a moderately low sodium 
and another five days of chronic salt loading, thiazolidinedione ‘tolerant’ subjects 
were characterised by a marginal change in their prevalent MAP [mean (95% CI) 
MAP = 101.8 (98.2, 105.4) mmHg (low sodium diet) vs 101.5 (97.1, 105.8) (high 
sodium diet)] mm Hg (appendix table II.9). While thiazolidinedione intolerant 
subject 11 exhibited a 2.9 mmHg increase in MAP in response to chronic salt loading 
(2.6% increase over baseline MAP), almost rendering her salt sensitive, intolerant 
subject 10 exhibited a 12.3 mmHg (10.7%)  shift in the opposite direction, rendering 
comparisons across thiazolidinedione categories equivocal (appendix table II.9). 
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2.25 Deuterium analysis 
 
Total body water (TBW), measured in kg, and percentage total body water (% TBW, 
relative to total body mass) were determined using deuterium analysis, as discussed 
earlier. FFM, FM, percentage FFM and percentage FM were derived from individual 
patients' TBW values, as outlined in section I. 
 
2.25.1 Total body water estimation  
 
Mean (95% CI) derived TBW and % TBW readings for thiazolidinedione tolerant 
patients were 39.76 (34.59, 44.93) kg and 44.42 (40.42, 48.42)% respectively. 
Available data (table 2.23) suggest no difference in TBW or % TBW between 
thiazolidinedione tolerant or intolerant patients. 
 
Table 2.23 - Total body water (TBW) measurements (kg) and derived % TBW 
values for thiazolidinedione 'tolerant' and 'intolerant' patients exposed to a 
moderately high sodium diet. 
 
 
Subject number 
by category 
 
Weight 
(kg) 
 
Height 
(cm) 
 
Body mass  
index  
(kg/m2) 
 
Mean (SD) 
true TBW 
(kg)a 
 
 
% 
TBW 
      
TZD tolerant      
1 76.4 168 27.07 33.88 (0.78) 44.35 
2 63.3 160 24.73 30.23 (0.59) 47.76 
3 92.6 180 28.58 52.94 (0.33) 57.17 
4 89.0 165 32.69 42.27 (0.41) 47.50 
5 89.4 160 34.92 33.16 (0.92) 37.09 
6 98.6 172 33.33 42.68 (0.18) 43.29 
7 93.4 174 30.85 41.34 (1.03) 44.26 
8 119.0 180 36.73 48.99 (0.12) 41.17 
9 86.8 160 33.91 32.30 (0.02) 37.21 
Mean 89.8 169 31.42 39.76 44.42 
(95% CI) (79.91,99.75) (163.6,174.4) (28.85, 33.99) (34.59, 44.93) (40.42, 48.42) 
      
TZD intolerant      
10 88.8 157 36.03 38.06 (1.06) 42.86 
11 85.8 160 33.52 31.88 (0.20) 37.16 
      
191 
 
 
2.25.2 Fat-free mass and fat mass 
 
Mean (95% CI) FFM values for thiazolidinedione tolerant patients was 54.31 (47.25, 
61.37) kg while the corresponding % FFM amounted to 60.69 (55.22, 66.16) % 
(table 2.24). TZD tolerant patients were characterised by a mean (95% CI) FM of 
35.52 (28.65, 42.39) and a mean % FM of 39.31 (33.84, 44.78) (table 2.24). 
Available data suggest no significant differences in FM, FFM, % FM or % FFM 
between either thiazolidinedione subgroup. Fat-free mass index (FFMI) and fat mass 
index (FMI) were derived by dividing each FFM and FM value by body weight in kg 
and expressed as kg/m2. Mean (95% CI) FFMI and FMI for thiazolidinedione 
'tolerant' patients amounted to 18.89 (17.45, 20.33) and 12.53 (10.08, 14.98) 
respectively (table 2.24). Exploratory data suggest that TZD intolerant may be 
characterised by a higher FMI than their oedema free counterparts (95% CI for the 
latter treatment group only marginally overlap individual data points for the former). 
However, there seems be no difference in FFMI values between either 
thiazolidinedione cohort, with individual plots for TZD intolerant patients being on 
either side of the 95% CI range for 'tolerant' subjects (table 2.24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
192 
 
 
Table 2.24 - Derived fat-free mass (FFM) and fat mass (FM) measurements (kg), 
and derived % FFM and % FM  for thiazolidinedione 'tolerant' and 'intolerant' 
patients exposed to a moderately high sodium diet). 
 
 
Subject 
number 
by category 
 
Fat  free  
mass  
(kg) 
 
 
%  
fat  free  
mass  
 
Fat 
mass  
(kg) 
 
%  
fat  
mass 
 
 
Fat  free  
mass 
index  
(kg/m2) 
 
 
Fat mass  
index 
(kg/m2) 
 
       
TZD 
tolerant 
      
1 46.29 60.58 30.11 39.42 16.40 10.67 
2 41.30 65.25 22.00 34.75 16.13 8.59 
3 72.32 78.10 20.28 21.90 22.32 6.26 
4 57.75 64.88 31.25 35.12 21.21 11.48 
5 45.30 50.67 44.10 49.33 17.70 17.23 
6 58.31 59.14 40.29 40.86 19.71 13.62 
7 56.48 60.47 36.92 39.53 18.65 12.20 
8 66.93 56.24 52.07 43.76 20.66 16.07 
9 44.12 50.83 42.68 49.17 17.23 16.67 
Mean  54.31 60.69 35.52 39.31 18.89 12.53 
(95%  
CI) 
(47.25, 
61.37) 
(55.22, 
66.16) 
(28.65, 
42.39) 
(33.84, 
44.78) 
(17.45, 
20.33) 
(10.08,  
14.98) 
       
TZD 
intolerant       
10 51.99 58.55 36.81 41.45 21.09 14.93 
11 43.55 50.76 42.25 49.24 17.12 16.61 
       
 
2.26 Inulin clearance  
 
Glomerular filtration rate was measured using the inulin clearance (InCl) method at 
each of the three salt loading states, as outlined in section I. Mean (95% CI) InCl 
readings for TZD tolerant patients increased following both acute and chronic salt 
exposure - with the magnitude of change being higher and likely significant in 
response to the former [13.78 (8.33, 19.23)% (acute high sodium exposure) vs 4.39 
% (-0.04, 8.82) % (chronic high sodium exposure)] (table 2.25). Individual readings 
for thiazolidinedione intolerant subject 10 (84.58 ml/min) exceeded the upper end of 
the 95% CI range for tolerant patients after intravenous saline infusion [mean (95% 
CI) =  68.95 (63.93, 73.97) ml/min]. However, this result was not replicated in TZD 
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intolerant subject 11. In contrast, the latter's InCl value marginally exceeded the 
mean (95% CI) readings for tolerant subjects exposed to a five day high salt diet 
[69.60 (subject 11) vs 64.54 (59.69, 69.39) (thiazolidinedione tolerant) mL/min] 
(table 2.25). Intolerant subject 10's percentage increase in glomerular filtration rate in 
response to acute high salt loading exceeded that for TZD tolerant patients [33.90% 
(subject 10) vs 13.78 (8.33, 19.23)% (thiazolidinedione tolerant)].  A similar pattern 
of difference in percentage change was only replicated in intolerant subject 11 
following chronic salt loading [18.8% (subject 11) vs 4.39 (-0.04, 8.82)% 
(thiazolidinedione tolerant)] (table 2.25). 
 
Table 2.25 - Inulin clearance (InCl) and derived % differences between sodium 
load exposures for visits 2 and 3. 
 
 
Subject 
number by 
category 
 
InCl 
(low Na) 
(mL/min) 
 
InCl 
 (acute high 
Na) 
(mL/min) 
 
InCl 
 (chronic 
high Na) 
(mL/min) 
 
% difference 
InCl 
(acute high 
Na - low Na) 
 
% difference 
InCl 
(chronic high 
Na - low Na) 
 
      
TZD tolerant      
1 66.27 a 75.24 b 13.53 
2 61.68 67.07 68.79 8.75 11.53 
3 68.09 79.67 69.02 17.00 1.37 
4 54.38 69.62 51.50 28.02 -5.30 
5 61.47 64.51 66.08 4.94 7.49 
6 61.71 70.15 60.73 13.68 -1.59 
7 64.94 73.45 66.89 13.10 2.99 
8 52.46 58.21 55.15 10.97 5.13 
9 a a 67.46 a a 
Mean 
(95% CI) 
61.38 
(57.58, 65.18) 
68.95 
(63.93, 73.97) 
64.54 
(59.69, 69.39) 
13.78 
(8.33, 19.23) 
4.39 
(-0.04, 8.82) 
      
TZD 
intolerant      
10 63.16 84.58 65.47 33.90 3.65 
11 58.58 69.39 69.60 18.44 18.80 
      
a Data unavailable; b calculation not possible due to missing data 
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2.27 Fractional excretion of sodium  
 
FeNa values were derived for nine, six and seven thiazolidinedione tolerant subjects 
at low sodium, acute high sodium and chronic sodium loading states respectively, 
and from both intolerant patients at all stages of sodium exposure (table 2.26). As 
expected, most thiazolidinedione-treated subjects increased their FeNa in response to 
chronic salt loading. Percentage change in FeNa was more marked in response to a 
five day high sodium diet compared with acute salt loading for either 
thiazolidinedione subgroup (table 2.26). Mean (95% CI) FeNa values for 
thiazolidinedione tolerant subjects overlapped across all three sodium load 
categories. Individual plots for oedema prone patient 11 suggested significantly 
lower FeNa values when exposed to a low sodium diet and acute salt loading (table 
2.26). This individual was also characterised by a particularly marked percentage 
increase in her FeNa on chronic salt loading [in excess of 4.5 fold increase over 
baseline low sodium FeNa reading vs mean (95% CI) value of 115.14 (11.48, 
218.80)% for thiazolidinedione tolerant subjects]. However, these results were not 
replicated in intolerant subject 10. 
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Table 2.26 - Fractional excretion of sodium (FeNa) and derived % differences 
between sodium load exposures for visits 2 and 3. 
 
 
Subject 
number by 
category 
 
FeNa 
(low Na) 
(%) 
 
FeNa 
(acute high 
Na) 
(%) 
 
FeNa 
(chronic 
high Na) 
(%) 
 
% difference 
FeNa 
(acute high 
Na - low Na) 
 
% difference 
FeNa 
(chronic high 
Na - low Na) 
 
      
TZD tolerant      
1 0.98 a a b b 
2 0.56 a a b b 
3 0.44 0.70 0.99 59.16 127.12 
4 1.08 0.86 1.45 -20.35 33.84 
5 0.09 0.18 0.45 109.81 416.11 
6 0.37 0.23 0.63 -36.42 71.30 
7 0.29 0.41 0.45 42.89 54.51 
8 0.21 0.32 0.43 55.32 108.40 
9 0.95 a 0.90 a -5.32 
Mean 
(95% CI) 
0.55 
(0.31, 0.79) 
0.45 
(0.23, 0.67) 
0.76 
(0.48, 1.04) 
35.07 
(-8.49, 78.63) 
115.14 
(11.48, 218.80) 
      
TZD 
intolerant      
10 0.56 0.68 1.14 21.57 103.17 
11 0.15 0.20 0.85 33.72 455.63 
      
a Data unavailable;  b calculation not possible due to missing data. 
 
 
2.28 Fractional excretion of lithium  
 
FeLi data could be accrued from eight, six and seven thiazolidinedione tolerant 
patients exposed to a moderately low sodium diet, acute saline infusion and chronic 
salt loading respectively, and from two intolerant patients for each of the three salt 
loading states (table 2.27).  Exploratory data suggest that TZD intolerant subject 10 
was characterised by a significantly higher FeLi than tolerant patients in response to 
acute and chronic salt loading. These results were partially replicated in intolerant 
subject 11, with the latter exhibiting a higher FeLi following exposure to a high salt 
diet (17.46%), albeit marginally lower FeLi (7.57%) under low salt conditions (table 
2.27). Analyzing for percentage change in FeLi across sodium categories, 
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thiazolidinedinone intolerant subject 11 was characterised by a greater increase over 
baseline (low sodium diet) on both acute and chronic salt loading. TZD intolerant 
subject 10's % FeLi change was within the 95% CI range for 'tolerant' subjects after 
exposure to one litre of intravenous saline, and exhibited a reduction in FeLi in 
response to chronic salt loading (table 2.27).  
 
Table 2.27 - Fractional excretion of lithium (FeLi) and derived % differences 
between sodium load exposures for visits 2 and 3. 
 
 
Subject 
number by 
category 
 
FeLi 
(low Na) 
(%) 
 
FeLi 
(acute high 
Na) 
(%) 
 
FeLi 
(chronic 
high Na) 
(%) 
 
% difference 
FeLi 
(acute high 
Na - low Na) 
 
% difference 
FeLi 
(chronic high 
Na - low Na) 
 
      
TZD tolerant      
1 18.09 a a b b 
2 40.00 a a b b 
3 19.28 15.43 15.17 -19.99 -21.34 
4 14.93 13.77 17.53 -7.77 17.42 
5 7.51 8.15 11.26 8.51 50.04 
6 10.83 9.76 11.63 -9.96 7.36 
7 7.40 12.19 11.16 64.82 50.90 
8 10.51 11.07 10.80 5.29 2.74 
9 a a 18.35 b b 
Mean 
(95% CI) 
16.07 
(8.68, 23.46) 
11.73 
(9.6, 13.86) 
13.7 
(11.29, 16.11) 
6.82 
(-17.40,31.04) 
17.85 
(-4.79, 40.49) 
      
TZD 
intolerant      
10 17.67 19.63 16.33 11.10 -7.56 
11 7.57 11.96 17.46 58.04 130.71 
      
a Data unavailable; b calculation not possible due to missing data. 
 
 
 
2.29 Fractional reabsorption of distally delivered sodium 
 
Fractional reabsorption of distally delivered sodium (FRDDNa) was calculated for 
each participant from FeNa and FeLi values, as outlined in section I. Data were 
accrued from eight, six and seven thiazolidinedione tolerant subjects after low, acute 
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high and chronic high sodium exposure respectively, and from each of the two 
intolerant subjects at each instance.  
 
Table 2.28 - Fractional reabsorption of distally delivered sodium (FRDDNa) and  
derived % differences between sodium load exposures for visits 2 and 3. 
 
 
Subject 
number by 
category 
 
FRDDNa 
(low Na) 
(%) 
 
FRDDNa 
(acute high Na) 
(%) 
 
FRDDNa 
(chronic high 
Na) 
(%) 
 
% difference 
FRDDNa 
(acute high 
Na - low Na) 
 
% difference 
FRDDNa 
(chronic high 
Na - low Na) 
 
      
TZD tolerant      
1 94.58 a a b b 
2 98.60 a a b b 
3 97.72 95.46 93.47 -2.31 -4.34 
4 92.77 93.75 91.73 1.07 -1.12 
5 98.80 97.79 96.00 -1.02 -2.83 
6 96.58 97.64 94.58 1.10 -2.07 
7 96.08 96.64 95.97 0.58 -0.12 
8 98.00 97.11 96.02 -0.91 -2.02 
9 a a 95.10 b b 
Mean 
(95% CI) 
96.64 
(95.18, 
98.10) 
96.40 
(95.17, 97.63) 
94.70 
(93.51, 95.89) 
-0.25 
(-1.35, 0.85) 
-2.08 
(-3.24, -0.92) 
      
TZD 
intolerant      
10 96.83 96.54 93.02 -0.30 -3.94 
11 98.02 98.33 95.13 0.32 -2.95 
      
a Data unavailable; b calculation not possible due to missing data 
 
 
Comparing with mean (95% CI) values for thiazolidinedione tolerant patients, TZD 
intolerant subject 11 (albeit not subject 10) was characterised by a higher absolute 
FRDDNa value in response to acute salt loading. TZD intolerant subject 10 exhibited 
a lower FRDDNa than her tolerant counterparts in response to a five day moderately 
high sodium diet (table 2.28). No differences in % shifts in FRDDNa between 
thiazolidinedione categories were reported in response to acute salt loading. 
Thiazolidinedione intolerant subject 11 decreased her FRDDNa to a greater extent 
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than her tolerant counterparts in response to chronic salt loading; however, this result 
was not replicated in TZD intolerant subject 11 (table 2.28).   
 
2.30 Discussion  
 
This study sought to investigate the hypotheses that patients previously known to be 
intolerant to thiazolidinediones would be characterised during either acute or chronic 
'high normal' sodium loading by impaired left ventricular diastolic function, high 
pulse wave velocity and higher plasma VEGF levels. There are two main theories of 
the mechanisms underpinning the development of oedema. Secondary (underfill) 
oedema results from a renal response to actual or sensed underfilling of the effective 
arterial blood volume (EABV). The resulting reduction in tissue perfusion sets forth 
a physiologically appropriate retention of sodium and water by the kidneys through 
activation of the sympathetic nervous system, the renin-angiotensin-aldosterone 
system and vasopressin release, and an increase in circulating catecholamines [540]. 
The relative contribution of VEGF in the aetiopathogenesis of thiazolidinedione-
associated oedema remains controversial. This study did not observe differences in 
VEGF according to tolerance of thiazolidinediones; moreover, no differences in any 
of the measured echocardiographic indices were detected between TZD tolerant and 
intolerant patients.  
 
Available evidence suggests that thiazolidinedione therapy may be primarily 
associated with inappropriate renal sodium handling. Renal PPAR-γ receptors are 
primarily concentrated in the collecting tubules [287], a major site of sodium and 
water retention occurring primarily under aldosterone, and to a lesser extent AVP, 
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ANP and insulin control [541].  PPAR-γ-mediated ENaC activity may favour sodium 
reabsorption and an increase in extracellular fluid volume [302, 303], causing an 
expansion of its subcompartments, manifesting clinically as oedema. In accordance 
with the overfill theory, this would be expected to enhance the normal central 
inhibition of the sympathetic nervous system, while suppressing both the renin-
angiotensin-aldosterone pathway and baroreceptor mediated AVP release [540].  
 
Thiazolidinedione intolerant patients exhibited a greater decrease in haematocrit, and 
increase in cAI and pAI (surrogate markers of arterial stiffness) in response to salt 
loading. This would suggest a preservation of the EABV. Thiazolidinedione therapy 
has been associated with a reduction in aldosterone [303, 304, 541] and an increase 
in ANP [335, 336] in published studies of animal models and human subjects. ANP 
is synthesised and stored (within granules) as pre-pro-ANP, cleaved to pro-ANP1-126, 
and secreted as the biologically active 28 amino acid peptide (together with 
biologically inactive N-terminal pro-ANP) [542]. These physiological processes 
proceed in the atria in response to increased atrial pressure and distension [543], 
occurring as a result of acute volume expansion, salt feeding, water immersion and 
postural changes. BNP is likewise synthesised as a 134 amino acid peptide called 
pre-pro-BNP, cleaved into pro-BNP 1-108 [544, 545], and secreted in bursts as 
biologically active BNP 1-32 (together with its inactive amino-terminal fragment NT-
pro-BNP) [545-547]. This synthetic activity progresses primarily in the ventricular 
myocardium, particularly in response to volume expansion [548, 549]. Both pro-
ANP and pro-BNP are cleaved into biologically active ANP and BNP by the cardiac 
myocyte transmembrane enzyme corin, a member of the serine protease family 
[550].  ANP and BNP play a pivotal role in salt and water homeostasis by increasing 
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glomerular filtration and filtration fraction despite a fall in mean arterial pressure 
[551]. Moreover they decrease sodium reabsorption in the cortical collecting tubule 
and inner medullary collecting duct (independently of effects on glomerular 
filtration) [552], decrease passive sodium chloride reabsorption in the thin ascending 
limb [553], reduce renin secretion, block aldosterone secretion and oppose the 
vasoconstrictive effect of angiotensin II [549, 554, 555]. This study did not report 
differences in aldosterone, renin, ANP and BNP concentrations between 
thiazolidinedione tolerant patients and those whose thiazolidinedione therapy was 
complicated by oedema and /or HF. However, TZD intolerant patients were 
characterised by a significantly greater reduction in their circulating renin (and 
possibly aldosterone), and a greater increase in ANP levels (and possibly BNP) 
following chronic salt loading. These observations are consistent with the overfill 
theory. Copeptin is a 39 amino-acid peptide released together with AVP during 
processing of the precursor peptide pro-AVP, and has proven to be a useful surrogate 
marker of circulating AVP [556].  AVP secretion is favoured by hypovolaemia, 
increased serum osmolality [556, 557], angiotensin II and norephinephrine [558]. As 
expected, high sensitivity copeptin decreased in response to chronic salt loading in 
thiazolidinedione tolerant subjects. Physiologically, this would be an expected 
response in the face of an increased EABV (as attested by an accompanying fall in 
haematocrit). 'Oedema-prone' subject 10's copeptin level was lower than the mean 
(95% CI) range for 'tolerant' subjects, in keeping with the overfill theory. Perhaps 
surprisingly, 'intolerant' subject 11 increased her copeptin on chronic salt loading. 
This study's small dataset precludes from judging whether this is a stress response 
[556] or a result worthy of further investigation. 
201 
 
 
In their study on healthy, normotensive male volunteers subjected to both low and 
high salt diets, Zanchi et al. reported that thiazolidinedione therapy is associated with 
a significant increase in plasma renin activity in both instances, as well a rise in 
daytime heart rate, which however, only reached statistical significance in low salt 
loading states. In the absence of a significant effect on nocturnal (supine) blood 
pressure, the authors ascribed this to thiazolidinedione-associated peripheral 
vasodilation [322]. Results arising from this study seem to imply that 'oedema-prone' 
patients are less likely to peripherally vasodilate in response to chronic salt loading, 
further enhancing intravascular volume, increasing atrial stretch (and hence ANP and 
BNP release), while propogating a further inhibition of the renin-angiotensin-
aldosterone pathway. While thiazolidinedione-mediated increases in ANP should 
theoretically mitigate any drug-associated oedema, this effect is blunted in T2DM 
patients [335].   
 
Although the synthetic activity of atrial and cardiac myocytes may be overwhelmed 
in severe HF (creating a relative deficiency) [559, 560], resistance to the effects of 
natriuretic peptides has been suggested as a possible contributory mechanism in the 
aetiopathogenesis of fluid overload. ANP and BNP bind to the natriuretic peptide A 
receptor (NPR-A) and exert their hormonal effects via 3', 5' - cyclic guanosine 
monophosphate (cGMP). Both natriuretic peptides are cleared via the natriuretic 
peptide C receptor (NPR-C), and degraded by the ectoenzyme neutral endopeptidase 
24.11 (NEP). ANP and/or BNP resistance reportedly arise as a consequence of 
decreased corin activity, down-regulation of NPR-A, increased metabolism of cGMP 
by cGMP phosphodiesterase V or increased clearance of the natriuretic peptides by 
NPR-C or NEP [561-564]. A higher relative increase in ANP and BNP levels in 
202 
 
 
response to chronic salt loading among thiazolidinedione 'intolerant' patients in this 
exploratory study could thus be ascribed to natriuretic peptide resistance. 
There is currently considerable interest in the association of common genetic variants 
at the Natriuretic Peptide Precursor A (NPPA) - Natriuretic Peptide Precursor B 
(NPPB) locus on chromosome 1 with circulating ANP and BNP concentrations. 
Cheh et al. reported that genetic variants rs5068 and rs198358 are associated with 
higher ANP concentrations, lower SBP and DBP values, and a lower risk of 
hypertension in a 14,743 individuals of European ancestry with no prior HF 
participating in the Framingham study [565]. These effects are not entirely surprising 
given ANP's modulation of natriuresis and vascular tone. Cannone et al. additionally 
associated genetic variant rs5068 with a better cardiometabolic profile (lower BMI, 
lower prevalence of obesity, lower waist circumference, lower C-reactive protein, 
higher high-density lipoprotein cholesterol), albeit no association with an altered risk 
for hypertension, congestive HF, coronary artery disease, atrial fibrillation or 
cerebrovascular accident in a study of 1608 randomly selected US subjects [566]. 
Similar results were reported in a Mediterranean population [567]. Moreover, the 
corin I555 (P568) allele, particularly common in blacks, has been associated with 
higher blood pressure and a higher prevalence of hypertension in a genotype-
phenotype genetic association study of US patients [568]. This study described 
considerable differences in prevalent ANP levels between individual subjects 
participating in this small exploratory study, particularly among those pertaining to 
the thiazolidinedione tolerant subgroup. While it would be unwise to draw specific 
conclusions, such differences could well be ascribed to genetic variants, and may be 
worthy of further study.   
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This study also sought to investigate the hypotheses that patients prone to 
thiazolidinedione-associated oedema and HF are characterised by increased AFV, 
salt sensitivity of blood pressure and differences in fractional sodium excretion,  free 
water handling and total body water when compared with thiazolidinedione tolerant 
subjects. A decline in haematocrit and an accompanying increase in total body 
weight was reported in response to chronic salt loading for all subjects. This 
observation would be consistent with a tendency to fluid overload.  The degree of 
haemodilution following acute compared with chronic salt loading tended to be 
greater within thiazolidinedione tolerant subjects suggesting a role for compensatory 
physiological mechanisms which become more effective in the 'longer' rather than 
'shorter' term. In contrast, patients whose thiazolidinedione therapy was previously 
complicated by oedema were characterised by a greater degree of haemodilution 
following chronic salt loading. This could imply a relative failure of counter-
regulatory mechanisms.  
 
Thiazolidinedione intolerant subject 11 virtually fulfils the criterion for salt-
sensitivity of blood pressure (SSBP) (being characterised by a 2.9 mmHg increase in 
MAP following chronic salt loading). This patient was also characterised by a 17.3 
mmHg increase in SBP following exposure to a chronic high salt diet. Oedema prone 
subject 10 shifted her MAP and SBP in the opposite direction. This study's reported 
mean (95% CI) reductions in SBP and MAP for thiazolidinedione 'tolerant' patients 
are perhaps surprising, and generally contrast with those reported in the literature. 
The INTERSALT study analyzed data from 10,079 patients aged 20 to 59 recruited 
from 52 centres across 32 countries. Multivariate analysis with and without BMI in 
the analysis showed that a 100 mmol daily dietary salt reduction results in a 3.1-6.0 
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mmHg and a 0.1 -6.0 mmHg reduction in SBP and DBP respectively [569]. The 
Dietary Approach to Stop Hypertension (DASH) study published data on the effect 
of the DASH diet and dietary salt restriction (<100 mmol/day) on SBP, claiming it is 
associated with a 7.1 mmHg reduction in normotensive individuals and a 11.5 mmHg 
reduction in hypertensive individuals compared to controls exposed to a high salt diet 
[570]. A recent Cochrane systematic review and meta-analysis of 34 trials recruiting 
3230 participants concluded that a 75 mmol reduction in daily urinary sodium 
excretion (equivalent to a reduction of 4.4 g/day) for at least four weeks is associated 
with a 4.18 mmHg reduction in prevalent SBP (95% CI - 5.18, -3.18) and a 2.06 
mmHg reduction in DBP (95% CI -2.67, -1.45), and that this was associated with a 
small physiological increase in plasma renin activity, aldosterone and noradrenaline 
(albeit no significant change in lipid concentrations) [571]. In a study of 70 Hong 
Kong Chinese patients with untreated hypertension and 47 normotensive controls, 
DBP correlated with 24 hour urinary sodium excretion in hypertensive patients, but 
not in controls [572]. Despite their undisputed validity, these studies findings' may 
not be directly relevant to this exploratory study, particularly as they either (i) 
recruited patients whose dietary sodium intake was modified for substantially longer 
periods (>30 days) [570, 571]  or  (ii) observed the effects of long-term (usual) 
dietary sodium habits [569, 572].  Closer to this study's design, Foo et al. analysed 
the impact of a 6-day high (220 mmol/day) and low (40 mmol/day) sodium diet on 
blood pressure, leg flow and insulin sensitivity in 18 healthy normotensive subjects. 
Salt loading was associated with a borderline significant increase in 24-hour SBP 
[mean (SD)  = +5.8 (± 14.2) mmHg], but no significant impact on DBP or MAP 
[573]. Twenty healthy normotensive volunteers were recruited into another study 
investigating the impact of dietary salt on insulin sensitivity. Although Townsend et 
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al. reported a 6/4 mmHg BP increase on progressing from a six-day 20 mmol/day 
sodium diet to a six-day 200 mmol/day diet, this change did not reach statistical 
significance [574]. Vedovato et al. examined the impact of a seven-day low (20 
mmol) and seven-day high (250 mmol) sodium diet on MAP and other parameters in 
a cohort of 20 T2DM patients with microalbuminuria and 21 T2DM patients without 
microalbuminuria. 24-hour MAP increased significantly from  95  (SEM ±2) mmHg 
to 103 (SEM ±2) mmHg on salt loading (p<0.0001). No significant MAP change was 
reported in normoalbuminuric patients [575]. Similar results were published in 
microalbuminuric T1DM patients [576]. Indeed, available evidence suggests that salt 
sensitivity of blood pressure (defined as a MAP increment > or = 3 mmHg on a salt 
loading) is least common in non-diabetic subjects (17%), increasing to 37% in 
normoalbuminuric T1DM patients and 50% in T1DM patients with 
microalbuminuria [577].  
 
Several mechanisms have been put forward to explain salt sensitivity in T2DM 
patients. These include low prevalent renin concentrations [578-580], hypertension, 
activated sympathetic nervous system and hyperinsulinism [575, 581-585]. 
Additionally, evidence points to two types of hereditary SSBP, namely the low renin 
(LR) phenotype and non-modulation. Whereas patients with the former are 
characterised by a blunted rise in plama renin activity in response to salt restriction 
[586], the latter typically display a muted aldosterone response to exogenous 
angiotensin II despite a normal renin response to a low sodium balance [587, 588].  
Underwood et al. reported that elevated BP is the strongest predictor of SSBP in 
T2DM patients, and that the latter is largely driven by non-modulation [589]. T2DM 
patients recruited into this exploratory clinical study were normoalbuminuric and 
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exhibited relatively well controlled blood pressure readings despite withdrawal of 
their antihypertensive therapy. This, coupled with the small number of participating 
subjects, lessened the possibility of identifying salt-sensitive patients in either 
thiazolidinedione subgroup. 
 
Both thiazolidinedione subgroups decreased their DBP in response to chronic salt 
loading, with the degree of reduction being greater among subjects prone to 
thiazolidinedione-associated oedema. Ventricular-arterial stiffening is 
characteristically accompanied by a reduction in DBP. As peripheral arterial 
resistance increases in older individuals (aged 20 to 70), expanded artery walls are 
less likely to recoil in diastole, leading to earlier  wave reflection, higher SBP, lower 
DBP, increased pulse pressure and an increase in cardiac afterload, with resultant 
ventricular-vascular uncoupling [590, 591]. The left ventricle becomes progressively 
stiffer (possibly an adaptive mechanism) and later hypertrophic, a phenomenon 
associated with increased cardiovascular risk [592-595]. Extrapolating from this 
study's exploratory data, a greater reduction in DBP in response to chronic salt 
loading among thiazolidinedione intolerant patients is consistent with this study's 
reported greater increase in cAI and pAI, suggesting that such patients are more 
prone to increase their arterial stiffness on chronic salt exposure. 
 
Exploratory data suggest no consistent differences in TBW between 
thiazolidinedione categories following a five-day high salt diet, albeit a higher FMI 
among patients prone to fluid overload. AFV tended to increase in response to both 
acute and chronic salt loading among tolerant subjects, but decreased following acute 
intravenous saline infusion in 'intolerant' patients. The degree of increase in AFV 
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seems to become mitigated in tolerant patients as they progress from acute to chronic 
salt loading. However, the small number of participating subjects and wide 95% CIs 
hamper definitive conclusions in this regard. Moreover, TZD intolerant patients 
seemingly exhibited inconsistent degrees of %AFV shifts in response to chronic salt 
loading. 
 
Both thiazolidinedione intolerant patients tended to be characterised by higher GFR 
on salt loading. Subject 10's GFR was higher than that for her 'tolerant' counterparts 
in response to acute salt loading, whereas subject 11 exhibited a similar trend 
following a five day high sodium diet. Percentage increase in GFR was generally 
higher for acute than for chronic salt loading, except for thiazolidinedione intolerant 
subject 11, where the reverse was true. Lithium ions are freely filtered at the 
glomerulus and reabsorbed at the proximal tubule in the same proportion as sodium 
and water. There could be some reabsorption of lithium in the loop of Henle in some 
extreme conditions [596]. This renders calculation of FeLi a valuable marker of 
proximal tubule salt and water handling. Thus, a higher FeLi would be consistent 
with less proximal tubule sodium and water reabsorption, and hence greater delivery 
to the distal tubules [596]. TZD intolerant subject 10 was characterised by a higher 
FeLi (implicating greater sodium and water delivery to the distal tubules) albeit no 
difference in FRDDNa on acute salt loading. Not surprisingly, this translated into a 
higher FeNa, implicating that this patient improved her natriuresis in response to 
acute salt loading. Following exposure to a five-day high sodium diet, subject 10's 
FeLi and FENa were higher, while FRDDNa was lower, again implicated better renal 
sodium handling than her 'oedema free' counterparts. Thiazolidinedione intolerant 
subject 11's FRDDNa was no different from that of thiazolidinedione tolerant 
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patients on acute salt loading. However, this patient was characterised by a lower 
FENa (less natriuresis) and a lower FeLi, implicating a greater degree of proximal 
tubular sodium and water reabsorption. In response to chronic salt loading, subject 
11 exhibited a higher FeLi (implicating more sodium and water delivery to the distal 
tubules), albeit no differences in FeNa and FRDDNa, suggesting impaired renal 
sodium and water handling between the proximal and distal tubules.  
 
In summary, the limited exploratory data for thiazolidinedione intolerant subjects 
suggest heterogeneity in sodium handling. Subject 11's results are generally 
consistent with those reported by Zanchi et al. [322], with a role for aquaporins 
(AQP) 1 and 7, the type 3 sodium hydrogen exchanger (NHE3) or the type 1 sodium-
bicarbonate cotansporter in the aetiopathogenesis of thiazolidinedione-associated 
oedema. On the other hand, subject 10 exhibited a better natriuresis in response to 
chronic salt loading with an increase in ANP (and possibly BNP) in the context of 
apparent suppression of renin (and possibly aldosterone); other as yet unidentified 
mechanisms play a role in fluid overload in her case. 
 
This is the first case-control study comprehensively investigating physiological 
differences between patients tolerant to thiazolidinediones and those developing HF 
and/or oedema within three months of their index thiazolidinedione exposure. The 
study design seemed ideally suited to investigate what was recognised as being a 
relatively infrequent adverse event (as confirmed in this thesis' population based 
study in Chapter 3). A case-control design thus permitted a detailed characterisation 
of both thiazolidinedione subgroups (over three study visits cumulatively lasting 
several hours), as exposed to different degrees of salt loading. Moreover, a case-
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control approach allowed detailed investigation of an adverse event arising from a 
class of drugs whose prescription has diminished over the years for reasons discussed 
elsewhere. This study's approach did not permit a calculation of incidence (absolute 
risk). However, this issue was specifically tackled at a population level elsewhere in 
this thesis (chapter 3). Ultimately, the main problem encountered was difficulty in 
identifying adequate numbers of confirmed cases of TZD-intolerant patients for 
formal statistical analysis, despite comprehensive searching using multiple methods. 
It is recognised that study design may also have been hampered by selection bias and 
reliance on recall of exposure to the drug of interest (rosiglitazone/pioglitazone), 
particularly with respect to the temporality of adverse drug reactions. However, this 
possibility was inherently minimised by cross-checking with prescription data readily 
linked to the SCI-DC database. Access to detailed clinical records at NHS Tayside 
permitted the inclusion of patients who fitted very strict inclusion and exclusion 
criteria, minimising confounding factors and major biases, particularly when 
selecting the control group of thiazolidinedione tolerant subjects.  
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Chapter 3 
 
Factors predicting diuretic prescription 
and heart failure after initiation of 
thiazolidinedione therapy 
 
A population based approach 
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Chapter 3 - Factors predicting diuretic prescription and heart failure 
after initiation of thiazolidinedione therapy 
A population based approach 
 
Section I - Methods 
 
3.1 Rationale of this study 
 
Given the difficulties in identifying thiazolidinedione intolerant patients for the 
aforementioned clinical study, I embarked on related secondary research based on 
anonymised person-specific data sets captured by the NHS and the University of 
Dundee, and managed by the Health Informatics Centre (HIC) at the latter 
institution. This enabled the identification and characterisation of patients exposed to 
thiazolidinediones and compared data with two control populations, namely (i) a 
metformin-sulphonylurea combination therapy cohort, comprising patients treated 
with established, cheap and effective first and second line oral glucose lowering 
agents, and (ii) insulin-treated cohort, comprising patients at a more advanced stage 
of their disease process. There is currently paucity of data comparing incident HF 
and ‘oedema’ rates between patients treated with index metformin-sulphonylurea 
combination therapy and index thiazolidinedione therapy. Moreover, it is unclear 
whether risk factors for incident HF /oedema are shared by patients in either cohort. 
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3.2 Research aims 
 
This population based research project was designed with the following objectives in 
mind: 
• Defining T2DM at a population level 
• Defining incident thiazolidinedione use 
• Defining comparator T2DM  populations 
• Defining index loop diuretic prescription as a surrogate marker of fluid 
overload /oedema 
• Defining incident HF 
• Phenotypic characterisation of thiazolidinedione-treated patients. 
• Identification and phenotypic characterisation of patients whose index 
thiazolidinedione therapy was complicated by index loop diuretic prescription 
and / or congestive HF, and comparing them with their loop diuretic / 
congestive HF  free counterparts 
• Defining the genetic characteristics of T2DM patients whose 
thiazolidinedione treatment was followed by incident loop diuretic use and 
/or hospitalization for HF 
• Comparing the genotypic characteristics of T2DM patients of patients whose 
treatment with thiazolidinediones was/was not followed by index loop 
prescription and/or diagnosis of congestive HF 
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3.3 Hypotheses 
 
This study aimed to investigate the hypotheses that thiazolidinedione-treated patients 
are at a higher risk of progressing to index loop diuretic prescription (a surrogate 
marker of oedema) and/or HF compared with patients on 'established' first and 
second line oral glucose lowering agents (metformin-sulphonylurea combination 
therapy). Additionally, this study hypothesised that such patients are more likely to 
progress to such adverse events if they fulfill one or more of the following baseline 
criteria: 
• macrovascular disease  
• co-administration of insulin and thiazolidinediones  
• non-steroidal anti-inflammatory agents (NSAIDS) and/or dihydropyridine 
calcium channel blockers  
• higher mean systolic blood pressure, higher mean DBP and higher mean 
arterial pressure (as surrogate markers of arterial stiffness)  
• impaired renal function  
• impaired left ventricular function  
• CYP2C8*1/*1 (wild type) carriers compared with CYP2C8*3 and / or 
CYP2C8*4 allelic variants 
 
3.4 Study outcomes 
 
Based on the results of epidemiology data, this study sought to explore simple 
clinical differences between individuals who are ‘tolerant’ and ‘intolerant’ to 
thiazolidinedione therapy, using a comparative approach. Two cohorts, comprising 
214 
 
 
metformin-sulphonylurea combination therapy treated patient’ and insulin-treated 
patients (defined in section 3.5) acted as control populations in this regard.  
 
Initially, the primary and secondary outcomes of this study were defined as time 
from index thiazolidinedione pharmacotherapy to index loop diuretic prescription 
and incident HF respectively. Acting upon available data, a decision was 
subsequently made to pursue a post-hoc analysis which amalgamated the metformin-
sulphonylurea and thiazolidinedione cohorts. This enabled inclusion of index TZD 
therapy (vs index metformin-sulphonylurea combination therapy) as a covariate in 
multivariate logistic and Cox regression analyses.  
 
3.5 Study population 
 
This observational cohort study was carried out among the resident population of the 
Tayside Health Board, Scotland (approximately 400, 000 people). Data were 
provided by the Health Informatics Centre (HIC), University of Dundee after 
approval by the Tayside Committee Medical Research Ethics. HIC has developed a 
record-linkage of multiple routinely-collected datasets to carry out anonymized 
health-related research in Tayside. Accurate electronic linkage was facilitated by the 
widespread use of a nine-digit Community Health Identifier that is assigned to all 
patients in Scotland who are registered with a general practitioner. Data-sets used for 
this study included: 
 
- Scottish Care Information-Diabetes Collaboration (SCI-DC): a validated 
population based diabetes clinical information system. The original Diabetes 
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Audit and Research Tayside (DARTS) database for Tayside has 95% 
sensitivity for identifying people with diabetes [437].  
 
- Additionally, patients were identified from an ongoing study of the Genetics 
of Diabetes Audit and Research Tayside (GoDARTS). Since October 1997, 
all patients with diabetes have been invited to give written informed consent 
to have their DNA and serum collected as part of the Wellcome Trust United 
Kingdom Type 2 Diabetes Case Control Collection [597]. As of June 2009, 
more than 8,000 individuals have participated in the Go-DARTS study [598]. 
 
- Scottish Morbidity Record (SMR) data: Forming part of a national database 
managed by ISD Scotland on behalf of NHS Scotland, the SMR project 
compiles a comprehensive core data-set based on a standard set of data 
definitions and codes for the key areas of (i) patient identification and 
demographic data, (ii) episode management data, and (iii) general clinical 
data [599]. SMR data were used to identify patients who have been registered 
with a clinical diagnosis of HF. 
 
- The Tayside echocardiography database: Maintained by the Department of 
Cardiology at Ninewells Hospital, Dundee, this database hosts all elective 
outpatient echocardiograms carried out by British Society of 
Echocardiography (BSE) accredited echocardiographers [600]. A random 
blinded re-reading of left ventricular functional assessment recorded a 90% 
concordance rate between results reported in the database and those recorded 
at independent review [600]. 
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- The above data were linked to the Medicines Monitoring Unit (MEMO) 
database [499]. The MEMO database was developed for 
pharmacoepidemiological research in the population of Tayside and contains 
detailed records of all prescription items dispensed to patients at community 
pharmacies. Thus for all Tayside patients, there are detailed records of all 
prescriptions dispensed for thiazolidinediones, insulin, diuretics, and all other 
drugs referred to hereafter.    
 
This data-linkage permitted a detailed retrospective phenotypic, genetic and 
pharmacoepidemiological comparison of ‘thiazolidinedione intolerant’ with 
‘thiazolidinedione tolerant’ cohorts, and with a control population of T2DM patients. 
 
3.5.1 Type 2 diabetes definition 
 
Patients were defined as suffering from T2DM if they were diagnosed after the age 
of 40, with no progression to insulin within six months of diagnosis, and currently 
treated with metformin and /or a sulphonylurea. Patients diagnosed above the age of 
90 were excluded. Patients commencing insulin more than six months after the 
diagnosis were eligible for inclusion. This T2DM definition has been adopted and 
validated elsewhere [601]. 
 
3.5.2 Type 2 diabetes cohorts 
 
(i) Thiazolidinedione cohort: a cohort of T2DM patients commenced on a 
thiazolidinedione (pioglitazone or rosiglitazone) in routine clinical care. This cohort 
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was further subdivided into patients whose pioglitazone or rosiglitazone therapy was 
being used (i) in the absence of insulin i.e. as add on to metformin and /or 
sulphonylurea or as monotherapy and (ii) in combination with insulin (+/- metformin 
and/or sulphonylurea). Patients treated with adjunct acarbose, nateglinide / 
repaglinide, sitagliptin / vildagliptin or exenatide / liraglutide (BNF section 6.1.2.3) 
while on pioglitazone or rosiglitazone were excluded from this cohort. 
 
Patients were eligible for inclusion from the date of index prescription of 
pioglitazone or rosiglitazone until the date of the last thiazolidinedione 
prescription/censor unless excluding factors came into effect. Patients were excluded 
from the thiazolidinedione cohort if they had received any treatment with 
thiazolidinediones (pioglitazone or rosiglitazone) at any point within the previous 
twelve months. The index date of thiazolidinedione prescription was defined as the 
date of first thiazolidinedione prescription which was followed by a subsequent 
thiazolidinedione prescription within the first three months. If the latter gap exceeded 
three months, the next eligible thiazolidinedione prescription for inclusion as an 
index thiazolidinedione prescription was one which had not been preceded by an 
earlier thiazolidinedione prescription over the previous 12 months. 
 
Thiazolidinedione-treated patients were censored if they commenced treatment with 
another oral glucose lowering agent, namely acarbose, nateglinide / repaglinide, 
sitagliptin / vildagliptin or exenatide / liraglutide (BNF sections 6.1.2.3) after index 
thiazolidinedione prescription. The censor date in this case was defined by the date 
of first prescription of the first additional oral glucose lowering agent. 
Thiazolidinedione-treated patients who had been treated with insulin prior to index 
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thiazolidinedione prescription, but whose insulin was stopped prior to index 
thiazolidinedione prescription were excluded from the thiazolidinedione cohort. 
Thiazolidinedione-treated patients who were treated with insulin both before and 
after index thiazolidinedione prescription were defined as belonging to the TZD + 
insulin group for the purposes of this study. The minimum number of insulin 
prescriptions required for inclusion into the TZD + insulin group was set at two - one 
prescription before index thiazolideindione therapy and one after. 
 
Thiazolidinedione-treated patients who had insulin added on to prevalent 
thiazolidinedione therapy, and whose thiazolidinedione therapy was continued 
uninterruptedly were defined by two study dates: 
 
- study period 1 comprising the time between index thiazolidinedione 
prescription (index date 1) and index insulin prescription. Such patients were 
included in the TZD – insulin group for the purpose of this study. 
 
- study period 2 comprising the time between the first thiazolidinedione 
prescription occurring after index insulin prescription (index date 2) and the 
last thiazolidinedione prescription. Such patients were included in the TZD + 
insulin group for the purposes of this study. 
 
Thiazolidinedione-treated patients who were commenced on insulin at some point 
after index thiazolidinedione prescription, and whose thiazolidinedione therapy was 
stopped at that point were included in the TZD-insulin group.  
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(ii) Metformin and sulphonylurea combination therapy cohort (MFSU cohort or 
control cohort 1): a cohort of T2DM patients treated with a combination of 
metformin and sulphonylurea therapy. This included patients who had a 
sulphonylurea added on to metformin monotherapy and patients who had metformin 
added on to sulphonylurea monotherapy. 
 
This cohort excludes treatment with thiazolidinediones at any time point. Patients 
were also excluded if they were treated with insulin (BNF sections 6.1.1.1 and 
6.1.1.2), acarbose, nateglinide / repaglinide, sitagliptin / vildagliptin or exenatide / 
liraglutide (BNF section 6.1.2.3). Censor date was defined by the date of first 
prescription of any of these drug or drugs (while on metformin-sulphonylurea 
combination), whichever was introduced first 
 
The index date of metformin prescription was defined as the date of first metformin 
prescription which was followed by a subsequent metformin prescription within the 
first three months. If the latter gap exceeded three months, the next eligible 
metformin prescription for inclusion as an index metformin prescription was one 
which had not been preceded by an earlier metformin prescription over the previous 
12 months. 
 
The index date of sulphonylurea prescription was defined as the date of first 
sulphonylurea prescription which was followed by a subsequent sulphonylurea 
prescription within the first three months. If the latter gap exceeded three months, the 
next eligible sulphonylurea prescription for inclusion as an index sulphonylurea 
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prescription was one which had not been preceded by an earlier sulphonylurea 
prescription over the previous 12 months. 
 
Patients who separately fulfilled index date criteria for metformin and sulphonylurea 
prescription, as defined above, and whose index dates for metformin and 
sulphonylurea prescription overlapped, were eligible for inclusion into control cohort 
1. Index date for inclusion into this combination control cohort 1 was defined as the 
first day of adjunct index metformin/sulphonylurea prescription. End date for 
inclusion into control cohort 1 was defined as the date of the last metformin or 
sulphonylurea prescription, whichever was withdrawn first.  Patients with an index 
date prior to 1st January 1994 were excluded from inclusion into the cohort. 
 
Patients were likewise censored if commenced on insulin (BNF sections 6.1.1.1 and 
6.1.1.2), acarbose, nateglinide / repaglinide, sitagliptin / vildagliptin or exenatide / 
liraglutide (BNF section 6.1.2.3) after index date. Censor date was defined by the 
date of first prescription of any of these drug or drugs, whichever was introduced 
first. 
 
(iii) Insulin-treated cohort (control cohort 2): a cohort of insulin treated T2DM 
patients treated with insulin  
- in combination with metformin and /or sulphonylurea OR 
- Monotherapy  
but excluding thiazolidinedione therapy (pioglitazone or rosiglitazone) 
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Patients were eligible for inclusion from the date of index insulin prescription until 
the date of the last insulin prescription/censor unless excluding factors come into 
effect. To be eligible for inclusion into the control cohort 2, patients must not have 
had any treatment with insulin within 12 months prior to index insulin prescription 
 
The index date of insulin prescription was defined as the date of first insulin 
prescription which was followed by a subsequent insulin prescription within the first 
three months. If the latter gap exceeded three months, the next eligible insulin 
prescription for inclusion as an index insulin prescription was one which had not 
been preceded by an earlier insulin prescription over the previous 12 months. 
 
Patients were excluded from this cohort if their index insulin prescription date 
occurred prior to 1st January 1994. 
 
3.6 Defining drug dose 
 
Thiazolidinedione therapy Population based drug dispensing records were used to 
express each prescribed dose of thiazolidinedione as a percentage of the maximal 
prescribed dose in the British National Formulary, deriving a mean percentage dose 
for each thiazolidinedione-treated patient. 
 
3.7 Definition of heart failure 
 
Individuals were defined as suffering from congestive HF if they fulfil one of the 
following criteria: 
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- have had a standardized morbidity record (SMR) for congestive HF. This was 
defined as a hospital admission International Classification of Diseases, Ninth 
Revision and 10th Revision (ICD 9/10) diagnostic code for congestive HF 
during the study period (ICD-9 code 428, ICD-10 code 150). The date of 
admission was defined as the date of CHF diagnosis.  An SMR for HF in 
Tayside gives the date of admission, type of admission (emergency or not), 
and the primary reason for admission according to the ICD code. 
  
      OR 
 
- have had echocardiographic evidence of left ventricular systolic dysfunction 
and  prescription of a loop diuretic (BNF code 2.2.2) within one year. The 
date of prescription of a loop diuretic and/or diagnosis of left ventricular 
systolic dysfunction, whichever came first, was defined as the date of CHF 
diagnosis. The latter echocardiographic based definition of HF has been 
validated elsewhere (reporting a 91% concordance with a clinical diagnosis 
of HF from case note review). 
     
Any subsequent CHF events after diagnosis date were defined using SMR data. 
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3.8 Clinical data extraction 
 
3.8.1 Basic demographics 
 
Basic demographic criteria captured within this dataset included index date of 
inclusion and the date until which individual patients satisfied the 
aforementioned set criteria for inclusion into their treatment cohort. This 
approach permitted calculation of duration of metformin-sulphonylurea 
combination, insulin or thiazolidinedione therapy for each individual patient. 
Duration of T2DM was defined by the number of days elapsed since diagnosis of 
T2DM at inclusion into the respective treatment cohort. Age (in years) and 
gender were likewise captured at inclusion into the cohort (table 3.1). 
 
Table 3.1 - Baseline demographics 
 
Clinical characteristic 
 
Units 
 
Definition 
   
Age years Age at inclusion into the cohort 
Gender - Male/female 
Duration of type 2 diabetes days days elapsed since registered diagnosis of type 2 
diabetes at inclusion into the respective cohort 
Duration of treatment days days elapsed between inclusion into the 
respective cohort and date until which patient 
satisfied criteria for inclusion into the cohort 
   
 
 
3.8.2 Past medical history 
 
Baseline and post-treatment past medical history (coronary artery disease, stroke, 
peripheral artery disease) were defined by ICD coding for the respective event prior 
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to, and after, inclusion into either of the three treatment cohorts respectively (table 
3.2). Additionally, a macrovascular composite (baseline/post-treatment) was 
generated from this dataset, encompassing the occurrence of either of these three 
events before or after index metformin-sulphonylurea, insulin or thiazolidinedione 
prescription. 
 
Table 3.2 - Past medical history 
 
Past medical history 
 
 
Definition 
  
Coronary artery disease ICD 10:120-125, ICD 9:410-414 
Stroke  ICD 10:160-169, ICD 9:430-438 
Peripheral artery disease ICD 10:1739, ICD 9:4439  
  
 
 
 
3.8.3 Drug history  
 
Individual drug therapy was defined by the respective drug’s BNF code, as outlined 
in table 3.3 below. Baseline and post-treatment drug therapy were defined by 
capturing evidence of a prescription prior to, and after, inclusion into the respective 
treatment cohort respectively.  
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Table 3.3 - Drug history 
 
Drug history 
 
 
Definition 
  
Peripheral vasodilators and related drugs BNF code 2.6.4  
Thiazide diuretics BNF code 2.2.1  
Loop diuretics BNF code 2.2.2  
Potassium sparing diuretics / aldosterone 
antagonists 
BNF code 2.2.3  
Non-steroidal anti-inflammatory drugs  BNF code 10.1.1  
Dihydropyridine calcium channel blockers  Amlodipine, felodipine, isradipine, 
lacipidine, lercanadipine, nicardipine, 
nifediipine or nimodipine  
Verapamil 
 
Diltiazem 
 
Beta-adrenoceptor blocking drugs BNF code 2.4  
Vasodilator antihypertensive drugs BNF code 2.5.1  
Centrally acting antihypertensive drugs BNF code 2.5.2  
Adrenergic neurone blocking drugs BNF code 2.5.3  
Alpha adrenoceptor blocking drugs BNF code 2.5.4  
Angiotensin-converting enzyme inhibitors BNF code 2.5.5.1  
Angiotensin-II receptor antagonists BNF code 2.5.5.2  
Renin inhibitors BNF code 2.5.5.3  
Nitrates  BNF code 2.6.1  
Other antianginal drugs BNF code 2.6.3  
  
 
 
 
3.8.4 Clinical measurements 
 
Given the likely fluctuant nature of blood pressure readings, baseline SBP and DBP 
were defined as mean values measured in the year prior to prescription of the index 
glucose lowering drug(s) of interest (table 3.4). Post-treatment SBP and DBP were 
defined by the mean of any readings measured within the first year (excluding 
readings taken less than 30 days) after inclusion into the cohort. In contrast, as 
weight changes are likely to be more progressive and sustained, baseline and post-
treatment weight and BMI measurements were defined by the respective closest 
values before, and at least 30 days after, prescription of index metformin-
sulphonylurea combination, insulin or thiazolidinedione therapy. 
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Table 3.4 - Clinical measurements 
 
Clinical measurements 
 
Units 
 
Definition 
   
Systolic blood pressure mmHg Mean values for the year before, 30-365 days after,  
inclusion a 
Diastolic blood pressure mmHg Mean values for the year before, 30-365 days after, 
inclusion a 
Weight kg Closest values before, 30-365 days after, inclusion a 
Body mass index kg/m2 Closest values before, 30-365 days after, inclusion a 
   
a into the respective treatment cohort 
 
 
 
3.8.5 Laboratory investigations 
 
Likewise, baseline and post-treatment values for basic laboratory investigations were 
captured from routine clinical measurements (table 3.5). Baseline values were 
defined by the most recent result issued prior to inclusion into the respective 
treatment cohort. Post-treatment laboratory investigation values were defined by the 
earliest result issued at least 30 days after inclusion, with the exception of post-
treatment HbA1c, defined as the earliest value measured between 30 days and 18 
months after recruitment into the metformin-sulphonylurea combination, insulin or 
thiazolidinedione cohort. Estimated glomerular filtration rate (eGFR) values 
(reported in mls/min/1.73 m2) were calculated from available age, weight and serum 
creatinine values using the established Cockcroft-Gault formula [602]: 
 
(140 – age) * lean body mass / plasma creatinine * 72 for males, and 
[(140 – age) * lean body mass / plasma creatinine * 72 ] * 0.85 for females 
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Table 3.5 - Laboratory investigations 
 
Laboratory 
investigations 
 
 
Units 
 
Definition 
   
Haematocrit % Most recent value prior to, at least 30 days after, 
inclusion a 
HbA1c  % Most recent value prior to, 30 days – 18 months after, 
inclusion a 
TC mmol/L Most recent value prior to, at least 30 days after, 
inclusion a 
HDL-C mmol/L Most recent value prior to, at least 30 days after, 
inclusion a 
LDL-C mmol/L Most recent value prior to, at least 30 days after, 
inclusion a 
Triglycerides mmol/L Most recent value prior to, at least 30 days after, 
inclusion a 
ALT IU/L Most recent value prior to, at least 30 days after, 
inclusion a 
Sodium mmol/L Most recent value prior to, at least 30 days after, 
inclusion a 
Creatinine μmol/L Most recent value prior to, at least 30 days after, 
inclusion a 
eGFR mls/min/1.73m2 Most recent value prior to, at least 30 days after, 
inclusion a 
Albumin g/L Most recent value prior to, at least 30 days after, 
inclusion a 
TSH IU/L Most recent value prior to, at least 30 days after, 
inclusion a 
   
a into the respective treatment cohort; ALT, alanine aminotransferase; eGFR, estimated glomerauld 
filtration rate; HbA1c, glysoylated haemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-
C, low density lipoprotein cholesterol; TC, total cholesterol; TSH, thyroid stimulating hormone 
 
 
 
3.8.6 Echocardiography measurements  
 
Likewise, this study captured echocardiographic measurements from recruited 
T2DM patients who had undergone tissue Doppler echocardiography (table 3.6). 
Baseline and post-treatment measurements were defined as the most recent values 
measured prior to, and at least 30 days after inclusion into their respective treatment 
cohort. Intraventricular septum width and left ventricular posterior wall thickness 
were measured at end-diastole.  
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Left ventricular mass (LVM) was defined as 
  
0.8 (1.04[(LVID + LVPW + IVS)3 – (LVID)3]) + 0.6g  
 
as conventionally defined by Devereux et al. [603], validated at necropsy (r = 0.90; p 
< 0.001) [604], and endorsed by the American Society of Echocardiography [605], 
where LVID denotes left ventricular internal diameter at diastole, LVPW thickness 
denotes left ventricular posterior wall thickness at end-diastoleand IVS thickness 
denotes intra-ventricular septum thickness at end-diastole. 
 
Table 3.6 - Echocardiography measurements 
 
Echocardiography 
measurements 
 
 
Units 
 
Definition 
   
IVS thickness cm Most recent values measured a prior to, at least 30 days after, 
inclusion b 
LVPW thickness cm Most recent values measured a prior to, at least 30 days after, 
inclusion b 
LV mass g Most recent values measured prior to, at least 30 days after, 
inclusion b 
   
a 
measured at end-diastole; b into the respective cohort; IVS, interventricular septum; ; LV, left 
ventricular;  LVPW, left ventricular posterior wall 
 
3.8.7 Genotyping 
 
Genotyping of CYP2C8*3 and CYP2C8*4 variants was carried out under the 
manufacturer's (Applied Biosystems) recommended standard conditions using 
Taqman-based allelic discrimination assays. The overall genotyping call rate was 
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94% and both SNPs were in Hardy-Weinberg Equilibrium in the sample (p > 0.05). 
Genotyping data were extracted and merged with the available datasets for analysis.  
 
3.9 Statistical methods 
 
3.9.1 Descriptive statistics 
 
Continuous variables were expressed as means and standard deviations. 
Dichotomous variables were expressed as percentages. Continuous variables did not 
satisfy criteria for normality (as assessed by visual plot inspection and estimation of 
skewness) were transformed (loge, square root or reciprocal) to achieve normality. 
Between-group differences across normally distributed variables were compared 
using one-way Analysis of Variance (ANOVA). Skewed variables which defied 
attempts at normalisation through transformation were compared using the Mann-
Whitney U test. Chi Square and Fisher’s exact tests were used to compare 
dichotomous variables. All tests were two-sided, with a p value < 0.05 considered as 
statistically significant. All post-hoc analyses were Bonferroni, Tukey-HSD or 
Games-Howell test corrected, as appropriate. Statistical analyses were performed 
using IBM Social Package for the Statistical Sciences (SPSS®) version 18.0. 
 
3.9.2 Logistic regression analysis 
 
Binary logistic regression analyses were conducted to predict (i) index loop diuretic 
prescription, and (ii) incident HF within one year after exposure to metformin-
sulphonylurea combination / thiazolidinedione therapy. The backward:LR regression 
230 
 
 
method was used in each case. The regression of the binary outcome (index loop 
diuretic prescription / incident HF) on the covariates included only those covariates 
passing the univariable screening. Binary univariate logistic regression was thus run 
between index loop diuretic prescription / incident HF (dependent variable) and 
individual continuous and categorical variables (individually acting as independent 
variables), separating the covariates into those significant and those not significant at 
p < 0.1. Categorical covariates were dummy coded, using non-exposure to the 
categorical variable of interest as the reference group (and conversely, exposure as 
the indicator group). Index thiazolidinedione prescription (vs metformin-
sulphonylurea combination) was included as a covariate in the logistic regression 
models, irrespective of the outcome of its univariate regression with the dependent 
categorical variables of interest, in a bid to emphazise its contribution or otherwise in 
predicting fluid overload/HF events. Logistic regression models were tested for 
residuals and overdispersion, and satisfied the assumptions of linearity of logit and 
multicollinearity. ROC curves were generated for each model to assess model 
discrimination. 
 
3.9.3 Time to event analysis 
 
Cox proportional hazards regression models (Backward:LR method) were used to 
predict (i) time to index loop diuretic prescription and (ii) time to incident HF within 
one year of inclusion into the metformin-sulphonylurea combination therapy or 
thiazolidinedione cohort, investigating (i) predictors of either event of interest and 
(ii) specifically whether thiazolidinedione prescription (as a categorical covariate) 
has a significant impact on either outcome.  
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Binary univariate logistic regression was run between prescription of index loop 
diuretic within one year of exposure to index metformin-sulphonylurea combination / 
thiazolidinedione therapy (dependent variable) and individual continuous and 
categorical variables (individually acting as independent variables), separating the 
covariates into those significant and those not significant at p < 0.1. Univariate 
regression of continuous variables was carried out using univariate Cox regression 
while univariate regression of categorical variables was carried out using Kaplan 
Meier survival analysis (separating significant and non-significant categorical 
covariates using the Log Rank test). Likewise, binary univariate logistic regression 
was run between development of incident HF within one year of inclusion into the 
metformin-sulphonylurea combination / thiazolidinedione cohort and the same 
individual continuous and categorical covariates (independent variables). Only 
covariates passing univariate screening (p < 0.1) were considered for inclusion into 
the Cox regression model. Time-independent covariates were included The 
Proportional Hazards assumption was formally assessed using  log-minus-log against 
survival/log survival time plots. Covariates not satisfying the Proportional Hazards 
Assumption on account of a time-varying effect were transformed into time-
dependent covariates by forming an interaction (product) term between the 
individual predictor (continuous or categorical) and a function of time (loge time to 
index loop diuretic prescription / incident HF, whichever was applicable), as 
described by Bellera et al. [606]. Covariates which seemingly satisfied the 
Proportional Hazards Assumption were nonetheless transformed into time-dependent 
covariates using the same procedures, in order to confirm their time-independent 
contribution to the final model. The correlation between any categorical variables 
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that proved to be significant (p < 0.1) at univariate regression (log rank test) was 
determined using a chi square test. When two variables were significantly correlated, 
the variable more significantly linked to index loop diuretic prescription / incident 
HF (and hence to ‘fluid overload’) was included in multivariate analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
233 
 
 
Section II - Results 
 
3.10 Data capture – number of patients in each treatment cohort  
 
3027 thiazolidinedione-treated T2DM patients potentially fitted the inclusion criteria 
for this cohort. Of these, 2754 individuals could be assigned an index prescription 
date. 55 patients were excluded given they were being treated with other antidiabetic 
drugs, leaving 2699 patients. A further 15 thiazolidinedione-treated patients were 
excluded as they had commenced and stopped insulin therapy prior to index 
thiazolidindedione prescription, leaving 2684 patients.  
 
Table 3.7 - Total number N (%) of thiazolidinedione-treated patients fitting the 
inclusion criteria for this study. 
 
 
Insulin prescribing definition 
 
N (%) 
 
TZD cohort subtype 
 
 
Insulin-naïve 
 
2070 (76.7) 
 
TZD - insulin group 
 
Insulin therapy commenced before and 
continued after index TZD prescription 
 
60 (2.3) 
 
TZD + insulin group 
 
Insulin introduced after index 
thiazolidinedione prescription, followed by 
cessation of TZDs 
 
475 (17.6) 
 
TZD - insulin group 
 
Insulin introduced after index 
thiazolidinedione prescription, followed by 
continuation of TZDs 
 
 
79 (2.9)* 
 
TZD - insulin group until 
index insulin prescription. 
TZD + insulin group after 
index insulin prescription 
 
* Only 38 out of these 79 patients had an identifiable index date for TZD prescription after index 
insulin prescription. 
 
In summary, the thiazolidinedione cohort comprised 2722 patients (1542 males, 1180 
females) ie 2684 patients + the 38 patients with an index date for thiazolidinedione 
prescription after index insulin therapy. 
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The TZD-insulin group comprised a total of 2624 patients (1489 males, 1135 
females) subdivided into: 
• 2070 thiazolidinedione-treated insulin-naïve patients (never treated with 
insulin) 
• 475 patients who had insulin therapy introduced after index thiazolidinedione 
prescription followed by cessation of thiazolidinedione therapy  
• 79 thiazolidinedione-treated patients whose adjunct insulin therapy 
(introduced after index thiazolidinedione prescription) was accompanied by 
continuation of thiazolidinedione therapy (censored at first insulin 
prescription).  
 
TZD + insulin group comprised a total of 98 patients (53 males, 45 females) 
subdivided into: 
• 60 thiazolidinedione-treated patients whose insulin therapy had been 
commenced before and continued after index thiazolidinedione prescription 
• 38 thiazolidinedione-treated patients whose insulin therapy was introduced 
after index thiazolidinedione prescription, followed by continuation of 
thiazolidinediones.  
 
The metformin-sulphonylurea cohort comprised a total of 3725 patients (2079 males, 
1646 females). 2205 patients (1124 males, 1081 females) were treated with insulin 
(without thiazolidinediones). 
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3.10.1 Patients treated with metformin-sulphonylurea combination therapy, 
insulin and thiazolidinediones in excess of 90 days. 
 
In order to control for confounding variables arising out of poor drug compliance, 
this study opted to analyze data from patients who were treated with 
thiazolidinediones for more than 90 days. 2664 thiazolidinedione-treated patients 
fitted these inclusion criteria (1511 males, 1153 females), of whom 2566 (1458 
males, 1108 females) belonged to the TZD – insulin group and 98 (53 males, 45 
females) belonged to the TZD + insulin group. A summary of the relative 
distribution of patients within each treatment group is summarised in table 3.8. 
 
 
Table 3.8 - Total number N of patients treated in excess of 90 days and fitting the 
inclusion criteria for this study. 
 
  
Metformin-
sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione 
cohort 
 
Males and females 
 
3706 2205 2664 
 
Males 
 
2067 1124 1511 
 
Females 
 
1639 1081 1153 
 
 
1021 (38.3%) patients prescribed pioglitazone at inclusion into the thiazolidinedione 
cohort, whereas 1643 (61.7%) patients were administered rosiglitazone as their first 
thiazolidinedione prescription. As patients tend to be switched from rosiglitazone to 
pioglitazone, or vice versa, an attempt was made to capture these prescription trends 
in the dataset (table 3.9). There were no data to this effect for 2052 (77%) patients 
[994 (97.36%) pioglitazone and 1058 (64.40 %) rosiglitazone-treated patients]. Only 
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548 (20.6%) patients had not had their initial thiazolidinedione replaced by another 
[13 (1.3%) pioglitazone and 535 (32.6%) rosiglitazone-treated patients]. Thus it can 
be concluded that 535 (20.08 %) of patients were treated with pioglitazone alone 
during their observation period, whereas only 13 patients (0.49%) received 
rosiglitazone monotherapy throughout their follow-up period. At least 64 (2.4%) 
patients switched between the two thiazolidinediones, for reasons which were not 
captured for the purposes of this study, rendering any ascertainment of drug-specific 
(as opposed to class-specific) adverse effects difficult and probably imprecise.  
 
 
Table 3.9 - Total number N (%) of patients treated with thiazolidinediones in 
excess of 90 days and fitting the inclusion criteria for this study, classified 
according to tendency to switch between rosiglitazone and pioglitazone therapy. 
 
  
Initial pioglitazone 
prescription 
(n = 1021) 
 
 
Initial rosiglitazone 
prescription 
(n = 1643) 
 
Data unavailable 
 
994 (97.36) 1058 (64.40) 
 
No switch 
 
13 (1.27) 535 (32.56) 
 
Switched between thiazolidinediones 
 
14 (1.37) 50 (3.04) 
 
 
3706 patients (2067 males, 1639 females) received treatment with metformin and 
sulphonylureas in combination for more than 90 days, and were thus included in 
subsequent analysis of index loop diuretic prescription and incident HF events within 
one year of inclusion into their respective cohorts (table 3.8). 
 
2205 patients (1124 males and 1081 females) were treated with insulin therapy in 
excess of 90 days, and were thus recruited for further analysis (table 3.8). 
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Interestingly, this approach did not diminish the original number of insulin-treated 
patients fitting the inclusion criteria, presumably because insulin is a ‘final’ 
therapeutic option in patients with T2DM. 
 
Further analysis will refer to patients treated with metformin-sulphonylurea (MFSU) 
combination, insulin and thiazolidinedione therapy in excess of 90 days. 
 
3.10.2 Background loop diuretic therapy at inclusion into each respective 
treatment cohort 
 
As the intention was to compare patients in whom index metformin-sulphonylurea 
combination therapy, insulin monotherapy or thiazolidinedione therapy was followed 
by index loop diuretic prescription, it was necessary to exclude patients with a 
background of loop diuretic therapy at inclusion into their respective cohort. This left 
a total of 2785 (1634 males, 1151 females), 1361 (744 males, 617 females) and 2097 
(1264 males, 833 females) in the metformin-sulphonylurea, insulin and 
thiazolidinedione cohorts respectively (tables 3.10 and 3.11, figures 3.1 and 3.2). 
 
The corollary to this observation is that 21.3 % of patients (567 out of 2664) were 
already being treated with a loop diuretic at index thiazolidinedione prescription. The 
respective proportions for MFSU and insulin-treated patients were 24.9 % and 38.3% 
respectively (tables 3.10 and 3.11, figures 3.1 and 3.2). Pairwise post-hoc 
comparisons between the cohorts (Bonferroni corrected) confirmed that these 
differences reached statistical significance (except for male patients prescribed a 
thiazolidinedione vs metformin-sulphonylurea combination therapy). Although rates 
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of background loop diuretic therapy for thiazolidinedione therapy were the lowest 
among the three cohorts, one would have expected a smaller proportion of such 
‘fluid overloaded’ patients being prescribed a drug repeatedly associated with weight 
gain, fluid retention and HF events. Background loop diuretic rates for T2DM 
patients prescribed insulin pharmacotherapy are not entirely surprising, given that the 
latter tends to be prescribed at a relatively ‘late’ stage of the disease, in patients 
prone to other cardiovascular risk factors and/or established coronary artery disease.  
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Table 3.10  - Differences in frequency of background loop diuretics therapy at inclusion into the metformin-sulphonylurea, insulin and 
thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort 
 
N = 3706 
(2067 males 
1639 females) 
 
 
Insulin cohort 
 
N = 2205 
(1124 males 
1081 females) 
 
 
Thiazolidinedione cohort 
 
N = 2664 
(1511 males 
1153 females) 
 
 
pa 
 
Background loop 
diuretic prescribed 
   
 
Background loop 
diuretic-free  
 
Background loop 
diuretic prescribed 
   
 
Background loop 
diuretic-free  
 
Background loop 
diuretic prescribed 
   
 
Background loop 
diuretic-free  
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
Males and 
females 
 
921 24.85 2785 75.15 844 38.28 1361 61.72 567 21.28 2097 78.72 < 0.001b 
 
Males 
 
433 20.95 1634 79.05 380 33.81 744 66.19 247 16.35 1264 83.65 < 0.001c 
 
Females 
 
488 29.77 1151 70.23 464 42.92 617 57.08 320 27.75 833 72.25 < 0.001d 
 
a Chi square test for the overall difference between metformin-sulphonlylurea, insulin and thiazolidinedione cohorts. Statistical significance is defined by a two-sided p value 
of < 0.05.   
b
 Chi Square = 194.055, df = 2 
c
 Chi Square = 117.917, df = 2 
d
 Chi Square = 70.338, df = 2 
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Table 3.11 - Post-hoc analysis: Chi square tests for the association between frequency of background loop diuretic therapy and inclusion into 
the metformin-sulphonylurea, insulin and thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort vs  
insulin cohort 
 
 
 
Metformin-sulphonylurea cohort vs 
thiazolidinedione cohort 
 
 
Insulin cohort vs  
thiazolidinedione cohort 
 
 
 
Chi square 
     
 
df 
 
 
pa 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
pa 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
pa 
 
 
Males and 
females 
 
118.969 1 < 0.001 11.020 1 0.001 169.264 1 < 0.001 
 
Males 
 
63.414 1 < 0.001 12.007 1 0.001 108.373 1 < 0.001 
 
Females 
 
49.504 1 < 0.001 1.344 1 0.246 56.364 1 < 0.001 
 
Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3).  
 
a two-sided p value 
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Figure 3.1 - Relative proportions (%) of background loop diuretic therapy at inclusion into each respective cohort for at least three months. 
 
 
 
 
 
 
 
p < 0.001 for the overall difference in loop diuretic treatment counts across the three treatment cohorts; *** p < 0.001; the three pairs of  post-hoc tests were Bonferroni corrected. 
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Figure 3.2 - Relative proportions (%) of background loop diuretic therapy at inclusion into each respective cohort for at least three months, stratified by 
gender. 
 
 
 
 
 
 
 
 
p< 0.001 for the overall difference in loop diuretic treatment counts across the three treatment cohorts; *** p < 0.001; ** p = 0.001; NS, no statistical difference;  the three pairs of  post-hoc 
tests were Bonferroni corrected
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3.10.3 Background heart failure at inclusion into each respective treatment 
cohort 
 
Likewise, this study sought to investigate for differences in rates of HF among 
thiazolidinedione-treated patients, and patients belonging to the two control cohorts. 
HF data were derived from SMR, index loop diuretic and echocardiography data, as 
outlined earlier. The relative proportions of patients identified as suffering from 
background HF based on these definitions are outlined in table 3.12 below: 
 
Table 3.12 - Derivation of baseline heart failure (HF) data at inclusion into the 
respective treatment cohort, based on data extraction definitions. 
 
 
Baseline HF 1 
definition 
 
 
Metformin-
sulphonylurea cohort 4 
 
 
Insulin  
cohort 4 
 
Thiazolidinedione 
cohort 4 
 
   
Echo + loop data 2    
Males and females 55 93 44 
Males  32 63 28 
Females  23 30 16 
    
SMR 3 data    
Males and females 175 295 71 
Males  102 166 44 
Females  73 129 27 
    
 
1 HF, heart failure; 2 echo + loop data, echocardiographic evidence of left ventricular systolic 
dysfunction and prescription of a loop diuretic within one year; 3 SMR, Scottish morbidity record; 4 
number of patients captured based on each data extraction definition. 
 
 
Analyzing for differences in the rates of occurrence of background HF (tables 3.13 
and 3.14, figures 3.3 and 3.4), 4.32% of patients were prescribed a thiazolidinedione 
against a background of HF. The corresponding figures for metformin-sulphonylurea 
combination and insulin-treated patients were 6.21% and 17.60%, which translates 
into a significant difference across the three treatment cohorts (p < 0.001). Overall, 
these proportions are consistent with observations reported for background loop 
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diuretic therapy. Pairwise comparisons (Bonferroni corrected) showed that 
thiazolidinedione-treated patients had lower rates of background HF compared with 
their metformin-sulphonylurea combination (p = 0.001) or insulin-treated (p < 0.001) 
counterparts. As discussed earlier, the latter observation is likely to represent the 
end-result of a progressive illness characterised by a tendency to progress to 
coronary artery disease. One would have expected a lower proportion of patients 
having thiazolidinediones prescribed against a background of HF, given the much 
publicized association with fluid overload. 
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Table 3.13 - Differences in frequency of occurrence of background heart failure at inclusion into the metformin-sulphonylurea, insulin and 
thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort 
 
N = 3706 
(2067 males 
1639 females) 
 
 
Insulin cohort 
 
N = 2205 
(1124 males 
1081 females) 
 
 
Thiazolidinedione cohort 
 
N = 2664 
(1511 males 
1153 females) 
 
 
pa 
 
Background heart 
failure present 
   
 
Background heart 
failure free  
 
Background heart 
failure present 
   
 
Background heart 
failure free  
 
Background heart 
failure present 
   
 
Background heart 
failure free  
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
Males and 
females 
 
230 6.21 3476 93.79 388 17.60 1817 82.40 115 4.32 2549 95.68 <0.001 
 
Males 
 
134 6.48 1933 93.52 229 20.37 895 79.63 72 4.77 1439 95.23 <0.001 
 
Females 
 
96 5.86 1543 94.14 159 14.71 922 85.29 43 3.73 1110 96.27 <0.001 
 
a Chi square test for the overall difference between metformin-sulphonlylurea, insulin and thiazolidinedione cohorts. Statistical significance is defined by a two-sided p value 
of < 0.05.   
b
 Chi Square = 317.942, df = 2 
c
 Chi Square = 220.714, df = 2 
d
 Chi Square = 108.194, df = 2 
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Table 3.14 - Post-hoc analysis: Chi square tests for the association between frequency of occurrence of background heart failure and 
inclusion into the metformin-sulphonylurea, insulin and thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort vs 
 insulin cohort 
 
 
 
Metformin-sulphonylurea cohort vs 
thiazolidinedione cohort 
 
 
Insulin cohort vs 
 thiazolidinedione cohort 
 
 
 
Chi square 
     
 
df 
 
 
pa 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
pa 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
pa 
 
 
Males and 
females 
 
191.579 1 < 0.001 10.800 1 0.001 229.667 1 < 0.001 
 
Males 
 
139.349 1 < 0.001 4.747 1 0.029 155.193 1 < 0.001 
 
Females 
 
60.067 1 < 0.001 6.478 1 0.011 81.772 1 < 0.001 
 
Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3).  
 
a two-sided p value 
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Figure 3.3 - Relative proportions (%) of background occurrence of heart failure (HF) at inclusion into each respective cohort for at least three months. 
 
 
 
 
 
 
 
 
p< 0.001 for the overall difference in background heart failure (HF) counts across the three treatment cohorts; *** p < 0.001; ** p = 0.001;  the three pairs of  post-hoc tests were Bonferroni 
corrected (statistical significance defined by a p value < 0.0167). 
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Figure 3.4 - Relative proportions (%) of background occurrence of heart failure (HF) at inclusion into each respective cohort for at least three months, 
stratified by gender. 
 
 
 
 
 
 
 
 
 
p < 0.001 for the overall difference in background heart failure counts across the three treatment cohorts; *** p < 0.001; * p = 0.011; NS, NS = no statistical difference;  the three pairs of  
post-hoc tests were Bonferroni corrected (statistical significance defined by a p value < 0.0167) 
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3.10.4 Prescription of index loop diuretic therapy within one year of inclusion 
into each respective treatment cohort 
 
Given the difficulties in controlling for all potential confounding variables that could 
account for index loop diuretic prescription and incident HF events, this study 
analysis was limited to events occurring within one year (365 days) after inclusion 
into the metformin-sulphonylurea, thiazolidinedione and insulin cohorts. Such an 
approach was more likely to capture this study's drug related adverse effects of 
interest. 4.3% of patients required an index loop diuretic within one year of their first 
prescription for rosiglitazone or pioglitazone. This figure was comparable to that for 
patients on metformin-sulphonylurea combination therapy (4.7%; p = 0.493), but 
significantly lower than for patients commenced on insulin (12.5%; p < 0.001) 
(tables 3.15 and 3.16, figure 3.5). Stratifying by gender yielded similar results (tables 
3.15 and 3.16, figure 3.6).  
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Table 3.15 - Differences in frequency of prescription of index loop diuretics within one year after inclusion into the metformin-
sulphonylurea, insulin and thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort 
 
N = 2785 
(1634 males 
1151 females) 
 
 
Insulin cohort 
 
N = 1361 
(744 males 
617 females) 
 
 
Thiazolidinedione cohort 
 
N = 2097 
(1264 males 
833 females) 
 
 
pa 
 
Index loop diuretic 
prescribed within 
one year 
   
 
Index loop diuretic-  
free within  
one year 
 
Index loop diuretic 
prescribed within 
one year 
   
 
Index loop diuretic-  
free within  
one year 
 
Index loop diuretic 
prescribed within 
one year 
   
 
Index loop diuretic-  
free within  
one year 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
Males and 
females 
 
131 4.7 2654 95.3 170 12.5 1191 87.5 90 4.3 2007 95.7 < 0.001 b 
 
Males 
 
74 4.5 1560 95.5 81 10.9 663 89.1 40 3.2 1224 96.8 < 0.001 c 
 
Females 
 
57 5.0 1094 95.0 89 14.4 528 85.6 50 6.0 783 94.0 < 0.001 d
 
 
a Chi square test for the overall difference between metformin-sulphonlylurea, insulin and thiazolidinedione cohorts   
b
 Chi Square = 115.327, df = 2 
c
 Chi Square = 59.101, df = 2 
d
 Chi Square = 55.860, df = 2 
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Table 3.16 - Post-hoc analysis: Chi square tests for the association between frequency of prescription of index loop diuretics within one year 
and inclusion into the metformin-sulphonylurea, insulin and thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort vs 
 insulin cohort 
 
 
 
Metformin-sulphonylurea cohort vs 
thiazolidinedione cohort 
 
 
Insulin cohort vs  
thiazolidinedione cohort 
 
 
 
Chi square 
     
 
df 
 
 
p 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
p 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
p 
 
 
Males and 
females 
 
82.337 1 < 0.001 0.470 1 0.493 79.790 1 < 0.001 
 
Males 
 
33.920 1 < 0.001 3.510 1 0.061 49.323 1 < 0.001 
 
Females 
 
47.573 1 < 0.001 1.045 1 0.307 29.009 1 < 0.001 
 
Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3). 
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Figure 3.5 - Relative proportions (%) of index loop diuretic prescription within one year of inclusion into each cohort. 
 
 
 
 
 
 
loop -, index loop diuretic-free; loop +, index loop diuretic-treated; *** p < 0.001; NS, no statistical difference; p< 0.001 for the overall difference in loop diuretic treatment counts across the 
three treatment cohorts; the three pairs of  post-hoc tests were Bonferroni corrected.(statistical significance defined by a p value < 0.0167) 
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Figure 3.6 - Relative proportions (%) of index loop diuretic prescription within one year of inclusion into each cohort, stratified by gender. 
 
 
 
 
 
 
  
 
 
 
loop -, index loop diuretic-free; loop +, index loop diuretic-treated; *** p < 0.001; NS, no statistical difference; p< 0.001 for the overall difference in loop diuretic treatment counts across the 
three treatment cohorts;  the three pairs of  post-hoc tests for each gender were Bonferroni corrected (statistical significance defined by a p value < 0.0167)
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Further investigating the increased risks associated with each treatment cohort, 
(unadjusted) odds ratios (OR) and relative risks (RR) (with 95% CI) were derived for 
each pairwise comparison. As outlined in table 3.17 below, the risk of requiring an 
index loop diuretic within one year of exposure to insulin is almost three times that 
of patients treated with thiazolidinediones. The risk is higher in insulin-treated males 
(3.4 fold) compared with insulin-treated female patients (2.4 fold). 
 
Table 3.17 - Unadjusted relative risk of index loop diuretic prescription after 
exposure to index insulin therapy vs thiazolidinedione therapy 
 
 
Gender status 
 
 
Unadjusted relative risk of 
index loop diuretic 
prescription after 
exposure to insulin (vs 
thiazolidinedione therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
 
Upper 
Males and females 2.91 2.28 3.72 
Males 3.44 2.38 4.97 
Females 2.40 1.73 3.34 
 
 
Insulin-treated patients have a 2.7 times higher risk of progressing to index loop 
diuretic prescription within one year compared to patients on metformin-
sulphonylurea combination therapy [RR 2.66 (95% CI 2.13, 3.30)]. Similar results 
were obtained when stratifying by gender (table 3.18). 
 
Table 3.18 - Unadjusted relative risk of index loop diuretic prescription after 
exposure to index insulin therapy vs metformin-sulphonylurea therapy 
 
 
Gender status 
 
 
Unadjusted relative risk of 
index loop diuretic 
prescription after 
exposure to insulin 
(vs metformin-
sulphonylurea therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
Males and females 2.66 2.13 3.30 
Males 2.40 1.78 3.26 
Females 2.91 2.12 4.00 
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As expected, given the non-significant differences in rates of index loop diuretic 
prescription between patients assigned a thiazolidinedione and those on metformin-
sulphonylurea combination therapy, 95% CI for RR spanned unity, as outlined in 
table 3.19 below. 
 
Table 3.19 Unadjusted relative risk of index loop diuretic prescription after 
exposure to index thiazolidinedione therapy (vs metformin-sulphonylurea 
therapy). 
 
 
Gender status 
 
 
Unadjusted relative risk of 
index loop diuretic 
prescription following 
exposure to 
thiazolidinediones (vs 
metformin-sulphonylurea 
therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
 
Upper 
Males and females 0.91 0.70 1.19 
Males 0.70 0.48 1.02 
Females 1.21 0.84 1.75 
 
 
 
OR values for each of the three pairwise comparisons between thiazolidinediones, 
metformin-sulphonylurea combination therapy and insulin therapy are outlined in 
appendix I (appendix tables III.1 to III.3) 
 
3.10.5 Kaplan-Meier survival curves for index loop diuretic therapy 
 
(Unadjusted) Kaplan-Meier survival curves were constructed to compare time to 
index loop diuretic prescription between the three treatment cohorts. Index insulin 
prescription was likely to be complicated by an index loop diuretic prescription at a 
significantly earlier stage than either of the other cohorts, as outlined in table 3.20 
and figure 3.7 below. There were no significant difference in loop diuretic-free 
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survival rates between metformin-sulphonylurea combination and thiazolidinedione 
cohorts. 
 
Table 3.20 - Survival (Kaplan-Meier) analysis comparing time to index loop 
diuretic prescription (censored at one year) after index metformin-sulphonylurea 
combination, insulin or thiazolidinedione therapy 
 
Treatment cohort Log-rank (Mantel-Cox)  Chi square df p 
Metformin-sulphonylurea combination  vs insulin vs 
thiazolidinediones 111.279 2 < 0.001 
Metformin-sulphonylurea combination vs thiazolidinediones 0.420 1 0.517 
Metformin-sulphonylurea combination vs insulin  79.035 1 < 0.001 
Insulin vs thiazolidinediones 75.655 1 < 0.001 
 
 
Figure 3.7 - Hazard curve comparing time to index loop diuretic prescription 
following index metformin-sulphonylurea combination, insulin and 
thiazolidinedione therapy 
 
 
 
 
 
 
 
 
Metformin-sulphonylurea 
Insulin 
Thiazolidinediones 
Metformin-sulphonyolurea censored 
Insulin censored 
Thiazolidinedione censored 
 
Time to index loop diuretic prescription (days) 
* 
* unadjusted  
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3.10.6 Timing of index loop diuretic prescription within a year after index 
metformin-sulphonylurea, insulin or thiazolidinedione therapy 
 
Table 3.21 and figure 3.8 stratify the number of index loop diuretic prescription in 
three monthly intervals following index metformin-sulphonylurea, insulin and 
thiazolidinedione therapy. Index loop diuretic prescription is fairly evenly distributed 
throughout this period of observation for both metformin-sulphonylurea and 
thiazolidinedione-treated patients. This pattern contrasts with that exhibited for 
insulin-treated subjects, in whom index loop diuretic prescription becomes less likely 
over each progressive treatment quarter. 
 
 
Table 3.21 - Index loop diuretic prescriptions stratified in three monthly intervals 
following index metformin-sulphonylurea combination, thiazolidinedione and 
thiazolidinedione therapy. 
 
 
Treatment quarter 
 
Metformin-
sulphonylurea cohort 
 
Insulin  
cohort 
 
Thiazolidinedione 
cohort 
 
0 - 90 days 
91-180 days 
181-270 days 
271-365 days 
 
30 
46 
26 
29 
 
65 
48 
30 
27 
 
20 
31 
16 
23 
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Figure 3.8 - Number of patients prescibed an index loop diuretic stratified in three monthly intervals after index metformin-sulphonylurea, 
insulin and thiazolidinedione therapy 
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3.10.7 Occurrence of incident heart failure within one year of inclusion into 
each respective treatment cohort 
 
Likewise, this study sought to investigate the rates of occurrence of incident HF 
within one year of inclusion into each respective cohort. This necessarily meant that 
patients with a background history of HF at inclusion were excluded, leaving 3476, 
1815 and 2549 patients within the metformin-sulphonylurea, insulin and 
thiazolidinedione cohorts respectively. The relative proportions of patients defined as 
developing index HF within one year, based on SMR, echocardiography and loop 
diuretic data (as outlined in the methods section) is outlined in table 3.22 below. 
 
Table 3.22 - Derivation of index heart failure (HF) data within one year of 
inclusion into the respective treatment cohort, based on data extraction definitions. 
 
 
Index HF  
definition 1 
 
 
Metformin-
sulphonylurea cohort 4 
 
 
Insulin  
cohort 4 
 
Thiazolidinedione 
cohort 4 
 
   
Echo + loop data 2    
Males and females 9 15 7 
Males  8 6 5 
Females  1 9 2 
    
SMR 3 data     
Males and females 40 50 21 
Males  25 28 13 
Females  15 22 8 
    
 
1 index HF definition, index heart failure developing within one year of inclusion into the respective 
treatment cohort; 2 echo + loop data, echocardiographic evidence of left ventricular systolic 
dysfunction and prescription of a loop diuretic within one year; 3 SMR, Scottish morbidity record; 4 
number of patients captured based on each data extraction definition. 
 
 
As outlined in tables 3.23 and 3.24, 1.1% of thiazolidinedione-treated patients 
developed incident HF within one year of prescription of their index rosiglitazoene 
or pioglitazone. This was not significantly different from patients on metformin-
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sulphonylurea combination therapy (1.4%; p = 0.288), but significantly lower than 
for patients prescribed insulin (3.5%; p < 0.001). Stratifying by gender yielded 
similar results. These relative proportions are also summarised in figures 3.9 and 
3.10. 
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Table 3.23 - Differences in frequency of occurrence of incident heart failure within one year after inclusion into the metformin-
sulphonylurea, insulin and thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort 
 
N = 3476 
(1933 males 
1543 females) 
 
 
Insulin cohort 
 
N = 1815 
(893 males 
922 females) 
 
 
Thiazolidinedione cohort 
 
N = 2549 
(1439 males 
1110 females) 
 
 
pa 
 
Incident heart 
failure developed 
within one year  
   
 
Incident heart 
failure free within  
one year 
 
Incident heart 
failure developed 
within one year 
   
 
Incident heart 
failure free within  
one year 
 
Incident heart 
failure developed 
within one year 
   
 
Incident heart 
failure free within  
one year 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
N 
 
     
   % 
 
Males and 
females 
 
49 1.4 3427 98.6 63 3.5 1752 96.5 28 1.1 2521 98.9 < 0.001b 
 
Males 
 
33 1.7 1900 98.3 32 3.6 861 96.4 18 1.3 1421 98.7 < 0.001c 
 
Females 
 
16 1.0 1527 99.0 31 3.4 891 96.6 10 0.9 1100 99.1 < 0.001d 
 
a Chi square test for the overall difference between metformin-sulphonlylurea, insulin and thiazolidinedione cohorts   
b
 Chi Square = 39.062, df = 2 
c
 Chi Square = 16.769, df = 2 
d
 Chi Square = 24.824, df = 2 
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Table 3.24 - Post-hoc analysis: Chi square tests for the association between frequency of occurrence of incident heart failure within one year 
and inclusion into the metformin-sulphonylurea, insulin and thiazolidinedione cohorts for at least three months. 
 
 
Gender subgroup 
 
Metformin-sulphonylurea cohort vs  
insulin cohort 
 
 
 
Metformin-sulphonylurea cohort vs 
thiazolidinedione cohort 
 
 
Insulin cohort vs  
thiazolidinedione cohort 
 
 
 
Chi square 
     
 
df 
 
 
p 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
p 
 
 
 
Chi square 
     
     
 
     
 
df 
 
 
p 
 
 
Males and 
females 
 
24.454 1 < 0.001 1.129 1 0.288 29.229 1 < 0.001 
 
Males 
 
9.569 1 0.002 1.153 1 0.283 14.290 1 < 0.001 
 
Females 
 
16.685 1 < 0.001 0.123 1 0.726 15.434 1 < 0.001 
 
Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3). 
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Figure 3.9 - Relative proportions (%) of occurrence of incident heart failure (HF) within one year of inclusion into each cohort. 
 
 
 
 
 
 
p< 0.001 for the overall difference in loop diuretic treatment counts across the three treatment cohorts; HF -, incident heart failure free; HF +, developed incident heart failure within one year; 
*** p < 0.001; NS, no statistical differencethe three pairs of  post-hoc tests were Bonferroni corrected.(statistical significance defined by a p value < 0.0167) 
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Figure 3.10 - Relative proportions (%) of development of incident heart failure (HF) within one year of inclusion into each cohort, stratified by gender. 
 
 
 
 
 
  
 
 
 
 
HF -, incident heart failure free; HF +,  developed incident heart failure within one year; *** p < 0.001; ** p < 0.01; NS, no statistical difference; p< 0.001 for the overall difference in loop 
diuretic treatment counts across the three treatment cohorts;  the three pairs of  post-hoc tests for each gender were Bonferroni corrected (statistical significance defined by a p value < 
0.0167)
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Similarly, (unadjusted) RR ratios were derived for incident HF for each cohort 
pairwise comparison (tables 3.25 to 3.27). Thus, patients exposed to insulin are at a 
three fold risk of developing this adverse event compared with their 
thiazolidinedione-treated counterparts [RR 3.16 (95% CI 2.03, 3.72)] (table 3.25). 
This risk is higher for female insulin-treated patients [RR 3.73 (95% CI 1.84, 7.57)], 
albeit characterised by wider 95% CI. The latter probably arose on account of a 
relatively small number of female patients developing HF on subgroup analysis. 
 
Table 3.25 - Unadjusted relative risk of occurrence of incident heart failure after 
exposure to index insulin therapy (vs thiazolidinedione therapy). 
 
 
Gender status 
 
 
Unadjusted relative risk  of 
incident heart failure after 
exposure to insulin 
(vs thiazolidinedione 
therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
Males and females 3.16 2.03 4.91 
Males 2.87 1.62 5.07 
Females 3.73 1.84 7.57 
 
 
Similarly insulin therapy carries a 2.5 fold risk of progression to incident HF 
compared with metformin-sulphonylurea combination therapy [RR 2.46 (95% CI 
1.70, 3.56)] (table 3.26). Female insulin-treated patients are more likely to develop 
this adverse event [RR 3.24 (95% CI 1.78, 5.90)].  
 
Table 3.26 - Unadjusted relative risk of occurrence of incident heart failure after 
exposure to index insulin therapy (vs metformin-sulphonylurea therapy). 
 
 
Gender status 
 
 
Unadjusted relative risk  of 
incident heart failure 
following exposure to 
insulin 
(vs metformin-
sulphonylurea therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
Males and females 2.46 1.70 3.56 
Males 2.10 1.30 3.39 
Females 3.24 1.78 5.90 
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Unadjusted RR values for exposure to thiazolidinediones vs metformin-
sulphonylurea combination therapy were characterised by 95% CI which span unity 
(table 3.27), in keeping with the non-significant associations described earlier. 
 
Table 3.27 - Unadjusted relative risk of occurrence of incident heart failure after 
exposure to index thiazolidinedione therapy (vs metformin-sulphonylurea 
therapy). 
 
 
Gender status 
 
 
Unadjusted odds ratio of 
incident heart failure 
following exposure to 
thiazolidinediones (vs 
metformin-sulphonylurea 
therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
 
Upper 
Males and females 0.779 0.491 1.236 
Males 0.733 0.414 1.296 
Females 0.869 0.396 1.907 
 
 
Derived ORs for each of the three pair-wise comparisons between treatment cohorts 
are summarised in appendix tables III.4 to III.6. 
 
3.10.8 Kaplan-Meier survival curves for incident heart failure  
 
Pairwise log-rank (Mantel-Cox) p values comparing time to index loop diuretic 
prescription between the three treatment cohorts were consistent with the above 
results, confirming significantly earlier progression to incident HF for insulin-treated 
patients, and comparable HF free survival times for thiazolidinedione and 
metformin-sulphonylurea combination cohorts (table 3.28, figure 3.11). 
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Table 3.28 - Survival (Kaplan Meier) analysis comparing time to incident heart 
failure (censored at one year) after index metformin-sulphonylurea combination, 
insulin or thiazolidinedione therapy 
 
Treatment cohort Log-rank (Mantel-Cox)  
Chi square df p 
    
Metformin-sulphonylurea combination  vs insulin vs 
thiazolidinediones 
35.990 2 < 0.001 
Metformin-sulphonylurea combination vs thiazolidinediones 1.089 1 0.297 
Metformin-sulphonylurea combination vs insulin  22.494 1 < 0.001 
Insulin vs thiazolidinediones 27.015 1 < 0.001 
 
 
Figure 3.11 - Hazard curves comparing time to incident heart failure following 
index metformin-sulphonylurea, insulin or thiazolidinedione therapy 
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Metformin-sulphonyolurea censored 
Insulin censored 
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* 
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3.10.9 Timing of incident heart failure events within a year after index 
metformin-sulphonylurea, insulin or thiazolidinedione therapy 
 
Timing of incident HF events largely mirrors that for index loop diuretic 
prescription, with occurrences of new-onset HF becoming progressively less likely at 
each successive three month interval following index insulin prescription. Incident 
HF events were more or less randomly distributed following index metformin-
sulphonylurea and thiazolidinedione therapy, as outlined in table 3.29 and figure 
3.12 below. 
 
 
Table 3.29 - Incident heart failure events stratified in three monthly intervals 
following index metformin-sulphonylurea combination, thiazolidinedione and 
thiazolidinedione therapy. 
 
 
Treatment quarter 
 
Metformin-
sulphonylurea cohort 
 
Insulin  
cohort 
 
Thiazolidinedione 
cohort 
 
0 - 90 days 
91-180 days 
181-270 days 
271-365 days 
 
7 
17 
9 
16 
 
20 
16 
14 
13 
 
2 
10 
4 
12 
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Figure 3.12 - Number of incident heart failure events occurring at three monthly intervals after index metformin-sulphonylurea, insulin and 
thiazolidinedione therapy 
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3.11 Baseline characteristics 
 
3.11.1  Age, diabetes duration and duration of follow-up  
 
Table 3.30 outlines mean (SD) values for age, diabetes duration and study duration 
for patients without background loop diuretic therapy. Thiazolidinedione-treated 
patients tended to be younger than their metformin-sulphonylurea [63.23 (9.77) vs 
64.96 (10.53) years; p < 0.001] and insulin-treated [63.23 (9.77) vs 64.92 (10.13) 
years; p < 0.001] counterparts. As perhaps expected for a second/third line glucose 
lowering agent such as a thiazolidinedione, patients prescribed the latter drugs 
tended to have been diagnosed with diabetes at an earlier stage than patients on 
metformin-sulphonylurea combination therapy [6.86 (4.90) vs 5.31 (4.74) years; p < 
0.001], although not as long as for insulin-treated subjects [6.86 (4.90) vs 8.70 (6.02) 
years; p < 0.001]. Thiazolidinedione-treated patients had the shortest follow-up 
observation period [3.02 (2.16) years], possibly reflecting tendency to drug 
withdrawal on developing/suspicion of developing adverse effects to these drugs. 
This duration of follow-up was significantly shorter than for insulin [6.22 (4.10) 
years] and metformin-sulphonylurea [3.53 (3.02) years] treated patients (p < 0.001 
for either treatment cohort vs thiazolidinediones).  
 
Table 3.31 outlines the mean (SD) values for age, diabetes duration and years of 
follow-up for each treatment cohort, stratified by index loop diuretic status and 
gender.  Thiazolidinedione-treated patients requiring an index loop diuretic within 
one year of inclusion into the cohort were older [67.98 (10.02) vs 63.02 (9.70) years; 
p < 0.001], and had been diagnosed with diabetes at a significant earlier stage [8.44 
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(5.61) vs 6.79 (4.85) years; p = 0.003] than their index loop diuretic-free 
counterparts. Index loop diuretic-treated TZD patients were also characterised by a 
tendency for a shorter observation period of follow-up (albeit not statistically 
significant) [2.60 (1.92) vs 3.04 (2.17) years; p = 0.056], once again, possibly 
reflecting a tendency to discontinue thiazolidinedione therapy, or shorter survival 
once there is clinical evidence of fluid overload. A similar analysis of incident HF 
events occurring within one year of inclusion into each of the three treatment cohorts 
(HF +) yielded largely similar results, albeit with differences in duration of follow-
up [1.50 (1.65) (HF +) vs 2.98 (2.12) (HF – ) years) reaching statistical significance 
(p < 0.001), in contrast to those for diabetes duration [8.15 (4.88) (HF +) vs 6.93 
(5.01) (HF –) years; p = 0.136) (data not shown in table format). 
 
Likewise, MFSU patients treated with an index loop diuretic after inclusion into the 
cohort were older [69.21 (9.81) vs 64.75 (10.52) years; p < 0.001], and had a longer 
duration of diabetes [6.56 (5.50) vs 5.24 (4.69) years; p = 0.005] compared with their 
index loop diuretic-free counterparts. The duration of follow-up of these patients was 
largely similar [3.46 (3.16) vs 3.53 (3.01) years; p = 0.669] (table 3.31), an 
observation that is perhaps not entirely surprising given the lack of a known 
association between metformin-sulphonylurea combination therapy and fluid 
overload. Similar trends were reported for incident HF events, with differences being 
more pronounced, and reaching statistical significance with respect to duration of 
follow-up [1.99 (2.24) (HF +) vs 3.49 (2.96) (HF -) years; p < 0.001) (data not 
shown in table format). This suggests that once HF sets in, patients are either (i) 
characterised by a shorter survival, or (ii) more likely to be switched to more 
intensive glucose lowering therapy (such as insulin).  
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Insulin-treated patients requiring an index loop diuretic were older [68.30 (9.24) vs 
64.44 (10.16) years; p < 0.001] and likely to be observed for a significantly shorter 
period after inclusion into their respective cohort [5.18 (3.81) vs 6.37 (4.11) years; p 
< 0.001] (table 3.31). Whilst discontinuation of insulin therapy is unlikely at such a 
late stage of the disease, a shorter observation period could reflect higher mortality 
rates for index loop diuretic-treated patients in this cohort. Diabetes duration was 
similar in either insulin subgroup [9.12 (6.61) vs 8.65 (5.93) years; p = 0.420] (table 
3.31). Similar results were reported for incident HF events (data not shown in table 
format), with particularly pronounced, statistically significant, differences in 
duration (years) of follow-up [3.30 (3.13) (HF +) vs 5.99 (4.06) (HF -) years; p < 
0.001]. 
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Table 3.30 - Comparison of mean (SD) values for baseline age, diabetes duration and study duration for patients treated with metformin-
sulphonylurea combination, insulin and thiazolidinedione therapy for at least three months, and having no background loop diuretic therapy 
at inclusion into their respective cohort. 
 
  
Metformin-
sulphonylourea 
cohort 
 
N = 2785 
 
 
 
Insulin 
cohort 
 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
 
N = 2097 
 
 
p value for 
the 
difference 
across the 
three 
cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin 
cohort vs 
TZD 
cohort 
b 
 
       
Age (years) 64.96 (10.53) 64.92 (10.13) 63.23 (9.77) < 0.001 0.993c < 0.001c < 0.001c 
 
       
Diabetes duration 
(years) 
5.31 (4.74) 8.70 (6.02) 6.86 (4.90) < 0.001d < 0.001c, d < 0.001c, d < 0.001c, d 
 
       
Study duration (years) 3.53 (3.02) 6.22 (4.10) 3.02 (2.16) < 0.001d < 0.001c, d < 0.001c, d < 0.001c, d 
 
a
 two-tailed p value [One-way analysis of variance (ANOVA)]; b two-tailed p value (pair-wise post-hoc analysis). Tests of the three a priori hypotheses were conducted using 
the Games-Howell test c; d differences calculated on square root transformed data 
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Table 3.31 - Comparison of mean (SD) values for age, duration of diabetes and years of follow-up between individuals requiring treatment 
with loop diuretics and those remaining loop diuretic-free within one year after exposure to metformin-sulphonylurea combination, insulin 
or thiazolidinedione therapy for a minimum of three months, and having no background loop diuretic therapy at inclusion into their 
respective cohort. 
 
 
 
 
Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
Loop diuretic  
-free 
 
N = 2654 
pa 
 
 
Loop diuretic  
-treated 
 
N = 170 
 
 
Loop diuretic  
 -free 
 
N = 1191 
 
pa 
 
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop diuretic  
-free 
 
N = 2007 
 
pa 
 
Age  
(years) 69.21 (9.81) 64.75 (10.52) < 0.001 68.30 (9.24) 64.44 (10.16) < 0.001 67.98 (10.02) 63.02 (9.70) < 0.001 
 
Diabetes duration 
(years) 
 
6.56 (5.50) 
 
5.24 (4.69) 
 
0.005 b 
 
9.12 (6.61) 
 
8.65 (5.93) 
 
0.420 b 
 
8.44 (5.61) 
 
6.79 (4.85) 
 
0.003 b 
 
Study duration 
(years) 
 
 
3.46 (3.16) 
 
3.53 (3.01) 
 
0.669 b 
 
5.18 (3.81) 
 
6.37 (4.11) 
 
< 0.001  
 
2.60 (1.92) 
 
3.04 (2.17) 
 
0.056 b  
a  two-tailed p  vslue for the difference between loop diuretic- treated and loop diuretic-  free patients [One-way analysis of variance (ANOVA)]; b differences calculated on 
square root transformed data 
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3.11.2 Past medical history 
 
Analyzing data pertaining to these patients’ past medical history, 317 (15.1%) of 
patients with no background loop diuretic therapy were prescribed an index 
thiazolidinedione on a background of known coronary artery disease or peripheral 
arterial disease or stroke. This is considerably lower than for metformin-
sulphonylurea- [549 (19.7%); p < 0.001] and insulin- [363 (26.7%); p < 0.001] 
treated patients (table 3.32). Analyzing these macrovascular complications 
separately, these post-hoc pairwise comparisons reached statistical significance only 
for coronary artery disease and stroke. There was no significant difference in the 
frequency of background peripheral artery disease between metformin-sulphonylurea 
and thiazolidinedione-treated patients, although the latter were significantly less 
likely to suffer from background PAD at index TZD prescription compared with 
their insulin-treated counterparts [43 (2.1%) vs 67 (4.9%); p < 0.001] (table 3.32). 
 
Analyzing for individuals who had never been prescribed a loop diuretic before 
inclusion into their respective cohort, there were no significant differences in the 
frequencies of background HF between thiazolidinedione and metformin-
sulphonylurea-treated patients [18 (0.9%) (TZD) vs 31 (1.1%) (MFSU); p = 0.377] 
(table 3.32). Lower background rates for HF at an early stage of T2DM (when 
metformin-sulphonylurea combination therapy is likely to be prescribed) are likely to 
be offset by lower background rates of HF among patients prescribed 
thiazolidinediones in accordance with established treatment guidelines. Insulin is 
statistically more likely to be prescribed in patients known to suffer from HF 
compared with thiazolidinediones [69 (5.1%) vs 18 (0.9%); p < 0.001], again 
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probably reflecting (i) consensus guided prescribing practices (thiazolidinediones are 
contraindicated in patients with HF) and (ii) the fact that insulin requiring patients 
are more prone to coronary artery disease with complicating HF given the more 
advanced stage of their disease.  
 
Interestingly, excluding patients with background loop diuretic therapy, HF rates 
following inclusion into the respective treatment cohorts were lowest for 
thiazolidinediones [64 (3.1%)], significantly less than for metformin-sulphonylurea 
[162 (5.8%); p < 0.001] or insulin [209 (15.4%); p < 0.001] (table 3.32), although 
this comparison must be interpreted with caution, as (i) these patients were followed 
up for a significantly shorter period than their metformin-sulphonylurea and insulin-
treated counterparts, and (ii) background HF rates were significantly lower for 
thiazolidinedione-treated patients compared with insulin-treated ones. Similar 
observations apply to post-treatment coronary artery disease, stroke and peripheral 
artery disease, or their composite. 
  
Patients requiring an index loop diuretic within one year after index 
thiazolidinedione prescription were more likely to suffer from background coronary 
artery disease [18 (20.0%) vs 225 (11.2%); p = 0.011], peripheral artery disease [6 
(6.7%) vs 37 (1.8%); p = 0.009] or the composite of macrovasular disease [27 
(30.2%) vs 290 (14.4%); p < 0.001] (table 3.33). Although background stroke rates 
were higher among patients requiring an index loop diuretic after TZD prescription 
[4 (4.6%) vs 53 (2.6%)], these differences did not reach statistical significance, 
possibly as a result of the relatively smaller number of patients with this disease 
category at TZD prescription. Similar differences, namely higher background rates 
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of coronary artery disease, peripheral artery disease and the composite of 
macrovascular disease were observed for index loop diuretic requiring metformin-
sulphonylurea-treated patients (table 3.33). Analyzing for incident HF events, both 
thiazolidinedione and metformin-sulphonylurea combination therapy patients 
diagnosed with new-onset HF within one year of inclusion into either cohort were 
likewise characterised by significantly higher rates of background coronary artery 
disease [11 (39.3%) vs 337 (13.4%), p = 0.001 for thiazolidinedione-treated patients; 
22 (44.9%) vs 540 (15.8%), p < 0.001 for MFSU-treated patients]. Higher 
background stroke rates among HF prone TZD- and MFSU-treated patients did not 
reach statistical significance – however, the number of incident HF events was 
particularly low for either cohort [3 (MFSU) and 2 (TZD)], rendering statistical 
interpretation somewhat dubious (data not shown in table format). 
 
Insulin-treated patients requiring requiring an index loop diuretic within one year 
after inclusion into this glucose lowering treatment category were more likely to 
have suffered from coronary artery disease [63 (37.1%) vs 214 (18.0%); p < 0.001] 
or the composite of macrovascular disease [74 (43.5%) vs 289 (24.3%); p < 0.001] at 
baseline. (table 3.33). Higher rates of index loop diuretic prescription among insulin-
treated patients with a history of stroke or peripheral artery disease did not reach 
statistical significance. Similar results were replicated for incident HF events in this 
treatment cohort (data not shown). 
 
Perhaps not surprisingly, index loop diuretic prescription was commoner among 
metformin-sulphonylurea or insulin-treated patients prescribed these drugs on a 
background of HF [6 (4.6%) vs 25 (0.9%); p = 0.003 (metformin-sulphonylurea); 32 
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(18.8%) vs 37 (3.1%); p < 0.001 (insulin)]. Such a difference, although reported for 
thiazolidinediones [2 (2.2%) vs 16 (0.8%)] did not reach statistical difference, 
probably because of lower rates of background HF for this cohort (table 3.33).  
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Table 3.32 - Comparison of the relative frequency [n (%)] of background and post-treatment macrovascular disease and heart failure among 
patients treated with metformin-sulphonylurea combination, insulin or thiazolidinedione therapy for a minimum of three months, and 
having no background loop diuretic therapy at inclusion into their respective cohort. 
 
 
Metformin-
sulphonylourea 
cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b 
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin 
cohort vs 
TZD cohort 
b 
 
Background CAD 
 
397 (14.3) 
 
277 (20.4) 
 
243 (11.6) 
 
< 0.001 
 
< 0.001 
 
0.006 
 
< 0.001 
 
       
Post-treatment CAD 358 (12.9) 410 (30.1) 170 (8.1) < 0.001 < 0.001 < 0.001 < 0.001 
 
       
Background stroke 152 (5.5) 85 (6.2) 57 (2.7) < 0.001 0.305 < 0.001 < 0.001 
 
       
Post-treatment stroke 127 (4.6) 147 (10.8) 39 (1.9) < 0.001 < 0.001 < 0.001 < 0.001 
 
Background PAD 
 
76 (2.7) 
 
67 (4.9) 
 
43 (2.1) 
 
< 0.001 
 
< 0.001 
 
0.128 
 
< 0.001 
 
       
Post-treatment PAD 93 (3.3) 137 (10.1) 27 (1.3) < 0.001 < 0.001 < 0.001 < 0.001 
 
       
Background  
macrovasc disease 549 (19.7) 363 (26.7) 317 (15.1) < 0.001 < 0.001 < 0.001 < 0.001 
 
       
Post-treatment  
macrovasc disease 490 (17.6) 534 (39.2) 217 (10.3) < 0.001 < 0.001 < 0.001 < 0.001 
CAD, coronary artery disease; macrovasc disease, composite of macrovascular disease comprising a history of known coronary artery disease or peripheral arterial disease 
or stroke; PAD, peripheral arterial disease; a two-tailed p value (Chi Square test), b two-tailed p value (Chi Square test). Tests of the three a priori hypotheses were 
conducted using Bonferroni adjusted alpha lelves of 0.0167 per test (0.05/3).  
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Metformin-
sulphonylourea cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for the 
difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin cohort 
vs TZD cohort 
b 
 
       
Background  
HF 31 (1.1) 69 (5.1) 18 (0.9) < 0.001 < 0.001 0.377 < 0.001 
 
Post-treatment  
HF 
 
162 (5.8) 
 
209 (15.4) 
 
64 (3.1) 
 
< 0.001 
 
< 0.001 
 
< 0.001 
 
< 0.001 
HF, heart failure; a two-tailed p value (Chi Square test), b two-tailed p value (Chi Square test). Tests of the three a priori hypotheses were conducted using Bonferroni 
adjusted alpha levels of 0.0167 per test (0.05/3) 
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Table 3.33 - Comparison of the relative frequency of background and post-treatment macrovascular disease and heart failure between individuals 
requiring treatment with loop diuretics and those remaining loop diuretic-free within one year after exposure to metformin-sulphonylurea combination, 
insulin or thiazolidinedione therapy for a minimum of three months, and having no background loop diuretic therapy at inclusion into their respective 
cohort. 
 
 
 
Metformin-Sulphonylurea cohort 
 
Insulin cohort 
 
Thiazolidinedione cohort 
 
  
Loop diuretic 
-treated 
 
N = 131 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b 
 
 
Loop diuretic  
-treated 
 
N = 170 
 
Loop diuretic  
-free 
 
N = 1191 
 
p a, b  
 
Loop diuretic 
-treated 
 
N = 90 
 
Loop diuretic  
-free 
 
N = 2007 
 
p a, b  
Background  
CAD 35 (26.7) 362 (13.6) < 0.001 
a
 63 (37.1) 214 (18.0) < 0.001 a 18 (20.0) 225 (11.2) 0.011 a 
 
         
Post-treatment  
CAD  37 (28.2) 321 (12.1) < 0.001
 a
 80 (47.1) 330 (27.7) < 0.001 a 15 (16.7) 155 (7.7) 0.002 a 
 
         
Background  
stroke 10 (7.6) 142 (5.4) 0.261
 a
 12 (7.1) 73 (6.1) 0.639 a 4 (4.4) 53 (2.6) 0.303 a 
 
         
Post-treatment 
stroke 
 
11 (8.4) 116 (4.4) 0.031a 26 (15.3) 121 (10.2) 0.044 a 2 (2.2) 37 (1.8) 0.683 b 
Background  
PAD  10 (7.6) 66 (2.5) 0.003
 b
 12 (7.1) 55 (4.6) 0.169 a 6 (6.7) 37 (1.8) 0.009 b 
 
         
Post-treatment 
PAD 9 (6.9) 84 (3.2) 0.039
 b
 21 (12.4) 116 (9.7) 0.289 a 2 (2.2) 25 (1.2) 0.324 b 
CAD, coronary artery disease; PAD, peripheral arterial disease;  a  two-tailed p value for the statistical difference between loop diuretic-treated and loop diuretic-free patients (Chi Square 
test); b  two-tailed p value for the statistical difference between loop diuretic-treated and loop diuretic-free patients (Fisher’s exact tes 
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Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b  
 
Loop diuretic  
-treated 
 
N = 170 
 
 
Loop diuretic  
 -free 
 
N = 1191 
 
 
p a, b  
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop diuretic 
-free 
 
N = 2007 
 
 
p a, b  
Background 
macrovasc 
disease  
47 (35.9) 502 (18.9) < 0.001 a 74 (43.5) 289 (24.3) < 0.001 a 27 (30.2) 290 (14.4) < 0.001a 
 
         
Post-treatment 
macovasc disease 46 (35.1) 444 (16.7) < 0.001
 a
 98 (57.6) 436 (36.6) < 0.001 a 17 (18.9) 200 (10.0) 0.007 a 
 
         
Background  
HF 6 (4.6) 25 (0.9) 0.003
 b
 32 (18.8) 37 (3.1) < 0.001 a 2 (2.2) 16 (0.8) 0.179 b 
 
         
Post-treatment  
HF  25 (19.1) 137 (5.2) < 0.001
 a
 
63 (37.1) 146 (12.3) < 0.001 a 12 (13.3) 52 (2.6) < 0.001 b 
HF, heart failure; macrovasc, composite of macrovascular disease comprising a history of known coronary artery disease or peripheral artery disease or stroke; a two-tailed 
p value for the statistical difference between loop diuretic- treated and loop diuretic-  free patients (Chi Square test); b two-tailed p value for the statistical difference between 
loop diuretic- treated and loop diuretic-  free patients (Fisher’s exact test) 
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3.11.3 Drug history 
 
This study captured data pertaining to a wide range of drugs which could possibly, at 
least partly, explain an increased risk for fluid overload following index 
thiazolidinedione prescription. Thiazolidinedione-treated patients were more likely 
to be prescribed these oral glucose lowering agents on a background of peripheral 
vasodilators (3.2%), thiazide diuretics (35.8%), non-steroidal anti-inflammatory 
drugs (69.8%), angiotensin converting enzyme inhibitors (54.9%) and aldosterone 
receptor antagonists (14.9%), compared with their metformin-sulphonylurea or 
insulin-treated counterparts (table 3.34).  
 
Thiazolidinedione-treated patients were additionally characterised by higher 
background rates of dihydropyridine calcium channel blockers (35.4%), diltiazem 
(6.5%), beta blockers (40.1%), nitrates (18.7%) and other anti-anginal drugs (2.2%) 
and lower background prescription of peripheral vasocilators (3.2%) compared with 
patients on insulin. Antecedent prescription of alpha adrenoceptor blocking drugs 
was commoner among thiazolidinedione prescribed patients (8.9%) compared with 
metformin-sulphonylurea-treated ones (table 3.34). 
 
Searching for possible causes of fluid overload, this study compared frequencies of 
background drug therapy between patients requiring loop diuretic (LD+), and those 
remaining loop diuretic-free (LD-) after index thiazolidinedione therapy (table 3.35). 
The former patients were more likely to be treated with a nitrate [25 (27.8%) (LD+) 
vs 367 (18.3%) (LD-); p = 0.024], in keeping with higher rates of coronary artery 
disease among this category of thiazolidinedione-treated patients. Higher 
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background use of thiazides [41 (45.6%) (LD+) vs 710 (35.4%) (LD-)] was 
borderline statistically significant (p = 0.049).  
 
Patients were more likely to require an index prescription of a loop diuretic after  
index metformin-sulphonylurea combination therapy if the latter was introduced 
against a background of peripheral vasodilators [12 (9.2%) (LD+) vs 118 (4.4%) 
(LD-); p = 0.013), dihydropyridine calcium channel blockers [55 (42.0%) (LD+) vs 
853 (32.1%) (LD-); p = 0.019], diltiazem [19 (14.5%) (LD+) vs 170 (6.4%) (LD-); p 
< 0.001); beta blockers [64 (48.9%) (LD+) vs 982 (37.0%) (LD-); p = 0.006] or 
nitrates [52 (39.7%) (LD) vs 532 (20.0%) (LD-); p < 0.001] (table 3.35).  
 
T2DM patients treated with insulin were more likely to require treatment with an 
index loop diuretic after their index insulin prescription if the latter was introduced 
on a background of thiazide diuretics [46 (27.1%) (LD+) vs 237 (19.9%) (LD-); p = 
0.031], diltiazem [25 (14.7%) (LD+) vs 115 (9.7%) (LD-); p = 0.043], alpha 
adrenoceptor blocking drugs [22 (12.9%) (LD+) vs 75 (6.3) (LD-); p = 0.002], 
angiotensin II receptor antagonists [16 (9.4%) (LD+) vs 58 (4.9%) (LD-); p = 0.015] 
or nitrates [60 (35.3%) (LD+) vs 280 (23.5%) (LD-); p = 0.001] (table 3.35). 
 
Likewise, a comparison of background drug prescription among individuals 
developing incident heart failure (HF+), and those remaining heart failure  free (HF-) 
within one year of inclusion into each of the three treatment cohorts yielded 
provocative but preliminary results (data not shown), as interpretation was limited in 
by small numbers of patients being prescribed less commonly used drugs, especially 
in the context of a relatively infrequent adverse event of interest (HF). Thus, patients 
285 
 
 
developing incident HF within one year of their index thiazolidinedione prescription 
were more likely to have had their oral glucose lowering agent introduced against a 
background of verapamil [4 (14.3%) (HF+) vs 34 (1.3%) (HF-); p = 0.001], 
diltiazem [7 (25.0%) (HF+) vs 206 (8.2%) (HF-); p = 0.007], beta blockers [18 
(64.3%) (HF+) vs 1084 (43.0%) (HF-); p = 0.024], and nitrates [16 (57.1%) (HF+) 
vs 548 (21.7%) (HF-); p < 0.001]. Analyzing for metformin-sulphonylurea 
combination therapy, patients were more likely to be diagnosed with new-onset HF 
if their glucose lowering therapy was prescribed while on potassium sparing 
diuretics/aldosterone antagonists [8 (16.3%) (HF+) vs 148 (4.3%) (HF-); p = 0.001], 
beta blockers [28 (57.1%) (HF+] vs 1402 (40.9%) (HF-); p = 0.022] or nitrates [25 
(51.0%) (HF+) vs 831 (24.2%) (HF-); p <0 .001]. Patients whose insulin therapy was 
commenced while on potassium sparing diuretics/aldosterone antagonists [10 
(15.9%) (HF+) vs 99 (5.7%) (HF-); p = 0.003], non-steroidal anti-inflammatory 
drugs [50 (79.4%) (HF+) vs 1148 (65.5%) (HF-); p = 0.023], dihydropyridine 
calcium channel blockers [34 (54.0%) (HF+) vs 673 (38.4%); p = 0.013], diltiazem 
[18 (28.6%) (HF+) vs 213 (12.2%) (HF-); p < 0.001], angiotensin converting 
enzyme inhibitors [33 (55.6%) (HF+) vs 725 (41.4%) (HF-); p = 0.025] or nitrates 
[36 (57.1%) (HF+) vs 495 (28.3%) (HF-); p < 0.001] were more likely to progress to 
incident HF within one year. Baseline angiotensin II receptor antagonists were only 
marginally significant [9 (14.3%) (HF+) vs 128 (7.3%) (HF-); p = 0.050). 
Associations with potassium sparing diuretics/aldosterone antagonists, angiotensin 
converting enzyme inhibitors, angiotensin II receptor antagonists and nitrates suggest 
a priori coronary artery disease, its risk factors (including hypertension) and its 
consequence of interest (namely HF), and are consistent with results reported earlier. 
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As expected, patients developing incident HF within one year of inclusion into either 
of the three cohorts were more likely to have had their glucose modulating drug 
introduced against a background of loop diuretic therapy [28 (57.1%) (HF+) vs 694 
(20.3%) (HF-), p < 0.001 for metformin-sulphonylurea-treated patients;  40 (63.5%) 
(HF+) vs 485 (27.7%) (HF-), p < 0.001 for insulin-treated patients; 15 (53.6%) 
(HF+) vs 455 (18.0%) (HF-), p < 0.001 for thiazolidinedione-treated patients] (data 
not shown). 
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Table 3.34 - Comparison of the relative frequency [n (%)] of background and post-treatment drug history among patients treated with 
metformin-sulphonylurea combination, insulin or thiazolidinedione therapy for a minimum of three months. 
 
 
Metformin-
sulphonylourea cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin cohort 
vs TZD cohort 
b 
 
       
Background p. 
vasodilators  130 (4.7) 80 (5.9) 67 (3.2) 0.001 0.095 0.010 < 0.001 
 
       
Post-treatment p. 
vasodilators 58 (2.1) 54 (4.0) 22 (1.0) < 0.001 < 0.001 0.005 < 0.001 
 
       
Background  
thiazide diuretics 783 (28.1) 283 (20.1) 751 (35.8) < 0.001 < 0.001 < 0.001 < 0.001 
 
       
Post-treatment 
thiazide diuretics 757 (27.2) 412 (30.3) 631 (30.1) 0.035 0.038 0.026 0.910 
 
       
Background K 
diuretics / 
aldosterone antag. 
45 (1.6) 28 (2.1) 26 (1.2) 0.168 0.310 0.277 0.058 
 
       
Post-treatment  K 
diuretics / 
aldosterone antag. 
112 (4.0) 164 (12.0) 61 (2.9) < 0.001 < 0.001 0.037 < 0.001 
K diuretics /aldosterone antag., potassiunm sparing diuretics /aldosterone antagonists; p. vasod5.ilators, peripheral vasodilators;; a two-tailed p value (Chi Square test), b 
two-tailed p value (Chi Square  test). Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha lelves of 0.0167 per test (0.05/3) 
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Metformin-
sulphonylourea cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin cohort 
vs TZD cohort 
b 
 
       
Background  
NSAIDs 1839 (66.0) 850 (62.5) 1463 (69.8) < 0.001 0.023 0.006 < 0.001 
 
       
Post-treatment  
NSAIDs 892 (32.0) 640 (47.0) 655 (31.2) < 0.001 < 0.001 0.555 < 0.001 
 
       
Background  
dihydropyridine 
CCBs 
908 (32.6) 423 (31.1) 742 (35.4) 0.021 0.324 0.042 0.009 
 
       
Post-treatment 
dihydropyridine 
CCBs 
1047 (37.6) 628 (46.1) 732 (34.9) < 0.001 < 0.001 0.053 < 0.001 
 
       
Background 
verapamil 30 (1.1) 18 (1.3) 26 (1.2) 0.760 0.488 0.597 0.832 
 
       
Post-treatment 
verapamil 19 (0.7) 18 (1.3) 13 (0.6) 0.049 0.040 0.789 0.032 
 
       
Background 
diltiazem 189 (6.8) 140 (10.3) 137 (6.5) < 0.001 < 0.001 0.726 < 0.001 
dihydropyridine CCBs, dihydropyridine calcium channel blockers; NSAIDs, non-steroidal anti-inflamnatory drugs; a two-tailed p value (Chi Square test), b two-tailed p value 
(Chi Square test). Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3) 
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Metformin-
sulphonylourea cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin cohort 
vs TZD cohort 
b 
Post-treatment 
diltiazem 175 (6.3) 151 (11.1) 89 (4.2) < 0.001 < 0.001 0.002 < 0.001 
 
       
Background beta 
blockers 1046 (37.6) 479 (35.2) 841 (40.1) 0.013 0.138 0.070 0.004 
 
       
Post-treatment beta 
blockers 895 (32.1) 591 (43.4) 663 (31.6) < 0.001 
a
 < 0.001 b 0.700 b < 0.001 b 
 
       
Background 
vasodilator drugs 15 (0.5) 9 (0.7) 10 (0.5) 0.770
 a
 0.625 b 0.765 b 0.474 b 
 
       
Post-treatment 
vasodilator drugs 4 (0.1) 13 (1.0) 1 (0.0) < 0.001
 a
 < 0.001 b 0.399 c < 0.001 b 
 
       
Background 
centrally acting 
antiht 
24 (0.9) 9 (0.7) 26 (1.2) 0.190 a 0.495 b 0.194 b 0.097 b 
 
       
Post-treatment 
centrally acting 
antiht 
31 (1.1) 21 (1.5) 18 (0.9) 0.174 a 0.243 b 0.377 b 0.063 b 
centrally acting antiht, centrally acting antihypertensive drugs; vasodilator drugs, vasodilator antihypertensive drugs; a two-tailed p value (Chi Square test), b two-tailed p 
value (Chi Square test). Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3); c two-tailed p value (Fisher’s 
exact test). Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3) 
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Metformin-
sulphonylourea cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b, c
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b, c 
 
p value for 
insulin cohort 
vs TZD cohort 
b, c 
 
       
Background  
anbd 4 (0.1) 3 (0.2) 5 (0.2) 0.729
 a
 0.690 c 0.511 c 1.000 c 
 
       
Post-treatment  
anbd 2 (0.1) 0 (0) 0 (0) 0.289 
a
 1.000 c 0.510 c - 
 
       
Background  
aabd 180 (6.5) 97 (7.1) 186 (8.9) 0.006
 a
 0.421 b 0.002 b 0.068 b 
 
       
Post-treatment 
 aabd 290 (10.4) 247 (18.1) 197 (9.4) < 0.001
 a
 < 0.001 b 0.240 b < 0.001 b 
 
       
Background  
ACEI 1040 (37.3) 491 (36.1) 1151 (54.9) < 0.001 0.427 < 0.001 < 0.001 
 
       
Post-treatment 
ACEI 1438 (51.6) 916 (67.3) 1179 (56.2) < 0.001 < 0.001 0.001 < 0.001 
 
       
Background  
ARB 226 (8.1) 74 (5.4) 313 (14.9) < 0.001 0.002 < 0.001 < 0.001 
ACEI, angiotensin convering enzyme inhibitors; anbd, adrenergic neurone blocking drugs; aabd, alpha adrenoceptor blocking drugs; ARB, angiotensin II receptor 
antagonists;  a two-tailed p value (Chi Square test), b two-tailed p value (Chi Square test). Tests of the three a priori hypotheses were conducted using Bonferroni adjusted 
alpha levels of 0.0167 per test (0.05/3); c two-tailed p value (Fisher’s exact test). Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels 
of 0.0167 per test (0.05/3) 
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Metformin-
sulphonylourea cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin cohort 
vs TZD cohort 
b 
Post-treatment  
ARB 391 (14.0) 272 (20.0) 423 (20.2) < 0.001 < 0.001 < 0.001 0.894 
 
       
Background renin 
inhibitors 0 (0) 0 (0) 0 (0) - - - - 
 
       
Post-treatment 
renin inhibitors 0 (0) 0 (0) 0 (0) - - - - 
 
       
Background  
nitrates 584 (21.0) 340 (25.0) 392 (18.7) < 0.001 0.004 0.049 < 0.001 
 
       
Post-treatment 
nitrates 558 (20.0) 455 (33.4) 336 (16.0) < 0.001 < 0.001 < 0.001 < 0.001 
 
       
Background other 
anti-anginal drugs 51 (1.8) 45 (3.3) 46 (2.2) 0.011 0.003 0.369 0.046 
 
       
Post-treatment other 
anti-anginal drugs 98 (3.5) 126 (9.3) 53 (2.5) < 0.001 < 0.001 0.048 < 0.001 
 
       
Background  
nitrates 584 (21.0) 340 (25.0) 392 (18.7) < 0.001 0.004 0.049 < 0.001 
ARB, angiotensin II receptor antagonists; a two-tailed p value (Chi Square test), b two-tailed p value (Ch Square test). Tests of the three a priori hypotheses were conducted 
using Bonferroni adjusted alpha levels of 0.0167 per test (0.05/3) 
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Metformin-
sulphonylourea cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b
 
 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
 
p value for 
insulin cohort 
vs TZD cohort 
b 
 
       
Post-treatment 
nitrates 558 (20.0) 455 (33.4) 336 (16.0) < 0.001 < 0.001 < 0.001 < 0.001 
 
       
Background other 
antianginal drugs 51 (1.8) 45 (3.3) 46 (2.2) 0.011 0.003 0.369 0.046 
 
       
Post-treatment other 
anti-anginal drugs 98 (3.5) 126 (9.3) 53 (2.5) < 0.001 < 0.001 0.048 < 0.001 
a
 two-tailed p value (Chi Square test), b two-tailed p value (Chi Square test). Tests of the three a priori hypotheses were conducted using Bonferroni adjusted alpha levels of 
0.0167 per test (0.05/3) 
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Table 3.35 - Comparison of the relative frequency (n [%]) oprescription of background drug therapy between individuals requiring treatment with loop 
diuretics and those remaining loop diuretic-free within one year after exposure to metformin-sulphonylurea combination, insulin or thiazolidinedione 
therapy for a minimum of three months, and having no background loop diuretic therapy at inclusion into their respective cohort. 
 
  
Metformin-sulphonylurea cohort 
 
Insulin cohort 
 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b 
 
 
Loop diuretic 
-treated 
 
N = 170 
 
 
Loop diuretic  
 -free 
 
N = 1191 
 
 
p a, b 
 
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop diuretic  
-free 
 
N = 2007 
 
 
p a, b 
 
Background p. 
vasodilators 12 (9.2) 118 (4.4) 0.013
 a
 15 (8.8) 65 (5.5) 0.081 a 3 (3.3) 64 (3.2) 0.763 b 
 
         
Post-treatment p. 
vasodilators 6 (4.6) 52 (2.0) 0.053
 b
 7 (4.1) 47 (3.9) 0.915 a 2 (2.2) 20 (1.0) 0.243 b 
 
         
Background 
thiazide diuretics 36 (27.5) 747 (28.1) 0.869
 a
 46 (27.1) 237 (19.9) 0.031 a 41 (45.6) 710 (35.4) 0.049 a 
 
         
Post-treatment 
thiazide diuretics 33 (25.2) 724 (27.3) 0.600 
a
 47 (27.6) 365 (30.6) 0.426 a 32 (35.6) 599 (29.8) 0.248 a 
 
         
Background K 
diuretics / 
aldosterone antag. 
2 (1.5) 43 (1.6) 1.000 b 6 (3.5) 22 (1.8) 0.149 b 3 (3.3) 23 (1.1) 0.098 b 
K diuretics/aldosterone antag., potassium sparing diuretics/aldosterone antagonists ; p. vasodilators, peripheral vasodilators ;   a two-sided p value for the statistical 
difference between loop diuretic-treated and loop diuretic-  free patients (Chi Square test); btwo-sided p value for the statistical difference between loop diuretic-treated and 
loop diuretic-  free patients (Fisher’s exact test) 
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Metformin-sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b 
 
 
Loop diuretic  
-treated 
 
N = 170 
 
Loop diuretic  
-free 
 
N = 1191 
 
p a, b 
  
 
Loop diuretic 
-treated 
 
N = 90 
 
Loop diuretic  
-free 
 
N = 2007 
 
p a, b 
 
Post-treatment  K 
diuretics / 
aldosterone antag. 
17 (13.0) 95 (3.6) < 0.001 a 56 (32.9) 108 (9.1) < 0.001 a 13 (4.4) 48 (2.4) < 0.001 b 
 
         
Background 
NSAIDs 91 (69.5) 1748 (65.9) 0.395 
a
 111 (65.3) 739 (62.0) 0.414 a 64 (71.1) 1399 (69.7) 0.776 a 
 
         
Post-treatment 
NSAIDs 43 (32.8) 849 (32.0) 0.842 
a
 79 (46.5) 561 (47.1) 0.877 a 32 (35.6) 623 (31.0) 0.366 a 
 
         
Background 
dihydropyridine 
CCBs 
55 (42.0) 853 (32.1) 0.019 a 63 (37.1) 360 (30.2) 0.072 a 40 (44.4) 702 (35.0) 0.066 a 
 
         
Post-treatment 
dihydropyridine 
CCBs 
56 (42.7) 991 (37.3) 0.212 a 75 (44.1) 553 (46.4) 0.571 a 36 (40.0) 696 (34.7) 0.300 a 
 
         
Background 
verapamil 2 (1.5) 28 (1.1) 0.650 
b
 3 (1.8) 15 (1.3) 0.590 a 2 (2.2) 24 (1.2) 0.308 b 
dihydropyridine CCBs, dihydopyridine calcium channel blockers; K diuretics / aldosterone antag., potassium sparing diuretics /  aldosterone antagonists; NSAIDs, non-steroidal anti-
inflammatory drugs; a  two-sided p value for the statistical difference between loop diuretic- treated and loop diuretic-free patients (Chi Square test); b two-sided p value for the statistical 
difference between loop diuretic-treated and loop diuretic-free patients (Fisher’s exact test) 
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Metformin-sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b 
 
 
Loop diuretic-
treated 
 
N = 170 
 
 
Loop diuretic  
 -free 
 
N = 1191 
 
 
p a, b 
 
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop diuretic  
-free 
 
N = 2007 
 
 
p a, b 
 
Post-treatment  
verapamil 1 (0.8) 18 (0.7) 0.601
 b
 5 (2.9) 13 (1.1) 0.063 b 2 (2.2) 11 (0.5) 0.105 b 
 
         
Background 
diltiazem 19 (14.5) 170 (6.4) < 0.001
a
 25 (14.7) 115 (9.7) 0.043 a 8 (9.9) 129 (6.4) 0.355 a 
 
         
Post-treatment 
diltiazem 22 (16.8) 153 (5.8) < 0.001 
a
 28 (16.5) 123 (10.3) 0.017 a 6 (6.7) 83 (4.1) 0.275 b 
 
         
Background beta 
blockers 64 (48.9) 982 (37.0) 0.006 
a
 71 (41.8) 408 (34.3) 0.055 a 34 (37.8) 807 (40.2) 0.645 a 
 
         
Post-treatment beta 
blockers 49 (37.4) 846 (31.9) 0.186
 a
 94 (55.3) 497 (41.7) 0.001 a 37 (41.1) 626 (31.2) 0.048 a 
 
         
Background 
vasodilator drugs 1 (0.8) 14 (0.5) 0.515 
b
 0 (0) 9 (0.8) 0.612 b 1 (1.1) 9 (0.4) 0.356 b 
 
         
Post-treatment 
vasodilator drugs 0 (0) 4 (0.2) 1.000
 b
 3 (1.8) 10 (0.8) 0.215 b 0 (0) 1 (<0.1) 1.000 b 
vasodilator drugs, vasodilator antithypertensive drugs;   a two-sided p value for the statistical difference between loop diuretic- treated and loop diuretic-  free patients (Chi 
Square test); b two-sided p value for the statistical difference between loop diuretic-treated and loop diuretic-free patients (Fisher’s exact test) 
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Metformin-sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b 
 
 
Loop diuretic  
-treated 
 
N = 170 
 
 
Loop diuretic  
 -free 
 
N = 1191 
 
 
p a, b 
 
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop diuretic  
-free 
 
N = 2007 
 
 
p a, b 
 
Background 
centrally acting 
antiht  
3 (2.3) 21 (0.8) 0.100 b 1 (0.6) 8 (0.7) 1.000 b 2 (2.2) 24 (1.2) 0.308 b 
 
         
Post-treatment 
centrally acting 
antiht  
3 (2.3) 28 (1.1) 0.177 b 4 (2.4) 17 (1.4) 0.321 b 2 (2.2) 16 (0.8) 0.179 b 
 
         
Background  
anbd 0 (0) 4 (0.2) 1.000
 b
 1 (0.6) 2 (0.2) 0.330 b 1 (1.1) 4 (0.2) 0.197 b 
 
         
Post-treatment 
anbd 0 (0) 2 (0.1) 1.000 
b
 0 (0) 0 (0) - 0 (0) 0 (0) - 
 
         
Background  
aabd 11 (8.4) 169 (6.4) 0.356 
a
 22 (12.9) 75 (6.3) 0.002 a 10 (11.1) 176 (8.8) 0.445 a 
 
         
Post-treatment 
aabd 20 (15.3) 270 (10.2) 0.062
 a
 38 (22.4) 209 (17.5) 0.128 a 13 (14.4) 184 (9.2) 0.093 a 
aabd, alpha adrenoceptor blocking drugs; anbd, adrenergic neurone blocking drugs; centrally acting antiht, centrally acting antihypertensive drugs; a two-sided p value for 
the statistical difference between loop diuretic- treated and loop diuretic-  free patients (Chi Square test); b two-sided p value for the statistical difference between loop 
diuretic-treated and loop diuretic-free patients (Fisher’s exact test) 
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Metformin-sulphonylurea cohort 
 
Insulin cohort 
 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b 
 
 
Loop diuretic  
-treated 
 
N = 170 
 
 
Loop diuretic  
 -free 
 
N = 1191 
 
 
p a, b 
 
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop diuretic  
-free 
 
N = 2007 
 
 
p a, b 
 
Background  
ACEI 50 (38.2) 990 (37.3) 0.841 
a
 71 (41.8) 420 (35.3) 0.099 a 53 (58.9) 1098 (54.7) 0.436 a 
 
         
Post-treatment  
ACEI 75 (57.3) 1363 (51.4) 0.187
 a
 119 (70.0) 797 (66.9) 0.423 a 55 (61.1) 1124 (56.0) 0.339 a 
 
         
Background  
ARB 10 (7.6) 216 (8.1) 0.836
 a
 16 (9.4) 58 (4.9) 0.015 a 18 (20.0) 295 (14.7) 0.167 a 
 
         
Post-treatment  
ARB  24 (18.3) 367 (13.8) 0.148 39 (22.9) 233 (19.6) 0.303 25 (27.8) 398 (19.8) 0.066 
 
         
Background renin 
inhibitors 0 (0) 0 (0) - 0 (0) 0 (0) - 0 (0) 0 (0) - 
 
         
Post-treatment 
renin inhibitors 0 (0) 0 (0) - 0 (0) 0 (0) - 0 (0) 0 (0) - 
 
         
Background  
nitrates 52 (39.7) 532 (20.0) < 0.001 
a
 60 (35.3) 280 (23.5) 0.001 a 25 (27.8) 367 (18.3) 0.024 a 
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor antagonists; a two-sided p value for the statistical difference between loop diuretic-treated and loop diuretic-  free 
patients (Chi Square test); b two-sided p value for the statistical difference between loop diuretic-treated and loop diuretic-free patients (Fisher’s exact test 
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Metformin-sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
 
Loop diuretic  
-free 
 
N = 2654  
 
p a, b 
 
 
Loop diuretic  
-treated 
 
N = 170 
 
 
Loop diuretic 
  -free 
 
N = 1191 
 
 
p a, b 
 
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop diuretic  
-free 
 
N = 2007 
 
 
p a, b 
 
Post-treatment 
nitrates 51 (38.9) 507 (19.1) < 0.001
 a
 86 (50.6) 369 (31.0) < 0.001 a 25 (27.8) 311 (15.5) 0.002 a 
 
         
Background other 
anti-anginal drugs 0 (0) 51 (1.9) 0.173 
b
 7 (4.1) 38 (3.2) 0.527 a 2 (2.2) 44 (2.2) 1.000 b 
 
         
Post-treatment 
other anti-anginal 
drugs 
6 (4.6) 92 (3.5) 0.463 28 (16.5) 98 (8.2) 0.001 3 (3.3) 50 (2.5) 0.495 
a two-sided p value for the statistical difference between loop diuretic-treated and loop diuretic-free patients (Chi Square test); b two-sided p value for the statistical  
difference between loop diuretic-treated and loop diuretic-  free patients (Fisher’s exact test) 
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3.11.4 Clinical measurements 
 
Table 3.36 summarises clinical measurements for patients belonging to each of the 
three treatment cohorts, together with two-sided p values for trend across the cohorts, 
and post-hoc pairwise comparisons between the treatment groups. Table 3.37 
outlines mean (SD) values, and two-sided p values for the comparison between loop 
diuretic-treated and  -free patients belonging to each of the three treatment cohorts.  
 
Comparing with metformin-sulphonylurea-treated patients, patients prescribed an 
index thiazolidinedione were characterised by lower baseline mean arterial pressure 
[99.32 (9.77) vs 100.29 (9.48) mmHg; p = 0.001], lower baseline systolic blood 
pressure [139.65 (12.92) vs 141.23 (15.70) mmHg; p = 0.001], lower baseline DBP 
[79.17 (7.92) vs 79.81 (8.64) mmHg; p = 0.032], higher baseline weight [88.97 
(17.54) vs 84.67 (16.84) kg; p < 0.001], and higher baseline BMI [31.29 (5.37) vs 
30.19 (5.32) kg/m2 ; p < 0.001] (table 3.36). Higher baseline values for weight and 
BMI among patients treated with a second or third line thiazolidinedione may reflect 
the ‘end-effect’ of several months/years of antecedent (first or second line) 
sulphonylurea therapy, with their characteristic insulinotropic, weight promoting, 
effect. 
 
Likewise, comparing thiazolidinedione with insulin-treated patients, the former were 
characterised by significantly lower baseline systolic blood pressure [139.65 (12.92) 
vs 141.26 (16.10) mmHg; p = 0.011], higher baseline weight [88.97 (17.54) vs 79.06 
(16.51) kg; p < 0.001] and higher baseline BMI [31.29 (5.37) vs 28.43 (5.45) kg/m2; 
p < 0.001] (table 3.36). 
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Index loop diuretic prescribed thiazolidinedione-treated patients were characterised 
by a significantly higher mean baseline BMI [33.11 (6.54) (LD+) vs 31.21 (5.31) 
(LD-) kg/m2; p = 0.002] compared with their index loop diuretic-free counterparts, 
despite no differences in baseline body weight (table 3.37). BMI is now established 
as a more precise marker of obesity than body weight. There were no differences in 
baseline mean arterial pressure and DBP between the two index loop diuretic 
categories. Mean baseline systolic blood pressure tended to be higher in index loop 
diuretic-treated patients – with the difference reaching borderline statistical 
significance [142.35 (13.91) (LD+) vs 139.53 (12.8) (LD); p = 0.048].  
 
Similar observations were reported for baseline mean arterial pressure, DBP and 
weight among patients on metformin-suphonylurea combination therapy and insulin 
(without TZD) respectively (table 3.37). Differences in baseline BMI reached 
statistical significance in either cohort. Baseline systolic blood pressure was 
significantly higher in loop diuretic prescibed insulin-treated patients; differences in 
systolic blood pressure did not reach statistical significance in patients on 
metformin-sulphonylurea combination therapy. Thus index loop diuretic requiring 
metformin-sulphonylurea-treated patients were characterised by a higher baseline 
BMI [31.50 (6.07) vs 30.13 (5.28) kg/m2; p = 0.012]. Likewise, insulin-treated 
patients characterised by a higher baseline systolic blood pressure [145.07 (16.17) vs 
140.73 (16.03) mmHg; p = 0.003] and higher baseline BMI [29.46 (5.60) vs 28.29 
(5.42) kg/m2; p = 0.014] were more prone to ‘oedema’ after index insulin 
prescription. 
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Analyzing separately for incident HF events occurring within one year of inclusion 
into each of the three treatment cohorts yielded no statistical difference in mean 
baseline systolic blood pressure or baseline body mass index between incident HF 
subgroups, albeit significantly lower baseline DBP readings for HF prone insulin-
treated patients [75.22 (8.70) HF + vs 79.01 (8.78) HF – mmHg; p = 0.001] (data not 
reproduced in table format).  
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Table 3.36 - Comparison of mean (SD) values for background and post-treatment clinical measurements among patients treated with 
metformin-sulphonylurea combination, insulin or thiazolidinedione therapy for a minimum of three months, and no background loop 
diuretic therapy. 
 
  
Metformin-
sulphonylourea 
cohort 
 
N = 2785 
(1634 males, 
1151 females) 
 
 
Insulin 
cohort 
 
N = 1361 
(744 males, 
617 females) 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
(1264 males, 
833 females) 
 
 
p value for 
the 
difference 
across the 
three cohorts 
a 
 
 
p value for  
metformin-
sulphonylur
ea cohort  vs 
insulin 
cohort b 
 
p value for 
metformin-
sulphonylur
ea cohort vs 
TZD cohort 
b 
 
p value for 
insulin 
cohort vs 
TZD cohort 
b 
 
       
Baseline MAP 
(mmHg) 100.29 (9.48) 99.83 (9.55) 99.32 (9.77) 0.003 0.381
c
 0.001c 0.303c 
        
Post-treatment MAP 
(mmHg) 99.37 (9.36) 98.61 (9.89) 97.08 (8.22) < 0.001 0.082
c
 < 0.001c < 0.001c 
        
Baseline SBP 
(mmHg) 141.23 (15.70) 141.26 (16.10) 139.65 (12.92) 0.001 0.999
c
 0.001c 0.011c 
 
       
Post treatment SBP 
(mmHg) 140.51 (15.38) 140.68 (16.21) 137.82 (13.34) < 0.001 0.952
c
 < 0.001c < 0.001c 
 
       
Baseline DBP 
(mmHg) 79.81 (8.64) 79.11 (8.53) 79.17 (7.92) 0.016 0.062
c
 0.032c 0.979c 
MAP, mean arterial pressure; SBP, mean systolic blood pressure; a two-tailed p value [One-way analysis of variance (ANOVA)]; b two-tailed p value (pair-wise post-hoc 
analysis). Tests of these three a priori hypotheses were conducted using the Games-Howell test c  
 
303 
 
 
 
  
Metformin-
sulphonylourea 
cohort 
 
N = 2785 
(1634 males, 
1151 females) 
 
 
Insulin 
cohort 
 
N = 1361 
(744 males, 
617 females) 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
(1264 males, 
833 females) 
 
 
p value for 
the 
difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylur
ea cohort  vs 
insulin 
cohort b 
 
p value for 
metformin-
sulphonylur
ea cohort vs 
TZD cohort 
b 
 
p value for 
insulin 
cohort vs 
TZD cohort 
b 
 
       
Post treatment DBP 
(mmHg) 78.80 (8.67) 77.57 (8.89) 76.71 (8.02) < 0.001 < 0.001
c
 < 0.001c 0.020c 
 
       
Baseline weight  
(kg)  84.67 (16.84) 79.06 (16.51) 88.97 (17.54) < 0.001
e
 < 0.001c, e < 0.001c, e < 0.001c, e 
 
       
Post treatment 
weight (kg) 84.42 (17.15) 81.40 (16.38) 90.04 (17.57) < 0.001 < 0.001
c
 < 0.001c < 0.001c 
 
       
Baseline BMI  
(kg/m2) 30.19 (5.32) 28.43 (5.45) 31.29 (5.37) < 0.001 < 0.001
d
 < 0.001d < 0.001d 
 
       
Post treatment BMI 
(kg/m2) 30.15 (5.42) 29.27 (5.43) 31.73 (5.42) < 0.001 < 0.001
d
 < 0.001d < 0.001d 
BMI, body mass index; DBP, diastolic blood pressure; a two-tailed p value [One-way analysis of variance (ANOVA)]; b two-tailed p value (pair-wise post-hoc analysis). 
Tests of these three a priori hypotheses were conducted using the Games-Howell test c and the Tukey-HSD test d; edifferences calculated on loge transformed data 
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Table 3.37 - Comparison of mean (SD) values for clinical measurements between individuals requiring treatment with loop diuretics and 
those remaining loop diuretic-free within one year after exposure to metformin-sulphonylurea combination, insulin or thiazolidinedione 
therapy for a minimum of three months. 
 
 
 
Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic-
treated 
 
N = 131 
 
 
Loop diuretic  
-free 
 
N = 2654 
 
 
pa,b 
 
 
Loop diuretic- 
treated 
 
N = 170 
 
 
Loop diuretic-  
free 
 
N = 1191 
 
 
pa, b 
 
 
Loop diuretic- 
treated 
 
N = 90 
 
 
Loop diuretic-  
free 
 
N = 2007 
 
 
pa, b 
 
Baseline MAP 
(mmHg) 100.98 (9.66) 100.26 (9.48) 0.468
a
 100.71 (9.88) 99.71 (9.50) 0.249a 99.53 (8.38) 99.33 (8.00) 0.819a 
 
         
Post-treatment MAP 
(mmHg) 100.30 (10.04) 99.32 (9.33) 0.304
a
 98.20 (12.07) 98.67 (9.54) 0.611b 96.22 (8.07) 97.12 (8.23) 0.334a 
 
         
Baseline SBP  
(mmHg) 144.33 (15.96) 141.00 (15.68) 0.051
a
 145.07 (16.17) 140.73 (16.03) 0.003a 142.35 (13.91) 139.53 (12.86) 0.048a 
 
         
Post treatment SBP 
(mmHg) 144.30 (17.04) 140.33 (15.28) 0.011
a
 141.73 (18.90) 140.53 (15.79) 0.278b 138.29 (14.22) 137.80 (13.30) 0.745a 
 
         
Baseline DBP 
(mmHg) 79.31 (8.81) 79.83 (8.63) 0.563
a
 78.52 (8.80) 79.20 (8.49) 0.381a 78.12 (7.86) 79.22 (7.92) 0.205a 
 
         
Post treatment DBP 
(mmHg) 78.30 (8.77) 78.82 (8.67) 0.552
a
 76.43 (10.95) 77.74 (8.55) 0.075b 75.18 (7.66) 76.78 (8.03) 0.079a 
DBP, mean diastolic blood pressure; MAP, mean arterial pressure; SBP, mean systolic blood pressure; a  two-sided p value for the difference between loop diuretic- treated 
and loop diuretic-  free patients (one-way ANOVA); btwo-sided p value for the difference between loop diuretic-treated and loop diuretic-  free patients (Mann-Whtney U test) 
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Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic-
treated 
 
N = 131 
 
 
Loop diuretic-  
free 
 
N = 2654 
 
 
pa 
 
 
Loop diuretic- 
treated 
 
N = 170 
 
 
Loop diuretic-  
free 
 
N = 1191 
 
 
pa 
 
 
Loop diuretic- 
treated 
 
N = 90 
 
 
Loop diuretic-  
free 
 
N = 2007 
 
 
pa 
 
Baseline weight  
(kg)  85.37 (17.49) 84.64 (16.81) 0.669 81.15 (16.21) 78.77 (16.54) 0.100 91.01 (19.81) 88.88 (17.44) 0.278 
          
Post treatment 
weight (kg) 88.63 (18.76) 84.22 (17.06) 0.013 83.46 (17.31) 81.11 (16.23) 0.098 93.55 (19.44) 89.88 (17.47) 0.073 
          
Baseline BMI  
(kg/m2) 31.50 (6.07) 30.13 (5.28) 0.012 29.46 (5.60) 28.29 (5.42) 0.014 33.11 (6.54) 31.21 (5.31) 0.002 
 
         
Post treatment BMI 
(kg/m2) 32.39 (6.06) 30.05 (5.37) <0.001 30.56 (6.25) 29.09 (5.30) 0.002 34.27 (6.61) 31.61 (5.33) <0.001 
BMI, mean body mass index; ; a  two-sided p value for the difference between loop diuretic-treated and loop diuretic-free patients (one-way ANOVA) 
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3.11.5 Haematology and biochemistry 
 
Inspection of baseline haematocrit, biochemistry profile and thyrotropin 
concentrations across the metformin-sulphonylurea, insulin and thiazolidinedione 
cohorts yielded unexpected findings. Patients requiring an index thiazolidinedione 
prescription were characterised by lower baseline total cholesterol [4.46 (0.93) vs 
4.84 (1.18) mmol/L; p < 0.001], lower baseline low density lipoprotein cholesterol 
(LDL-C) [2.29 (0.90) vs 2.50 (1.04) mmol/L; p < 0.001], higher baseline serum 
sodium [136.68 (2.73) vs 138.39 (2.86) mmol/L; p = 0.001], higher baseline 
estimated glomerular filtration rate [96.40 (35.91) vs 91.54 (36.13) mls/min/1.73 m2; 
p < 0.001], and a higher baseline serum albumin [44.00 (2.88) vs 43.51 (3.55) g/L; p 
< 0.001] (table 3.38) compared with their metformin-sulphonylurea-treated 
counterparts. Higher baseline values for estimated glomerular filtration rate and 
serum albumin for thiazolidinedione-treated patients are perhaps rather surprising, 
but could stem from an a priori tendency to avoid metformin and/or sulphonylureas 
in patients with impaired renal and/or  liver function, shifting mean (SD) values for 
these variables. Lower baseline serum total cholesterol concentrations at index 
thiazolidinedione prescription could perhaps reflect a metformin-associated benefical 
effect on lipid status, as reported in a meta-analysis by Wulffele et al [607].  
 
Comparing thiazolidinedione and insulin-treated patients, the former were 
characterised by a higher baseline haematocrit [42.26 (3.68) vs 40.22 (4.59) %; p < 
0.001], a lower baseline HbA1c [8.89 (1.37) vs 9.67 (1.82) %; p < 0.001], lower 
baseline total cholesterol [4.46 (0.93) vs 4.94 (1.21) mmol/L; p < 0.001], lower 
baseline LDL-C [2.29 (0.90) vs 2.60 (1.01) mmol/L; p < 0.001], higher baseline 
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alanine aminotransferase (ALT) [33.51 (19.56) vs 31.84 (24.66); p < 0.001], higher 
baseline serum sodium [138.68 (2.73) vs 137.32 (3.18); p < 0.001], higher baseline 
estimated glomerular filtration rate (eGFR) [96.40 (35.91) vs 79.39 (31.11) 
mls/min/1.73 m2; p < 0.001], higher baseline TSH [2.03 (1.33) vs 1.99 (1.45) mIU/L; 
p = 0.017], higher baseline serum albumin [44.00 (2.88) vs 41.53 (4.81) g/dL; p < 
0.001] and a lower baseline serum creatinine [88.16 (20.70) vs 94.83 (33.57); p < 
0.001] (table 3.38). Lower baseline values for serum haematocrit for insulin-treated 
patients could stem from a tendency to switch patients from thiazolidinediones to 
insulin therapy in the face of fluid overload. It is perhaps not entirely surprising that 
patients prescribed insulin therapy are prone to poorer renal function at baseline – 
probably reflecting the gradual deterioration characteristic of patients with poorly 
controlled T2DM (higher HbA1c, total cholesterol and LDL-C concentrations). 
Given the reported association between ALT and visceral fat accumulation, higher 
baseline ALT for thiazolidinedione-treated patients could stem from a tendency to 
prescribe these ‘third line’ insulin sensitizers in patients with surrogate markers of 
insulin resistance. As a corollary, a lower mean baseline ALT in insulin-treated 
T2DM patients could reflect the ‘end result’ of thiazolidinedione prescription in 
patients moving on to ‘fourth line’ insulin therapy. 
 
As outlined in table 3.39, patients requiring an index loop diuretic within one year of 
index thiazolidinedione therapy were characterised by significantly lower baseline 
values for serum albumin [42.54 (3.69) (LD+) vs 44.06 (2.82) (LD-) g/dL; p < 
0.001] and estimated glomerular filtration rates [67.65 (21.21) (LD+) vs 76.61 
(19.03) (LD-) mls/min/1.73m2; p < 0.001] despite no differences in baseline serum 
creatinine [93.80 (28.18) (LD+) vs 87.93 (20.30) (LD-) μmol/L; p = 0.152]. This is 
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consistent with the observation of lower haematocrit values (a surrogate measure of 
haemodilution, and hence fluid balance) for such patients [40.93 (4.26) (LD+) vs 
42.32 (3.64) (LD-) %; p = 0.001]. Index loop diuretic-treated TZD patients had 
lower baseline ALT values than their loop diuretic-free counterparts [28.60 (16.07) 
(LD+) vs 33.72 (19.67) IU/L (LD-); p = 0.003]. Given the reported association 
between prevalent ALT and visceral fat accumulation, this observation surprisingly 
seems to suggest that insulin sensitivity is a predisposing factor to thiazolidinedione-
associated fliud retention. There were no differences in baseline HbA1c, sodium, 
total cholesterol (and its lipoprotein fractions), triglycerides and TSH (albeit a trend 
towards higher TSH values for loop diuretic-treated patients [2.37 (1.52) (LD+] vs 
2.01 (1.32) (LD-) mIU/L; p = 0.054] (table 3.39). Indeed, subclinical hypothyroidism 
has been associated with increased capillary permeability to protein in a small 
clinical study of nine female patients [608]. Whether this association holds true for 
TSH values within the reference range remains to be determined. 
 
Analyzing for patients both control cohorts, loop diuretic-treated patients were 
likewise characterised by a lower baseline haematocrit, estimated glomerular 
filtration rate and serum albumin and a significantly higher serum creatinine than 
their loop diuretic-free counterparts (table 3.39). There were no differences in 
baseline lipid profile and thyrotropin concentrations for either cohort. Insulin-treated 
patients requiring an index loop diuretic were characterised by better glycaemic 
control (lower HbA1c). Individuals treated with an index loop diuretic after index 
metformin-sulphonylourea combination therapy were uniquely characterised by a 
lower baseline serum sodium concentration, suggesting a role for altered sodium 
haemodynamics in such patients at a relatively early stage of T2DM. An alteration in 
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the prevalent sodium milieu in ‘oedema prone’ patients could be masked by other 
(stronger) contributory factors in thiazolidinedione and insulin-treated patients 
whose T2DM is more likely to be complicated by macrovascular and microvascular 
disease
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Table 3.38 - Comparison of mean (SD) values for heamatology and biochemistry results of patients treated with metformin-sulphonylurea 
combination, insulin and thiazolidinedione therapy for at least three months, and having no background loop diuretic therapy at inclusion 
into their respective cohort. 
 
Metformin-
sulphonylourea 
cohort 
 
N = 2785 
 
Insulin 
cohort 
 
N = 1361 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
p value for 
the 
difference 
across the 
three 
cohortsa 
p value for  
metformin-
sulphonylurea 
cohort  vs 
insulin cohort 
b 
p value for 
metformin-
sulphonylurea 
cohort vs TZD 
cohort 
b 
p value for 
insulin 
cohort vs 
TZD cohort 
b 
Baseline haematocrit 
(%) 42.10 (3.95) 40.22 (4.59) 42.26 (3.68) < 0.001 < 0.001
c
 0.398 c < 0.001 c 
        
Post-treatment 
haematocrit (%) 40.93 (4.40) 40.46 (4.67) 40.56 (4.32) 0.006 0.011
d
 0.040 d 0.812 d 
        
Baseline HbA1c  
(%) 8.91 (1.54) 9.67 (1.82) 8.89 (1.37) < 0.001
e
 < 0.001c, e 0.928c, e < 0.001c, e 
 
       
Post treatment HbA1c 
(%) 7.83 (1.47) 8.57 (1.55) 8.23 (1.47) < 0.001
e
 < 0.001c, e < 0.001c, e < 0.001c, e 
        
Baseline total 
cholesterol (mmol/L) 4.84 (1.18) 4.94 (1.21) 4.46 (0.93) < 0.001
e
 0.057c, e < 0.001c, e < 0.001c, e 
        
Post treatment total 
cholesterol (mmol/L) 4.70 (1.13) 4.87 (1.26) 4.61 (1.05) < 0.001
e
 0.001c, e 0.108c, e < 0.001c, e 
HbA1c, glycosylated haemoglobin; a two-tailed p value [one-way analysis of variance (ANOVA)]; b two-tailed p value (pair-wise post-hoc analysis). Tests of these three a 
priori hypotheses were conducted using the Games-Howell test c and the Tukey-HSD test d;  e differences calculated on loge transformed data 
311 
 
 
  
Metformin-
sulphonylourea 
cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the 
difference 
across the 
three 
cohorts 
a 
 
 
p value for  
metformin-
sulphonylur
ea cohort  vs 
insulin 
cohort b 
 
p value for 
metformin-
sulphonylur
ea cohort vs 
TZD cohort 
b 
 
p value for 
insulin 
cohort vs 
TZD cohort 
b 
 
       
Baseline HDL-C 
(mmol/L)  1.20 (0.33) 1.21 (0.36) 1.21 (0.31) 0.074 
e
 0.856 c, e 0.055 c, e 0.470 c, e 
 
       
Post treatment HDL-C 
(mmol/L) 1.21 (0.34) 1.30 (0.40) 1.29 (0.32) < 0.001 
e
 < 0.001 c, e < 0.001 c, e 0.485 c, e 
        
Baseline LDL-C  
(mmol/L) 2.50 (1.04) 2.60 (1.01) 2.29 (0.90) < 0.001
 f
 0.112 c, f < 0.001 c, f < 0.001 c, f 
 
       
Post treatment LDL-C 
(mmol/L) 2.37 (0.91) 2.44 (1.01) 2.15 (0.80) < 0.001 
f
 0.142 c, f < 0.001 c, f < 0.001 c, f 
        
Baseline triglycerides 
(mmol/L) 2.71 (1.83) 2.73 (1.83) 2.60 (1.67) 0.358 
e
 0.989 c, e 0.351 c, e 0.606 c, e 
        
Post-treatment 
triglycerides (mmol/L) 2.37 (1.55) 2.35 (1.63) 2.41 (1.60) 0.223 
e
 0.408 d, e 0.853 d, e 0.206 d, e 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; a two-tailed p value [one-way analysis of variance (ANOVA)]; b two-tailed p value 
(pair-wise post-hoc analysis). Tests of these three a priori hypotheses were conducted using the Games-Howell test c and the Tukey-HSD test d;  e differences calculated on 
loge transformed data;  f differences calculated on square root transformed data 
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Metformin-
sulphonylourea 
cohort 
 
N = 2785 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the 
difference 
across the 
three cohorts 
a 
 
 
p value for  
metformin-
sulphonylur
ea cohort  vs 
insulin 
cohort b 
 
 
p value for 
metformin-
sulphonylur
ea cohort vs 
TZD cohort 
b 
 
p value for 
insulin 
cohort vs 
TZD cohort 
b 
 
       
Baseline ALT  
(IU/L) 33.15 (20.68) 31.84 (24.66) 33.51 (19.56) < 0.001
e
 0.001 c, e 0.180 c, e < 0.001c, e 
        
Post treatment ALT 
(IU/L) 31.19 (21.94) 28.19 (22.08) 28.59 (16.97) < 0.001
e
 < 0.001 c, e 0.019 c, e 0.001c, e 
        
Baseline sodium 
(mmol/L) 138.39 (2.86) 137.32 (3.18) 138.68 (2.73) < 0.001 < 0.001
 c
 0.001 c < 0.001c 
 
       
Post treatment sodium 
(mmol/L) 138.96 (2.96) 138.45 (3.16) 139.25 (2.68) < 0.001 < 0.001
 c
 0.002 c < 0.001c 
        
Baseline eGFR 
(mls/min/1.72 m2) 91.54 (36.13) 79.39 (31.11) 96.40 (35.91) < 0.001
e
 < 0.001 c, e < 0.001 c, e < 0.001c, e 
        
Post treatment eGFR 
(mls/min/1.72 m2) 85.80 (34.38) 75.83 (30.82) 95.77 (36.42) < 0.001
e
 < 0.001 d, e < 0.001 d, e < 0.001d, e 
ALT, alanine aminotransferase;  eGFR, estimated glomerular filtration rate; a two-tailed p value [one-way analysis of variance (ANOVA)]; b two-tailed p value (pair-wise 
post-hoc analysis). Tests of these three a priori hypotheses were conducted using the Games-Howell test c and the Tukey-HSD test d;  e differences calculated on loge 
transformed data 
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Metformin-
sulphonylourea 
cohort 
 
N = 2785 
 
 
 
Insulin 
cohort 
 
N = 1361 
 
 
Thiazolidinedione 
(TZD) cohort 
 
N = 2097 
 
 
p value for 
the 
difference 
across the 
three cohorts 
a
 
 
p value for  
metformin-
sulphonylur
ea cohort  vs 
insulin 
cohort b 
 
p value for 
metformin-
sulphonylur
ea cohort vs 
TZD cohort 
b 
 
p value for 
insulin 
cohort vs 
TZD cohort 
b 
 
       
Baseline TSH  
(mIU/L) 2.00 (1.52) 1.99 (1.45) 2.03 (1.33) < 0.00 
e
 0.638 c,e 0.023 c,e 0.017 c,e 
 
       
Post treatment  
TSH (mIU/L) 2.18 (1.72) 2.08 (1.73) 2.15 (1.47) 0.015 
e
 0.029 d,e 0.428 d,e 0.004 d,e 
        
Baseline serum 
albumin (g/L) 43.51 (3.55) 41.53 (4.81) 44.00 (2.88) < 0.001
e
 < 0.001 c, e < 0.001 c, e < 0.001 c, e 
 
       
Post treatment serum 
albumin (g/L) 43.35 (3.52) 41.20 (4.24) 43.93 (2.86) < 0.001
e
 < 0.001 c, e < 0.001 c, e < 0.001 c, e 
        
Baseline serum 
creatinine (μmol/L) 87.00 (20.88) 94.83 (33.57) 88.16 (20.70) < 0.001
f
 < 0.001d, f 0.139 d, f < 0.001 d, f 
        
Post treatment serum 
creatinine  (μmol/L) 90.75 (27.74) 102.58 (41.94) 89.45 (24.69) < 0.001
 f
 < 0.001d, f 0.157 d, f < 0.001 d, f 
TSH, thyroid stimulating hormone; a two-tailed p value [one-way analysis of variance (ANOVA)]; b two-tailed p value (pair-wise post-hoc analysis). Tests of these three a 
priori hypotheses were conducted using the Games-Howell test c and the Tukey-HSD test d;  e differences calculated on square root 
 
transformed data;  f differences calculated 
on reciprocally transformed data 
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Table 3.39 - Comparison of mean (SD) values for blood investigations between individuals requiring treatment with loop diuretics and those 
remaining loop diuretic-free within one year after exposure to metformin-sulphonylurea combination, insulin or thiazolidinedione therapy 
for a minimum of three months. 
 
 
 
Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic 
-treated 
 
N = 131 
 
 
Loop 
diuretic-free 
 
N = 2654 
 
 
pa, b 
 
 
Loop diuretic 
-treated 
 
N = 170 
 
 
Loop 
diuretic-free 
 
N = 1191 
 
 
pa, b 
 
 
Loop diuretic 
-treated 
 
N = 90 
 
 
Loop 
diuretic-free 
 
N = 2007 
 
 
pa, b 
 
Baseline haematocrit  
(%) 41.21 (4.31) 42.14 (3.93) 0.037
a
 38.87 (5.21) 40.43 (4.45) 0.001a 40.93 (4.26) 42.32 (3.64) 0.001a 
          
Post-treatment 
haematocrit (%) 39.14 (5.03) 41.02 (4.34) <0.001
a
 38.62 (5.26) 40.74 (4.51) <0.001a 38.78 (4.73) 40.65 (4.28) <0.001a 
          
Baseline HbA1c  
(%) 8.82 (1.45) 8.91 (1.54) 0.563
a
 9.23 (1.91) 9.71 (1.80) 0.002a 8.78 (1.47) 8.90 (1.37) 0.432a 
 
         
Post treatment HbA1c  
(%) 7.95 (1.44) 7.82 (1.48) 0.333
a,c
 8.49 (1.69) 8.58 (1.53) 0.330a,c 8.06 (1.61) 8.24 (1.46) 0.180a,c 
          
Baseline total cholesterol 
(mmol/L) 4.85 (1.19) 4.84 (1.18) 0.936
a
 4.98 (1.36) 4.94 (1.19) 0.676a,c 4.38 (0.99) 4.46 (0.93) 0.419a 
          
Post treatment total 
cholesterol (mmol/L) 4.75 (1.23) 4.69 (1.12) 0.526
b
 4.79 (1.30) 4.89 (1.26) 0.314a,c 4.39 (1.03) 4.62 (1.05) 0.028a,c 
HbA1c, glycosylated haemoglobin; a two-tailed p value for the difference between loop diuretic-treated and loop diuretic-  free patients (one-way ANOVA); btwo-tailed p 
value for the difference between loop diuretic-treated and loop diuretic-free patients (Mann Whitney U test); c differences calculated on loge transformed data 
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Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic-
treated 
 
N = 131 
 
 
Loop 
diuretic-free 
 
N = 2654 
 
 
pa, b 
 
 
Loop diuretic- 
treated 
 
N = 170 
 
 
Loop 
diuretic-free 
 
N = 1191 
 
 
pa, b 
 
 
Loop diuretic- 
treated 
 
N = 90 
 
 
Loop 
diuretic-free 
 
N = 2007 
 
 
pa, b 
 
Baseline HDL-C 
(mmol/L)  1.20 (0.32) 1.20 (0.33) 0.933
a,c
 1.26 (0.35) 1.20 (0.36) 0.067a,c 1.27 (0.32) 1.21 (0.31) 0.126a,c 
 
         
Post treatment HDL-C 
(mmol/L) 1.23 (0.43) 1.21 (0.34) 0.555
b
 1.24 (0.38) 1.30 (0.40) 0.040a,c 1.31 (0.30) 1.29 (0.32) 0.501a,c 
          
Baseline LDL-C  
(mmol/L) 2.37 (1.30) 2.51 (1.03) 0.110
b,c
 2.63 (1.03) 2.59 (1.01) 0.784a 2.16 (0.90) 2.29 (0.90) 0.264a 
 
         
Post treatment LDL-C 
(mmol/L) 2.34 (0.87) 2.37 (0.92) 0.778
a
 2.44 (1.04) 2.44 (1.01) 0.974a 2.07 (0.81) 2.15 (0.80) 0.449a 
          
Baseline triglycerides 
(mmol/L) 2.99 (2.39) 2.70 (1.81) 0.833
b,c
 2.76 (1.86) 2.73 (1.83) 0.838a,c 2.57 (2.04) 2.60 (1.65) 0.475a,c 
          
Post-treatment 
triglycerides (mmol/L) 2.39 (1.63) 2.37 (1.55) 0.904
a,c
 2.41 (1.54) 2.34 (1.65) 0.276a,c 2.24 (1.29) 2.42 (1.61) 0.605a,c 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; a two-sided p value for the difference between loop diuretic-treated and loop diuretic-free patients 
(one-way ANOVA); b two-sided p value for the difference between loop diuretic-treated and loop diuretic-free patients (Mann Whitney U test); c differences calculated on loge transformed 
data;  f differences calculated on square root transformed data 
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Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic-
treated 
 
N = 131 
 
 
Loop diuretic-  
free 
 
N = 2654 
 
 
pa, b 
 
 
Loop diuretic- 
treated 
 
N = 170 
 
 
Loop 
diuretic-free 
 
N = 1191 
 
 
pa, b  
 
Loop diuretic- 
treated 
 
N = 90 
 
 
Loop 
diuretic-free 
 
N = 2007 
 
 
pa, b  
Baseline ALT  
(IU/L) 31.43 (18.18) 33.23 (20.78) 
0.316 
a, c 31.98 (21.69) 31.82 (25.11) 0.714 a, c 28.60 (16.07) 33.72 (19.67) 0.003 a, c 
          
Post treatment ALT  
(IU/L) 28.19 (19.33) 31.34 (22.06) 
0.045 
a, c 26.94 (18.89) 28.38 (22.52) 0.409 a, c 27.79 (23.70) 28.63 (16.59) 0.157 a, c 
          
Baseline sodium  
(mmol/L) 137.79 (3.38) 138.42 (2.83) 0.028
a
 137.59 (3.54) 137.28 (3.13) 0.125b 138.80 (3.09) 138.68 (2.71) 0.613a 
 
         
Post treatment sodium  
(mmol/L) 138.44 (3.66) 138.98 (2.92) 0.220
b
 138.35 (3.18) 138.46 (3.15) 0.671a 139.61 (2.88) 139.23 (2.67) 0.183a 
          
Baseline eGFR 
(mls/min/1.73 m2) 69.60 (18.53) 77.01 (19.71) 
0.009 
a, c 63.07 (20.48) 71.34 (19.94) <0.001a, c
 
67.65 (21.21) 76.61 (19.03) <0.001 a, c 
          
Post treatment eGFR 
(mls/min/1.73 m2) 67.57 (20.74) 75.09 (19.74) 
0.232 
a, c
 
58.33 (20.22) 68.45 (19.90) <0.001a, c
 
66.80 (22.58) 76.21 (20.08) 0.002a, c
 
ALT, alanine aminotransferase; eGFR,, estimated glomerular filtration rate; a two-sided p value for the difference between loop diuretic-treated and loop diuretic-free patients (one-
way ANOVA); b two-sided p value for the difference between loop diuretic-treated and loop diuretic-free patients (Mann Whitney U test); c differences calculated on loge transformed data 
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Metformin-Sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic- 
treated 
 
N = 131 
 
 
Loop 
diuretic-free 
 
N = 2654 
 
 
pa, b 
 
 
Loop diuretic- 
treated 
 
N = 170 
 
 
Loop 
diuretic-free 
 
N = 1191 
 
 
pa, b 
 
 
Loop diuretic- 
treated 
 
N = 90 
 
 
Loop 
diuretic-free 
 
N = 2007 
 
 
pa, b 
 
Baseline TSH  
(mIU/L) 1.92 (1.37) 2.00 (1.53) 
0.381 
a, c 1.84 (1.15) 2.01 (1.50) 0.255 a, c 2.37 (1.52) 2.01 (1.32) 0.054 b, c 
 
         
Post treatment TSH 
(mIU/L) 2.21 (1.35) 2.18 (1.74) 
0.699 
a, c 2.05 (1.79) 2.08 (1.72) 0.652 a, c 2.44 (2.02) 2.13 (1.43) 0.526 b, c 
          
Baseline serum albumin 
(g/L) 41.97 (4.12) 43.59 (3.50) 
<0.001  
a, c 39.44 (5.35) 41.85 (4.65) <0.001 a, c 42.54 (3.69) 44.06 (2.82) <0.001 a, c 
 
         
Post treatment serum 
albumin (g/L) 41.61 (3.71) 43.44 (3.49) 
<0.001 
a, c 39.79 (4.59) 41.42 (4.14) <0.001 a, c 42.84 (3.14) 43.98 (2.84) 0.001 a, c 
          
Baseline serum creatinine 
(μmol/L) 93.65 (32.84) 86.67 (20.07) 
0.006 
a, d 104.89 (42.82) 93.29 (31.67) <0.001 a, d 93.80 (28.18) 87.93 (20.30) 0.152 b, d 
          
Post treatment serum 
creatinine  (μmol/L) 103.24 (55.72) 90.10 (25.32) 
<0.001 
a, d
 
118.05 (55.86) 100.20 (38.85) <0.001 a, d
 
99.15 (33.44) 88.98 (24.10) 0.001 a, d
 
TSH, serum Thyroid Stimulating Hormone; a two-sided p value for the difference between loop diuretic-treated and loop diuretic-  free patients (one-way ANOVA); b two-
sided p value for the difference between loop diuretic-treated and loop diuretic-free patients (Mann Whitney U test); c differences calculated on square root transformed data; 
d differences calculated on reciprocally transformed dat
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3.11.6 Echocardiography 
 
Echocardiographic data were available for only a small subset of patients within each 
of the three treatment cohorts, as outlined in tables 3.40 and 3.41 below. 
Nonetheless, this study analysed baseline and post-treatment echocardiographic 
parameters in this subgroup of patients having echocardiographic data before and 
after prescription of index thiazolidinedione, metformin-sulphonylurea combination 
and insulin therapy. Baseline interventricular septum wall thickness, left ventricular 
posterior wall thickness and left ventricular mass for thiazolidinedione-treated 
patients did not significantly differ from corresponding values for metformin-
sulphonylurea or insulin prescribed subjects (table 3.40).  
 
In general, loop diuretic-treated patients were characterised by higher mean (SD) 
values for each of the baseline echocardiographic parameters. Thus, ‘oedema prone’ 
thiazolidinedione-treated patients were characterised by a significantly higher 
baseline left ventricular mass compared with their index loop diuretic-free 
counterparts [288.52 (81.78) (LD+) vs 234.54 (77.00) (LD-) g; p = 0.029] (table 
3.41). Likewise, statistical differences were observed between index loop diuretic 
categories for metformin-sulphonylurea-treated patients [301.35 (50.52) (LD+) vs 
235.33 (74.44) (LD-); p = 0.010] but not among patients administered insulin. 
Baseline interventricular septum thickness was significantly higher among patients 
prescribed an index loop diuretic after index metformin-sulphonylurea combination 
therapy [1.51 (0.16) (LD+) vs 1.27 (0.28) (LD); p = 0.005]. Such differences, 
although noticeable in the insulin and thiazolidinedione cohorts, did not reach 
statistical significance, possibly as a result of small sample size (table 3.41).
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Table 3.40 - Comparison of mean (SD) values for echocardiographic parameters for a subset of patients a treated with metformin-
sulphonylurea combination, insulin and thiazolidinedione therapy for at least three months, and having no background loop diuretic therapy 
at inclusion into their respective cohort. 
  
Metformin-
sulphonylourea 
cohort 
 
 
 
Insulin 
cohort 
 
 
 
Thiazolidinedione 
(TZD) cohort 
 
 
 
p value for 
the 
difference 
across the 
three cohorts 
b, c 
 
 
p value for  
metformin-
sulphonylur-
ea cohort  vs 
insulin 
cohort d 
 
p value for 
metformin-
sulphonylur-
ea cohort vs 
TZD cohort 
d 
 
p value for 
insulin 
cohort vs 
TZD 
cohort 
d 
Baseline IVS 
thickness (cm) 
n = 162a 
1.29 (0.28) 
n = 104 a 
1.25 (0.28) 
n = 129 a 
1.31 (0.26) 0.247 
b, f
 0.419 d, f 0.310 d, f 0.100 d, f 
        
Post-treatment IVS 
thickness (cm) 
n = 173 a 
1.31 (0.27) 
n = 201 a 
1.32 (0.28) 
n = 111 a 
1.36 (0.27) 0.309 
b, f
 0.730 d, f 0.142 d, f 0.215 d, f 
        
Baseline LVPW 
thickness (cm) 
n = 150 a 
1.12 (0.22) 
n = 90 a 
1.18 (0.53) 
n = 110 a 
1.19 (0.38) 0.159 
b, g
 0.732d, g 0.137d, g 0.064 d, g 
    
    
Post-treatment LVPW 
thickness (cm) 
n = 143 a 
1.17 (0.40) 
n = 178 a 
1.16 (0.24) 
n = 90 a 
1.28 (0.50) 0.028 
b, g
 0.605d, g 0.010d, g 0.028 d, g 
        
Baseline LV  
mass (g) 
n = 146 a 
238.50 (74.70) 
n = 87 a 
248.55 (161.07) 
n = 108 a 
238.04 (78.07) 0.980 
c
 0.806 e 0.927 e 0.985 e 
        
Post-treatment LV  
mass (g) 
n = 139 a 
250.32 (109.36) 
n = 173 a 
246.88 (74.49) 
n = 88 a 
275.63 (141.07) 0.225 
b, f
 0.675 d, f 0.098 d, f 0.160 d, f 
IVS, interventricular septum; LV, left ventricle; LVPW, left ventricular posterior wall;  a subset of the whole cohort containing echocardiographic data; btwo-tailed p value 
(one-way ANOVA);  c two-tailed p value [Kruskal-Wallis test]; d pair-wise post-hoc parametric tests were conducted using the Tukey-HSD test;  eMann-Whitney U test (post-
hoc analysis) - two-tailed p values were Bonferroni corrected;  f differences calculated on log e  transformed data; g differences calculated on reciprocally transformed data 
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Table 3.41 - Comparison of mean (SD) values for baseline and post-treatment bechocardiographic parameters between individuals requiring 
treatment with loop diuretics and those remaining loop diuretic-free within one year after exposure to metformin-sulphonylurea 
combination, insulin or thiazolidinedione therapy for a minimum of three months, and no background loop diuretic therapy 
 
 
 
Metformin-sulphonylurea cohort 
 
 
Insulin cohort 
 
Thiazolidinedione cohort 
  
Loop diuretic -
treated 
 
Loop diuretic 
-free 
 
pb, c 
 
 
Loop diuretic-
treated 
 
Loop diuretic  
-free 
 
pb, c 
 
 
Loop diuretic-
treated 
 
Loop diuretic  
-free 
 
pb, c 
 
Baseline IVS 
thickness (cm) 
n = 7a 
1.51 (0.16) 
n =155a 
1.27 (0.28) 
0.005 
b, d
 
n = 22a 
1.31 (0.35) 
n = 82a 
1.23 (0.25) 
0.356
b
 
n = 8a 
1.38 (0.28) 
n = 121a 
1.30 (0.26) 
0.394
c
 
   
 
  
 
  
 
Post-treatment IVS 
thickness (cm) 
n = 17a 
1.33 (0.28) 
n = 156a 
1.30 (0.27) 
0.712
c
 
n = 42a 
1.29 (0.26) 
n = 159a 
1.33 (0.28) 
0.403
c
 
n = 9a 
1.39 (0.20) 
n = 102a 
1.35 (0.28) 
0.737
c
 
 
  
 
  
 
  
 
Baseline LVPW 
thickness (cm) 
n = 7a 
1.20 (0.25) 
n = 143a 
1.11 (0.22) 
0.321
c, d
 
n = 18a 
1.25 (0.44) 
n = 72a 
1.16 (0.55) 
0.269
c, e
 
n = 7a 
1.30 (0.28) 
n = 103a 
1.18 (0.39) 
0.201
c, e
 
 
  
 
  
 
  
 
Post-treatment LVPW 
thickness (cm) 
n = 16a 
1.37 (0.73) 
n = 127a 
1.15 (0.33) 
0.115
b
 
n = 38a 
1.12 (0.23) 
n = 140a 
1.16 (0.24) 
0.362
c
 
n = 10a 
1.60 (1.17) 
n = 80a 
1.24 (0.33) 
0.367
b
 
          
Baseline LV  
mass (g) 
n = 7a 
301.35 (50.52) 
n = 139a 
235.33 (74.44) 
0.010
b
 
n = 18a 
263.54 (90.90) 
n = 69a 
244.64 (175.13) 
0.212 
c, e 
n = 7a 
288.52 (81.78) 
n = 101a 
234.54 (77.00) 
0.029
b
 
          
Post-treatment LV  
mass (g) 
n = 15a 
333.57 (188.56) 
n = 124a 
240.25 (91.78) 
0.003
b
 
n = 38a 
250.83 (59.58) 
n = 135a 
245.77 (78.33) 
0.493
b
 
n = 9a 
390.22 (343.23) 
n = 79a 
62.58 (91.79) 
0.213
b
 
   
 
  
 
  
 
IVS, interventricular septum; LVPW, left ventricular posterior wall; a subset of the whole cohort containing echocardiographic data; btwo-tailed p value for the statistical 
difference between loop diuretic- treated and loop diuretic-  free patients (Mann Whitney U test); c two-tailed p value for the statistical difference betwen loop diuretic- 
treated and loop diuretic-free patients (one-way ANOVA); d differences calculated on loge transformed data; e differences calculated on reciprocally transformed data 
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3.12 Logistic regression model: predicting risk factors for index loop diuretic 
prescription required within one year after index metformin-sulphonylurea 
combination or thiazolidinedione therapy 
 
3.12.1 Univariate logistic regression 
 
Given the similar proportions of patients requiring an index loop diuretic 
prescription after incident metformin-sulphonylurea combination or 
thiazolidinedione therapy, I opted to investigate whether index thiazolidinedione 
therapy is associated with an increased risk of fluid retention compared with 
metformin-sulphonylureas combination therapy on multivariate analysis. Patients on 
insulin therapy were not included as a comparator cohort in this logistic regression 
analysis, given that they are likely to represent a more diseased cohort, with 
potentially different confounding factors influencing index loop diuretic prescription, 
as suggested by the results of this study's descriptive analysis. None of the patients 
were being treated with a baseline renin inhibitor at inclusion into the treatment 
cohort, and thus could not be included in univariate or multivariate analysis. 
Categorical covariates were dummy coded, using non-exposure to the categorical 
variable of interest as the reference group (and conversely, exposure as the indicator 
group). Univariate analysis found that index loop diuretic prescription within one 
year of inclusion into either the metformin-sulphonylurea/metformin cohort was 
significantly associated with the following characteristics (tables 3.42 and 3.43): 
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Demographics 
• age in years [OR 1.047 (95% CI 1.033, 1.061); p < 0.001]  
• diabetes duration in years (square root transformed data) [OR 1.290 (95% CI 1.131, 
1.472); p < 0.001]  
• female gender [OR 1.392 (95% CI 1.062, 1.824); p = 0.016]  
 
Past medical history 
• baseline macrovascular disease [OR 2.459 (95% CI 1.841, 3.285); p < 0.001]  
 
Drug history 
• % maximal thiazolidinedione dose [OR 1.009  (95% CI 0.999, 1.020); p = 
0.074] 
• baseline peripheral vasodilator therapy [OR 1.792  (95% CI 1.039, 3.090); p 
= 0.036]  
• baseline calcium channel blocker therapy [OR 1.506 (95% CI 1.146, 1.979); 
p = 0.003]  
• baseline diltiazem therapy [OR 2.030 (95% CI 1.335, 3.088); p = 0.001]  
• baseline beta blocker therapy [OR 1.279 (95% CI 0.975, 1.679); p = 0.076] 
• baseline central antihypertensive therapy [OR 2.374 (95% CI 0.933, 6.042); p 
= 0.070] 
• baseline nitrates [OR 2.238, (95% CI 1.681, 2.979); p < 0.001] 
 
Clinical measurements 
• baseline systolic blood pressure in mmHg [OR 1.014 (95% CI 1.004, 1.024); 
p = 0.007]  
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• baseline BMI in kg/m2 [OR 1.053 (95% CI 1.026, 1.080); p < 0.001]  
 
Laboratory-based clinical  investigations 
• baseline haematocrit expressed as % value [OR 0.930  (95% CI 0.895, 
0.966); p < 0.001] 
• baseline estimated glomerular filration rate in mls/min/1.73m2 (loge transformed 
data) [OR 0.422 (95% CI 0.285, 0.627); p < 0.001] 
• baseline serum creatinine > 130 μmol/L [OR 1.993 (95% CI 1.056, 3.761); p 
= 0.033]  
• baseline serum albumin in g/L (loge transformed data) [OR 0.146 (95% CI 0.078, 
0.274); p < 0.001]  
• baseline alanine aminotransferase in IU/L (loge transformed data) [OR 0647 (95% CI 
0.474, 0.883); p = 0.006]  
 
Echocardiographic parameters 
• baseline left ventricular mass > 228 g [OR 6.522 (95% CI 1.429, 29.766); p = 
0.015]  
• baseline interventricular septal width in cm [OR 6.485 (95% CI 1.178, 
35.694); p = 0.032] 
 
A detailed description of Odd’s ratios for each individual covariate, with their 95% 
CI, are given in tables 3.42 and 3.43 respectively. 
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Table 3.42 - Univariate logistic regression analysis: baseline continuous independent variables predicting index loop diuretic prescription 
within one year of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort. 
 
Baseline continuous 
variable 
 
N 
(index loop 
diuretics 
prescribed 
[patients with 
variable 
data]) 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
[Exp (B)] 
 
 Lower 
95% CI 
for Exp 
(B) 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
NR2 
 
H-L 
statistic 
Age (years) 221 (4882) 0.046 0.007 43.436 1 < 0.001 1.047 1.033 1.061 0.030 0.841 
Diabetes duration (years)a 221(4882) 0.255 0.067 14.435 1 < 0.001 1.290 1.131 1.472 0.010 0.457 
            
MAP (mmHg) 180 (4283) 0.006 0.609 0.465 1 0.495 1.006 0.989 1.023 0.000 0.466 
SBP (mmHg) 180 (4283) 0.014 0.005 7.400 1 0.007 1.014 1.004 1.024 0.006 0.419 
DBP (mmHg) 180 (4283) - 0.012 0.009 1.649 1 0.199 0.988 0.971 1.006 0.001 0.351 
Weight (kg) 193 (4453) 0.004 0.004 1.090 1 0.296 1.005 0.996 1.013 0.001 0.737 
BMI (kg/m2) 183 (4453) 0.052 0.013 15.585 1 < 0.001 1.053 1.026 1.080 0.012 0.001 
            
Haematocrit (%) 158 (3579) - 0.073 0.020 13.678 1 < 0.001 0.930 0.895 0.966 0.012 0.184 
Baseline HbA1c (%) 199 (4538) - 0.047 0.051 0.881 1 0.348 0.954 0.864 1.053 0.001 0.402 
Total cholesterol (mmol/L)b 181 (4388) - 0.208 0.332 0.393 1 0.531 0.812 0.424 1.557 0.000 0.546 
HDL-C (mmol/L)b 153 (3953) 0.334 0.324 1.061 1 0.303 1.396 0.740 2.636 0.001 0.001 
LDL-C (mmol/L)a 111 (2973) - 0.558 0.308 3.289 1 0.070 0.572 0.313 1.046 0.004 0.497 
Trigs (mmol/L)b 139 (3419) - 0.014 0.153 0.009 1 0.926 0.986 0.731 1.330 0.000 0.494 
ALT (IU/L)b 170 (4010) - 0.435 0.159 7.524 1 0.006 0.647 0.474 0.883 0.006 0.852 
Sodium (mmol/L) 193 (4469) - 0.037 0.026 2.027 1 0.154 0.964 0.916 1.014 0.002 0.565 
eGFR (mls/min/1.73m2)b 160 (3995) - 0.862 0.201 18.358 1 < 0.001 0.422 0.285 0.627 0.016 0.067 
TSH (mIU/L)a 173 (3778) 0.119 0.171 0.485 1 0.486 1.126 0.806 1.574 0.000 0.056 
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Baseline continuous 
variable 
 
N 
(index loop 
diuretics 
prescribed 
[patients with 
variable data]) 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
[Exp (B)] 
 
 Lower 
95% CI 
for Exp 
(B) 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
NR2 
 
H-L 
statistic 
Serum albumin (g/L)b 183 (4203) - 1.921 0.319 36.197 1 < 0.001 0.146 0.078 0.274 0.029 0.915 
TZD dose (% 
maximal) 
90 (2097) 0.009 0.005 3.198 1 0.074 1.009 0.999 1.020 0.005 0.023 
            
IVS (cm) 15 (291) 1.869 0.870 4.616 1 0.032 6.485 1.178 35.694 0.044 0.901 
LVPW (cm)b 14 (260) 1.751 1.070 2.677 1 0.102 5.760 0.707 46.911 0.027 0.344 
 
a
 square root transformed; b loge transformed; c reciprocally transformed; ALT, alanine aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; eGFR, 
estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin; HDL-C, high density lipoprotein cholesterol; IVS, interventricular septum width; LDL-C, low density 
lipoprotein cholesterol; LVM, left ventricular mass; LVPW, left ventricular posterior wall thickness; MAP, mean arterial pressure; SBP, systolic blood pressure; trigs, 
triglycerides; TSH, thyroid stimulating hormone; TZD thiazolidinedione. 
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Table 3.43  - Univariate logistic regression analysis: baseline categorical independent variables predicting index loop diuretic prescription 
within one year of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort 
 
Baseline categorical 
variable 
 
N 
(categorical variable 
of interest [patients 
with variable data]) 
 
N 
(categorical 
variable loop 
diuretic +ve 
[categorical 
variable loop 
diuretic –ve]) 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
 
[Exp 
(B)] 
 
 Lower 
95%  
CI  
 for Exp 
(B) 
 
 
Upper 95% 
CI 
 for Exp (B) 
 
NR2 
            Male gender 2898 (4882) 114 (2784) - 0.331 0.138 5.758 1 0.016 0.718 0.548 0.941 0.004 
Female gender 1984 (4882) 107 (1877) 0.331 0.138 5.758 1 0.016 1.392 1.062 1.824 0.004 
TZD + insulin 70 (2097) 5 (65) 0.564 0.477 1.397 1 0.237 1.757 0.690 4.477 0.002 
TZD (vs MFSU) 2097 (4882) 90 (2007) - 0.096 0.140 0.469 1 0.493 0.908 0.690 1.196 0.000 
            
Creat  > 130 μmol/L 183 (4203) 11 (172) 0.690 0.324 4.529 1 0.033 1.993 1.056 3.761 0.003 
            
Peripheral vasodilator 197 (4882) 15 (182) 0.583 0.278 4.405 1 0.036 1.792 1.039 3.090 0.003 
Thiazide diuretic 1534 (4882) 77 (1457) 0.162 0.145 1.254 1 0.263 1.176 0.886 1.561 0.001 
Potassium sp. diuretic 71 (4882) 5 (66) 0.477 0.469 1.035 1 0.309 1.612 0.643 4.041 0.001 
NSAID 3302 (4882) 155 (3147) 0.122 0.150 0.660 1 0.417 1.130 0.842 1.517 0.000 
Dihydropyridine CCB 1650 (4882) 95 (1555) 0.409 0.139 8.630 1 0.003 1.506 1.146 1.979 0.006 
Verapamil 56 (4882) 4 (52) 0.491 0.524 0.879 1 0.348 1.634 0.586 4.558 0.001 
Diltiazem 326 (4882) 27 (299) 0.708 0.214 10.960 1 0.001 2.030 1.335 3.088 0.006 
Beta blockers 1887 (4882) 98 (1789) 0.246 0.139 3.149 1 0.076 1.279 0.975 1.679 0.002 
Vasodilat 25 (4882) 2 (23) 0.611 0.740 0.680 1 0.410 1.842 0.431 7.861 0.000 
Caanitht 50 (4882) 5 (45) 0.865 0.477 3.293 1 0.070 2.374 0.933 6.042 0.002 
Anbd 9 (4882) 1 (8) 0.972 1.063 0.837 1 0.360 2.644 0.329 21.231 0.000 
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Baseline categorical 
variable 
 
 
N 
[categorical 
variable of 
interest 
(patients with 
variable data)] 
 
 
N 
[categorical 
variable loop 
diuretic +ve 
(categorical 
variable loop 
diuretic -ve)] 
 
 
 
B 
 
 
SE 
 
 
Wald 
 
 
df 
 
 
p 
 
 
OR 
 
[Exp (B)] 
 
  
Lower 
95% CI 
for Exp 
(B) 
 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
 
NR2 
Aabd 366 (4882) 21 (345) 0.273 0.236 1.334 1 0.248 1.314 0.827 2.087 0.001 
ACEI 2191 (4882) 103 (2088) 0.073 0.138 0.279 1 0.597 1.076 0.821 1.410 0.000 
ARB 539 (4882) 28 (511) 0.164 0.208 0.624 1 0.429 1.178 0.784 1.770 0.000 
Nitrates 976 (4882) 77 (899) 0.805 0.146 30.441 1 <0.001 2.238 1.681 2.979 0.018 
Otherantiang 97 (4882) 2 (95) - 0.823 0.718 1.316 1 0.251 0.439 0.107 1.792 0.001 
            
Macrovascular 
disease 866 (4882) 74 (792) 0.900 0.148 37.078 1 < 0.001 2.459 1.841 3.285 0.022 
            
LVM > 228g 14 (254) 12 (2) 1.875 0.775 5.860 1 0.015 6.522 1.429 29.766 0.093 
 
Aabd, alpha adrenoceptor drugs; ACEI, angiotensin converting enzyme inhibitors; Anbd, adrenergic neurone blocking drugs; ARB, angiotensin II receptor antagonists; 
Caantiht, centrally acting antihypertensive drugs; Dihydropyridine CCB, dihydropyridine calcium channel blockers; Creat, serum creatinine; LVM, left ventricular mass; 
MFSU, metformin-sulphonylurea combination therapy; NSAID, non-steroidal anti-inflammatory drug; otherantiang, other antianginal drugs; Potassium sp. diuretic, 
potassium sparing diuretic therapy; trigs, triglycerides; TZD, thiazolidinedione; TZD + insulin, thiazolidinedione-insulin combination therapy; Vasodilat, vasodilator 
antihypertensive drugs;  
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3.12.2 Multivariate logistic regression 
 
90 and 131 patients required prescription of an index loop diuretic within one year 
after exposure to thiazolidinedione therapy and metformin-sulphonylurea 
combination therapy respectively. 2007 thiazolidinedione-treated patients and 2654 
patients on metformin-sulphonylurea combination therapy did not develop require an 
index loop diuretic after inclusion into their respective cohort. Hence, the overall 
proportion of patients requiring an index loop diuretic prescription amounts to 
0.04526 (or 4.53%).  
 
Based on statistical work reported by Peduzzi et al. [609], given the proportion of 
patients requiring an index loop diuretic after index thiazolidinedione prescription, 
the maximum number of covariates that can be included in any model amounts to 22. 
 
Based on univariate analysis, and taking into account the number of patients for 
whom data for each covariate were available, covariates of interest were modelled 
into two stepwise index loop diuretic logistic regression models (1 and 2). 
 
(i) Index loop diuretic logistic regession model 1 
 
The following predictors (covariates) were included in index loop diuretic logistic 
regression model 1 
 
• Age (years) 
• diabetes duration (years) (square root transformed data)  
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• baseline BMI (kg/m2) 
• baseline haematocrit (%) 
• baseline serum creatinine > 130 μmol/L 
• baseline albumin (g/L) (loge transformed data)  
• baseline ALT (IU/L) (loge transformed data)  
• baseline systolic blood pressure (mmHg) 
• female gender 
• baseline macrovascular disease (composite of coronary artery disease, 
peripheral artery disease and cerebrovascular disease) 
• index thiazolidinedione prescription (vs baseline metformin-sulphonylurea 
combination therapy) 
 
% maximal thiazolidinedione dose was not included into the logistic regression 
model, so as not to restrict the model to thiazolidinedione-treated patients. Index 
thiazolidinedione prescription (vs metformin-sulphonylurea combination therapy) 
was included as a covariate despite not reaching statistical significance on univariate 
regression, given this study’s aim of investigating whether PPAR-γ agonist therapy 
predicts index loop diuretic prescription in a multivariate model. 
 
3116 patients were included into the logistic regression model. Employing a 0.05 
criterion of statistical significance, the Wald criterion demonstrated that baseline 
BMI, baseline age, baseline macrovascular disease, baseline serum albumin and 
diabetes duration made a significant contribution to prediction, as shown in table 
3.44. 
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A test of the full model versus a model with intercept only was statistically 
significant (chi square 82.198, p < 0.001 with df = 5). The p value for the Hosmer 
and Leneshow test statistic (H-L statistic) was greater than 0.05 (chi square 6.761, df 
= 8, p = 0.563), implying that the model’s estimates fit the data at an acceptable 
level. Nagelkerke’s R2 = 0.091, effectively indicating a relationship of 9.1% between 
predictors (covariates) and the prediction (ie index loop diuretic prescription). 
Prediction success overall was 96.0%. 
 
Wald’s statistic for the final model indicate that baseline BMI, age and baseline 
macrovascular disease are the strongest predictors of fluid overload (in decreasing 
order of importance). From table 3.44, the fitted model is: 
Logit (p) = - 7.413 + (0.085*BMI) + (0.053*age) + (0.723*macrovascular disease) + 
(-1.339*serum albumin [loge transformed data]) + (0.214*diabetes duration [square root 
transformed data])  
where p is the probability of progessing to index loop diuretic prescription within 
one year.
 
 
Thus, when holding all other variables constant, a patient known to suffer from 
macrovascular disease at metformin-sulphonylurea combination or thiazolidinedione 
prescription is 2.06 times more likely to require prescription of an index loop diuretic 
within one year after inclusion into either cohort. With each unit square root (√) 
passing year since diagnosis of T2DM, a patient’s risk of requiring index loop 
diuretic prescription after inclusion into either cohort increases by 23.9%, assuming 
all other covariates are unchanged during the observation period. Holding all other 
variables constant, each one year increase in age at prescription of metformin-
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sulphonylurea combination or thiazolidinedione therapy is associated with a 5.5% 
increased risk of fluid overload. Each 1 kg/m2 increase in baseline BMI is likewise 
associated with an 8.8% increased risk of index loop diuretic prescription, assuming 
all other covariates are held constant. Inverting odd’s ratios and holding all other 
variables constant, T2DM patients treated with metformin-sulphonylurea 
combination therapy/thiazolidinediones are at 3.82 times increased risk of fluid 
overload per g/L reduction in baseline loge serum albumin. Index thiazolidinedione 
therapy did not contribute as a covariate in both the final model, as was observed in 
univariate regression, suggesting that any thiazolidinedione-associated index loop 
diuretic prescription (acting as a surrogate marker of fluid retention) is accounted for 
by other predisposing factors. 
 
ROC curve analysis was used to discriminate between positive and negative cases. 
Concardance index (c-statistic/AUC) for this model amounted to 0.713 (95% CI 
0.673, 0.753) (p < 0.001), suggesting that the final model has an ability to distinguish 
between the two outcome groups 
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Table 3.44 - Index loop diuretic logistic regression model 1: final model covariates 
predicting index loop diuretic prescription within one year of inclusion into the 
metformin-sulphonylurea combination or thiazolidinedione cohort* 
 
 
Final model 
covariates 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
 
[exp 
(B)] 
 
 
95% 
CI 
lower 
 
95% 
CI 
upper 
         
Baseline body mass 
index (kg/m2) 0.085 0.018 23.204 1 < 0.001 1.088 1.052 1.127 
Age (years) 0.053 0.011 22.043 1 < 0.001 1.055 1.032 1.078 
Baseline 
macrovascular 
disease 
0.723 0.195 13.727 1 < 0.001 2.061 1.406 3.021 
Baseline serum 
albumin (g/L)a -1.339 0.420 10.176 1 0.001 0.262 0.115 0.597 
Diabetes duration 
(years)b 0.214 0.096 4.982 1 0.026 1.239 1.026 1.495 
Constant -7.413 1.514 23.973 1 < 0.001 0.001   
         
 
*Baseline covariates included in the model were age, diabetes duration b, body mass index, 
haematocrit, serum creatinine > 130 µmol/L, serum albumin a, alanine aminotranferase a, systolic 
blood pressure, female gender, macrovascular disease, thiazolidinedione therapy (vs metformin-
sulphonylurea combination therapy); a loge transformed data; bsquare root transformed data;  
 
 
(ii) Index loop diuretic logistic regression model 2 
 
In order to model for baseline drug therapy, a binary logistic regression model was 
run with age, diabetes duration (square root transformed data), baseline clinical variables 
(BMI, systolic blood pressure, haematocrit, serum creatinine > 130 µmol/L, serum 
albumin (loge transformed data), alanine aminotransferase (loge transformed data), female gender, 
baseline drug therapy (dihydropyridine calcium channel blockers, diltiazem, beta 
blockers, nitrates) and baseline index thiazolidinedione prescription (vs metformin-
sulphonylurea combination therapy). Essentially, these covariates are identical to 
those included in logistic regression step 1, save baseline macrovascular disease, 
with the addition of the baseline drugs referred to above. 3116 patients were fitted 
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into the model, with age, diabetes duration, baseline BMI, baseline serum albumin 
and baseline nitrate therapy predicting index loop diuretic prescription within one 
year of index thiazolidinedione / metformin-sulphonylurea combination therapy 
(table 3.45). Thus baseline nitrate therapy carries an 84.3% increased risk of 
progressing to index loop diuretic therapy within one year, provided all other 
covariates are held constant. 
 
 
Table 3.45 - Index loop diuretic logistic regression model 2: final model covariates 
predicting index loop diuretic prescription within one year of inclusion into the 
metformin-sulphonylurea combination or thiazolidinedione cohort* 
 
 
Final model 
covariates 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
[exp 
(B)] 
 
 
95% 
CI 
lower 
 
95%  
CI 
upper 
         
Age  
(years) 0.054 0.011 23.219 1 < 0.001 1.055 1.032 1.078 
Baseline body 
mass index (kg/m2) 0.080 0.018 20.678 1 < 0.001 1.083 1.046 1.121 
Baseline serum 
albumin (g/L)a - 1.506 0.420 12.857 1 < 0.001 0.222 0.097 0.505 
Baseline  
nitrate 0.611 0.193 10.079 1 0.002 1.843 1.263 2.687 
Diabetes duration 
(years)b 0.214 0.096 4.951 1 0.026 1.238 1.026 1.494 
Constant - 6.900 1.501 21.133 1 < 0.001 0.001   
         
 
*Baseline covariates included in the model were age, diabetes duration, body mass index, 
haematocrit, serum creatinine, serum albumin, alanine aminotranferase, systolic blood pressure, 
female gender, calcium channel blockers, diltiazem, beta-blockers, nitrates and thiazolidinedione 
therapy (vs metformin-sulphonylurea combination therapy). a loge transformed data; b square root 
transformed data. 
 
Model chi square = 78.862, p < 0.001 with df = 5; NR 2 = 0.087; H-L statistic chi square = 6.183, p 
= 0.627 with df = 8; prediction success overall = 96.0 %; ROC (AUC) = 0.711 (95% CI 0.670, 
0.752), p < 0.001 
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3.13 Cox regression model: predicting risk factors for index loop diuretic 
prescription required within one year after index metformin-sulphonylurea 
combination or thiazolidinedione therapy 
 
3.13.1 Univariate Cox regression 
 
Following on from the results of logistic regression analysis, this study sought to 
model onset time to index loop diuretic prescription (the ‘failure event’) following 
index prescription to metformin-sulphonylurea combination therapy or 
thiazolidinediones, using Cox proportional hazards regression analysis.   
 
On univariate analysis (tables 3.46 and 3.47) the following clinical and pathological 
factors were associated with time to index loop diuretic prescription: 
 
Demographics 
• age in years [HR 1.046 (95% CI 1.032, 1.059); p < 0.001]  
• diabetes duration in years (square root transformed data) [HR 1.294 (95% CI 1.138, 
1.472); p < 0.001]  
• female gender (p = 0.011)  
 
Past medical history 
• baseline macrovascular disease (p < 0.001)  
 
Drug history 
• baseline peripheral vasodilator therapy (p = 0.031)  
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Table 3.46 - Univariate Cox regression: baseline continuous independent variable predicting index loop diuretic prescription within one year 
of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort 
 
 
Baseline continuous variable 
 
N 
[index loop 
diuretics 
prescribed 
(patients with 
variable 
data)] 
 
 
 
B 
 
 
SE 
 
 
Wald 
 
 
df 
 
 
p 
 
 
Hazard 
ratio 
 
[Exp (B)] 
 
  
Lower 
95% CI for 
Exp (B) 
 
 
 
Upper 
95% CI for 
Exp (B) 
 
            
- 2 Log      
Likelehood 
           
Age 221 (4882) 0.045 0.007 44.290 1 <0.001 1.046 1.032 1.059 3660.894 
Diabetes duration (years) a 221 (4882) 0.258 0.066 15.392 1 <0.001 1.294 1.138 1.472 3690.840 
           
MAP (mmHg) 180 (4283) 0.005 0.008 0.387 1 0.534 1.005 0.989 1.022 2970.030 
SBP (mmHg) 180 (4283) 0.013 0.005 7.194 1 0.007 1.013 1.004 1.023 2963.439 
DBP (mmHg) 180 (4283) - 0.012 0.009 1.829 1 0.176 0.988 0.970 1.006 2968.585 
Weight (kg) 183 (4453) 0.004 0.004 1.017 1 0.313 1.004 0.996 1.013 3034.441 
BMI (kg/m2) 183 (4453) 0.050 0.013 15.601 1 <0.001 1.052 1.026 1.078 3020.699 
           
Haematocrit (%) 158 (3579) - 0.074 0.019 15.447 1 <0.001 0.929 0.895 0.964 2532.968 
HbA1c (%) 199 (4538) - 0.040 0.050 0.632 1 0.427 0.961 0.872 1.060 3306.628 
Total cholesterol (mmol/L) b 181 (4388) - 0.264 0.327 0.654 1 0.419 0.768 0.404 1.457 2993.218 
HDL-C (mmol/L) b 153 (3953) 0.319 0.321 0.991 1 0.320 1.376 0.734 2.581 2498.555 
LDL-C (mmol/L) a 111 (2973) - 0.571 0.301 3.589 1 0.058 0.565 0.313 1.020 1745.692 
Trigs (mmol/L) b 139 (3419) - 0.033 0.150 0.048 1 0.827 0.968 0.721 1.299 2229.738 
ALT (IU/L) b 170 (4010) - 0.448 0.156 8.208 1 0.004 0.639 0.471 0.868 2772.766 
Sodium (mmol/L) 193 (4469) - 0.038 0.026 2.149 1 0.143 0.963 0.916 1.013 3198.839 
eGFR (mls/min/1.73m2) b 160 (3995) - 0.859 0.198 18.790 1 <0.001 0.423 0.287 0.624 2599.658 
TSH (mIU/L) a 173 (3778) 0.121 0.168 0.512 1 0.474 1.128 0.811 1.569 2810.337 
Serum albumin (g/L) b 183 (4203) -1.910 0.312 37.396 1 < 0.001 0.148 0.080 0.273 2974.080 
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Baseline continuous 
variable 
 
 
N 
(index loop 
diuretics 
prescribed 
[patients with 
variable 
data]) 
 
 
 
B 
 
 
SE 
 
 
Wald 
 
 
df 
 
 
p 
 
 
Hazard 
ratio 
 
(Exp [B)]) 
 
 
 Lower 
95% CI 
for Exp 
(B) 
 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
            
             - 2 Log 
 Likelehood 
           
TZD dose (% 
maximal) 
90 (2007) 0.007 0.005 1.915 1 0.166 1.007 0.997 1.017 1354.430 
           
IVS (cm) 15 (291) 1.948 0.838 5.397 1 0.020 7.014 1.356 36.280 162.385 
LVPW (cm) b 14 (260) 1.538 0.874 3.092 1 0.079 4.653 0.838 25.826 150.408 
           
 
ALT, alanine aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin; HDL-
C, high density lipoprotein cholesterol; IVS, interventricular septum width; LDL-C, low density lipoprotein cholesterol; LVM, left ventricular mass; LVPW, left ventricular 
posterior wall thickness; MAP, mean arterial pressure; SBP, systolic blood pressure; trigs, triglycerides; TSH, thyroid stimulating hormone; TZD thiazolidinedione; a square 
root transformed data; b loge transformed data 
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Table 3.47 - Univariate Cox regression analysis (Kaplan-Meier survival): baseline categorical independent variables predicting index loop 
diuretic prescription within one year of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort. 
 
  
 
Categorical variable of interest 
 
 
Comparator categorical variable  
 
 
Log rank test 
 
 
Baseline categorical 
variable 
 
 
          N 
[categorical 
variable of 
interest 
(patients with 
variable data)] 
 
 
N 
[categorical 
comparator 
variable  
loop diuretic 
+ve 
(patients 
with 
comparator 
variable 
data)]  
 
 
 
Mean 
 Survival 
 time 
 
 
SE 
Survival 
 time 
 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
 
Mean 
 Survival 
 time 
 
 
SE 
Survival 
 time 
 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
 
Chi 
Square  
 
 
df 
 
 
p 
 
  
            
Male gender 2898 (4882) 114 (2784) 357.032 0.815 355.434 358.631 354.485 1.118 352.293 356.677 6.394 1 0.011 
Female gender 1984 (4882) 107 (1877) 354.485 1.118 352.293 356.677 357.032 0.815 355.434 358.631 6.394 1 0.011 
TZD (vs MFSU) 70 (2097) 90 (2007) 356.670 0.977 354.756 358.584 355.506 0.902 353.739 357.274 0.420 1 0.517 
TZD + insulin 2097 (4882) 5 (65) 347.677 7.624 332.734 362.620 356.970 0.975 355.058 358.882 2.489 1 0.115 
  
            
Creat > 130µmol/L 183 (4203) 11 (172) 344.951 5.855 333.476 356.426 356.990 0.678 355.661 358.320 5.421 1 0.020 
  
            
Peripheral vasodilators 197 (4882) 15 (182) 350.529 3.955 342.777 358.281 356.232 0.671 354.917 357.548 4.661 1 0.031 
Thiazide diuretics 1534 (4882) 77 (1457) 354.998 1.248 352.553 357.444 356.463 0.781 354.932 357.994 1.486 1 0.223 
Potassium sp. diuretics 71 (4882) 5 (66) 354.448 6.044 342.602 366.293 356.028 0.668 354.719 357.336 1.094 1 0.296 
NSAIDs 3302 (4882) 155 (3147) 355.927 0.808 354.344 357.510 356.157 1.167 353.871 358.444 0.752 1 0.386 
Dihydropyridine CCBs 1650 (4882) 95 (1555) 352.620 1.344 349.986 355.255 357.736 0.729 356.307 359.164 9.189 1 0.002 
Verapamil 56 (4882) 4 (52) 352.502 6.231 340.289 364.716 356.049 0.667 354.740 357.357 0.769 1 0.380 
Diltiazem 326 (4882) 27 (299) 348.725 3.414 342.034 355.416 356.524 0.668 355.216 357.832 11.764 1 0.001 
Beta blockers 1887 (4882) 98 (1789) 353.968 1.191 351.634 356.303 357.299 0.778 355.775 358.824 3.392 1 0.066 
Vasodilat 25 (4882) 2 (23) 342.760 15.236 312.897 372.623 356.072 0.663 354.774 357.371 0.583 1 0.445 
Caanitht 50 (4882) 5 (45) 346.209 9.536 327.519 364.899 356.106 0.663 354.808 357.406 3.495 1 0.062 
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Categorical variable of interest 
 
 
Comparator categorical variable  
 
 
Log rank test 
 
 
Baseline categorical  
variable 
 
 
          N 
(categorical 
variable of 
interest 
[patients with 
categorical 
variable data]) 
 
 
N 
(categorical 
comparator 
variable  loop 
diuretic +ve 
[patients with 
comparator 
variable 
data]) 
 
 
 
Mean 
 Survival 
 time 
 
 
SE 
Survival 
 time 
 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
 
Mean 
 Survival 
 time 
 
 
SE 
Survival 
 time 
 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
 
Chi Square  
 
 
df 
 
 
p 
 
  
            
Anbd 9 (4882) 1 (8) 327.778 35.093 258.995 396.561 356.057 0.662 354.760 357.354 1.031 1 0.310 
Aabd 366 (4882) 21 (345) 353.674 2.594 348.590 358.759 356.180 0.687 354.834 357.526 1.747 1 0.186 
ACEI 2191 (4882) 103 (2088) 356.013 0.964 354.124 357.901 355.992 0.914 354.200 357.784 0.401 1 0.527 
ARB 539 (4882) 28 (54) 354.076 2.208 349.749 358.403 356.242 0.694 354.882 357.603 0.854 1 0.355 
Nitrates 976 (4882) 77 (899) 349.032 1.933 345.244 352.819 357.742 0.672 356.425 359.059 33.074 1 <0.001 
Otherantiang 97 (4882) 2 (95) 360.144 3.694 352.904 367.385 355.920 0.673 354.601 357.240 1.365 1 0.243 
              
Macrovascular disease 866 (4882) 74 (792) 347.749 2.135 343.565 351.932 357.784 0.660 356.491 359.076 40.515 1 <0.001 
              
LVM > 228g 14 (254) 12 (2) 341.470 6.917 327.913 355.027 362.222 2.145 358.017 366.427 7.513 1 0.006 
              
 
aabd, alpha adrenoceptor drugs; ACEI, angiotensin converting enzyme inhibitors; anbd, adrenergic neurone blocking drugs; ARB, angiotensin II receptor antagonists; 
caantiht, centrally acting antihypertensive drugs; CAD, coronary artery disease; Ccb, calcium channel blockers; creat, serum creatinine;  Ks, potassium sparing diuretic 
therapy; macrovasc, macrovascular disease; NSAID, non-steroidal anti-inflammatory drug; otherantiang, other antianginal drugs; trigs, triglycerides; TZD + insulin, 
thiazolidinedione-insulin combination therapy; vasodilat, vasodilator antihypertensive drugs;  
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• baseline dihydropyridine calcium channel blocker therapy (p = 0.002)  
• baseline diltiazem therapy (p = 0.001)  
• baseline beta blocker therapy (p = 0.066)  
• baseline central antihypertensive therapy (p = 0.062)  
• baseline nitrates (p < 0.001) 
 
Clinical measurements 
• baseline systolic blood pressure in mmHg [HR 1.013 (95% CI 1.004, 1.023); 
p = 0.007] 
• baseline BMI in kg/m2 [HR 1.052 (95% CI 1.026, 1.078); p < 0.001]  
 
Laboratory-based clinical  investigations 
• baseline haematocrit expressed as % value  [HR 0.929 (95% CI 0.895, 
0.964)]; p < 0.001] 
• baseline estimated glomerular filration rate in mls/min/1.73m2 (loge transformed 
data) [HR 0.423 (95% CI 0.287, 0.624); p < 0.001] 
• baseline serum creatinine >130 µmol/L (p = 0.020)  
• baseline serum albumin in g/L (loge transformed data) [HR 0.148 (95% CI 0.080, 
0.273); p < 0.001] 
• baseline LDL-cholesterol in mmol/L (square root transformed data) [HR 0.565 (95% 
CI 0.313, 1.020); p = 0.058]  
• baseline alanine aminotransferase in IU/L (loge transformed data) [HR 0.639 (95% 
CI 0.471, 0.868); p = 0.004]  
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Echocardiographic parameters 
• baseline left ventricular mass > 228g (p = 0.006)  
• baseline interventricular septal width in cm [HR 7.014 (95% CI 1.356, 
36.280); p = 0.020] 
• baseline left ventricular posterior wall thickness in cm (loge transformed data) [HR 
4.653 (95% CI 0.838, 25.826); p = 0.079] 
 
Thus, neither baseline thiazolidinedione therapy nor % maximal thiazolidinedione 
dose were associated with time to progression to fluid overload. 
 
 
3.13.2 Multivariate Cox regression 
 
(i) Loop diuretic Cox regression model 1 
 
Based on the outcomes of univariate analysis, Cox regression was used to assess the 
strength of association between time to index loop diuretic prescription and clinical 
and pathological risk factors. As outlined in multivariate logistic regression analysis, 
the maximum number of covariates that could be included in Cox regression 
analysis, based on the available data, amounted to 22. 
 
Variables (covariates) included in multivariate Cox regression analysis were those 
deemed significant (p < 0.1) on univariate screening (tables 3.46 and 3.47), namely: 
• Age (years) 
• Female gender 
• Diabetes duration (years) (square root transformed data) 
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• Baseline BMI (kg/m2) 
• Baseline systolic blood pressure (mmHg) 
• Baseline haematocrit (%) 
• Baseline serum creatinine > 130 μmol/L 
• Baseline serum albumin (g/L) (loge transformed data) 
• Baseline alanine aminotransferase (IU/L) (loge transformed data) 
• Baseline macrovascular disease 
• Index thiazolidinedione prescription (vs metformin-sulphonylurea) 
 
Given that female gender, baseline serum creatinine > 130 µmol/L, macrovascular 
disease and index thiazolidinedione prescription defied the Proportional Hazards 
Assumption, time-dependent variables were constructed for each variable by adding 
an interaction term that involved loge time (days) to index loop diuretic prescription 
into the Cox model, and testing for its significance. Time-dependent variables were 
also constructed in the same fashion for age, diabetes duration, BMI, systolic blood 
pressure, haematocrit, serum albumin (loge transformed data) and alanine aminotransferase 
(loge transformed data)  as evidence that hazard ratios for these covariates do not change 
over time. 
 
There were no significant interactions between any of the included covariates in this 
model. Out of a total of 3116 patients, for whom data were available for this model, 
126 patients required an index loop diuretic within one year of prescription of 
metformin-sulphonylurea combination or thiazolidinedione therapy. 2990 patients 
were censored within the aforementioned period of observation. The covariates as a 
set reliably improved the predictability of the Cox regression model (chi square 
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2517.726, p < 0.001 with df = 15). The standard error (SE) of each variable included 
in the model was small, suggesting no significant multicollinearity. The Wald 
criterion demonstrated that (in decreasing order of importance) age, baseline 
haematocrit, baseline BMI, baseline alanine aminotransferase, baseline systolic 
blood pressure and baseline macrovascular disease, and their respective interactions 
with time made a significant contribution to predicting time to index loop diuretic 
prescription in this setting, as outlined in table 3.48.  Covariate*time interactions 
suggested a decreasing hazard ratio over time for baseline macrovascular disease, 
alanine aminotransferase and serum albumin. Hazard ratios for age, BMI, systolic 
blood pressure, and haematocrit remained relatively (albeit not completely) stable 
over the period of observation, in keeping with log-minus-log plots which had 
suggested that each of the latter covariates satisfied the Proportiona Hazards 
Assumption (table 3.49, figure 3.13). 
 
Thus, the hazard ratio for requiring an index loop diuretic at time t (HRt) associated 
with baseline macrovascular disease can be summarised by the equation: 
 (HRt)  = exp (8.810 -  1.527*t) 
which at t = 180 days (ie six months, loge of which = 5.19, amounts to exp (8.810 - 
1.527*5.19) = 2.423 
whereas at t = 270 days (ie 9 months, loge of which = 5.60), equals exp (8.810-
1.527*5.60) = 1.295 
while at t = 365 days (ie one year, loge of which = 5.90) amounts to exp (8.810 - 
1.527*5.90) = 0.819. 
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It can thus be concluded that baseline macrovascular disease is indeed a strong risk 
factor for index loop diuretic prescription within the first nine months of therapy, but 
that this effect wears off over time.   
 
Table 3.48 – Loop diuretic Cox regression model 1 predicting index loop diuretic 
prescription within one year of inclusion into the metformin-sulphonylurea 
combination or thiazolidinedione cohort. 
 
 
Final baseline 
model covariates 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Hazard  
ratio 
 
 
 
95% CI 
lower 
 
95% CI 
upper 
         
Age  
(years) 1.064 0.137 60.405 1 <0.001 2.899 2.217 3.792 
Body mass index 
(kg/m2) 1.142 0.197 33.449 1 <0.001 3.133 2.128 4.614 
Systolic BP 
(mmHg) 0.313 0.075 17.467 1 <0.001 1.367 1.181 1.583 
Haematocrit  
(%) 2.029 0.265 58.484 1 <0.001 7.610 4.524 12.802 
Serum albumin 
(g/L) a 8.955 4.692 3.642 1 0.056 7746.095 0.785 76423616.57 
ALT 
(IU/L) a 13.816 2.509 30.334 1 <0.001 1000699.348 7328.611 136642431.4 
Macrovascular 
disease 8.810 2.276 14.979 1 <0.001 6698.006 77.342 580066.109 
Age 
(years)*logetime -0.190 0.025 57.021 1 <0.001 0.827 0.787 0.869 
Body mass index 
(kg/m2)*logetime -0.199 0.037 28.725 1 <0.001 0.820 0.762 0.881 
Systolic BP 
(mmHg)*logetime -0.058 0.014 16.686 1 <0.001 0.943 0.918 0.970 
Haematocrit 
(%)*logetime -0.371 0.049 57.450 1 <0.001 0.690 0.627 0.759 
Serum albumin 
(g/L) *logetime -1.950 0.875 4.964 1 0.026 0.142 0.026 0.791 
ALT (IU/L) 
*logetime 
-2.595 0.471 30.330 1 <0.001 0.075 0.030 0.188 
Macrovascular 
disease*logetime 
-1.527 0.435 12.320 1 <0.001 0.217 0.093 0.510 
         
 
*Baseline covariates included in the model were age, female gender, diabetes duration b, body mass 
index, systolic blood pressure, haematocrit, serum creatinine > 130 µmol/L, serum albumin a, alanine 
aminotranferase a, macrovascular disease, index thiazolidinedione (vs metformin-sulphonylurea 
therapy) 
 
Events = 126, censored = 2990; - 2 LL = 683.747; Model chi square = 2679.979, p < 0.001 with df = 
14 
a
 Square root transformed data; b loge transformed data 
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Table 3.49 - Three monthly variation in estimated hazard ratios (HR) for index loop 
diuretic prescription after index metformin-sulphonylurea or thiazolidinedione 
prescription.  HR were estimated at six months, nine months and one year for all 
significant covariates in loop Cox regression model 1. 
 
 
Time-dependent covariates 
 
 
HR at 6 months  
(180 days) 
  
 
HR at 9 months  
(270 days) 
 
HR at 12 months  
(365 days) 
    
Age (years) 1.08 1.00 0.95 
Body mass index (kg/m2) 1.12 1.03 0.97 
Systolic blood pressure 
(mmHg) 1.01 0.99 0.97 
Haematocrit (%) 1.11 0.95 0.85 
Serum albumin (g/L) a 0.31 0.14 0.08 
Alanine aminotransferase 
(IU/L) a 1.42 0.49 0.22 
Macrovascular disease 2.42 1.30 0.82 
    
 
a
 loge transformed data 
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Figure 3.13 - Variation in hazard ratio values for index loop diuretic prescription within one year of index metformin-sulphonylurea 
combination or thiazolidinedione prescription: loop Cox regression model 1. Data are plotted at 180, 270 and 365 days. Patients treated with 
metformin-sulphonylurea combination or thiazolidinedione therapy for less than 90 days were excluded. 
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(ii) Loop diuretic Cox regression model 2 
 
In this model, baseline dihydropyridine calcium channel blockers, diltiazem, beta 
blockers and nitrates were included as covariates in lieu of baseline macrovascular 
disease. All other covariates included in step 1 were maintained. Baseline age, BMI, 
systolic blood pressure, haematocrit, serum albumin, alanine aminotransferase and 
nitrates emerged as significant predictors of time to index loop diuretic prescription 
on multivariate analysis, as shown in table 3.50 below. 
 
Hazard ratios for serum albumin and alanine aminotransferase exhbited a time-dependent 
reduction over the period of observation, as outlined in loop Cox regression model 1. 
Varation in risk associated with age, BMI, systolic blood pressure and  haematocrit was 
relatively mild. Hazard ratios for background nitrate therapy remained constant throughout 
the first year after index metfformin-sulphonylure combination or thiazolidinedione 
prescription (table 3.51, figure 3.14). 
 
The relatively small number of patients with data for baseline left ventricular mass 
and interventricular septum width did not permit a generation of a Cox regression 
model incorporating these echocardiographic variables as covariates. 
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Table 3.50 – Loop diuretic Cox regression model 2 predicting index loop diuretic 
prescription within one year of inclusion into the metformin-sulphonylurea combination 
or thiazolidinedione cohort 
 
 
Final baseline 
model covariates 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Hazard ratio 
 
 
 
95% CI 
lower 
 
95% CI 
upper 
         
Age  
(years) 0.978 0.131 55.412 1 <0.001 2.660 2.056 3.442 
Body mass index 
(kg/m2) 0.999 0.200 24.930 1 <0.001 2.715 1.834 4.017 
Systolic BP 
(mmHg) 0.301 0.076 15.831 1 <0.001 1.352 1.165 1.568 
Haematocrit  
(%) 1.754 0.269 42.589 1 <0.001 5.776 3.411 9.782 
Serum albumin 
(g/L) a 12.633 5.008 6.365 1 0.012 306583.759 16.755 5609800937 
ALT 
(IU/L) a 13.035 2.465 27.964 1 <0.001 458286.577 3655.219 57459369.51 
Nitrates  0.505 0.217 5.426 1 0.020 1.656 1.083 2.533 
Age 
(years)*logetime -0.175 0.024 52.179 1 <0.001 0.839 0.801 0.880 
Body mass index 
(kg/m2)*logetime -0.174 0.038 21.473 1 <0.001 0.840 0.780 0.904 
Systolic BP 
(mmHg)*logetime -0.056 0.014 15.388 1 <0.001 0.945 0.919 0.972 
Haematocrit 
(%)*logetime -0.322 0.050 41.967 1 <0.001 0.725 0.658 0.799 
Serum albumin 
(g/L) *logetime -2.654 0.933 8.093 1 0.004 0.070 0.011 0.438 
ALT (IU/L) 
*logetime 
-2.473 0.463 28.520 1 <0.001 0.084 0.034 0.209 
         
 
*Baseline covariates included in the model were age, female gender, diabetes duration b, body mass 
index, systolic blood pressure, haematocrit, serum creatinine > 130 µmol/L, serum albumin ; alanine 
aminotranferase, dihydropyridine calcium channel blockers, diltiazem, beta blockers, nitrates and 
index thiazolidinedione (vs metformin-sulphonylurea therapy), together with their respective loge 
time-dependent covariates 
 
a
 loge transformed data;  b square root transformed data; Events = 126, censored = 2990; - 2 LL = 
703.617; Model chi square = 2537.137, p < 0.001 with df = 1 
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Table 3.51 - Three monthly variation in estimated hazard ratios (HR) for index loop 
diuretic prescription after index metformin-sulphonylurea or thiazolidinedione 
prescription.  HR were estimated at six months, nine months and one year for all 
significant covariates in loop Cox regression model 2 
 
 
Time-dependent covariates 
 
 
HR at 6 months  
(180 days) 
  
 
HR at 9 months  
(270 days) 
 
HR at 12 months  
(365 days) 
    
Age (years) 1.07 1.00 0.95 
Body mass index (kg/m2) 1.10 1.03 0.97 
Systolic blood pressure (mmHg) 1.01 0.99 0.97 
Haematocrit (%) 1.09 0.95 0.86 
Serum albumin (g/L) a 0.32 0.11 0.05 
Alanine aminotransferase (IU/L)a 1.22 0.44 0.21 
Nitrates 1.66 1.66 1.66 
    
 
a
 loge transformed data 
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Figure 3.14 - Variation in hazard ratio values for index loop diuretic prescription within one year of index metformin-sulphonylurea 
combination or thiazolidinedione prescription: loop Cox regression model 2. Data are plotted at 180, 270 and 365 days. Patients treated with 
metformin-sulphonylurea combination or thiazolidinedione therapy for less than 90 days were excluded 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Hazard ratio
(HR)
Age (years)
Body mass index (kg/m2)
Systolic blood pressure (mmHg)
Serum haematocrit (%)
Serum albumin (g/L)¹
Alanine aminotransferase (IU/L)¹
Nitrates
180 days 270 days 365 days
1
 Loge transformed data 
350 
 
 
3.14 Logistic regression model: predicting risk factors for incident heart failure 
events occurring within one year after index metformin-sulphonylurea 
combination or thiazolidinedione therapy 
 
 
3.14.1 Univariate logistic regression 
 
Univariate analysis found that incident HF occurring within one year of inclusion 
into either the metformin-sulphonylurea/thiazolidinedione cohort was significantly 
associated with the following characteristics (tables 3.52 and 3.53): 
 
Demographics 
• age in years [OR 1.064 (95% CI 1.040, 1.088); p < 0.001] 
• diabetes duration in years (square root transformed data) [OR 1.503 (95% CI 1.209, 
1.867); p < 0.001]  
• female gender [OR 0.644 (95% CI 0.401, 1.036); p = 0.070] 
 
Past medical history 
• baseline macrovascular disease [OR 4.711 (95% CI 2.997, 7.405); p < 0.001] 
 
Drug history 
• baseline potassium channel blocker/aldosterone antagonist therapy [OR 3.744  
(95% CI 1.902, 7.373); p < 0.001]  
• baseline verapamil therapy [OR 4.470 (95% CI 1.764, 11.326); p = 0.002] 
• baseline diltiazem therapy [OR 2.233 (95% CI 1.221, 4.082); p = 0.009]  
• baseline beta blocker therapy [OR 2.066 (95% CI 1.307, 3.268); p = 0.002] 
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• baseline alpha adrenoceptor drugs [OR 1.794 (95% CI 0.963, 3.341); p = 
0.066] 
• baseline nitrates [OR 3.773 (95% CI 2.402, 5.928); p = 0.041] 
• baseline other antianginals [OR 2.419 (95% CI 0.964, 6.066); p = 0.060] 
 
Laboratory-based clinical  investigations 
• baseline haematocrit expressed as % value [OR 0.902 (95% CI 0.845, 0.962); 
p = 0.002] 
• baseline HDL-C concentration in mmol/L (loge transformed data) [OR 3.495 (95% 
CI 1.204, 10.146); p = 0.021] 
• baseline estimated glomerular filration rate in mls/min/1.73m2 (loge transformed 
data) [OR 0.305 (95% CI 0.171, 0.543); p < 0.001] 
• baseline serum creatinine > 130 µmol/L [OR 3.586 (95% CI 1.810, 7.104); p 
< 0.001]  
• baseline serum albumin in g/L (loge transformed data) [OR 0.135 (95% CI 0.051, 
0.359); p < 0.001]  
• baseline alanine aminotransferase in IU/L (loge transformed data) [OR 0.428 (95% 
CI 0.254, 0.721); p = 0.001] 
 
3.14.2 Multivariate logistic regression  
 
28 and 49 patients developed incident HF within one year after exposure to 
thiazolidinedione therapy and metformin-sulphonylurea combination therapy 
respectively. 2521 thiazolidinedione-treated patients and 3427 patients on 
metformin-sulphonylurea combination therapy remained incident HF free within one  
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Table 3.52 - Univariate logistic regression analysis: baseline continuous independent variables predicting incident heart failure events within 
one year of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort. 
 
 
 
Baseline continuous variable 
 
 
N 
[index loop 
diuretics 
prescribed 
(patients with 
variable 
data)] 
 
 
 
B 
 
 
SE 
 
 
Wald 
 
 
df 
 
 
p 
 
 
OR 
 
(Exp [B]) 
 
  
Lower  
95% CI 
 for  
Exp (B) 
 
 
 
Upper 
95% CI 
for  
Exp (B) 
 
 
NR2 
 
 
H-L statistic 
            
Age (years) 77 (6025) 0.062 0.012 27.911 1 < 0.001 1.064 1.040 1.088 0.038 0.850 
Diabetes duration (years)a  77 (6025) 0407 0.111 13.509 1 < 0.001 1.503 1.209 1.867 0.017 0.414 
            
MAP (mmHg) 66 (5302) - 0.005 0.014 0.105 1 0.745 0.996 0.969 1.023 0.000 0.432 
SBP (mmHg) 66 (5302) 0.009 0.008 1.353 1 0.245 1.009 0.994 1.026 0.002 0.961 
DBP (mmHg) 66 (5302) - 0.023 0.015 2.380 1 0.123 0.978 0.950 1.006 0.004 0.026 
Weight (kg) 66 (5520) 0.004 0.007 0.331 1 0.565 1.004 0.990 1.018 0.000 0.838 
BMI (kg/m2) 66 (5520) 0.008 0.022 0.113 1 0.736 1.008 0.964 1.053 0.000 0.259 
            
Haematocrit (%) 46 (4525) -0.104 0.033 9.893 1 0.002 0.902 0.845 0.962 0.019 0.670 
HbA1c (%) 68 (5638) 0.112 0.077 2.075 1 0.150 1.118 0.961 1.302 0.003 0.758 
Total cholesterol (mmol/L)b 66 (5466) 0.817 0.537 2.315 1 0.128 2.265 0.790 6.491 0.003 0.367 
HDL-C (mmol/L)b 50 (4931) 1.251 0.544 5.296 1 0.021 3.495 1.204 10.146 0.010 0.177 
LDL-C (mmol/L)a 41 (3717) 0.370 0.491 0.569 1 0.451 1.448 0.553 3.789 0.001 0.121 
Triglycerides (mmol/L)b 51 (4267) - 0.392 0.260 2.271 1 0.132 0.676 0.406 1.125 0.004 0.201 
ALT (IU/L)b 63 (5026) - 0.848 0.266 10.184 1 0.001 0.428 0.254 0.721 0.017 0.061 
Sodium (mmol/L) 69 (5571) - 0.019 0.042 0.199 1 0.655 0.981 0.904 1.066 0.000 0.448 
eGFR (mls/min/1.73m2)b 61 (5012) - 1.188 0.294 16.278 1 < 0.001 0.305 0.171 0.543 0.025 0.022 
TSH (mIU/L) 57 (4806) 0.002 0.088 0.001 1 0.980 1.002 0.844 1.190 0.000 0.061 
Serum albumin (g/L)b 68 (5278) - 2.005 0.500 16.077 1 < 0.001 0.135 0.051 0.359 0.024 0.577 
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Baseline continuous 
variable 
 
 
N 
(index loop 
diuretics 
prescribed 
[patients 
with variable 
data]) 
 
 
 
B 
 
 
SE 
 
 
Wald 
 
 
df 
 
 
p 
 
 
OR 
 
[Exp (B)] 
 
 
 Lower 
95% CI 
for Exp 
(B) 
 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
 
NR2 
 
 
H-L 
statistic 
            
TZD dose (% 
maximal)b 28 (2549) - 0.004 0.556 0.000 1 0.995 0.996 0.335 2.964 0.000 0.033 
            
IVS (cm) 6 (447) 0.573 1.405 0.166 1 0.683 1.773 0.113 27.847 0.003 0.629 
LVPW (cm)b 5 (397) 0.444 2.044 0.047 1 0.828 1.558 0.028 85.697 0.001 0.787 
            
 
 
ALT, alanine aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin; Hct, 
haematocrit; HDL-C, high density lipoprotein cholesterol; IVS, interventricular septum width; LDL-C, low density lipoprotein cholesterol; LVM, left ventricular mass; 
LVPW, left ventricular posterior wall thickness; MAP, mean arterial pressure; SBP, systolic blood pressure; TSH, thyroid stimulating hormone; TZD thiazolidinedione; a 
square root transformed data; b loge transformed data  
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Table 3.53 - Univariate logistic regression analysis: baseline categorical independent variables predicting index heart failure events within 
one year of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort. 
 
 
Baseline categorical 
variable 
 
 
N 
[categorical variable of 
interest (patients with 
variable data)] 
 
 
N 
[categorical 
variable loop 
diuretic +ve 
(categorical 
variable loop 
diuretic –ve)] 
 
 
 
B 
 
 
SE 
 
 
Wald 
 
 
df 
 
 
p 
 
 
OR 
 
[Exp 
(B) 
 
 
 Lower 
95%  
CI  
 for Exp 
(B) 
 
 
 
Upper 
95% CI 
 for Exp 
(B) 
 
 
NR2 
            
Male gender 3372 (6025) 51 (3321) 0.439 0.242 3.285 1 0.070 1.552 0.965 2.495 0.004 
Female gender 2653 (6025) 26 (2627) - 0.439 0.242 3.285 1 0.070 0.644 0.401 1.036 0.004 
TZD + insulin 92 (2549) 2 (90) 0.731 0.742 0.972 1 0.324 2.078 0.486 8.889 0.003 
TZD (vs MFSU) 2549 (6025) 28 (2521) - 0.253 0.238 1.123 1 0.289 0.777 0.487 1.239 0.001 
            
Creat  >130µmol/L 68 (5278) 10 (58) 1.277 0.349 13.409 1 <0.001 3.586 1.810 7.104 0.015 
            
Peripheral vasodilators 287 (6025) 2 (285) - 0.635 0.719 0.780 1 0.377 0.530 0.129 2.169 0.001 
Thiazide diuretics 2045 (6025) 24 (2021) - 0.128 0.248 0.267 1 0.605 0.880 0.542 1.429 0.000 
Potassium sp. diuretics 238 (6025) 10 (228) 1.320 0.346 14.588 1 <0.001 3.744 1.902 7.373 0.014 
NSAIDs 4224 (6025) 52 (4172) - 0.122 0.245 0.247 1 0.620 0.885 0.548 1.431 0.000 
Dihydropyridine CCBs 2257 (6025) 34 (2223) 0.281 0.231 1.483 1 0.223 1.325 0.842 2.084 0.002 
Verapamil 96 (6025) 5 (91) 1.497 0.474 9.962 1 0.002 4.470 1.764 11.326 0.009 
Diltiazem 428 (6025) 13 (496) 0.803 0.308 6.809 1 0.009 2.233 1.221 4.082 0.007 
Beta blockers 2532 (6025) 46 (2486) 0.726 0.234 9.633 1 0.002 2.066 1.307 3.268 0.013 
Vasodilat 36 (6025) 1 (35) 0.799 1.021 0.612 1 0.434 2.223 0.301 16.435 0.001 
Caanitht 94 (6025) 1 (93) - 0.188 1.012 0.035 1 0.852 0.828 0.114 6.020 0.000 
Anbd 13 (6025) 0 (13) - 16.858 11147.52 0.000 1 0.999 0.000 0.000 - 0.000 
Aabd 567 (6025) 12 (555) 0.584 0.317 3.391 1 0.066 1.794 0.963 3.341 0.004 
ACEI 2924 (6025) 44 (2880) 0.351 0.232 2.293 1 0.130 1.420 0.902 2.237 0.003 
ARB 745 (6025) 10 (735) 0.057 0.341 0.028 1 0.868 1.059 0.542 2.066 0.000 
Nitrate 1420 (6025) 41 (1379) 1.328 0.230 33.204 1 <0.001 3.773 2.402 5.928 0.041 
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Baseline categorical 
variable 
 
 
N 
(categorical 
variable of 
interest 
[patients with 
variable data]) 
 
 
N 
(categorical 
variable loop 
diuretic +ve 
[categorical 
variable loop 
diuretic -ve) 
 
 
 
B 
 
 
SE 
 
 
Wald 
 
 
df 
 
 
p 
 
 
OR 
 
[Exp (B)] 
 
 Lower 
95% CI 
for Exp 
(B) 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
 
NR2 
            
Otherantiang 171 (6025) 5 (166) 0.883 0.469 3.545 1 0.060 2.419 0.964 6.066 0.004 
            
Macrovascular disease 1199 (6025) 41 (1158) 1.550 0.231 45.119 1 <0.001 4.711 2.997 7.405 0.055 
            
LVM  >228g 5 (392) 2 (3) - 0.462 0.919 0.253 1 0.615 0.630 0.104 3.811 0.005 
            
 
aabd, alpha adrenoceptor drugs; ACEI, angiotensin converting enzyme inhibitors; anbd, adrenergic neurone blocking drugs; ARB, angiotensin II receptor antagonists; 
caantiht, centrally acting antihypertensive drugs; creat, serum creatinine; Dihydropyridine ccb, dihydropyridine calcium channel blockers;  Ks, potassium sparing diuretic 
therapy; LVM, left ventricular mass; MFSU, metformin-sulphonylurea combination therapy; NSAID, non-steroidal anti-inflammatory drug; otherantiang, other antianginal 
drugs; peripheral vasodilators, peripheral vasodilator therapy; reninh, renin inhibitors; TZD, thiazolidinedione; TZD + insulin, thiazolidinedione-insulin combination 
therapy; vasodilat, vasodilator antihypertensive drugs 
 
 
 
 
 
 
 
 
 
 
356 
 
 
year after inclusion into their respective cohort. Hence, the overall proportion of 
patients developing incident HF amounts to 0.0129455 (or 1.29%).  
 
As advised by Peduzzi et al. [609], given the proportion of patients developing 
incident HF within one year after index thiazolidinedione prescription, the maximum 
number of covariates that can be included in any model amounted to eight. 
 
(i) Incident heart failure logistic regression model 1 
 
Based on univariate analysis (tables 3.52 and 3.53), and taking into account the 
number of patients for whom data for each covariate were available, the following 
predictors (covariates) were included: 
• Age (years) 
• diabetes duration (years) (square root transformed data) 
• baseline ALT (IU/L) (loge transformed data) 
• baseline albumin (g/L) (loge transformed data) 
• baseline serum creatinine > 130 μmol/L 
• female gender 
• baseline macrovascular disease (composite of coronary artery disease, 
peripheral artery disease and cerebrovascular disease) 
• index thiazolidinedione prescription (vs MFSU)  
 
4690 patients were included into the logistic regression model. Employing a 
significance level of 0.05, the Wald criterion demonstrated that age, baseline serum 
albumin, baseline serum creatinine and baseline macrovascular disease made a 
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significant contribution to prediction (see table 3.54). A test of the full model versus 
a model with intercept only was statistically significant (chi square 70.293, p < 0.001 
with df = 4). Hosmer and Leneshow test statistic indicated that the model’s estimates 
fit the data at an acceptable level (chi square 5.661, df = 8, p = 0.685). Nagelkerke’s 
R2 = 0.113, effectively indicating a relationship of 11.3% between predictors 
(covariates) and the prediction (i.e. incident HF within one year of inclusion into the 
cohort). Prediction success overall was 98.8%.  
 
As shown in the final model (table 3.54), index thiazolidinedione prescription per se 
does not emerge as a significant predictor, suggesting that the risk factors for 
developing of incident HF are similar to those for patients prescribed metformin-
sulphonylurea combination therapy. Once again, Wald’s statistics for baseline 
macrovascular disease suggest it is the strongest predictor. It is associated with more 
than four times higher risk of progression to incident HF within one year of index 
metformin-sulphonylurea or thiazolidinedione prescription, assuming all other 
covariates are unchanged during the observation period. Likewise, a baseline serum 
creatinine exceeding 130 µmol/L at index metformin-sulphonylurea or 
thiazolidinedione prescription is the second most strong predictor in this model, 
being associated with more than two fold higher risk of progression to HF. Each 
passing year of life is associated with a 4.9 % increased risk of developing incident 
HF in this scenario. Inverting odds ratios, and holding all other covariates constant, 
each 1 g/dL reduction in baseline loge serum albumin at index metformin-
sulphonylurea combination or thiazolidinedione prescription results in an 3.42 fold 
increased risk of developing incident HF within one year.  
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Table 3.54 - Incident heart failure binary logistic regression model 1 - final model 
covariates predicting incident heart failure within one year of exposure to index 
metformin-sulphonylurea combination or thiazolidinedione therapy* 
 
 
Final model covariates 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Odds 
ratio 
 
[exp (B)] 
 
 
95% 
CI 
lower 
 
95% 
CI 
upper 
         
Baseline 
macrovascular disease 1.415 0.268 27.859 1 < 0.001 4.118 2.435 6.966 
Age  
(years) 0.047 0.014 11.304 1 < 0.001 1.049 1.020 1.078 
Baseline serum 
creatinine > 
130μmol/L 
0.821 0.365 5.074 1 0.024 2.273 1.113 4.644 
Baseline serum 
albumin (g/L)a  -1.232 0.552 4.982 1 0.026 0.292 0.099 0.861 
Constant - 5.832 1.648 12.521 1 < 0.001 0.003   
         
 
* Baseline covariates included in the model were age, diabetes durationb, female gender, alanine 
aminotransferasea, serum albumina, serum creatinine > 130µmol/L, macrovascular disease and 
index thiazolidinedione therapy (vs metformin-sulphonylurea combination therapy); a loge 
transformed data; b square root transformed data 
 
Model chi square 70.293, p < 0.001 with df = 4; NR2 = 0.116; H-L statistic chi square = 5.661, p = 
0.685 with df =8; - 2 LL = 587.545; prediction success overall = 98.8%; ROC (AUC) = 0.800 (95% 
CI 0.754, 0.846), p < 0.001 
 
 
ROC curve analysis was used to discriminate between positive and negative cases. 
Concardance index (c-statistic/AUC) for this model amounted to 0.800 (95% CI 
0.754, 0.846) (p < 0.001), suggesting that the final model has an ability to distinguish 
between the two outcome groups.  
 
(ii) Incident heart failure logistic regression model 2 
 
Given the constraints of including additional covariates into the model (discussed 
above), an additional binary logistic regression model was run to explore the 
potential impact of baseline haematocrit on the model. Replacing female gender and 
retaining all other baseline covariates, age, serum albumin, serum creatinine > 130 
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µmol/L and macrovascular disease remained significant predictors of incident HF 
within one year in the final model (table 3.55). 
 
 
Table 3.55 - Incident heart failure binary logistic regression model 2 - final model 
covariates predicting incident heart failure within one year of exposure to index 
metformin-sulphonylurea combination or thiazolidinedione therapy* 
 
 
Final model covariates 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Odds 
ratio 
 
[exp (B)] 
 
 
95% 
CI 
lower 
 
95% 
CI 
upper 
         
Baseline 
macrovascular disease 1.729 0.332 21.173 1 < 0.001 5.636 2.942 10.797 
Age  
(years) 0.047 0.017 7.835 1 0.005 1.048 1.014 1.082 
Baseline serum 
creatinine > 
130μmol/L 
1.032 0.395 6.817 1 0.009 2.805 1.293 6.085 
Baseline serum 
albumin (g/L) a -1.337 0.647 4.273 1 0.039 0.263 0.074 0.933 
Constant - 6.021 1.943 9.606 1 0.002 0.002   
         
*Baseline covariates included in the model were age, diabetes duration b, haematocrit, alanine 
aminotransferase a, serum albumin a, serum creatinine > 130 µmol/L, macrovascular disease and 
index thiazolidinedione therapy (vs metformin-sulphonylurea combination therapy); a loge 
transformed data; b square root transformed data 
 
Model chi square = 67.106, p < 0.001 with df = 4; NR2 = 0.144; H-L statistic chi square = 6.621, p = 
0.578 with df =8; - 2LL = 423.324; prediction success overall = 99.0%; AUC = 0.798 (95% CI 
0.752, 0.844), p < 0.001 
 
 
3.15 Cox regression model: predicting risk factors for incident heart failure 
events occurring within one year after index metformin-sulphonylurea 
combination or thiazolidinedione therapy 
 
 
3.15.1 Univariate Cox regression 
 
On univariate analysis, the following clinical and pathological factors were 
associated with time to incident HF, as outlined fully in tables 3.56 and 3.57: 
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Demographics 
• age in years [HR 1.066 (95% CI 1.041, 1.090); p < 0.001]  
• diabetes duration in years (square root transformed data) [HR 1.513 (95% CI 1.219, 
1.876); p < 0.001]  
• female gender (p = 0.082)  
 
Past medical history 
• baseline macrovascular disease (p < 0.001)  
 
Drug history 
• baseline potassium channel blocker/aldosterone antagonist therapy (p < 
0.001)  
• baseline verapamil therapy (p = 0.001)  
• baseline diltiazem therapy (p = 0.007)  
• baseline beta blocker therapy (p = 0.001)  
• baseline alpha adrenoceptor blocking drugs (p = 0.048)  
• baseline nitrates (p < 0.001) 
• baseline other antianginal drugs (p = 0.051) 
 
Laboratory-based clinical  investigations 
• baseline haematocrit expressed as % value [HR 0.900  (95% CI 0.845, 
0.959); p = 0.001] 
• baseline HDL-C concentration in mmol/L (loge transformed data) [HR 3.515 (95% 
CI 1.203, 10.268); p = 0.022] 
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• baseline estimated glomerular filration rate in mls/min/1.73m2 (loge transformed 
data) [HR 0.984 (95% CI 0.975, 0.992); p < 0.001] 
• baseline serum creatinine > 130 µmol/L (p < 0.001)  
• baseline serum albumin in g/L (loge transformed data) [HR 0.129 (95% CI 0.048, 
0.345); p < 0.001] 
• baseline alanine aminotransferase in IU/L (loge transformed data) [HR 0.413 (95% 
CI 0.245, 0.696); p = 0.001]  
 
3.15.2 Multivariate Cox regression  
 
Based on the outcomes of univariate analysis, Cox regression was used to assess the 
strength of association between time to incident HF and clinical and pathological risk 
factors. As outlined in multivariate logistic regression analysis, the maximum 
number of covariates that could be included in Cox regression analysis, based on the 
available data, amounted to eight. 
 
(i) Incident heart failure Cox regression model  
 
Variables  (covariates) included in multivariate Cox regression analysis were those 
deemed significant (p < 0.1) on univariate screening (as summarised in tables 3.56 
and 3.57), namely: 
• Age (years) 
• Diabetes duration (years) (square root transformed data) 
• Baseline haematocrit (%) 
• serum creatinine > 130 µmol 
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Table 3.56 - Univariate Cox regression: baseline continuous independent variable predicting incident heart failure events occurring within 
one year of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort. 
 
 
Baseline continuous variable 
 
N 
[HF+ 
(patients with 
variable 
data)] 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Hazard 
ratio 
 
[Exp (B)] 
 
 
 Lower 
95% CI for 
Exp (B) 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
- 2 Log 
Likelehood 
           
Age 77 (6025) 0.063 0.012 29.177 1 <0.001 1.066 1.041 1.090 1291.793 
Diabetes duration (years) a 77 (6025) 0.414 0.110 14.173 1 <0.001 1.513 1.219 1.876 1308.752 
           
MAP (mmHg) 66 (5302) - 0.006 0.014 0.166 1 0.684 0.994 0.968 1.022 1116.980 
SBP (mmHg) 66 (5302) 0.009 0.008 1.235 1 0.266 1.009 0.993 1.025 1115.937 
DBP (mmHg) 66 (5302) - 0.024 0.015 2.677 1 0.102 0.976 0.948 1.005 1114.471 
Weight (kg) 66 (5520) 0.004 0.007 0.272 1 0.602 1.004 0.990 1.017 1122.252 
BMI (kg/m2) 66 (5520) 0.007 0.022 0.094 1 0.759 1.007 0.964 1.052 1122.428 
           
Haematocrit (%) 46 (4525) - 0.105 0.032 10.747 1 0.001 0.900 0.845 0.959 754.198 
HbA1c (%) 68 (5638) 0.120 0.077 2.397 1 0.122 1.127 0.969 1.312 1157.427 
Total cholesterol (mmol/L) b 66 (5466) 0.748 0.537 1.940 1 0.164 2.114 0.737 6.060 1188.260 
HDL-C (mmol/L) b 50 (4931) 1.257 0.547 5.283 1 0.022 3.515 1.203 10.268 832.495 
LDL-C (mmol/L) a 41 (3717) 0.333 0.487 0.467 1 0.494 1.395 0.537 3.627 661.400 
Triglycerides (mmol/L) b 51 (4267) - 0.415 0.259 2.556 1 0.110 0.661 0.397 1.098 835.814 
ALT (IU/L) b 63 (5026) - 0.884 0.266 11.046 1 0.001 0.413 0.245 0.696 1046.630 
Sodium (mmol/L) 69 (5571) - 0.020 0.042 0.230 1 0.631 0.980 0.902 1.065 1173.750 
Egfr (mls/min/1.73m2) b 61 (5012) - 0.016 0.004 13.388 1 <0.001 0.984 0.975 0.992 1009.952 
TSH (mIU/L) 57 (4806) 0.009 0.088 0.010 1 0.921 1.009 0.848 1.200 953.295 
Serum albumin (g/L) b 68 (5278) - 2.051 0.504 16.597 1 <0.001 0.129 0.048 0.345 1133.048 
TZD dose (% maximal) b 28 (2549) - 0.179 0.554 0.104 1 0.747 0.836 0.282 2.478 431.999 
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Baseline continuous 
variable 
 
N 
(index loop 
diuretics 
prescribed 
[patients with 
variable 
data]) 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Hazard 
ratio 
 
[Exp (B)] 
 
Lower 
95% CI 
for Exp 
(B) 
 
 
Upper 
95% CI 
for Exp 
(B) 
 
- 2 Log 
Likelehood 
           
Baseline IVS (cm) 6 (447) 0.682 1.439 0.225 1 0.636 1.978 0.118 33.217 71.841 
Baseline LVPW (cm) b 5 (397) 0.512 1.976 0.067 1 0.796 1.668 0.035 80.266 58.636 
           
 
ALT, alanine aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin; Hct, 
haematocrit; HDL-C, high density lipoprotein cholesterol; IVS, interventricular septum width; LDL-C, low density lipoprotein cholesterol; LVM, left ventricular mass; 
LVPW, left ventricular posterior wall thickness; MAP, mean arterial pressure; SBP, systolic blood pressure; TSH, thyroid stimulating hormone; TZD thiazolidinedione; a 
square root transformed data; b loge transformed data 
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Table 3.57 - Univariate Cox regression analysis (Kaplan-Meier survival): baseline categorical independent variables predicting incident 
heart failure events occurring within one year of inclusion into the metformin-sulphonylurea or thiazolidinedione cohort 
 
  
 
Categorical variable of interest 
 
 
Comparator categorical variable  
 
 
Log rank test 
 
Baseline categorical variable of 
interest 
 
N 
(categorical variable 
of interest [patients 
with variable data]) 
 
N 
HF +ve 
(patients 
with 
comparator 
variable 
data) 
 
 
Mean 
 Survival 
 time 
 
SE 
Survival 
 time 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
Mean 
 Survival 
 time 
 
SE 
Survival 
 time 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
Chi 
Square  
 
df 
 
p 
 
   
           
Male gender 3372 (6025) 51 (3321) 362.488 0.407 361.691 363.285 363.273 0.389 362.511 364.036 3.026 1 0.082 
Female gender 2653 (6025) 26 (2627) 363.273 0.389 362.511 364.036 362.488 0.407 361.691 363.285 3.026 1 0.082 
TZD (vs MFSU) 92 (2549) 2 (90) 359.462 3.876 351.864 367.060 363.413 0.374 362.679 364.147 1.781 1 0.182 
TZD + insulin 2549 (6025) 28 (2521) 363.279 0.385 362.525 364.034 362.504 0.405 361.709 363.299 1.089 1 0.297 
   
           
Creat > 130 µmol/L 68 (5278) 10 (58) 356.268 2.904 350.576 361.960 363.108 0.289 362.541 363.675 17.428 1 < 0.001 
   
           
Peripheral vasodilators 287 (6025) 2 (285) 363.900 0.811 362.310 365.489 362.777 0.297 362.196 363.358 0.782 1 0.377 
Thiazide diuretics 2045 (6025) 24 (2021) 362.948 0.473 362.021 363.876 362.771 0.357 362.073 363.470 0.197 1 0.666 
Potassium sp. diuretics 238 (6025) 10 (228) 357.899 2.673 352.660 363.139 363.031 0.276 362.491 363.572 17.448 1 < 0.001 
NSAIDs 4224 (6025) 52 (4172) 362.909 0.338 362.246 363.572 362.653 0.529 361.617 363.688 0.178 1 0.673 
Dihydropyridine CCBs 2257 (6025) 34 (2223) 362.530 0.493 361.562 363.497 363.011 0.347 362.331 363.691 1.610 1 0.204 
Verapamil 96 (6025) 5 (91) 362.115 1.532 359.112 365.118 362.843 0.289 362.278 363.409 11.885 1 0.001 
Diltiazem 428 (6025) 13 (496) 359.953 1.505 357.002 362.903 363.095 0.279 362.549 363.641 7.400 1 0.007 
Beta blockers 2532 (6025) 46 (2486) 361.719 0.546 360.648 362.790 363.638 0.290 362.069 364.208 10.210 1 0.001 
Vasodilat 36 (6025) 1 (35) 356.278 8.600 339.421 373.134 362.870 0.282 362.317 363.423 0.660 1 0.417 
Caanitht 94 (6025) 1 (93) 362.725 2.261 358.294 367.156 362.831 0.288 362.267 363.395 0.025 1 0.873 
Anbd 13 (6025) 0 (13) - - - - - - - - 0.177 1 0.674 
Aabd 567 (6025) 12 (555) 361.850 1.053 359.786 363.913 362.928 0.295 362.349 363.507 3.918 1 0.048 
ACEI 2924 (6025) 44 (2880) 362.581 0.429 361.740 363.422 363.065 0.378 362.324 363.806 2.546 1 0.111 
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Categorical variable of interest 
 
 
Comparator categorical variable  
 
 
Log rank test 
 
Baseline categorical variable of 
interest 
 
N 
(categorical variable of 
interest [patients with 
variable data]) 
 
N 
HF +ve 
[patients with 
comparator 
variable data])  
 
 
Mean 
 Survival 
 time 
 
SE 
Survival 
 time 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
Mean 
 Survival 
 time 
 
SE 
Survival 
 time 
 
Lower  
95%  
CI  
 for  
survival  
time  
 
 
Upper  
95%  
CI 
 for  
survival  
time 
 
Chi 
Square  
 
df 
 
p 
 
              
ARB 745 (6025) 10 (735) 362.339 0.902 360.570 364.107 362.898 0.300 362.311 363.486 0.067 1 0.796 
Nitrates 1420 (6025) 41 (1379) 359.537 0.942 357.691 361.383 363.844 0.233 363.388 364.300 39.136 1 <0.001 
Otherantiang 171 (6025) 5 (166) 359.774 2.782 354.320 365.227 362.921 0.282 362.368 363.473 3.794 1 0.051 
              
Macrovascular disease 1199 (6025) 41 (1158) 358.644 1.105 356.479 360.809 363.870 0.224 363.430 364.309 55.665 1 <0.001 
              
LVM > 228g 5 (392) 2 (3) 363.198 1.413 360.429 365.966 361.786 2.052 357.765 365.807 0.230 1 0.631 
              
 
aabd, alpha adrenoceptor drugs; ACEI, angiotensin converting enzyme inhibitors; anbd, adrenergic neurone blocking drugs; ARB, angiotensin II receptor antagonists; 
caantiht, centrally acting antihypertensive drugs; dihydropyridine CCB, dihydropyridine calcium channel blockers;  potassium sp. diuretics, potassium sparing diuretic 
therapy; LVM, left ventricular mass; NSAID, non-steroidal anti-inflammatory drug; otherantiang, other antianginal drugs; TZD + insulin, thiazolidinedione-insulin 
combination therapy; vasodilat, vasodilator antihypertensive drugs  
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• Baseline serum albumin (g/L) (loge transformed data) 
• Baseline alanine aminotransferase (IU/L) (loge transformed data) 
• Baseline macrovascular disease 
• Index thiazolidinedione prescription (vs metformin-sulphonylurea) 
 
Given baseline serum creatinine > 130 µmol/L, macrovascular disease and index 
thiazolidinedione prescription defied the Proportional Hazards Assumption, time-
dependent variables were constructed for each variable by adding an interaction term 
that involved loge time (days) to index loop diuretic prescription into the Cox model, 
and testing for its significance. Time-dependent variables were also constructed in 
the same fashion for age, diabetes duration (square root transformed data), baseline 
haematocrit, serum albumin (loge transformed data) and alanine aminotransferase (loge 
transformed data) as evidence that hazard ratios for these covariates do not change over 
time. 
 
There were no significant interactions between any of the included covariates in this 
model. Out of a total of 4260 patients, for whom data were available for this model, 
44 patients developed incident HF within one year of prescription of metformin-
sulphonylurea combination or thiazolidinedione therapy. 4216 patients were 
censored within the aforementioned period of observation. The covariates as a set 
reliably improved the predictability of the Cox regression model (chi square 
2111.312, p < 0.001 with df = 13). The standard error (SE) of each variable included 
in the model was small, suggesting no significant multicollinearity. The Wald 
criterion demonstrated that (in decreasing order of importance) age, baseline 
haematocrit, serum albumin, baseline macrovascular disease, and baseline alanine 
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aminotransferase and their respective interactions with time made a significant 
contribution to predicting time to index loop diuretic prescription in this setting, as 
outlined in table 3.58. Baseline serum creatinine was a marginally significant 
covariate (p = 0.05). Covariate*time interactions suggested a decreasing hazard ratio 
over time for baseline macrovascular disease, alanine aminotransferase, serum 
creatinine and serum albumin. Hazard ratios for age and haematocrit, remained 
stable over the period of observation, in keeping with log-minus-log plots which had 
suggested that each of the latter covaariates satisfied the Proportiona Hazards 
Assumption (table 3.59, figure 3.15) 
 
There were insufficient data to permit modelling baseline drug therapy, left 
ventricular mass or interventricular septum width as covariates in a Cox regression 
model predicting incident HF events. 
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Table 3.58 - Incident heart failure Cox regression model 1 predicting incident heart failure events within one year of inclusion into the 
metformin-sulphonylurea combination or thiazolidinedione cohort. 
 
 
Final baseline 
model covariates 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Hazard ratio 
 
 
 
95% CI lower 
 
95% CI upper 
         
Age (years) 1.777 0.271 42.850 1 <0.001 5.911 3.472 10.062 
Haematocrit (%) 2.310 0.560 17.015 1 <0.001 10.070 3.361 30.174 
Serum creatinine > 130 µmol/L 11.015 5.610 3.855 1 0.050 60750.163 1.020 3619757003 
Serum albumin  (g/L) a 35.320 8.811 16.068 1 <0.001 2.184E+15 69049468.21 6.907E+22 
ALT (IU/L) a 17.043 5.614 9.217 1 0.002 25217422.95 420.051 1.514E+12 
Macrovascular disease 15.773 5.071 9.674 1 0.002 7079269.741 341.613 1.467E+11 
Age(years)*logetime -0.317 0.049 41.449 1 <0.001 0.728 0.661 0.802 
Haematocrit (%)*logetime -0.422 0.102 17.091 1 <0.001 0.656 0.537 0.801 
Serum creatinine > 130 µmol/L*logetime -1.939 1.064 3.323 1 0.068 0.144 0.018 1.157 
Serum albumin (g/L)*logetime -6.689 1.656 16.306 1 <0.001 0.001 <0.001 0.032 
ALT(IU/L) *logetime -3.058 1.033 8.762 1 0.003 0.047 0.006 0.356 
Macrovascular disease*logetime -2.532 0.929 7.422 1 0.006 0.080 0.013 0.492 
TZD (vs MFSU)*logetime 0.172 0.071 5.876 1 0.015 1.187 1.033 1.364 
         
 
*Baseline covariates included in the model were age, diabetes duration b, haematocrit, serum creatinine > 130 µmol/L, serum albumin a; alanine aminotransferase a, 
macrovascular disease, index thiazolidinedione (vs metformin-sulphonylurea therapy) 
a
 loge transformed data; b square root transformed data 
 
Events = 44 censored = 4216; - 2 LL = 230.664; Model chi square = 2111.312, p < 0.001 with df = 13 
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Table 3.59 - Incident heart failure Cox regression model 1 predicting incident 
heart failure within one year of inclusion into the metformin-sulphonylurea or 
thiazolidinedione cohort. Variation of estimated hazard ratios (HR) is given  at 
three monthly intervals (six months, nine months and one year) for all covariates. 
 
 
Time-dependent covariates 
 
 
HR at 6 months  
(180 days) 
 
 
HR at 9 months  
(270 days) 
 
HR at 12 months  
(365 days) 
    
Age (years) 1.141 1.002 0.911 
Haematocrit (%) 1.127 0.948 0.835 
Serum creatinine > 130 µmol/L 2.590 1.170 0.654 
Serum albumin (g/L)a 1.830 0.118 0.016 
Alanine aminotransferase (IU/L)a 3.228 0.921 0.368 
Macrovascular disease 13.900 4.922 2.303 
    
 
a
 loge transformed data 
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Figure 3.15 - Variation in hazard ratio values for incident heart failure developing within one year of index metformin-sulphonylurea 
combination or thiazolidinedione prescription. Data are plotted at 180, 270 and 365 days. Patients treated with metformin-sulphonylurea 
combination or thiazolidinedione therapy for less than 90 days were excluded. 
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3.16 Do CYP2C8*3 and *4 genotypes infer a reduced oedematogenic risk 
following thiazolidinedione exposure? 
 
Out of a total of 2664 thiazolidinedione-treated patients, CYP2C8 data were 
available for 1309 patients. Of these, 318 (24.3%) carried the CYP2C8*3 allele 
(whether homozygotes, heterozygotes or compound heterozygotes with CYP2C8*4), 
while 120 (9.2%) carried the CYP2C8*4 allele. Expressed differently, 888 (76.8%) 
were wild type carriers (CYP2C8 *1/*1), 372 (28.4%) were heterozygotes for the *3 
or *4 allele (CYP2C8 *1/*3 or *1/*4), whereas 49 (1.8%) were homozygotes or 
compound heterozygotes (CYP2C8 *3/*3, *3/*4 or *4/*4) 
 
There were no significant differences in the frequencies of index loop diuretic 
prescription or incident HF rates (occurring within one year of index 
thiazolidinedione prescription) between patients carrying at least one copy of the 
CYP2C8*3 or CYP2C8*4 allele and wild type carriers (CYP2C88 *1/*1) (Fisher 
exact test p = 0.483, 0.185 respectively). Likewise, as outlined in tables 3.60 and 
3.61 below, the frequency of occurrence of index loop diuretic prescription and 
incident HF was similar across heterozygous (CYP2C8 *1/*3 or CYP2C8 *1/*4), 
compound heterozygous (CYP2C8 *3/*4) and homozygous (CYP2C8 *3/*3 or 
CYP2C8 *4/*4) subgroups (compared to wild type carriers). 
 
Univariate logistic regression did not identify CYP2C8*3 or *4 variants as being 
significant risk factors for the outcomes of interest, whether in the heterozygous or 
homozygous state (tables 3.62 and 3.63 below). 
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Table 3.60 - Number (%) of patients treated with an index loop diuretic within one 
year after inclusion into the thiazolidinedone cohort. 
 
 
 
CYP2C8 genotype variant 
 
*1/*1 
 
 
*1/*3 or *1/*4 
 
*3/*3 or *3/*4 or 
*4/*4 
 
Index loop - ve 658 (95.8) 290 (96.7) 33 (94.3) 
Index loop +ve 29 (4.2) 10 (3.3) 2 (5.7) 
Loop data missing 201 72 14 
Total 888 372 49 
 
   
Chi Square = 0.700, p = 0.705 with df = 2 
 
 
Table 3.61 - Number (%) of patients developing heart failure within one year after 
inclusion into the thiazolidinedone cohort. 
 
 
 
CYP2C8 genotype variant 
 
*1/*1 
 
 
*1/*3 or *1/*4 
 
*3/*3 or *3/*4 or 
*4/*4 
 
HF - ve 847 (98.8) 350 (98.6) 46 (100) 
HF +ve 10 (1.2) 5 (1.4) 0 (0) 
HF data missing 31 17 3 
Total 888 372 49 
 
   
Chi Square = 0.701, p = 0.705 with df = 2 
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Table 3.62 - Univariate binary logistic regression predicting index loop diuretic prescription within one year of index 
thiazolidinedione therapy. 
 
Baseline categorical variable 
 
N 
(index loop 
diuretics 
prescribed 
[patients with 
variable data]) 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Odds  
ratio 
 
(Exp 
[B)]) 
 
Lower 
95% CI 
for Exp 
(B) 
 
 
Upper 
95% CI 
for Exp 
(B) 
          
CYP2C8 *3 variant 9/248 - 0.136 0.385 0.124 1 0.724 0.873 0.411 1.855 
CYP2C8 *4 variant 3/301 - 0.341 0.609 0.313 1 0.576 0.711 0.216 2.347 
CYP2C8 *3 or CYP2C8 *4 variant 12/335 - 0.171 0.350 0.238 1 0.625 0.843 0.425 1.674 
CYP2C8 *3/*3 (vs no *3) 1/16 0.436 1.048 0.173 1 0.678 1.546 0.198 12.067 
CYP2C8 *4/*4 (vs no *4) 1/5 1.759 1.130 2.423 1 0.120 5.809 0.634 53.233 
          
 
Table 3.63 - Univariate binary logistic regression predicting incident heart failure within one year of index thiazolidinedione therapy. 
 
Baseline categorical variable 
 
N 
(incident heart 
failure [patients 
with variable 
data]) 
 
 
B 
 
SE 
 
Wald 
 
df 
 
p 
 
Odds  
ratio 
 
(Exp 
[B)]) 
 
 
Lower 
95% CI 
for Exp 
(B) 
 
 
Upper 
95% CI 
for Exp 
(B) 
          
CYP2C8 *3 variant 4/302 0.142 0.588 0.059 1 0.808 1.153 0.364 3.648 
CYP2C8 *4 variant 1/115 - 0.346 1.040 0.111 1 0.739 0.707 0.092 5.429 
CYP2C8 *3 or CYP2C8 *4 variant 5/401 0.067 0.551 0.015 1 0.903 1.069 0.363 3.150 
CYP2C8 *3/*3 (vs no *3) 0/23 - 16.750 8380.814 0.000 1 0.998 0.000 0.000 - 
CYP2C8 *4/*4 (vs no *4) 0/23 - 18.813 15191.515 0.000 1 0.999 0.000 0.000 - 
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3.17  Discussion 
 
This study has identified risk factors for index loop diuretic prescription and incident 
HF in a cohort of T2DM patients treated with the most commonly prescribed 
anithyperglycaemic combination therapy (metformin and sulphonylureas) and 
thiazolidinediones. Importantly, available data suggest that risk factors for index 
loop diuretic prescription (a surrogate marker of fluid retention) and incident HF are 
shared between patients in both treatment categories, and that neither index 
metformin-sulphonylurea combination therapy nor thiazolidendione prescription are 
risk factors for these adverse events on multivariate analysis.  
 
To my knowledge, this is the first study comparing incident HF rates in these two 
treatment subgroups, as most available data have compared thiazolidinediones solely 
with monotherapy / placebo comparators. RECORD, an open-label prospective trial 
randomising T2DM patients inadequately controlled on metformin or sulphonylurea 
monotherapy to add-on rosiglitazone or metformin-sulphonylurea combination 
therapy, is a notable exception. The approach in the present study may be more 
generalisable as it mirrors clinical practice, particularly given the reported 
differential effects of metformin and sulphonylureas on incident HF events, and 
recurrent HF in T2DM patients with established HF.  
 
Given the unanticipated difficulties recruiting patients for my clinical study, analysis 
of population-based data of clinically significant peripheral oedema necessitating 
index loop diuretic therapy was a novel approach to unravelling the mechanisms 
underpinning thiazolidinedione-associated fluid overload. Based on available 
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evidence, one may consider this surrogate marker of fluid overload as a sentinel sign 
of clinical HF or (unexplained) peripheral oedema [610]. In PROactive, 27.4% of 
patients randomised to pioglitazone reported oedema [vs 15.9% (placebo); < 0.001), 
while 21.6% developed serious or nonserious oedema without HF [vs 13.0% 
(placebo); p < 0.001]. Oedema preceded HF in 34.2% and 24.1% of patients 
randomised to pioglitazone and placebo respectively [261]. An insulin comparator 
subgroup was included as a valuable source of descriptive data, given the reported 
association of insulin therapy with fluid overload [352, 611-613], but was not 
included in multivariate analysis, given that insulin therapy is generally reserved for 
patients at a more advanced stage of T2DM.  
 
The relative frequency of prescription of thiazolidinediones to patients with 
established HF (4.32%), albeit lower than for metformin-sulphonylurea combination 
(6.21%) and insulin therapy (17.60%) is rather surprising, given the unequivocal 
advice voiced by multiple clinical practice guidelines. Nonetheless, thiazolidinedione 
prescription among such patients was lower than that reported among Medicare 
beneficiaries (7.1% for patients prescribed between 1998-1999 and 16.1% for those 
prescribed between 2000-2001) [614]. Similarly, a retrospective analysis of 24 746 
elderly Korean patients with T2DM reported that thiazolidinediones were prescribed 
to 10.4% of patients with established HF and 8.8% of patients without [615].  
 
While following similar trends, thiazolidinedione prescription rates among patients 
prone to oedema (and hence loop diuretic prescription) were even higher (21.28%). 
Differences generally reached statistical signifance with either comparator cohorts 
on post-hoc testing. There were no differences in background use of loop diuretics 
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between metformin-sulphonylurea and thiazolidinedione-treated female patients, and 
for background HF rates between metformin-sulphonylurea and thiazolidinedione-
treated male patients. Results of the latter two post-hoc analyses may have been 
limited by sample size, and do not necessarily reflect gender related differences in 
prescription practices. Despite the reported association between insulin therapy and 
fluid retention / HF [352], insulin prescription was necessarily more likely in patients 
prone to cardiovascular disease and renal impairment, possibly as a consequence of 
progressive beta-cell exhaustion precipitating inadequate glycaemic control on 
established oral glucose lowering agents.  
 
This study reported that 1.1% of patients develop incident HF within one year of 
their thiazolidinedione prescription. This rate was considerably lower than for insulin 
therapy (3.5%), and comparable to metformin-sulphonylurea combination therapy 
(1.4%). This study’s reported incident HF rates for thiazolidinedione-treated patients 
(rosiglitazone / pioglitazone) was virtually twice that reported in the DREAM trial 
(rosigitazone, 0.54%), comparable to HF events in ADOPT (rosligitazone, 1.51%) 
and considerably lower than those reported in RECORD (rosiglitazone, 2.7%) and 
PROactive (pioglitazone, 10.7%). 4.3% of patients in this study's cohort required 
prescription of an index loop diuretic (a surrogate marker of oedema) within one 
year of exposure to a thiazolidinedione. This is considerably lower than that reported 
in DREAM (6.6%), ADOPT (14.1%) and ProACTIVE (21.6%). However, as has 
been ascertained in the introductory chapter, these four prospective trials recruited 
patients with a spectrum of glycaemia and cardiovascular risk, ranging from 
prediabetes (DREAM) to pharmacologically naïve T2DM (ADOPT), high risk 
T2DM inadequately controlled on metformin or sulphonylurea monotherapy 
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(RECORD) and T2DM treated with diet or oral glucose lowering agents or insulin 
(PROactive).  
 
Comparisons of incident HF rates need to be made with caution, given differences in 
HF definitions across these four prospective trials. Moreover, none of these trials 
were primarily designed to investigate oedema and HF rates. All four prospective 
trials captured incident HF events for a longer time period ranging from 34.5 months 
(PROactive) to 66 months (RECORD), and did not report outcomes after one year of 
treatment. Oedema outcomes were likewise reported at the end of the observation 
period in all four prospective trials (except RECORD). Given the published effects 
of rosiglitazone and pioglitazone on other macrovascular outcomes, capturing 
incident HF and index loop diuretic prescription within one year of prescription of a 
thiazolidinedione (or comparator drug) was more likely to yield unbiased 
information on the outcome of interest.  
 
Unlike these four prospective clinical trials, this study's retrospective analyses did 
not permit a comparison of incident HF events between rosiglitazone and 
pioglitazone-treated patients. Patients recruited in these prospective trials were 
generally younger (mean range 54.7 [DREAM] to 61.8 [PROactive] years vs mean 
[SD] = 63.23 [9.77] years for this study). Additionally, patients recruited in each 
study were characterised by a relatively homogenous cardiovascular risk (ranging 
from low-risk pre-diabetes [DREAM] to high risk T2DM patients [PROactive]). As 
15.1% of patients were known to suffer from macrovascular disease at index 
thiazolidinedione prescription, this study's cohort encompasses T2DM patients with 
a range of cardiovascular risk, akin to that in a T2DM population. This study's 
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observations of higher (unadjusted) incident HF rates for insulin-treated T2DM are 
consistent with those reported by several observational studies on multivariate 
adjustment [239, 277, 616]. 
 
Age, BMI, systolic blood pressure,  haematocrit, alanine aminotransferase and 
macrovascular disease emerged as significant baseline predictors of time to  oedema 
requiring loop diuretics on Cox regression analysis. Age, haematocrit, serum 
creatinine > 130 µmol/L (borderline significance), serum albumin, alanine 
aminotransferase and macrovascular disease emerged as significant baseline 
predictors of time to incident HF within one year of inclusion into the metformin-
sulphonylurea combination or thiazolidinedione cohort. Modelling incident HF 
events generally validated this study's predictors for loop diuretic prescription, and is 
consistent with the observation that diuretic use predicts HF in T2DM patients 
randomised to pioglitazone or placebo in the PROactive trial [261].  
 
Importantly, thiazolidinedione prescription did not emerge as a significant 
contributor to fluid retention requiring loop diuretics and HF on univariate or 
multivariate analysis, suggesting that risk factors for developing these adverse events 
following index thiazolidinedione prescription are shared with patients prescribed 
metformin-sulphonylurea combination therapy. These results contrast sharply with 
those reported in a post-hoc analysis of data from RECORD and PROactive for 
rosiglitazone and pioglitazone respectively [258, 261]. Both ascribed an increased 
risk for the respective thiazolidinedione on multivariate post-hoc analyses. However, 
RECORD investigators excluded patients awaiting a cardiovascular intervention, 
those hospitalized for a major cardiovascular event within the previous three months 
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and individuals with renal and/or liver impairment, uncontrolled hypertension or an 
HbA1c of <7% / >9% [153]. Likewise, PROactive excluded patients on insulin 
monotherapy and those with severe peripheral vascular disease, end-stage renal 
disease requiring haemodialysis, significantly elevated alanine aminotransferase, and 
subjects awaiting coronary or peripheral arterial revascularisation [256]. This 
approach will have exluded patients at higher a priori risk of incident HF, 
introducing selection bias into the post-hoc models. Patients recruited into the 
PROactive trial were randomised to a placebo rather than active comparator. In 
agreement with this study's findings, neither metformin nor sulphonylureas emerged 
as significant predictors of incident congestive HF in multivariate Cox regression 
analysis of T2DM US patients [239]. Toprani et al. were also reassuring in this 
regard, ascribing a decreased risk of thiazolidinedione associated incident HF [273].  
 
This study's findings are consistent with differences in baseline characteristics 
between patients progressing to index loop diuretic prescription / incident HF and 
those who did not. The association between age and incident HF has long been 
established [617, 618], both in diabetic cohorts [219, 239, 277-279, 619], and in the 
general population [620-625], and has been replicated in this study. Likewise, 
baseline macrovascular disease predicted index loop diuretic prescription and 
incident HF events in this Tayside cohort. This is consistent with results from studies 
analyzing new-onset HF events in patients whose T2DM was complicated by 
coronary artery disease [219, 239, 277, 278], peripheral artery disease or stroke [219, 
278], and in individuals recruited from population based cohorts who suffered from 
coronary artery disease at baseline [235, 621, 623, 624, 626-628]. 
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In general, this study's reported findings for age, albumin, systolic blood pressure, 
serum creatinine and macrovascular disease follow those reported in the Health ABC 
Heart Failure Score for elderly (diabetic and non-diabetic) patients [629]. Nichols et 
al. published similar findings in a cohort of 8231 patients with T2DM, additionally 
attributing an increased incident HF risk to diabetes duration, baseline BMI, mean 
HbA1c, insulin use, gross proteinuria, end-stage renal disease and mean DBP, and a 
(surprisingly) lower risk for microalbuminuria [239]. The authors had ascribed the 
latter finding to a confounding effect of ACE inhibitors. One does not exclude that 
this may also have masked the effect of baseline serum creatinine on the final model 
for index loop diuretic prescription in this study, in patients prone to, but not yet 
developing clinical HF, given the strong association on univariate analysis (p < 
0.001). Given recommendations that metformin should be used with caution in 
individuals with moderate renal impairment (eGFR 30-45 mls/min/1.73 m2), and is 
contraindicated in patients with severe renal impairment (eGFR < 30 mls/min/1.73 
m
2) [630], it is possible that metformin was not prescribed in patients with poor renal 
function who are particularly prone to lactic acidosis and HF.  
 
There were no significant differences in baseline HbA1c between metformin-
sulphonylurea combination and thiazolidinedione cohorts, or between loop diuretic 
and HF categories. Most patients in either cohort had suboptimal baseline glycaemic 
control. Additionally, baseline HbA1c did not predict index loop diuretic 
prescription or incident HF on univariate analysis. The association between 
glycaemic control and incident HF in T2DM is somewhat complex. While Nichols et 
al. reported no association with baseline measurements, reduction in HbA1c values 
averaged over the 30 month follow-up period predicted incident HF, suggesting a 
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role for cumulative rather than recent glycaemic burden [277]. The data in the 
present study concurs with this observation, particularly given that outcomes of 
interest were analysed at a relatively short time after baseline HbA1c measurement. 
In contrast, analysis of data from the PROactive trial revealed that a baseline HbA1c 
exceeding 7.4% predicted incident HF during a mean (± SD) follow-up period of 
34.5 (± 2.3) months [261]. Several other studies suggest that poorer glycaemic 
control is associated with higher incidence rates for HF, both in diabetic and in non-
diabetic patients [212, 218, 238, 631, 632]. A recently published systematic review 
and meta-analysis of ten prospective epidemiological studies comprising 178 929 
participants and 14 176 incident congestive HF cases ascribed an overall adjusted 
risk ratio for CHF of 1.15 (95% CI 1.10, 1.21) for each percentage point higher 
HbA1c. However, there was significant heterogeneity between the studies, not 
explained by available study-level characteristics [633].  
 
This study's reported lack of association between female gender and oedema on 
multivariate analysis are consistent with those reported for incident HF on 
multivariate survival analysis by Nichols et al. [239]. In contrast, Maru and 
colleagues had reported that type 2 diabetic males were at an increased risk of 
incident HF within the first year of diagnosis across all age groups [278]. However, 
this study’s observation period antedated the introduction of thiazolidinediones into 
the European market, and was restricted to metformin, sulphonylureas, acarbose, 
guam gum and insulin (monotherapy or in combination). Concomitant use of insulin 
and thiazolidinediones did not predict oedema requiring loop diuretic treatment or 
incident HF on univariate analysis in this study. These results need to be interpreted 
with caution, given that, as expected, only 70 patients had been prescribed 
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thiazolidinediones in combination with insulin. Nonetheless, post-hoc analysis of 
PROactive data showed that baseline insulin therapy did not predict serious HF 
events on multivariate analysis, despite observations that serious HF occurred more 
frequently in patients treated with insulin at baseline, irrespective of pioglitazone or 
placebo [261].  
 
BMI emerged as a significant predictor of time to index loop diuretic prescription on 
multivariate analysis. Rather surprisingly, this covariate was not significant on 
univariate analysis for incident HF events. The latter observation may have been 
limited by the small number of HF events in this dataset. Nonetheless, this study's 
observations for index loop diuretic prescription are consistent with those reported 
for incident HF in the Framingham study [634, 635], NHANES I [235]  and in a 
community-based elderly cohort [636]. In contrast, obesity did not remain a 
significant predictor of incident HF when correcting for insulin resistance (measured 
as euglycaemic clamp glucose diposal rate) [626] or inflammatory markers 
(interleukin-6 or C-reactive protein) [620] in other studies. 
 
As a major determinant of prevalent oncotic pressure, serum albumin would be 
expected to influence the threshold for pulmonary oedema in response to an 
elevation in left atrial pressure. Filippatos et al. demonstrated that baseline 
hypoalbuminaemia (defined as < 3.5 g/dL) predicts incident HF in community 
dwelling older adults without baseline evidence of this disease entity during ten 
years of follow-up [637]. Analysis of data from the Health, Aging and Body 
Composition Study revealed that baseline serum albumin concentrations are 
inversely related to incident HF events in a time-dependent manner, even when 
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controlling for inflammatory markers, incident coronary heart disease [638]. In this 
prospective study (median follow-up 9.4 years), Gopal et al. demonstrated that 
participants developing incident HF earlier were characterised by a lower serum 
albumin concentration than individuals developing HF over the remaining 
observation period [638]. Patients requiring an index loop diuretic within one year of 
index metformin-sulphonylurea combination or thiazolidinedione therapy were 
characterised by lower baseline serum albumin concentrations in this study's cohort. 
This study's time-to-event data consistently confirm this inverse relationship for both 
incident HF and index loop diuretic prescription at a relatively early stage of oral 
glucose lowering agent exposure (one year) across all models.  Morevoer, this 
association holds true even for T2DM patients whose baseline serum albumin hovers 
within the normal range [mean (SD) baseline serum albumin = 43.51 (3.55) g/L 
(metformin-sulphonylurea combination), 44.00 (2.88) g/L (thiazolidinediones)]. 
 
ALT was identified as a predictor of time to index loop diuretic prescription and 
incident HF events. This relationship exhibited a sigificant time-varying effect which 
mirrors that seen for macrovascular disease. The increased risk associated with ALT 
is largely seen in the first six to nine months after index metformin-sulphonylurea 
combination or thiazolidinedione therapy, and subsequently wears off to become a 
protective effect. The initial increased risk is consistent with ALT's association with 
non-alcoholic liver disease [639], endothelial dysfunction [640] and carotid 
atherosclerosis [641]. Moreover, ALT has been shown to predict coronary artery 
disease events independently of other risk factors [642, 643], including its 
association with the metabolic syndrome [644]. This remarkable time-varying effect 
could be explained by the insulin-sensitizing actions of metformin and 
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thiazolidinediones. A lower baseline ALT would be consistent with greater insulin 
sensitivity, and could suggest a greater response to metformin and/or 
thiazolidinediones, rendering such patients increasingly prone to thiazolidinedinone-
associated fluid overload. 
 
Prevalent haematocrit levels have been associated with cardiovascular events in a 
few studies [645, 646]. A higher haematocrit concentration, even within the normal 
range, has recently been associated with an increased risk of new-onset HF in an 
observational study capturing data from 3523 patients aged 50 to 65 years who had 
been enrolled in the Framingham Heart Study [647]. Coglianese et al. partly ascribed 
their observations to haemoconcentration-associated endothelial dysfunction. This 
study's time-to-event data for both index loop diuretic prescription and incident HF 
seemingly concur with these observations within the first six to nine months of index 
metformin-sulphonylurea combination or thiazolidinedione therapy.  
 
Logistic and Cox regression models identified baseline nitrates as predictors of index 
loop diuretic prescription and time to index loop diuretic prescription.  These data 
partially concur with those reported by McAlister et al. in their retrospective study of 
5631 newly diagnosed T2DM patients [279], who additionally ascribed an increased 
risk to baseline beta-blockers and a reduced risk to ACE inhibitors and ARBs. Beta-
blockers did not emerge as significant univariate predictors of index loop diuretic 
prescription (p = 0.076) and time to index loop diuretic prescription (p = 0.066) in 
this study's dataset. Additionally they were not significant on multivariate analysis. 
Baseline ACE inhibitors, ARBs or thiazolidinedione-insulin combination therapy 
were not significant on univariate analysis. Similarly, post-hoc analysis of data from 
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the PROactive study reported no significant excess incident HF events among 
patients randomised to treatment with pioglitazone on a background of nitrates, ACE 
inbibitors /ARBs or insulin [648]. Percentage maximum thiazolidinedione dose was 
not included in multivariate modelling of index loop diuretic prescription (despite a p 
value of 0.074 on univariate logistic regression), so as not to restrict the model to 
thiazolidinedione-treated patients.  
 
In general, the present results are consistent with those reported by Castagno et al. 
[649]. In a meta-analysis of HF events from the PROactive, ACCORD, VADT and 
RECORD trials, these authors reported that patients allocated intensive glycaemic 
control using high dose thiazolidinediones were more likely to develop incident HF 
compared with those receiving low dose therapy [649]. Such a dose-dependent effect 
was not seen when analysing for metformin and sulphonylureas; neither was it 
investigated in this study's dataset. 
 
The present study reported that baseline left ventricular mass (a surrogate measure of 
left ventricular hypertrophy) [603] predicted index loop diuretic prescription (p = 
0.015) and time to index loop diuretic prescription (p = 0.006) on univariate 
modelling for metformin-sulphonylurea combination or thiazolidinedione-treated 
patients (there were insufficient data for multivariate modelling). This is consistent 
with this study's observation of higher baseline left ventricular mass values for index 
loop diuretic requiring patients on univariate in both cohorts. While left ventricular 
hypertrophy has been identified as a risk factor for incident congestive HF at a 
population level in several studies [620, 621, 650], there are no such associations in 
T2DM patients. The present study's observations generally agree with data 
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suggesting that T2DM patients are characterised by a higher mean left ventricular 
mass (even in the absence of hypertension, albumunuria and apparent ischaemic 
heart disease) [651, 652], and are thus more likely to have clinically inapparent left 
ventricular dysfunction [653].  
 
In conclusion, given the paucity of evidence from prospective clinical trials, an 
epidemiological observational study was undertaken to provide information to 
clarify the relationship between fluid overload, HF and thiazolidinedione exposure. 
This study identified clinically relevant and applicable prediction models in a well 
characterised, typical T2DM population inherently at risk of HF, exposed to 
treatment with first, second and third line oral glucose lowering agents. Most of the 
risk factors are potentially modifiable, providing an opportunity at risk assessment, 
close follow-up of at risk patients and aggressive clinical risk management. 
Moreover, given that most patients have multiple risk factors in various 
combinations, multivariate modelling is likely to be more robust in predicting 
individual risk.  
 
Despite its limitations, the retrospective cohort approach offered a valuable insight 
into prescribing practices in Tayside, and minimised the possibility of selection bias. 
Given the widely reported association between thiazolidinediones and HF/oedema, 
the possibility cannot be excluded that high risk patients were barred from 
thiazolidinedione exposure by prescribers (negative allocation bias), and that this 
may have impacted on the results of the present study's multivariate models. 
Moreover, patients may have discontinued their thiazolidinedione therapy soon after 
their prescription on account of perceived or real harm. The present study sought to 
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control for this in its cohort definitions by including only patients whose initial 
thiazolidinedione prescription was followed by at least another prescription within 
three months. Patients were additionally exluded from a cohort if they had been 
treated with the same antihyperglycaemic agent within the previous year. Inclusion 
of a metformin-sulphonylurea combination therapy control cohort in multivariate 
analysis allowed contextualisation of any hypothesised thiazolidinedione effect by 
comparing it to ‘standard’ ‘first’ and ‘second line’ glucose lowering agents. Access 
to accurate drug dispension records ensured that the cohorts are representative of true 
drug use in the population being examined while minimising misclassification of 
exposure. Notwithstanding the limitations imposed by retrospective research 
analysis, this study's approach permitted good characterisation of reasonably 
extensive covariate data. Including index thiazolidinedione (vs metformin-
sulphonylurea combination) therapy as a covariate mitigated any measured or 
unmeasured baseline differences between either treatment cohort, and avoided the 
need for propensity scoring.  
 
Nonetheless, the potential existence of other unrecognised and unmeasured 
counfounding variables cannot be excluded, particularly given the paucity of 
reported data predicting susceptibility to thiazolidinedione and metformin-
sulphonylurea combination therapy induced fluid retention / HF in the literature. The 
present study sought to minimise (albeit not eliminate) this risk by including as many 
significant covariates as possible in multivariate modelling. The relative infrequency 
of incident HF events in the combined metformin-sulphonylurea and 
thiazolidinedione cohorts inevitably imposed restrictions on the maximum number of 
covariates that could be included into any one model. This study did not capture data 
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on race, cigarette smoking, physical activity, electrocardiography, hypoglycaemia 
and cardiac valvular dysfunction, all of which have been implicated to influence 
propensity for HF in other studies [235, 627, 654, 655]. Nonetheless, this study's 
approach permitted recruitment of a larger sample, analysis of sequence of events 
surrounding outcomes of interest, and the inclusion of a larger number of potential 
confounders than would have been possible in a prospective trial.  
 
In conclusion, on the basis of the present population-based data, thiazolidinediones 
per se do not appear to contribute significantly to the risk of HF or index loop 
diuretic prescription (as a surrogate for oedema). Risk factors for such adverse 
events occurring after index thiazolidinedione exposure are common to patients 
exposed to index metformin-sulphonylurea combination therapy. Careful patient 
selection may mitigate these adverse outcomes. 
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Chapter 4 - Systematic review and meta-analysis 
Is there a role for adjunct metformin in type 1 diabetes? 
 
Section I - Methods 
 
4.1 Eligible studies  
 
This objective was to capture all trials of metformin in T1DM which  were  i) 
randomised, ii) used a treatment duration of at least one week, iii) used either a 
comparator drug, placebo or used a crossover design, and iv) included consenting 
patients. This study extracted any data on cardiovascular disease, HbA1c, body 
weight or BMI, insulin dose, lipids and adverse effects.  
 
4.2 Search strategy  
 
All publications pertaining to T1DM and metformin for any outcomes were captured 
as follows in PubMed (1950 to week 4th January 2009, updated 6th October 2009) 
and EMBASE (1974 onwards).  The search was conducted as follows using medical 
search headings (MeSH): 
1. "Diabetes Mellitus, Type 1"[MeSH] 
2. (DIABET*) AND (TYPE 1[TW] OR IDDM[TW] OR ("INSULIN 
DEPENDENT"  not "NON-INSULIN DEPENDENT")) 
3. 1 OR 2  
4. "Metformin"[MeSH] 
5. metformin [TW] 
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6. 4 OR 5  
 
The abstracts of all identified publications were manually searched for studies that 
attempted to evaluate the effect of metformin on any clinically relevant outcome 
whether in a randomised trial or open label or other design.  The citations of all 
relevant publications were manually searched for any additional studies. Where 
uncertainty existed, the full text of the article was obtained and reviewed.  All 
potentially relevant studies were assessed and data extraction performed. The 
resulting tables of evidence were then reviewed. Disagreement was resolved by 
discussion with Professor John Petrie and Professor Helen Colhoun; independent 
adjudication was not required.   
 
In addition all ongoing and unpublished trials were searched as follows:  
• Cochrane Library 2009 issue 1  
• Science Citation Index meeting abstracts  (includes European Association for 
the Study of Diabetes and American Diabetes Association meetings) 1980-
October 2008   
• Diabetes UK meeting abstracts 2002-2008 Endocrine Society Abstracts  
2005-2008  
• Science Citation Index meeting Abstracts 1980-2008  
• National Research Register (NRR)  
• Controlled Trials.com  
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On the United Kingdom NRR, five trials were registered, all with glycaemic/ 
metabolic outcomes with end dates in 2005 or earlier.  All were emailed to request 
data:  
N0176113569: Completed but unpublished (pilot study). 
N0231133055: Completed and published [656]. 
N0394131469: Not completed. 
N0301111201: Completed and published [657]. 
N0046091476: Not completed. 
 
An online reference to trial N0394131469, initially accessed in the first search (week 
4th January 2009), was no longer accessible on searching across multiple research 
registers on relevant websites (www.nrr.org.uk; www.controlled-trials.com) in the 
updated search (6th October 2009). 
 
On the controlled-trials.com meta-register, one additional glycaemic/ metabolic trial 
was found:  
NCT00145379: Not completed, still recruiting (n=50). 
 
4.2.1 Subjects  
 
Participants were those of any age described by the authors of the publications as 
having T1DM or insulin dependent diabetes or youth onset diabetes. 
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4.2.2 Analysis  
 
A decision was made to summarise the data mostly in text and tabular form since 
there was obvious heterogeneity between studies in methods, design and outcome 
measures.  However, some data were also presented using standard meta-analysis 
techniques [658]; the two trials of very short duration [659, 660] were excluded from 
these. Strictly speaking these formal meta-analysis techniques should only be used 
when a group of studies is sufficiently homogeneous in terms of participants, 
interventions and outcomes to provide a meaningful summary [658].  Nevertheless, 
it was considered useful to have a measure of the statistical significance of apparent 
effects.    
 
With these caveats, a fixed effects model using the inverse variance method was 
fitted to give a crude measure of the overall treatment effect, to assess its statistical 
significance and to assess the heterogeneity of treatment effect between studies. 
Outcomes of effect on %HbA1c and on insulin dose were also examined. The metan 
STATA user command was used, which quantifies heterogeneity using the I-squared 
measure [661]. Of the eight eligible studies, one study [657] was excluded as it may 
have been incorrectly analysed as if it were a parallel group study (in which case the 
standard deviations will not be valid). Three other studies could not be included as 
they either did not report the outcomes of interest [659, 660], or because the data 
items necessary for inclusion in a combined analysis were not reported [662].  The 
data were extracted as %HbA1c and as units per day for insulin dose (using mean 
weight at baseline in each treatment group to convert insulin units per kg per day to 
units per day).  For some studies, only attained mean levels were available rather 
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than changes from baseline by treatment group; therefore, treatment effect was 
derived as the net difference in absolute units of outcome between metformin and 
placebo groups. The obvious methodological heterogeneity in study design, drug 
dose, age of subjects, and length of follow up render the combined estimates of 
effect somewhat imprecise. 
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Section II - Results  
 
4.3 Systematic review  
 
The initial electronic search identified 187 studies (figure 4.1). A manual review of 
the citations yielded an additional ten studies.  In total, 47 of these publications were 
judged to be relevant to metformin therapy in T1DM. Analysis of publications 
revealed: 17 were observational studies with no random allocation and/or no 
comparator group [656, 663-678];  11 were reviews, letters or commentaries [679-
689]; two did not contain any quantitative estimates of effects [690, 691]; one 
concerned an outcome (erythrocyte binding of insulin) not judged relevant [692]; 
and four were abstracts of later published papers [693-696]. Of the remaining 12  
publications, one concerned insulin-requiring T2DM rather than T1DM (noted after 
translation) [697], and one covered a treatment period of less than seven days [698].  
Only 10 studies were therefore identified [657, 659, 660, 662, 699-704]. Of these, 
one which was conducted on participants living in a children’s home and did not 
mention informed consent, was excluded from further analysis [703].  
  
The final nine studies [657, 659, 660, 662, 699-702, 704] covered a total of 192.8 
patient years, and the number of completed subjects ranged from 10-92 (median 26) 
(two studies did not report number completed [660, 662] (Table 4.1). Total 
maximum daily metformin dose varied from 1000 mg  to 2550 mg; duration of 
therapy ranged from 7 days to 12 months (median 4  months). Two studies were only 
available in abstract form [660, 662], including one of the largest studies (n = 80) 
which dated from 2000 [662].   
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All nine studies evaluated at least one parameter of glycaemic control or blood 
glucose in association with metformin treatment (table 4.1) but only seven reported 
mean change in HbA1 or HbA1c
 
[657, 662, 699-702, 704], which was reduced by 
0.6-0.9% in four studies [657, 662, 700, 701], with no significant change in three 
[699, 702, 704] (overall range +0.13% [699] to -0.9% [701]) (table 4.2).  The 
remaining two (shorter term) studies reported other glycaemic benefits including an 
18% increase in glucose uptake (artificial pancreas hyperinsulinaemic euglycaemic 
clamp) [659], and improved post-prandial glucose handling [660]. 
 
Of the seven studies in which insulin dose was not fixed by design) [657, 662, 699-
702, 704], insulin dose requirement was reduced by 5.7-10.1 units/ day in six of 
seven studies (the study which reported no change was conducted in adolescents 
[701]. The same seven studies were of sufficient duration to report data on changes 
in weight or BMI. Metformin reduced weight by 1.7-6.0 kg in three [662, 699, 704] 
of six studies [657, 662, 699, 701, 702, 704]. A sustained and statistically significant 
reduction (mean 1.74 kg) was reported in the largest study, which was also of the 
longest duration [699] (table 4.2). 
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 Figure 4.1 - Flow chart of the literature search 
 
 
 
 
 
 
PUBMED and/or EMBASE 
(n= 187) 
 
Hand-search of citations 
(n=10) 
Potentially relevant articles 
(n= 47) 
 
Articles excluded (n = 37) 
- observational; no random allocation and/or comparator groups 
(n=17) [553, 664-679] 
- review, commentary, letter (n = 11) [680-690] 
- insufficient numerical data (n = 2) [691, 692] 
- no relevant outcome (n = 1) [693] 
- abstract of later paper (n = 4) [694-697] 
- no evidence of type 1 diabetes after translation (n = 1) [698] 
- duration of treatment < 7 days (n = 1) [699] 
 
Randomised metformin trials in adults with type 1 
diabetes (n = 10) 
[554, 556, 557, 559, 700-705] 
No informed consent 
(n = 1) [704]  
Intervention trials meeting inclusion criteria 
(n = 9) 
[554, 556, 557, 559, 700-703, 705] 
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Table 4.1 - Study design and baseline characteristics of participants. 
 
First author 
[reference] 
 
Year 
 
Form of 
publication 
 
Design 
 
Random 
allocation 
sequence 
 
 
Compar-
ison  
group 
 
Blinding of 
investigator 
/patient  
 
Number of 
patients 
randomised 
(completed) 
 
 
Duration in 
months (or 
as stated) 
 
Mean age 
(years) 
 
 
Mean 
weight 
(kg) 
 
HbA1c 
(%)  
at 
baseline 
 
Daily dose 
metformin 
(mg) 
 
Gin [659] 
 
1985 
 
Full 
 
Crossover 
 
b
 
 
Placebo  
 
 
No /No 
 
10 (10) 
 
(7 days) 
 
41 
 
62 
 
10.0a 
 
1700 
 
Keen [660] 
 
1987 
 
Abstract 
 
Crossover 
 
b
 
 
Placebo  
 
Yes /Yes 
 
8 (b) 
 
(3 weeks) 
 
‘Adults’b 
 
84 
 
b 
 
1500 
 
Walravens 
[662] 
 
2000 
 
Abstract 
 
Parallel 
group 
 
b
 
 
Placebo  
 
Yes /Yes 
 
80 (b) 
 
6 
 
16  
 
68 
 
9.6 
 
1000 
 
Meyer [702] 
 
2002 
 
Full 
 
Parallel c 
group 
 
 b
 
 
Placebo  
 
Yes /Yes 
 
62 (59) 
 
6 
 
41 
 
76 
 
7.6 
 
1700 
 
Hamilton 
[700] 
 
2003 
 
Full 
 
Parallel 
group 
 
Computer 
generated 
 
 
Placebo  
 
Yes /Yes 
 
30 (27) 
 
3 
 
16  
 
63 (MF),  
71 (PL) 
 
9.4 (MF), 
8.9 (PL) 
 
Up to 2000 
(weight-
dependent) 
 
Särnblad 
[701] 
 
2003 
 
Full 
 
Parallel 
group 
 
b
 
 
Placebo  
 
Yes /Yes 
 
30 (26)d 
 
3 
 
17 
 
68 
 
9.3 
 
Forced titration 
to 2000 
 
Khan [657] 
 
2006 
 
Full 
 
Crossover 
 
Computer 
generated 
 
Placebo  
 
Yes /Yes 
 
15 (15) 
 
4 
 
48 
 
92 
 
8.6 
 
Forced titration 
to 2550 
 
Lund [699] 
 
 
Jacobsen 
[704] 
 
2008 
 
 
2009 
 
 
Full 
 
 
Full 
 
Parallel c 
group 
 
Parallel 
group 
 
Computer 
generated 
 
b
 
 
Placebo  
 
 
Placebo 
 
Yes /Yes 
 
 
Yes /Yes 
 
100 (92) 
 
 
24 (23) 
 
12 
 
 
6 
 
46  
 
 
0 
 
80 
 
 
90 
 
9.5 
 
 
8.9 (MF) 
9.3 (PL) 
 
Forced titration 
to 2000 
 
Forced titration 
to 2000 
                         
 
a  HbA1; b Further data unavailable; c  intention to treat analysis; d 24 completed the hyperinsulinaemic euglycaemic clamp procedure; MF, metformin; PL, placebo 
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Table 4.2 - Study outcomes 
 
 
First author 
[reference] 
 
Year 
 
Main 
outcome 
 
Effect on 
%HbA1c 
 
Effect on insulin 
dose 
 
Effect on weight/ 
anthropometry 
  
 
Other main effect(s) 
 
No of hypoglycaemic 
events 
 
Lipids 
 
Gin [659] 
 
1985 
 
Glucose 
uptake 
 
a
 
 
Fixed by design 
(HEC with 
Biostator) 
 
 
a
 
 
18% increase in insulin 
sensitivity (p<0.01)b,c 
 
a
 
 
No significant differences 
with MFb 
Keen [660] 1987 Fasting and 
postprandial 
glucose 
Not measured 
(reduced mean 
7 point 
capillary 
glucose 
-1.6c [MF] vs 
0.1c [PL] 
mmol/L; 
p<0.05) 
 
No change 
(fixed CSII) 
No significant 
changeb 
No significant difference in 
change in fasting venous 
plasma  
glucose (-1.7c [MF] vs  
-0.9c [PL] mmol/L; p=NS) 
7 (MF), 0 (PL); ‘trend 
towards more hypos’; 
p=NS 
severity of events not 
specified 
a 
Walravens 
[662] 
2000 HbA1c 0.7% lower 
with MF at 3 
months 
(p<0.05); no 
difference at 6 
monthsc,d  
Reduced by 10% 
with MF in males 
at 6 months onlya 
Wt: MF 64 kgd, 
PL 70 kgd; 
p<0.05 
at 3 months 
 
WC: MF 74 cmd, 
PL 77 cmd; 
p<0.05 
at 3 months 
 
No significant 
effects at 6 
months 
 
a
 
a
 HDL increased by 7 
mmol/Lc,d (22%) with MF 
(p=‘significant’)a 
 
 
400 
 
 
Table 4.2 continued - Study outcomes  
 
 
Author 
 
Year 
 
Main 
outcome 
 
Effect on 
%HbA1c 
 
Effect on insulin 
dose 
 
Effect on weight/ 
anthropometry 
 
 
Other main effect(s) 
 
No of hypoglycaemic 
events 
 
Lipids 
 
Meyer [702] 
 
2002 
 
Insulin dose 
(CSII) 
 
No significant 
difference 
-0.13%c (MF) 
vs -0.11%c 
(PL) 
(‘remained 
unchanged’b) 
 
6.0 fewer U per 
dayc with MF 
compared with PL 
(p=0.0043) 
 
No significant 
changea  
 
4.5 fewer Uc of basal 
insulin dose per day with 
MF compared with PL 
(p<0.023) 
 
Minor: similar for MF and 
PL  
47.2c (MF) vs 45.1c (PL) 
events patient-1 month-1  
(p=NS) 
Major:19 (MF) vs 8 (PL) 
‘no significant difference’ 
 
MF: TC reduced by 0.41 
mmol/Lc (p=0.04); 
PL: no datab 
 
Hamilton 
[700] 
 
2003 
 
Insulin 
sensitivity 
(FSIGT); 
HbA1c 
 
0.6 %c lower 
with MF 
compared with 
PL (p=0.03) 
 
0.16c U kg-1 day-1 
lower with MF 
compared with PL 
(p=0.01) 
 
‘Trend towards 
lower BMI in 
MF group’  
-0.05c (MF) vs 
0.2c (PL) kg/m2 
(p=NS) 
 
No significant difference in 
the change in insulin 
sensitivity from baseline 
between MF and PL 
2.6 ×10-4 min-1 μU-1 ml-1 
(1.0-4.1)e (MF) vs 2.5 ×10-
4 min-1 μU-1 ml-1 (1.9-2.9)e 
(PL) (p=NS) 
 
Minor: 1.8c (MF) vs 0.9c 
(PL) events patient-1 week-1  
(p=0.03) 
Major: 2 (MF), 1 (PL) 
 
‘No significant change’d 
 
Särnblad 
[701] 
 
2003 
 
HbA1c 
 
0.9 % (-1.6, -
0.1)e lower 
with MF 
(p<0.05)b 
 
No significant 
change over time 
for either 
treatment groupb 
 
No significant 
change in wt  
66 to 67 kgc 
(MF) 
65 to 66 kgc 
(PL)b 
 
No significant 
change in BMI, 
WC or WHRb  
 
Statistically significant (but 
variable) increase in insulin 
sensitivity from baseline 
with MF, not with placebo 
(HEC) (p<0.05)b 
 
Minora 
Major: none reported 
 
‘No significant change over 
time for either treatment 
group’a 
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Table 4.2 continued - Study outcomes  
 
 
Author 
 
Year 
 
Main 
outcome 
 
 
Effect on 
%HbA1c 
 
Effect on insulin 
dose 
 
Effect on weight/ 
anthropometry 
 
 
Other main effect(s) 
 
No of hypoglycaemic 
events 
 
Lipids 
 
Khan [657] 
 
2006 
 
HbA1c 
 
0.7 %a lower 
with MF 
compared with 
PL (p<0.005) 
 
 
 
 
8 Ua fewer per day 
with MF 
compared with PL 
(p<0.05) 
 
-2 kgc (MF) vs  
-1 kgc (PL) 
(p=NS) 
 
Fasting plasma glucose 4.3 
mmol/Lc lower with MF 
compared with PL 
(p<0.001) 
 
Minor: 12 (MF) vs 11 (PL) 
episodes patient-1 4 weeks-1  
(p=NS) 
Major: ‘none were reported’ 
 
TC and LDL lowered by 
0.3 mmol/Lc and 0.2 
mmol/Lc, respectively, by 
MF (p=NS for the 
difference between MF and 
PL)  
Lund [699] 2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HbA1c No significant 
effect with MF 
(0.13%  
[-0.19, 0.44]e; 
p=NS) 
 
5.7 U (-8.6, -2.9)e 
fewer per day with 
MF 
(p<0.001) 
Wt reduced by 
1.74 kg (-3.32,-
0.17)e with MF 
compared with 
PL (p=0.03) 
 
BMI reduced by 
0.56kg/m2 (-1.06, 
-0.05)e with MF 
compared with 
PL (p=0.03) 
 
HC reduced by 
2.90cm  
(-5.03, -0.77)e 
with MF 
compared with 
PL (p=0.008) 
 
Significant reduction in 
cobalamin (-83.3 pmol/L  
[-139.3, -27.3]e; p=0.004) 
and alkaline phosphatase 
(5.91 U l-1  [-10.77, -
1.05]e; p=0.018) from 
baseline with MF 
compared with PL 
 
Significant increase in 
potassium (0.20 mmol/L 
[0.02, 0.38]e; p=0.029) 
with MF compared with PL 
Minor: 48% of patients 
(MF) vs 49% of patients 
(PL) (not compared 
statistically)  
Major: 15% of patients 
(MF) vs 10% of patients 
(PL) (p=NS) 
 
Borderline increase in 
patients experiencing 
unconsciousness: 6% (MF) 
vs 1% (PL) (p=0.06) 
 
Major hypoglycaemic 
events leading to 
unconciousness during 
follow-up:  
10 (MF) vs 2 (PL) (p<0.05) 
 
 
 
 
Significant reductions in 
TC and LDL in MF-treated 
patients compared with PLf  
 
TC: -0.37 mmol/L (-0.67, -
0.06)e (p=0.021) 
LDL: -0.33 mmol/L  
(-0.61, –0.06)e  
(p = 0.018) 
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Table 4.2 continued - Study outcomes 
 
 
 
Author 
 
Year 
 
Main 
outcome 
 
Effect on 
%HbA1c 
 
Effect on insulin 
dose 
 
Effect on weight/ 
anthropometry 
 
 
Other main effect(s) 
 
No of hypoglycaemic 
events 
 
Lipids 
 
Jacobsen  
[704] 
 
 
2009 
 
HbA1c 
 
No significant 
difference  
(-0.48c [MF] 
vs -0.17c 
(PL)%; p = 
NS) 
 
8.8 U (-14.62, -
3.04)e fewer per 
day with MF (p = 
0.004) 
 
Wt was 3.9 kg  
(-7.01, -0.71)e 
lower with MF 
compared with 
PL 
(p = 0.02) 
      
No significant difference in 
systolic or diastolic blood 
pressure (daytime or night-
time) compared with 
baseline or between 
treatment groups  
 
Comparing with baseline 
values: 
DSBP: -1.1c (MF) vs  
-4.2c (PL) mmHg (p = NS) 
DDBP: -2.4c (MF) vs  
-8.7c (PL) mmHg  
(p = NS) 
NSBP: -4.8c (MF) vs  
-0.4c (PL) mmHg (p = NS) 
NDBP: -4.5c (MF) vs  
2.4c (PL) mmHg (p = NS)  
                       
 
g 
 
Significantly higher 
frequency with MF  
(0.7c [MF] vs 0.3c [PL] 
events patient-1 week-1  (p= 
0.005])  
‘the increased frequency 
was most distinct in the first 
8 weeks’a 
 
No significant differences 
in change in TC, LDL, 
between treatment groupsf 
 
TC: -0.09 c (MF) vs  
0.03 c (PL) mmol/L (p = 
0.80) 
LDL: -0.23c (MF) vs  
-0.10c (PL) mmol/L (p = 
NS) 
 
 
To convert values for insulin sensitivity to SI units (from ×10–4 min–1 [pmol/L]–1) multiply by 0.167 
aFurther data unavailable 
bNo p value reported for between-treatment comparison  
c95% CI unavailable 
dNo variance estimates stated 
e95% CI 
fLipid data published separately [705] 
gOnly biochemical hypoglycaemia was registered 
CSII, continuous subcutaneous insulin infusion; DDBP, daytime diastolic blood pressure; DSBP, daytime systolic blood pressure; FSIGT, frequently sampled intravenous glucose tolerance 
test; HC, hip circumference; HEC, hyperinsulinaemic–euglycaemic clamp; MF, metformin; NDBP, night-time diastolic blood pressure; NSBP, night-time systolic blood pressure; PL, placebo; 
TC, total cholesterol; WC, waist circumference; Wt, weigh
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Total cholesterol was reported in seven studies: it was reduced by 0.37 mmol/L in 
comparison with placebo in the largest study  [705], and by 0.3-0.41 mmol/L with 
respect to baseline (but not placebo) in two others [657, 702]. “No change” was 
reported in the other four studies [659, 700, 701, 704] (table 4.2).  
 
4.4 Meta-analyses 
 
For formal meta-analysis, only five studies reported the necessary means and 
standard deviations for insulin dose and HbA1c [699-702, 704]; there were 
insufficient data for weight and lipids. Figures 4.2 to 4.5 summarise the data in 
standardised mean differences between treatment groups (i.e. the mean difference/ 
standard deviation of mean difference). Analysing for all five studies, the overall 
effect on %HbA1c was a standardised mean difference between treatment groups of – 
0.10 (i.e. 0.10 standardised units lower in the metformin group 95% CI: standardised 
mean difference reduction of – 0.36 to 0.15, p = 0.42). This translates into an 
absolute difference of 0.11 units lower %HbA1c in the metformin than placebo 
groups (not statistically significant) (figure 4.2).  As there was some suggestion of 
heterogeneity (p = 0.175), we carried out a sensitivity analysis of the four smaller 
and shorter studies [700-702, 704].  Thus, excluding the largest study [699] the 
overall effect on %HbA1c was a standardised mean difference between treatment 
groups of -0.30 (i.e. 0.30 standardised units lower in the metformin group 95% CI: 
standardised mean difference of -0.64 to 0.037, p = 0.081). This translates into an 
absolute difference of 0.28 units lower %HbA1c (not statistically significant) in the 
metformin than placebo groups, with little evidence of heterogeneity (p = 0.353) 
(figure 4.3).   
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All five studies [699-702, 704] showed a reduction in daily insulin dose with 
metformin, with the overall measure of the treatment effect being a standardised 
mean difference between treatment groups of -0.65 (i.e. 0.65 standardised units 
lower in the metformin group 95% CI: standardised mean difference of – 0.92 to -
0.39 units, p < 0.001). This translates into an absolute difference of 6.6 insulin units 
per day lower in the metformin than placebo groups. The chi-squared test of 
heterogeneity was not statistically significant (p = 0.41) with most of the information 
coming from the Lund et al.. study [699] (figure 4.4). A similar sensitivity analysis 
of the four smaller and shorter studies [700-702, 704], excluding Lund et al. [699] 
confirmed a reduction in daily insulin dose with metformin, with the overall measure 
of the treatment effect being a standardised mean difference between treatment 
groups of -0.55 (i.e. 0.55 standardised units lower in the metformin group 95% CI: 
standardised mean difference of – 0.90 to -0.21 units, p = 0.002). This translates into 
an absolute difference of 7.16 insulin units per day lower in the metformin than 
placebo groups. The chi-squared test of heterogeneity was not statistically significant 
(p = 0.365) with most of the information coming from Meyer et al.. [702] (figure 
4.5). 
 
There were trends for increased major and/or minor hypoglycaemia with metformin 
therapy in six [657, 660, 699, 700, 702, 704] out of seven studies in which this 
adverse effect was mentioned [657, 660, 699-702, 704] (table 4.2); this reached 
statistical significance in two of the smaller studies [700, 704]. There were no reports 
of lactic acidosis associated with metformin therapy.  Rates of gastrointestinal 
adverse effects were not systematically reported except in two studies [699, 704], 
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with rates being nearly identical in metformin and placebo groups in the largest 
study [699],  
 
No studies of any design evaluating cardiovascular function, structure or events were 
identified. 
 
4.5 Discussion 
 
This study found only nine randomised studies of metformin therapy in T1DM, two 
of which were small and experimental. There were only 192.8 patient years of 
randomised follow-up in the literature which compares adversely with the evidence 
for statin therapy in T1DM (over 6000 patient years), although even this is 
inconclusive [706].  Reflecting the paucity of the evidence underpinning metformin 
in T1DM, recent publication of a single study [699] from the Steno Diabetes Centre 
almost doubled the available patient years of randomised follow-up. Overall the 
grade of evidence according to the Cochrane GRADE system for the main outcomes 
of glycaemic control and insulin dose is at best 'moderate' [658].  
 
Only five studies [699-702, 704] could be formally combined in a meta-analysis: 
there are obvious constraints to the interpretations of such sparse and heterogeneous 
data.  Nevertheless, there was evidence of a significant effect of metformin in 
reducing daily insulin dose requirement. Overall, the evidence reviewed in this study 
is consistent with a whole-body insulin-sensitising effect of metformin. A predicted 
concomitant attenuation in weight gain with lowering of required insulin doses was 
seen in the largest and longest trial [699], which was twice the duration of any other  
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Overall  (I-squared = 36.9%, p = 0.175)
Jacobsen et al. [705] 
Lund et al. [700] 
Study
Meyer et al. [703] 
Hamilton et al. [701] 
Sarnblad et al. [702] 
-0.10 (-0.36, 0.15)
SMD (95% CI)
-0.41 (-1.24, 0.42)
0.17 (-0.23, 0.56)
-0.01 (-0.51, 0.48)
-0.86 (-1.65, -0.07)
-0.37 (-1.14, 0.41)
100.00 
Weight
9.67 
42.05 
% 
26.71 
10.57 
11.00 
 
   
0 -1.65 1.65 
Standardised Mean Difference 
Metformin better  <----------     ----------> Metformin worse 
Figure 4.2 - Standardised mean difference of HbA1c level between metformin-treated and metformin free type 1 diabetes patients for 
five randomised controlled studies, including the largest study to date [699] (see text for equivalent %HbA1c units) 
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Overall  (I-squared = 8.1%, p = 0.353)
Jacobsen et al. [705] 
Sarnblad et al. [702] 
Meyer et al. [703] 
Study
Hamilton et al. [701] 
-0.30 (-0.64, 0.04)
-0.41 (-1.24, 0.42)
-0.37 (-1.14, 0.41) 
-001 (-0.51, 0.48)
SMD (95% CI) 
-0.86 (-1.65, -0.07)
100.00 
16.69
18.98
46.09
Weight% 
18.24
 
  0 
-1.65 
 
1.65 
Standardised Mean Difference 
Metformin better  <----------     ----------> Metformin worse 
 
Figure 4.3 - Standardised mean difference of HbA1c level between metformin-treated and metformin free type 1 diabetes patients for 
four randomised controlled studies, excluding the largest study to date [699] (see text for equivalent %HbA1c units)  
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Overall  (I-squared = 0.0%, p = 0.410) 
Study 
Hamilton et al. [701] 
Lund et al. [700] 
Jacobsen et al. [705] 
   Meyer et al. [703] 
Sarnblad et al. [702] 
-0.65 (-0.92, -0.39)
-0.94 (-1.74, -0.14)
-0.80 (-1.21, -0.39)
-0.44 (-1.27, 0.38) 
-0.68 (-1.19, -0.17)
SMD (95% CI)
-0.00 (-0.77, 0.76) 
100.00 
%
10.87
40.90
10.09
26.41
Weight
11.74
  
0 -1.74 1.74 
Standardised Mean Difference 
Metformin better  <----------     ----------> Metformin worse 
 
Figure 4.4 - Standardised mean difference of insulin dose between metformin-treated and metformin free type 1 diabetes patients 
for five randomised controlled studies, including the largest study to date [699] (see text for equivalent insulin dose units) 
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Overall  (I-squared = 5.5%, p = 0.365)
Sarnblad et al. [702] 
Study 
Hamilton et al. [701] 
Meyer et al. [703] 
Jacobsen et al. [705] 
-0.55 (-0.90, -0.21)
SMD (95% CI)
-0.00 (-0.77, 0.76)
-0.94 (-1.74, -0.14)
-0.68 (-1.19, -0.17)
-0.44 (-1.27, 0.38)
100.00
Weight
19.86
% 
18.39
44.68
17.07
  
0 -1.74 1.74 
Standardised Mean Difference 
Metformin better <----------     ----------> Metformin worse 
 
Figure 4.5 - Standardised mean difference of insulin dose between metformin-treated and metformin free type 1 diabetes patients for 
four randomised controlled studies, excluding the largest study to date [699] (see text for equivalent insulin dose units) 
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study. A reduction in weight was also reported over six months’ treatment in the 
most recently-published study [704], in which use of a specific algorithm for insulin 
titration resulted in a mean dose reduction of 20%. In keeping with the evidence in 
T2DM, as recently reviewed by Wulffele et al. [607], there was also a relatively 
consistent signal that metformin may reduce total and LDL cholesterol in adults with 
T1DM [705].   
 
In terms of adverse effects, this study noted trends towards increased rates of 
hypoglycaemia in association with adjunct metformin therapy, although this reached 
statistical significance in only two of the smaller trials [700, 704]. Furthermore, 
although the largest trial did not report increased rates of metformin-associated 
major or minor hypoglycaemia, there were significantly more major hypoglycaemic 
events leading to unconciousness among metformin-treated T1DM individuals [699]. 
Clearly, even with this weak evidence, physicians contemplating a recommendation 
of metformin therapy for their patients with T1DM should advise them carefully 
regarding insulin dose adjustment and blood glucose monitoring. Surprisingly, 
gastrointestinal adverse effects were infrequently mentioned by investigators. In the 
largest trial, two of 108 patients screened dropped out for this reason in a run-in 
period; thereafter, these effects occurred in almost half of the remaining patients, but 
in almost exactly equal proportions in the active and placebo groups [699]. No cases 
of lactic acidosis were reported in any of the trials.  Although evidence from a 
Cochrane review has been reassuring on this account in T2DM [707], randomised 
follow-up is clearly insufficient in T1DM, and concern continues to be expressed by 
some physicians [682]. 
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The findings of the present review disagree to some extent from those of another 
recent review [708].  Pang and Narendran reported a reduction in HbA1c with 
metformin therapy in T1DM on the basis of their meta-analysis of the three smaller 
trials on this topic [657, 700, 701] which they chose to combine with one of the three 
larger trials [702], (but not the two largest [662, 699]), along with an observational 
(controlled but non-randomised) trial which did not meet this study's inclusion 
criteria [663]. At the time of their review, the largest trial [699] was only available in 
abstract form [696]. Thus, although this review has the limitation of being based on 
only 192.8 patient years of follow up, it is a significant advance on the 54 patient 
years available in the only comparable publication to date. The conclusions of both 
reviews on outcomes other than HbA1c (weight reduction, insulin dose requirement 
and cholesterol) were, however, generally similar. While acknowledging that studies 
as short as one to three weeks are unlikely to yield information on efficacy, this 
review opted to include them simply as potential sources of information on safety 
and tolerability, particularly given the paucity of evidence available. These studies 
were excluded from the formal meta-analysis. 
 
As potential chance differences (randomisation error) at baseline between groups 
allocated to treatment can influence the outcome of smaller studies, an ideal 
approach for meta-analysis is to base calculations on data adjusted for baseline 
values.  As such information was not available for all studies, this study derived the 
treatment effects reported from absolute units of outcome; one acknowledges this as 
a limitation, but believe it unlikely to have significantly impacted on the conclusions. 
A further constraint is that magnitude of treatment effect can be influenced by 
differences in entry criteria between trials (e.g. for HbA1c): I believe that such 
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methodological issues inherent to meta-analysis only strengthen the case for further 
larger trials. 
 
Following UKPDS [36] and its more recent 10-year post-randomisation follow-up 
[489], metformin is widely-considered to protect against cardiovascular 
complications in T2DM, which is the principal reason for its current status as first 
line therapy in this condition. It should be recalled that only 753 patients were 
included in this specific UKPDS randomisation, and that an effect in the other 
direction was observed when it was combined with a sulphonylurea [36, 164]. 
Recently published results from the HOME-trial have shown that metformin 
improves macrovascular outcomes in insulin-treated T2DM patients [493]. This is 
consistent with some data that metformin may have intrinsic (and possibly direct) 
beneficial effects independent of glucose-lowering on the cardiovascular system via 
activation of AMPK [709-711] in a number of conditions [709, 712, 713]. If this is 
accepted, the hypothesis that metformin might prevent cardiovascular complications 
in T1DM should also be tested formally, as even young adults with this condition 
have an extremely high relative risk of cardiovascular disease [714-716]. The data 
reviewed herein provides useful information to guide the design of such a future 
trial.  
 
At the time of publication of this systematic review and meta-analysis, metformin 
therapy was not advocated in any major national or international guidelines for the 
management of T1DM, nor in Tayside's own regional guidelines.  However, routine 
searches the authors recently conducted of anonymised T1DM prescription data in 
Tayside, Scotland [437] (population 400,000; ≅1850 classified as having T1DM and 
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diagnosed aged < 35 years), estimated that 7.9% with BMI > 27 kg/m2 were 
receiving this medication, rising to 13.0% for those with BMI > 30 kg/m2.  Even 
allowing for any residual misclassification, it is therefore likely that many thousands 
of people with T1DM worldwide are receiving an unproven therapy of unknown 
long-term efficacy (albeit a familiar one with an attractive theoretical underpinning 
and the potential to result in reductions in rates of cardiovascular disease). 
Considering that T1DM is usually diagnosed in childhood or adolescence and is a 
lifelong condition, I believe that properly-designed randomised controlled clinical 
trials of sufficient size and duration to have the power to show reductions in 
cardiovascular disease should be conducted forthwith. Given that metformin use in 
T2DM has also been associated with reduced cancer risk [717], it would additionally 
be desirable to investigate this relationship in metformin-treated people with T1DM.  
 
Since the publication of this systematic review and meta-analysis, Burchardt et al. 
published the results of a prospective pilot clinical study of 33 obese young 
intensively-treated T1DM patients randomised to additional treatment with 
metformin for six months (vs 19 patients treated with insulin alone) [718]. The 
authors concluded that adjunct metformin was associated with a reduction in HbA1c 
(1.3%), fasting plasma glucose (3.10 mmol/L), post-prandial plasma glucose (3.59 
mmol/L), average daily plasma glycaemia (1.62 mmol/L), triglycerides (0.24 
mmol/L), glycated-LDL-cholesterol (0.02 mmol/L) and BMI (0.6 kg/m2), albeit no 
significant changes in total cholesterol, LDL-cholesterol, oxidized LDL cholesterol 
and HDL cholesterol levels. Such differences were not reported among patients 
treated with insulin alone [718]. This study was however limited by a small sample 
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size, high drop-out rate (an additional 16 randomised patients did not complete the 
study) and open-label design.  
 
In line with the results of this systematic review and meta-analysis, a recently 
published prospective pilot study of 42 uncomplicated T1DM patients [mean (SD) 
age = 46 (8) years for the metformin group; 41 (10) years for placebo]  reported that 
use of adjunct metformin for six months improved flow mediated dilation (a 
surrogate marker of endothelial function/atherosclerosis) by 1.32% (95% CI 0.30, 
2.43) and increased urinary 8-iso-prostaglandin F2α (a biomarker of oxidative stress) 
by 149 pg/mg creatinine (95% CI 50, 248), irrespective of its effects on body weight 
and glycaemic control [719]. It is hoped that the REducing with MetfOrmin Vascular 
Adverse Lesions in type 1 diabetes (REMOVAL) study, a phase III prospective trial 
currently recruiting 500 T1DM patients, will yield much-needed definitive data on 
the impact of adjunct metformin on common carotid artery intima media thickness 
(another surrogate marker of atherosclerosis), endothelial function, glycaemic 
control, insulin dose, weight, LDL-cholesterol, renal function (change in albuminuria 
and estimated glomerular filtration rate) and change in retinopathy stage [720].  
 
In summary, this systematic review and meta-analysis of the randomised trials in the 
literature indicates that metformin therapy in T1DM is associated with a reduced 
insulin dose requirement but no clear evidence of an improvement in glycaemic 
control.  In addition, there may be small reductions in weight and total/LDL- 
cholesterol, but there are no data on cardiovascular outcomes or their surrogates. 
This thesis' data suggest this is an important area for future study.   
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Chapter 5 - Conclusions and future work 
 
This thesis set out to examine mechanisms underlying intolerance to 
thiazolidinedione therapy but concluded that oedema and heart failure as a clear 
consequence of thiazolidinedione therapy was less common than anticipated. 
Thiazolidinedione therapy was apparently less significant as a risk factor for 
oedema/HF than other common patient characteristics shared across first and second 
line oral glucose lowering agents (including metformin - sulphonylurea combination 
therapy). Thus, the reported association between thiazolidinedione therapy and 
oedema/HF may have been over-emphasised.  
 
The population-based approach I employed permitted the identification of significant 
time-varying risk factors, notably macrovascular disease, alanine aminotransferase 
(ALT) and serum albumin. To my knowledge, such time-dependent risk variation 
pertinent to thiazolidinedone or metformin-sulphonylurea combination therapy has 
not been reported in the literature. Macrovascular disease consistently emerged as 
the strongest predictive factor for the adverse events of interest, with its relative 
contribution being highest in the first three to six months following thiazolidinedone 
or metformin-sulphonylurea prescription.  
 
The relative infrequency of incident loop diuretic prescription (4.3%) and incident 
HF events (1.1%) following index thiazolidinedione therapy are consistent with the 
difficulties encountered identifying suitable patients fitting strict inclusion criteria 
for the exploratory, case-control study. Nonetheless, the latter renders the resulting 
cohort of thiazolidinedione tolerant subjects particularly valuable in research terms, 
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and permitted a novel comprehensive, albeit exploratory, physiological 
characterisation of such patients. Limited exploratory data from the two 
thiazolidinedione intolerant patients failed to suggest a role for VEGF during either 
acute or chronic 'high normal' salt loading. However, renin (and possibly 
aldosterone) appeared to reduce in these patients beyond the boundaries of reference 
intervals derived from their TZD-tolerant counterparts in this context. Moreover, 
concentrations of ANP (and possibly BNP) increased to a greater extent following 
chronic sodium exposure in these patients.  
 
No echocardiographic differences were detected between the thiazolidinedione 
tolerant and intolerant subgroups, but haematocrit and DBP fell in the latter to a 
greater extent in response to salt loading, while cAI and pAI rose, suggesting that 
patients prone to thiazolidinedone-associated fluid retention may be characterised by 
a higher degree of ventricular-arterial stiffening in response to salt loading.  
 
The systematic review and meta-analysis of publications investigating a role for 
adjunct metformin in T1DM underscored the paucity of data in this field, despite the 
fact that this commonly prescribed, cheap and effective first line oral glucose 
lowering agent is frequently prescribed to T1DM patients, particularly those at 
higher BMI ranges. A formal meta-analysis reported that use of adjunct metformin 
translates into a reduction in daily insulin dose requirements (6.6 units/day), despite 
no improvements in glycaemic control, possibly as T1DM patients tend to self-titrate 
their insulin dose towards their usual HbA1c. Adjunct metformin was generally well 
tolerated, with few reports of gastrointestinal upset and no evidence of lactic 
acidosis, albeit an increased tendency for hypoglycaemia. None of the available 
418 
 
 
studies reported cardiovascular outcomes. This thesis' published systematic review 
and meta-analysis [721] supported the successful grant application for the (currently 
recruiting) REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes 
(REMOVAL) trial, an ongoing prospective, randomised clinical trial investigating 
the potential benefits of adjunct metformin in T1DM over three years [720]. 
 
The work described in this thesis highlights the unanticipated difficulties that can be 
encountered when attempting to recruit patients fitting strict inclusion criteria. 
However, the detailed characterisation of those TZD 'tolerant' and 'intolerant' 
patients that could be enrolled provides some information on the characteristics of 
patients who may be lower risk for adverse effects; it may also help to guide research 
aimed at designing modified agents with a better profile. I would be particularly 
interested to pursue further research in this field, recruiting patients from a larger 
catchment area. It may be prudent to subdivide the clinical study into multiple small 
studies with targeted inclusion and exclusion criteria pertinent to the specific 
measurements being made, so as to maximise patient recruitment without 
compromising on study quality. It would also be wise to repeat the population based 
study on a larger cohort of patients (possibly nation-wide), so as to validate the 
(unexpected) results arising from this Tayside cohort, and possibly allow the 
inclusion of a larger number of covariates in multivariate logistic and Cox regression 
models.  
 
Recent results arising from the SAVOR-TIMI trial have alerted clinicians on a 
possible causal relationship between dipeptidyl peptidase-IV (DPP-IV) inhibitors 
and incident heart failure [722]. My thesis' population-based study validated index 
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loop diuretic prescription as a surrogate marker of fluid retention and heart failure. 
Such an approach could prove useful in the setting of DPP-IV inhibitor therapy (and 
other 'novel' glucose lowering agents), particularly as none of the available 
prospective clinical trials was specifically designed to investigate this adverse event. 
 
In summary, as new pathways underpinning insulin signalling and insulin resistance 
are unravelled, there is likely to be renewed interest in new pharmacological insulin 
sensitizing agents to improve glycaemic control. A better understanding of licensed 
agents regarded as insulin sensitizers (metformin and thiazolidinediones) should 
provide beneficial insights in this regard. Published data arising from this thesis 
imply a potential advantageous role for adjunct metformin in T1DM, and should 
serve as a catalyst for large scale prospective research in this field. The association 
between thiazolidinediones and fluid retention/HF remains incompletely understood, 
and may have been over-emphasized. Population and clinical data suggest that 
careful prescribing practices, such as avoiding patients with known macrovascular 
disease, high BMI or raised alanine aminotransferase (ALT) may reduce the risk of 
adverse events in patients at risk, without removing a therapy with considerable 
efficacy from the glucose-lowering armamentarium. 
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Appendix  
Table II.1 - Left ventricular ejection fraction (LVEF) measurements (%) and 
derived % differences between sodium load exposures for visits 2 and 3. 
 
 
Subject number 
by category 
 
LVEF (%) 
(low Na) 
 
LVEF (%) 
(acute high Na) 
 
LVEF (%)  
(chronic high 
Na) 
 
% difference 
LVEF 
(acute high 
Na - low 
sodium) 
 
% difference 
LVEF 
(chronic 
high Na - 
low sodium) 
 
  
 
   
TZD tolerant      
1 55.3 a 57.0  3.1 
2 68.0 68.0 66.0 0.0 -2.9 
3 45.0 52.0 45.0 15.6 0.0 
4 55.0 56.0 63.0 1.8 14.5 
5 72.0 67.0 72.0 -6.9 0.0 
6 67.3 62.3 58.0 -7.4 -13.8 
7 58.0 60.0 63.0 3.4 8.6 
8 63.0 66.0 63.0 4.8 0.0 
9 55.0 55.0 64.0 0.0 16.4 
Mean 
(95% CI) 
59.8  
(54.3, 65.3) 
60.8  
(56.6, 65.0) 
61.2  
(56.3, 66.1) 
0.4  
(3.2, -2.4) 
2.9  
(-3.2, 9.0) 
      
TZD intolerant      
10 67.0 62.0 62.0 -7.5 -7.5 
11 64.0 69.0 63.0 7.8 -1.6 
      
a Patient declined echocardiographic assessment on this occasion.  
 
 
Table II.2 - E-wave/A-wave (E/A) ratio readings and derived % differences 
between sodium load exposures for visits 2 and 3. 
 
 
Subject number 
by category 
 
E/A ratio 
(low Na) 
 
E/A ratio 
(acute high Na) 
 
E/A ratio 
(chronic high 
Na) 
 
% difference 
E/A ratio 
(acute high 
Na - low 
sodium) 
 
% difference 
E/A ratio 
(chronic 
high Na - 
low sodium) 
 
      
TZD tolerant      
1 0.8 a 0.9  12.5 
2 1.2 1.1 1.3 -8.3 8.3 
3 0.9 0.8 0.9 -11.1 0.0 
4 1.0 1.1 0.8 10.0 -20.0 
5 1.0 0.9 0.8 -10.0 -20.0 
6 0.7 1.1 0.8 57.1 14.3 
7 0.7 0.9 0.7 28.6 0.0 
8 0.6 0.6 0.7 0.0 16.7 
9 0.7 0.7 0.9 0.0 28.6 
Mean 
(95% CI) 
0.8  
(0.67, 0.93) 
0.9  
(0.76, 1.04) 
0.9  
(0.77, 1.03) 
8.3  
(-8.1, 24.7) 
4.5  
(-6.2, 15.2)  
      
TZD intolerant      
10 1.0 1.0 0.9 0.0 -10.0 
11 0.7 0.7 1.2 0.0 71.4 
      
a Patient declined echocardiographic assessment on this occasion.  
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Table II.3 - E prime (E') readings and derived % differences between sodium load 
exposures for visits 2 and 3. 
 
 
Subject number 
by category 
 
E prime 
(low Na) 
 
E prime 
(acute high Na) 
 
E prime 
(chronic high 
Na) 
 
% difference 
E prime 
(acute high 
Na - low Na) 
 
% difference 
E prime 
(chronic 
high Na - 
low Na) 
 
      
TZD tolerant      
1 5.70 a
 
6.82 b 19.6 
2 4.19 4.87 4.90 16.2 16.9 
3 4.97 5.17 5.19 4.0 4.4 
4 6.20 6.70 6.82 8.1 10.0 
5 9.07 7.50 5.10 -17.3 -43.8 
6 6.80 6.60 6.90 -2.9 1.5 
7 5.56 5.07 5.07 -8.8 -8.8 
8 3.51 4.39 4.58 25.1 30.5 
9 4.09 3.61 4.87 -11.7 19.1 
Mean 
(95% CI) 
5.60  
(4.50, 6.70) 
5.50  
(4.60, 6.40) 
5.60 
(4.90, 6.30) 
1.6  
(-8.5, 11.7) 
5.5  
(-8.7, 19.7) 
      
TZD intolerant      
10 5.46 5.95 5.95 9.0 9.0 
11 5.17 5.07 5.20 -1.9 0.6 
      
a Patient declined echocardiographic assessment on this occasion.; bcalculation not possible due to 
missing data 
 
 
Table II.4 - E wave/E prime (E/e') ratio readings and derived % differences 
between sodium load exposures for visits 2 and 3. 
 
 
Subject number 
by category 
 
E/e' 
(low Na) 
 
E/e' 
(acute high Na) 
 
E/e' 
(chronic high 
Na) 
 
% difference 
E/e' 
(acute high Na 
- low Na) 
 
% difference 
E/e' 
(chronic high 
Na - low Na) 
 
      
TZD tolerant      
1 8.4 a
 
8.3 b -1.2 
2 19.7 17.8 18.5 -9.6 -6.1 
3 12.9 9.4 9.3 -27.1 -27.9 
4 11.1 11.7 9.1 5.4 -18.0 
5 7.2 10.3 11.8 43.1 63.9 
6 11.3 15.4 9.0 36.3 -20.4 
7 11.3 14.7 11.3 30.1 0.0 
8 20.1 16.3 11.1 -18.9 -44.8 
9 13.5 14.8 13.1 9.6 -3.0 
Mean 
(95% CI) 
12.8  
(9.86, 15.74) 
13.8  
(11.72, 15.88) 
11.3  
(9.27, 13.33) 
8.61 
 (-9.55,26.77) 
-6.39  
(26.09,13.31) 
 
     
TZD intolerant      
10 16 15.8 16.4 -1.3 2.5 
11 7.2 8.3 11 15.3 52.8 
      
a Patient declined echocardiographic assessment on this occasion; b calculation not possible due to 
missing data 
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Table II.5 - Left ventricular mass (LVM) readings (g) and derived % differences 
between sodium load exposures for visits 2 and 3. 
 
 
Subject number 
by category 
 
LVM (g) 
(low Na) 
 
LVM (g) 
 (acute high Na) 
 
LVM (g) 
 (chronic high 
Na) 
 
% difference 
LVM (g) 
(acute high 
Na - low Na) 
 
% difference 
LVM (g) 
(chronic 
high Na - 
low Na) 
 
      
TZD tolerant      
1 220.0 a
 
221.0 b 0.5 
2 241.2 240.0 242.0 -0.5 0.3 
3 257.0 257.0 260.0 0.0 1.2 
4 194.0 194.0 206.0 0.0 6.2 
5 150.0 150.0 150.0 0.0 0.0 
6 170.0 170.0 170.0 0.0 0.0 
7 237.0 237.0 235.0 0.0 -0.8 
8 263.0 263.0 269.0 0.0 2.3 
9 251.0 251.0 251.9 0.0 0.4 
Mean 
(95% CI) 
220.4  
(194.1, 246.7) 
220.3  
(190.5, 250.1) 
222.8 
 (196.2, 249.4) 
-0.06  
(-0.20, 0.08) 
1.12  
(-0.25, 2.49) 
      
TZD intolerant      
10 175.0 176.0 175.6 0.6 0.3 
11 198.0 198.0 198.0 0.0 0.0 
      
a Patient declined echocardiographic assessment on this occasion; b calculation not possible due to 
missing data. 
 
 
Table II.6 - Vascular endothelial growth factor (VEGF) measurements (pg/mL) 
and derived % differences between sodium load exposures for visits 2 and 3. 
 
 
Subject number by 
category 
 
VEGF (pg/mL) 
(low  sodium) 
 
VEGF (pg/mL)  
(chronic high sodium) 
 
% difference VEGF 
(chronic high sodium - 
low sodium) 
 
    
TZD tolerant    
1 42.8 39.8 -7.0 
2 27.7 42 51.6 
3 21.7 19.1 -12.0 
4 39 31.1 -20.3 
5 217.7 94.8 -56.5 
6 30.4 28.3 -6.9 
7 47.4 34.7 -26.8 
8 31.8 27 -15.1 
9 a 30.4 b 
Mean  
(95% CI) 
57.3 
(12.0, 102.6) 
38.6 
(24.1, 53.1) 
-11.6 
(-32.53, 9.33) 
 
   
TZD intolerant    
10 21 25.6 21.9 
11 33.2 25.2 -24.1 
    
a Patient's VEGF data unavailable; bderivation of % difference not possible due to missing data 
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Table II.7 - Plasma copeptin measurements (pmol/L) and derived % differences 
between sodium load exposures for visits 2 and 3 
 
 
Subject number by 
category 
 
Copeptin (pmol/L) 
(low  sodium) 
 
Copeptin (pmol/L)  
(chronic high sodium) 
 
% difference  
copeptin 
(chronic high sodium - 
low sodium) 
 
    
TZD tolerant    
1 4.80 4.20 -12.5 
2 6.13 6.70 9.3 
3 9.19 5.26 -42.8 
4 9.20 4.31 -53.2 
5 1.22 1.76 44.3 
6 4.30 3.72 -13.5 
7 3.00 2.47 -17.7 
8 8.78 4.27 -51.4 
9 a 4.36 b 
Mean  
(95% CI) 
5.83 
(3.73, 7.93) 
4.10 
(3.19, 5.01) 
-17.2 
(-40.87, 5.67) 
 
   
TZD intolerant    
10 1.81 1.26 -30.4 
11 9.57 10.29 7.5 
    
a
 patient's plasma copeptin data were unavailable;   b estimation of % difference not possible due to 
missing data 
 
Table II.8 - Systolic blood pressure (SBP) readings (mmHg) and derived % 
differences between sodium load exposures for visits 2 and 3. 
 
 
Subject number by 
category 
 
SBP (mmHg) 
(low  sodium) 
 
SBP (mmHg)  
(chronic high sodium) 
 
% difference SBP 
(chronic high sodium - 
low sodium) 
 
    
TZD tolerant    
1 119.0 132.3 11.2 
2 149.0 150.0 0.7 
3 143.3 134.3 -6.3 
4 139.7 143.7 2.9 
5 132.7 127.3 -4.0 
6 148.7 148.3 -0.2 
7 131.7 119.3 -9.4 
8 145.3 135.0 -7.1 
9 138.0 153.0 10.9 
Mean  
(95% CI) 
138.6 
(132.3, 144.9) 
138.1 
(130.7, 145.5) 
-0.2 
(-5.1, 4.7) 
 
   
TZD intolerant    
10 157.3 134.7 -14.4 
11 141.0 158.3 12.3 
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Table II.9 - Mean arterial pressure (MAP) readings (mmHg) and derived % 
differences between sodium load exposures for visits 2 and 3. 
 
 
Subject number by 
category 
 
MAP (mmHg) 
(low  sodium) 
 
MAP (mmHg) 
(chronic high sodium) 
 
% difference MAP 
(chronic high sodium - 
low sodium) 
 
    
TZD tolerant    
1 95.9 103.9 8.3 
2 99.0 98.7 -0.3 
3 98.9 100.8 1.9 
4 107.2 109.2 1.9 
5 94.7 89.6 -5.4 
6 108.2 107.4 -0.7 
7 102.1 93.1 -8.8 
8 109.8 103.7 -5.6 
9 100.4 107.0 6.5 
Mean 
(95% CI) 
101.8 
(98.2, 105.4) 
101.5 
(97.1, 105.8) 
-0.2 
(-3.9, 3.5) 
 
   
TZD intolerant    
10 114. 7 102.4 -10.7 
11 109.4 112.3 2.6 
    
 
 
Appendix Table III.1 - Unadjusted odds ratio of index loop diuretic prescription 
after exposure to index insulin therapy (vs thiazolidinedione therapy) 
 
 
Gender status 
 
 
Unadjusted odds ratio of 
index loop diuretic 
prescription following 
exposure to insulin 
(vs thiazolidinedione therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
Males and females 3.18 2.44 4.15 
Males 3.74 2.53 5.52 
Females 2.64 1.84 3.80 
 
 
Appendix table III.2 - Unadjusted odds ratio of index loop diuretic prescription 
after exposure to index insulin therapy (vs metformin-sulphonylurea combination 
therapy) 
 
 
Gender status 
 
 
Unadjusted odds ratio of 
index loop diuretic 
prescription following 
exposure to insulin 
(vs metformin-sulphonylurea 
combination therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
Males and females 2.89 2.28 3.67 
Males 2.58 1.86 3.58 
Females 3.24 2.28 4.58 
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Appendix table III.3 - Unadjusted odds ratio of index loop diuretic prescription 
after exposure to index thiazolidinedione therapy (vs metformin-sulphonylurea 
therapy) 
 
 
Gender status 
 
 
Unadjsuted odds ratio of 
index loop diuretic 
prescription following 
exposure to 
thiazolidinediones (vs 
metformin-sulphonylurea 
combination therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
 
Males and females 0.91 0.69 1.20 
Males 0.69 0.47 1.02 
Females 1.23 0.83 1.81 
 
 
Appendix table III.4 - Unadjusted odds ratio of incident heart failure after 
exposure to index insulin therapy (vs thiazolidinedione therapy) 
 
 
Gender status 
 
 
Unadjusted odds ratio for 
incident heart failure 
following exposure to 
insulin 
(vs thiazolidinedione 
therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
Males and females 3.24 2.07 5.07 
Males 2.93 1.64 5.26 
Females 3.83 1.87 7.85 
 
 
Appendix table III.5 - Unadjusted odds ratio of incident heart failure after 
exposure to index insulin therapy (vs metformin-sulphonylurea combination 
therapy) 
 
 
Gender status 
 
 
Unadjusted odds ratio of 
incident heart failure 
following exposure to insulin 
(vs metformin-sulphonylurea 
combination therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
Males and females 2.52 1.72 3.67 
Males 2.14 1.31 3.50 
Females 3.32 1.81 6.11 
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Appendix table III.6 - Unadjusted odds ratio of incident heart failure after 
exposure to index thiazolidinedione therapy vs metformin-sulphonylurea therapy 
 
 
Gender status 
 
 
Unadjusted odds ratio of 
incident heart failure 
following exposure to 
thiazolidinediones (vs 
metformin-sulphonylurea 
combination therapy) 
 
 
95% confidence intervals 
 
 
Lower 
 
Upper 
 
Males and females 0.78 0.49 1.24 
Males 0.73 0.41 1.30 
Females 0.87 0.39 1.92 
 
